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The synthesis of a homoaporphine-type alkaloid was accomplished in 10-steps. 
The synthesis featured a synthetic strategy to establish the key quaternary center through 
an early Suzuki cross coupling and a late-stage p-phenolic C-alkylation reaction, which 
proceeded in high yields. 
 A medicinal chemistry and rational drug design approach was undertaken 
to design and synthesize a new class of Trypanosoma brucei growth inhibitors. This hit-
to-lead strategy resulted in compounds with up to a 25-fold increase in efficacy towards 
T. brucei growth inhibition, with respect to the initial hit compound, and a single 
compound with activity in sub-micromolar concentrations.  
 A collaborative effort has begun to develop a function based method to 
label or tag neurons. We have developed a photocaged derivative of erythromycin A in 
order to control gene expression within neurons using light. The photochemical 
properties of the photocaged-erythromycin derivative were studied and in vitro proof of 
principle assays are currently underway. 
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1 
P-PHENOLIC C-ALKYLATION AS A STRATEGY TO ACCESS 
HOMOPROAPORPHINE AND HOMOAPORPHINE ALKALOIDS 
Chapter 1: Previous Synthetic Studies Towards Natural and Unnatural 
Homoaporphine Alkaloids 
1.1. NATURAL PRODUCTS AND ISOLATION 
 
 Homoaporphine alkaloids are a class of naturally occurring 1-
phenethylisoquinoline alkaloids containing a tetracyclic core with a 7-membered ring 
(1.1) (Figure 1.1). The naturally occurring homoaporphines are generally N-methylated 
on the isoquinoline ring and penta-oxygenated on the biaryl moiety.1,2 Variations of the 
O-methyl or hydroxyl substitution patterns give rise to the various members in the 
alkaloid family. 
Figure 1.1. Generalized homoaporphine skeleton (1.1) and numbering convention, 
examples of homoaporphine natural products 
 
 
 The first reported isolation of these compounds came from Bradbury and Badger 
in 1960. Upon extraction from dried Kreysigia multiflora, they isolated three previously 
unknown alkaloids.3 Further isolation and synthetic studies by Battersby characterized 
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2 
the structures of (±)-kreysigine (1.2), (-)-multifloramine (1.3), and (+)-floramultine 
(1.4).4,5 Since these initial studies, 17-naturally occurring homoaporphine alkaloids have 
been isolated from the Lilaceae family of plants, specifically from the genera: 
Androcymbium, Colchicum, Kreysigia, Bulbocodium, Iphigenia, Merendera, and 
Gloriosa. Interestingly, it was found that the stereochemistry of these compounds at C6 
depends on the genus of plant from which they were isolated. For instance, all 
compounds isolated from the genus Androcymbium were found to be dextrorotatory, 
while compounds from the Colchicum genus were isolated as either the dextrorotatory or 
levorotatory configurations. Furthermore, of the three homoaporphine alkaloids isolated 
from Kreysigia multiflora, both floramultine (1.4) and multifloramine (1.3) were isolated 
as the levorotatory isomer, yet both stereoisomers of kreysigine (1.2) were isolated from 
the same source.1  
1.2. BIOSYNTHESIS OF HOMOAPORPHINE ALKALOIDS  
 
In discussing the biosynthetic pathway towards homoaporphine alkaloids, it is 
interesting to note that these compounds are biosynthetically related to the alkaloid 
colchicine (1.7). The biosynthesis of colchicine has been shown to proceed through a 
para-para-oxidative phenolic coupling from automnaline (1.5) (Scheme 1.1) to give the 
hexadienone androcymbine (1.6), the biosynthetic precursor of colchicine (1.7). 
Conversely, the homoaporphine alkaloids are thought to arise through an ortho-para-
oxidative phenolic coupling 
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Scheme 1.1. Biosynthesis of floramultine (1.4) and colchicine (1.7) from automnaline 
(1.5) 
 
 
Given the co-occurrence of homoaporphine alkaloids with tropolone alkaloids 
from natural sources, Battersby et. al. undertook studies to show that homoaporphines, 
specifically floramultine (1.4), could arise from automnaline (1.5).6 In this study, 
synthetic radiolabeled samples of automnaline (1.5) were fed to Kreysigia multiflora. 
Upon isolation and treatment with diazomethane, they isolated pure radiolabeled O-
methylkreysigine, suggesting that the homoaporphine alkaloids can arise from a direct 
ortho-para-oxidative phenolic coupling of automnaline (1.5).  
 While the previous study was a good indication that some homoaporphine 
alkaloids could arise from automnaline (1.5), this study did not explain the occurrence of 
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4 
homoproaporphine alkaloids with the differing substitution patterns found in nature. The 
homoproaporphine kreysiginone (1.9) (Scheme 1.2) was isolated in small quantities from 
Kreysigia multiflora.7 The presence of 1.9 indicates that some of these compounds may 
arise from the ortho-para-oxidative phenolic coupling of phenethylisoquinoline 
precursors, like 1.8. The ortho-para-oxidative phenolic coupling of 1.8 would yield 
kreysiginone (1.9), of which, dienone-phenol rearrangement would yield the 
corresponding homoaporphine 1.10.  While this second potential biosynthetic pathway 
has yet to be proven via tracer studies, it’s analogous to the biosynthetic formation of the 
homologous aporphine alkaloids.8  
Scheme 1.2. Homoaporphine biosynthesis from isolated intermediate kreysiginone (1.9)  
 
1.3. PREVIOUS SYNTHETIC STUDIES  
 
 A number of synthetic efforts towards the synthesis of homoaporphine alkaloids 
have been reported since their discovery in 1960. Strategically, all of these approaches 
(with one exception) focus on constructing the phenethylisoquinoline scaffold and 
subsequent formation the key biaryl bond. Many synthetic efforts have been made to 
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5 
effect a biomimetic o-p-oxidative phenolic coupling strategy to form this bond, but this 
method has been met with limited success throughout the history of these (and related) 
alkaloids. The following sections summarize the synthetic efforts towards both natural 
and unnatural homoaporphines and is organized by key bond transformation. 
1.3.1. Oxidative Phenolic Coupling Strategies 
1.3.1.1. Battersby’s Approach 
 
The first reported synthesis of a homoaporphine alkaloid was Battersby’s 
synthesis of (±)-multifloramine (1.3) (Scheme 1.3).5 This synthesis was performed to 
confirm the structural assignment of (±)-kreysigine (1.2), (±)-multifloramine (1.3), and 
(±)-floramultine (1.4). In this route, diphenol 1.11 was prepared according to “standard 
methods”. Treatment of 1.11 with potassium ferricyanide in a biphasic mixture led to 
homoproaporphine 1.12 in 49% yield. Subsequent dienone-phenol rearrangement in 
concentrated sulfuric acid led to (±)-multifloramine (1.3) in 45% yield.  
The key step in this synthesis was the o-p-oxidative phenolic coupling. In this 
sequence, (±)-multifloramine (1.3) was synthesized from 1.11 in two steps with an 
overall yield of 22%. Throughout his studies of homoaporphines, Battersby performed 
this reaction on a number of different phenolic phenethylisoquinoline substrates and in 
each case the yields were quite poor (~30-50%).4,7  
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Scheme 1.3. Battersby’s approach to (±)-multifloramine (1.3) 
 
1.3.1.2. Kupchan’s Synthesis of (±)-Kreysigine and (±)-Multifloramine 
 
 In a series of studies, Kupchan used the same late stage oxidative phenolic 
coupling strategy to synthesize (±)-kreysigine (1.2) and (±)-multifloramine (1.3). The 
major difference in this method was the use of vanadium (V) oxytrifluoride as the 
oxidant.9,10 The use of this reagent allowed for the oxidative phenolic coupling to occur 
on monophenolic substrates. When phenol 1.13 was oxidized using vanadium (V) 
oxytrifluoride, the N-trifluoroacetamide of kreysigine 1.14 was isolated in 46% yield, as 
well as the homoproaporphine 1.15 in 4% yield (Equation 1.1). However, when the N-
methyl derivative 1.16 was subjected to the same conditions, the major product was the 
corresponding homoproaporphine 1.12 in 54% yield, and (±)-kreysigine (1.2) was only 
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7 
isolated in 16% yield (Equation 1.2). The homoproaporphine 1.12 was transformed into 
(±)-multifloramine (1.3) in 72% yield via treatment with boron trifluoride etherate 
(Equation 1.3). 
 
(1.1) 
 
(1.2) 
 
(1.3) 
 
 The fact that the corresponding homoproaporphines 1.15 and 1.12 were isolated 
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8 
conditions, it is reasonable that the formation of (±)-kreysigine (1.2) and 1.14 could arise 
through a homoproaporphine-type intermediate 1.17 (Scheme 1.4). However, dienone-
phenol rearrangement of the isolated homoproaporphines 1.15 and 1.12 would lead to the 
corresponding (±)-multifloramine analogues, instead of the isolated (±)-kreysigine 
derivatives 1.14 and 1.2. For this reason, Kupchan proposed that oxidation of the starting 
material yields homoproaporphine-type intermediate 1.17. This homoproaporphine-type 
intermediate could then undergo a dienone-phenol rearrangement to give the (±)-
kreysigine compounds 1.14 and 1.2 (Path A, Scheme 1.4) or hydrolyze to the 
corresponding homoproaporphines 1.15 and 1.12 upon aqueous work-up (Path B, 
Scheme 1.4). 
Scheme 1.4. Proposed mechanistic rationale for observed homoproaporphine and 
homoaporphine products 
 
 
 In these reports, the syntheses of 1.13 and 1.16 were merely commented upon. 
The authors state that 1.13 and 1.16 were synthesized according to “standard methods”.11 
These methods include the condensation of substituted phenethylamine 1.18 and 
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9 
phenylpropionic acid 1.19, followed by Bischler-Napieralski cyclization and sodium 
borohydride reduction to give the corresponding phenethylisoquinoline 1.21 (Scheme 
1.5). Compound 1.21 was either treated with trifluoroacetic anhydride or formaldehyde 
and sodium cyanoborohydride, followed by hydrogenolysis to give substrates 1.13 or 
1.16, respectively.  
Scheme 1.5. General methods used to synthesize phenethylisoquinolines 1.13 and 1.16 
 
 To summarize, Kupchan synthesized (±)-kreysigine (1.2) and (±)-multifloramine 
(1.3) in 16% and 39% yield, respectively, from 1.16. While the overall yield cannot be 
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10 
determined, (±)-kreysigine (1.2) and (±)-multifloramine (1.3) were synthesized in a total 
of six- and seven-steps, respectively.  
1.3.1.3. Thallium(III) Trifluoroacetate (TTFA) Oxidative Nonphenolic Coupling 
 
 In the early 1980s, it was found that thallium (III) trifluoroacetate (TTFA) could 
effect an oxidative nonphenolic coupling. As shown in Equation 1.4, this reagent, in 
conjunction with catalytic boron trifluoride, was used rather elegantly to effect the 
oxidative coupling of benzyloxy-phenethylisoquinoline 1.22 to yield (±)-kreysigine (1.2) 
directly in 40% yield.12  
 
(1.4) 
 In a rather stark contrast to the previous example, when the bisbenzyloxy 
compound 1.23 was treated with TTFA, the oxidation occurred extremely rapidly (ca. 
three minutes for 1.23 vs. 28 hours for 1.22). However, in this case, the monobenzyloxy-
homoproaporphine 1.24 was isolated in 70% yield (Scheme 1.6). Tandem debenzylation 
and dienone-phenol rearrangement proceeded smoothly in concentrated sulfuric acid to 
give (±)-multifloramine (1.3) in 81% yield.12 
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Scheme 1.6. Synthesis of (±)-multifloramine (1.3) via thallium induced oxidative 
nonphenolic coupling 
 
 
 Synthesis of substrates 1.22 and 1.23 were reported to proceed via condensation 
of the requisite benzyloxy-phenethylamine and phenyl-3-propionic acid, followed by 
Bischler-Napieralski cyclization, methylation, and sodium borohydride reduction. The 
yields for these specific substrates were not given, thus an overall yield for these 
syntheses cannot be determined. In total, (±)-kreysigine (1.2) and (±)-multifloramine 
(1.3) were synthesized in at least five- and six-steps, respectively. The use of strong acids 
in these reactions to give tandem debenzylation ultimately limits the number of synthetic 
manipulations required in these syntheses.  
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1.3.1.4. Umezawa: p-Quinol Acetate Intermediates 
 
 One of the more unique approaches undertaken in the 1970’s towards the 
synthesis of homoaporphine alkaloids, was Umezawa’s use of the intermediate p-quinol 
acetates.13–17 In these studies, he found that treatment of phenolic compounds with lead 
(IV) tetraacetate oxidized the phenol, and upon nucleophilic capture by acetic acid, 
formed the p-quinol acetate. When treated with strong acid, these intermediates 
underwent an electrophilic aromatic substitution reaction to give the resultant aporphine 
or homoaporphine.  
 Umezawa utilized this strategy in the total synthesis of (±)-kreysigine (1.2) 
(Scheme 1.7).18,19 The phenethylisoquinoline 1.16 was constructed through standard 
conditions. Heating of phenethylamine 1.18 with propionic acid 1.19 gave amide 1.20 in 
88% yield. Bischler-Napieralski cyclization of 1.20 afforded the dihydroisoquinoline 1.25 
in 77% yield. The three-step sequence of methylation, reduction, and hydrogenolysis 
proceeded in 88% to give the phenethylisoquinoline 1.16. Treatment of 1.16 with lead 
(IV) tetraacetate led to a brown amorphous substance that was “undoubtedly” the p-
quinol acetate 1.26, as characterized by IR.18 Immediate treatment with concentrated 
sulfuric acid in acetic anhydride led to the formation of O-acetylkreysigine (1.27) in 18% 
yield. Finally, hydrolysis via hydrochloric acid gave (±)-kreysigine (1.2) in 56% yield.  
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Scheme 1.7. Umezawa’s total synthesis of (±)-kreysigine (1.2)  
 
 
 In a similar sequence, Umezawa synthesized (±)-multifloramine (1.3) utilizing 
another p-quinol acetate (Scheme 1.8).20 In this synthesis, condensation of 
phenethylamine 1.28 and propionic acid 1.29 gave amide 1.30 in 59% yield. Subsequent 
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14 
Bischler-Napieralski cyclization, reduction, and reductive amination led to the formation 
of isoquinoline 1.31 in 44% yield over three steps. Treatment of 1.31 with lead (IV) 
tetraacetate, followed by addition of trifluoroacetic acid led to the formation of 
benzylmultifloramine 1.32 in 27% yield. Finally, hydrogenolysis of the benzyl ether 
afforded (±)-multifloramine (1.3) in 87% yield.  
Scheme 1.8. Umezawa’s total synthesis of (±)-multifloramine (1.3) 
 
 
 In these syntheses, Umezawa developed a strategy to effect an oxidative phenolic 
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and the use of highly toxic lead (IV) tetracetate is far from ideal. Nonetheless, Umezawa 
was able to synthesize (±)-kreysigine (1.2) and (±)-multifloramine (1.3) in seven- and 
six-steps, respectively, with a 6% overall yield for both compounds. 
1.3.2. Dehydroaporphine Ring Homologation Strategy 
 
 To date there is only a single strategy towards the synthesis of homoaporphine 
alkaloids that does not involve the late stage formation of the biaryl bond. Unfortunately, 
this synthesis started from the corresponding dehydroaporphine, which is a non-trivial 
starting material to synthesize. In this strategy, ring homologation was achieved through 
reduction of the dichlorocyclopropane, which resulted from the treatment of 
dehydroaporphines with dichlorocarbene.21,22 
Scheme 1.9. Synthesis of unnatural homoaporphine 1.36 via C-ring homologation 
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 In one example, the dehydroaporphine 1.33 was treated with base in chloroform 
under phase transfer conditions to give the dichlorocyclopropane 1.34 in 86% yield 
(Scheme 1.9). Lithium aluminum hydride reduction of 1.34 led to ring homologation and 
concomitant reduction of the ethyl carbamate to form 1.35 in 78% yield. Finally, 
reduction of vinyl chloride 1.35 via hydrogenation gave the unnatural homoaporphine 
1.36 in 94% yield. Even though this method formed the homoaporphine in just three 
steps, with an overall yield of 63%, the major drawback was that the starting material is 
not readily available. The authors do not comment on the synthesis of the starting 
dehydroaporphines. 21,22  
1.3.3. Direct Arylation Strategies  
 
This section will review synthetic strategies in which the key step was a direct 
arylation reaction. This differs from the oxidative phenolic coupling strategies, in that this 
strategy requires functionalization of one of the aromatic moieties. Consequently, the 
formation of the biaryl bond is a redox neutral operation. This strategy, and thus the 
following examples, effectively span the chronology of homoaporphine syntheses from 
some of the oldest examples, to the most recently reported synthesis of homoaporphine 
alkaloids. 
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1.3.3.1. Kametani: Photocyclization and Photo-Pschorr Reaction 
 
 Throughout the late 1960’s and into the early 1970’s, Kametani was considered a 
pioneer in the synthesis of homoaporphine and related alkaloids. At the onset of his 
studies, Kametani focused a significant amount of effort to understanding the effects of 
substrate substitution patterns on the oxidative phenolic coupling.23,24 Much of this work 
overlaps with that of Battersby, which has been previously described and is not subject to 
this discussion. Kametani also put significant effort into understanding the 
stereochemical bias of the dienone- and dienol-phenol rearrangements.25–27 Additionally, 
he was able to resolve the enantiomers of a number of synthetic samples to verify the 
stereochemical assignments of the respective natural homoaporphine alkaloids.28,29 
Further studies into the synthesis of homoaporphine and related alkaloids led to the use of 
the photo-Pschorr and photolytic-cyclization reactions.30,31   
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Scheme 1.10. Total synthesis of (±)-multifloramine (1.3) via photolytic-cyclization 
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 Utilizing this direct arylation strategy via photolytic cyclization from the 
tetrahydroisoquinoline 1.47, (±)-multifloramine (1.3) was isolated in very poor 2% yield 
(Scheme 1.10).32 Even though the synthesis was inefficient, historically it marked the 
first synthetic route to a homoaporphine alkaloid by direct coupling of two biaryl 
moieties, negating the formation of the corresponding homoproaporphine. The synthesis 
started from phenylpropionic acid 1.39, which was synthesized in a previous study via 
condensation of malonic acid and 1.37 followed by reduction with Raney nickel to give 
1.39. Carboxylic acid 1.39 was esterified to the methyl ester 1.40 in 71% yield. 
Bromination of 1.40 and subsequent formation of the benzyl ether proceeded in 69% and 
54% yields, respectively, to give ester 1.42. Heating a neat mixture of 1.42 and 1.18 
afforded amide 1.43 in 70% yield. Bischler-Napieralski cyclization gave the 
dihydroisoquinoline 1.44 in 81% yield. Dissolving 1.44 in neat iodomethane followed by 
reduction with sodium borohydride proceeded in 87% and 82% yields, respectively, to 
give the tetrahydroisoquinoline 1.46. Finally, benzyl deprotection by heating in 
concentrated hydrochloric acid and ethanol gave the photocyclization precursor 1.47 in 
89% yield. Photolytic cyclization occurred upon irradiation of 1.47 in an alkaline solution 
of ethanol and water. Despite the fact that 1.9 g of crude material (84% mass balance) 
was recovered, only 34 mg of (±)-multifloramine (1.3) was isolated upon 
chromatography.  
 In two related syntheses, Kametani synthesized (±)-kreysigine (1.2) via a 
photolytic cyclization and by a photo-Pschorr reaction. The tetrahydroisoquinoline 1.48 
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was synthesized in an analogous fashion to 1.47. The photolytic cyclization of 1.48 
yielded only 3% of pure (±)-kreysigine (1.2) (Equation 1.5).33 In another synthesis of (±)-
kreysigine (1.2), diazonation of 1.49 followed by irradiation with light, induced a photo-
Pschorr reaction to give (±)-kreysigine (1.2) in 5% yield and the hydroxy compound 1.50 
in 32% yield (Equation 1.6).34 In summary, the photolytic cyclizations to afford 
homoaporphines were quite inefficient. The total synthesis of (±)-multifloramine (1.3) 
proceeded in 11-steps with an overall yield of less than 0.2%.  
 
(1.5) 
 
(1.6) 
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1.3.3.2. SRN1 Arylation 
 
 In a more recent example, the synthesis of unnatural homoaporphine 1.52 was 
achieved through a photostimulated radical nucleophilic substitution reaction of 
tetrahydroisoquinoline 1.51 (Equation 1.7). The reaction proceeded in 40% yield and was 
the only example of a homoaporphine-type compound to be synthesized in this report. 
The report did not make any comment as to how 1.51 was synthesized.35 
 
(1.7) 
1.3.3.3. Palladium-Catalyzed Direct Arylation 
 
 To date, the most recent synthesis of a homoaporphine alkaloid was the synthesis 
of (±)-homonantenine (1.63), which is an unnatural homoaporphine and the homologue 
of the naturally occurring aporphine (±)-nantenine.36 This strategy relied on a late stage 
palladium-catalyzed arylation to form the key biaryl bond (Scheme 1.11). The synthesis 
started with the bromination of acid 1.53, which proceeded in 87% yield, to give 
bromoacid 1.54. Amide coupling of 3,4-dimethoxyphenethylamine (1.55) and 1.54 gave 
amide 1.56 in 77% yield. Bischler-Napieralski cyclization and subsequent sodium 
borohydride reduction led to the formation of phenethylisoquinoline 1.57 in 93% yield 
NCO2MeHO
MeO
Br
t-BuOK, hν
NH3
NCO2MeHO
MeO
40%
1.51 1.52
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over two steps. Formation of the ethyl carbamate proceeded in 92% yield to give 1.58. 
Unfortunately, palladium-catalyzed direct arylation of 1.58 proved to be difficult. After 
optimization attempts, through screening of a number of bases, ligands, and 
stoichiometric ratios, the highest yield achieved for the conversion of 1.58 to carbamate 
protected homonantenine 1.59 was 36% yield, which was formed alongside the des-
brominated starting material in 54% yield. 
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Scheme 1.11. Attempted synthesis of (±)-homonantenine (1.63) 
 
 
 
 After these initial attempts, (±)-homonantenine (1.63) was synthesized from 1.60 
in five steps (Scheme 1.12). The synthesis of 1.60 was achieved using “similar methods” 
to that of 1.58, but the yields are unreported. The palladium-catalyzed arylation of 1.60 
gave an inseparable mixture (~7:1) of the corresponding benzyloxyhomoaporphine (not 
shown) and the respective des-brominated starting material. It was found that arylation, 
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followed immediately by hydrogenolysis of the crude material, led to the isolation of 
homoaporphine 1.61 in 85% yield over two steps. No comment was made as to why the 
benzyloxy/N-Boc substrate 1.60 proceeded in significantly higher yield than that of 1.58. 
following the arylation, O-methylation of 1.61 proceeded to give 1.62 in 83% yield. 
Finally, N-Boc deprotection and reductive amination of 1.62 gave (±)-homonantenine 
(1.63) in 66% yield over two steps.36 
Scheme 1.12. Synthesis of (±)-homonantenine (1.63) 
 
 
 Though not explicitly stated, it appears that this direct arylation reaction was very 
sensitive to the aryl substitution patterns. In other examples, it was found that the 
substrates containing the benzyloxy or hydroxy substituent at C1 proceed in respectable 
yields (~70%), even when the nitrogen was protected as the ethyl carbamate. Since the 
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synthesis of substrate 1.60 was not given in the report or the cited references, an overall 
yield was not able to be determined. But using the sequence shown for substrate 1.58, we 
can estimate that (±)-homonantenine (1.63) was synthesized in about 10-steps with an 
overall yield around 27%.  
1.4. MAGNUS SYNTHETIC STRATEGY TOWARDS DIENONE-DERIVED ALKALOIDS  
1.4.1. para-Phenolic C-Alkylation  
 
 A p-phenolic C-alkylation was first reported by Winstein and Baird in 1957. They 
found that heating a solution of the phenolic brosylate 1.64, in a slight excess of 
potassium tert-butoxide, afforded the spirocyclic hexadienone 1.65 in roughly 50% yield 
(Equation 1.8).37 Further mechanistic and synthetic studies have since been covered in 
reviews.38   
 
(1.8) 
 Since the initial report, a number of terpenoid natural products have been 
synthesized utilizing this method. In a particularly elegant series of papers, Masamune 
cyclized phenol 1.66 to give dienone 1.67 in 90% yield.39,40 Dienone 1.67 was then 
transformed into a divergent intermediate 1.68, which was used to access a series of 
OH
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natural products namely, garryine (1.69), atisine (1.70), and kaurene (1.71) (Scheme 
1.13).41–43 
Scheme 1.13. p-Phenolic C-alkylation in divergent total syntheses  
 
1.4.2. Previous Work in the Magnus Lab: p-Phenolic C-Alkylation 
 
 In developing new methodologies applicable towards the synthesis of complex 
natural products, the Magnus lab utilized the p-phenolic C-alkylation in the synthesis of 
(±)-narwedine (1.74) and (±)-codeine (1.75) (Scheme 1.14).44 In this work, Magnus 
developed a novel synthetic strategy to ultimately effect the connectivity of the oxidative 
phenolic coupling, by reversing the order of bond formation. To this end, an early Suzuki 
cross coupling reaction established the key biaryl bond (shown in blue) of 1.72, negating 
the necessity of the problematic oxidative phenolic coupling. Subsequent p-phenolic C-
alkylation, which was induced via fluoride deprotection of phenolic silyl ether 1.72, led 
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to the cross-conjugated cyclohexadienone 1.73 in 96% yield. This step formed the 
quaternary center (bond shown in red) and in-effect established the same skeletal carbon 
framework as the oxidative phenolic coupling, albeit in reverse order.45,46  
Scheme 1.14. Magnus synthetic strategy to (±)-narwedine (1.74) and (±)-codeine (1.75) 
 
1.4.3. Magnus Total Synthesis of (±)-Narwedine and (±)-Codeine 
 
 The total synthesis of (±)-narwedine (1.74) and (±)-codeine (1.75) commenced 
with a Suzuki cross coupling between benzaldehyde 1.76 and the corresponding 
boroxime trimer, to give biaryl aldehyde 1.77 in 99% yield (Scheme 1.15). Alkylation of 
1.77, with in situ brominated ethylvinyl ether, led to the formation of bromoacetal 1.78 in 
99% yield. The key p-phenolic C-alkylation of 1.78 proceeded smoothly to give cross-
conjugated cyclohexadienone 1.73 in 96% yield. The p-phenolic C-alkylation efficiently 
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established the quaternary carbon in just three steps with high yields, circumventing the 
use of the inefficient oxidative phenolic coupling. At this point, the syntheses of (±)-
narwedine (1.74) and (±)-codeine (1.75) diverge from intermediate dienone 1.73.  
Scheme 1.15. Synthesis of divergent intermediate 1.73  
 
 
 The synthesis of (±)-narwedine (1.74) was completed in three additional synthetic 
steps from intermediate 1.73. Treatment of 1.73 with acid led to a tandem double 
conjugate addition and hemi-acetal formation to give 1.79 in 93% yield (Scheme 1.16). 
Reductive amination with methylamine hydrochloride gave the amino-boron adduct 1.80, 
the structure of which was confirmed by X-ray crystallography. Finally, heating an acidic 
solution of 1.80 in 1,4-dioxane gave (±)-narwedine (1.74) in 72% yield over two steps. 
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Given that previous reports have shown that the treatment of (±)-narwedine (1.74) with 
L-Selectride leads to reduction and spontaneous resolution to give (-)-galanthamine 
(1.81) in near quantitative yield,47 this study marks the formal synthesis of (-)-
galanthamine (1.81) in eight steps with an overall yield of 63%, which is approximately 
five-fold greater yield than the current commercial process.48–50  
Scheme 1.16. Total synthesis of (±)-narwedine (1.74) and formal synthesis of (-)-
galanthamine (1.81) 
 
 
 Upon completion of the total synthesis of (±)-narwedine (1.74), hexadienone 1.73 
was then transformed into (±)-codeine (1.75). A Henry reaction of 1.73 led to the 
formation of cyclized nitrostyrene 1.82 in 97% yield (Scheme 1.17). Selective conjugate 
reduction of 1.82, via treatment with acetic acid and sodium cyanoborohydride, gave 1.83 
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in 88% yield. Exposure of 1.83 to lithium aluminum hydride afforded 1,2-reduction of 
the enone to give allylic alcohol 1.84 in 72% yield. Upon opening of the cyclic acetal 
with acid, 1.84 underwent a tandem conjugate substitution and intramolecular reductive 
amination to give 1.85 in 66% yield, which contains the carbon skeleton of (±)-codeine 
(1.75). Finally, protecting the amine as the ethyl carbamate formed 1.86 in 90% yield. 
Scheme 1.17. Synthesis of the carbon skeleton of (±)-codeine (1.75) 
 
 
 In the final sequence of the synthesis, it was found that conditions for direct 
epoxidation of the olefin in 1.86 consistently led to epoxide formation on the undesired 
b-face. Fortunately, upon forming the halohydrin 1.87, by reacting 1.86 with 5,5-
dimethyl-1,3-dibromohydantoin, exposure of 1.87 to base gave the desired epoxide 1.88 
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in 91% over two steps (Scheme 1.18). Nucleophilic epoxide opening of 1.88 with sodium 
benzenethiolate gave sulfide 1.89 in nearly quantitative yield. Oxidation and subsequent 
sulfoxide elimination gave the desired allylic alcohol 1.91 in 76% yield over two steps. 
Finally, concomitant reduction of the ethyl carbamate and aryl bromide of 1.91 gave (±)-
codeine (1.75) in 87% yield. In this study, (±)-codeine (1.75) was synthesized in a total of 
13-steps with an overall yield of 20%. 
Scheme 1.18. Total synthesis of (±)-codeine (1.75) 
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1.4.4. Magnus Total Synthesis of (±)-Cepharatine A 
Scheme 1.19. Total synthesis of (±)-cepharatine A (1.96) 
 
 
 
 In a particularly elegant application of this synthetic strategy, the total synthesis 
of hasubanan alkaloid (±)-cepharatine A was completed in seven steps with a 16% 
overall yield (Scheme 1.19). The synthesis started with the Suzuki cross coupling of 
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benzaldehyde 1.76 and the corresponding boroxime trimer to give biaryl aldehyde 1.92 in 
70% yield. Alkylation of 1.92 with in situ brominated ethylvinyl ether gave 1.93 in 89% 
yield. The key p-phenolic C-alkylation of 1.93 proceeded to give the corresponding 
cyclohexadienone 1.94, which spontaneously underwent an intramolecular vinylogous 
aldol reaction to give cyclohexadienone 1.95 in 76% yield. Finally, a two-step procedure 
afforded reductive amination, vinyl ether hydrolysis, and addition of the resulting amine 
to give the title compound, (±)-cepharatine A (1.96), in 42% yield.  
1.4.5. Summary of the Magnus Synthetic Strategy  
Figure 1.2. Natural products accessed via the Magnus synthetic strategy 
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 The utility of this synthetic strategy has been demonstrated through the efficient 
syntheses of multiple natural products, shown in Figure 1.2. As previously mentioned, 
(±)-narwedine (1.74) and (±)-codeine (1.75) were synthesized in seven-steps (63% 
overall yield) and 13-steps (20% overall yield), respectively.44 In a related synthesis, 
8,14-dihydromorphinandienone isosinomenine (1.97) was synthesized in 10-steps, 17% 
overall yield.51 This synthetic strategy was also shown to be effective in the concise total 
synthesis of hasubanan alkaloids, culminating the total synthesis of (±)-cepharatine A 
(1.96) in seven-steps, 16% overall yield.52 Finally, it is worth noting, that in the time 
since the following research was conducted, the synthesis of proaporphine alkaloid (±)-
stepharine (1.98) was completed in eight steps and 29% overall yield.53 
 Though the previous syntheses nicely demonstrated the utility of the p-phenolic -
C-alkylation towards the synthesis of morphinan and hasubanan alkaloids, this strategy 
has yet to be demonstrated on substrates with a nitrogen-containing substrate. 
Historically, this reaction found utility in the synthesis of terpene natural products, which 
inherently lack a nitrogen substituent. The recent Magnus syntheses performed the p-
phenolic C-alkylation on substrates without a nitrogen atom, and subsequently introduced 
the nitrogen atom later in the syntheses. To truly create a generalizable and useful method 
towards the synthesis of alkaloid natural products, these potential shortcomings must be 
addressed. In addressing these current problems with the dienone synthetic strategy, we 
undertook studies towards the total synthesis of homoproaporphine and homoaporphine 
alkaloids.   
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Chapter 2: Total Synthesis of Homoaporphine-Type Alkaloids 
2.1. HOMOAPORPHINE SYNTHETIC TARGETS 
 
 The synthetic strategy discussed in the preceding chapter, in which the 
biomimetic oxidative phenolic coupling is circumvented through a Suzuki cross coupling 
and subsequent p-phenolic C-alkylation, has yet to be reported on a substrate with a 
nitrogen-atom. The goal of this work was to address this shortcoming and to expand the 
structural motifs accessible with this methodology, through the total synthesis of 
homoaporphine alkaloids containing a nitrogen substituent during the key p-phenolic C-
alkylation. At the onset of the project, we planned to synthesize 2.1, an unnatural 
homoaporphine with a simplified aryl substitution pattern, as a model system and proof 
of principle that this strategy is applicable for the synthesis of these alkaloids (Figure 
2.1). Upon establishing the underlying efficacy of this methodology through the synthesis 
of 2.1, subsequent studies will focus on synthesizing homoaporphine natural products 
that mapped onto our route namely, (±)-kreysigine (2.2) and (±)-multifloramine (2.3). By 
changing the aryl substitution patterns of the given starting materials, we will be able to 
access the corresponding natural homoaporphines alkaloids in an analogous sequence to 
that for 2.1. However, due to the unexpected retirement of Dr. P. Magnus, the syntheses 
of (±)-kreysigine (2.2) and (±)-multifloramine (2.3) were unable to be attempted.  
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Figure 2.1. Homoaporphine model system (2.1) and target homoaporphine natural 
products (±)-kreysigine (2.2) and (±)-multifloramine (2.3)  
 
2.2. RETROSYNTHETIC ANALYSIS  
 The retrosynthetic analysis of homoaporphine model system 2.1 is shown in 
Scheme 2.1. We intended to synthesize 2.1 via an acid-catalyzed dienone-phenol 
rearrangement from homoproaporphine 2.4. We envisioned homoproaporphine 2.4 
arising from the p-phenolic C-alkylation of phenethylisoquinoline 2.5. For this key step, 
we were unsure if the 6-exo-tet cyclization (favored by Baldwin’s rules54,55) would occur 
readily. For that reason, we anticipated the identity of both the nitrogen substituent (-R) 
and the leaving group (-X) would play a significant role in the efficiency of this 
transformation. Nonetheless, we planned to synthesize 2.5 in a classical manner, upon 
condensation of 2.6 with the appropriate aldehyde, Pictet-Spengler cyclization would 
yield 2.5. After a Henry reaction of biaryl aldehyde 2.7, phenethylamine 2.6 would arise 
from a reduction of the resulting b-nitrostyrene. Finally, biaryl aldehyde 2.7 would come 
from a Suzuki cross coupling of commercially available 5-bromoveratraldehyde (2.8) and 
the corresponding boronic acid.  
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Scheme 2.1. Retrosynthetic analysis of homoaporphine model system 2.1 
 
2.3. SYNTHESIS OF 5-BROMOVERATRALDEHYDE  
 Although 5-bromoveratraldehyde (2.8) is commercially available, this compound 
can be synthesized on large scale from vanillin (2.9), which is significantly cheaper (5-
bromoveratraldehyde: $51/g vs. vanillin $0.02/g, Sigma-Aldrich, as of the time of this 
writing). In a very straightforward procedure, vanillin (2.9) was allowed to react with 
bromine in acetic acid to give crude 5-bromovanillin. Upon exposure of the crude 
material to iodomethane, 5-bromoveratraldehyde (2.8) was obtained in 81% yield over 
two steps (Equation 2.1).  
NH
MeO
MeO
HO
NR
O
MeO
MeO
NR
MeO
MeO
OSiR3
X
NH2
OSiR3
MeO
MeO MeO
MeO
OSiR3
CHO
MeO
MeO
CHO
Br
2.1 2.4 2.5
2.6 2.7 5-bromoveratraldehyde (2.8)
 
 
 
38 
 
(2.1) 
2.4. SYNTHESIS OF b-NITROSTYRENE  
 
 With 5-bromoveratraldehyde (2.8) in hand, we focused our attention towards the 
synthesis of the boroxime coupling partner 2.12. 4-Bromophenol (2.10) was protected as 
the tert-butyldimethylsilyl ether 2.11 in 92% yield (Scheme 2.2). Based on previous work 
in the Magnus lab, silyl ether 2.11 was treated successively with n-butyllithium, 
triisopropyl borate, and azeotropically dehydrated with toluene to give boroxime 2.12 in 
81% yield.  
Scheme 2.2. Synthesis of Suzuki coupling partner 2.12 
 
 
 We next attempted the Suzuki cross coupling of 2.8 and 2.12. The initial set of 
conditions used for the Suzuki cross coupling were based on previous results within the 
Magnus lab.56 To our delight, these conditions efficiently formed the biarylaldehyde 2.13 
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in 96% yield (Scheme 2.3). Following the Suzuki cross coupling, 2.13 was subjected to a 
Henry reaction by heating in nitromethane in the presence of catalytic ammonium acetate 
to give b-nitrostyrene 2.14 in 77% yield.  
Scheme 2.3. Synthesis of b-nitrostyrene 2.14 
 
2.5. b-NITROSTYRENE REDUCTION: PART I.  
 Following the Henry reaction, reduction of 2.14 to the corresponding 
phenethylamine 2.15, was surprisingly difficult (Equation 2.2). A wide range of 
conditions were attempted and ultimately failed to give satisfactory yields of 2.15. We 
first attempted to reduce 2.15 using lithium aluminum hydride in THF under reflux.57 
While this method successfully reduced the b-nitrostyrene moiety, we also observed 
concomitant loss of the phenolic-TBS group. Additional attempts utilizing previously 
reported conditions including, borane with catalytic sodium borohydride,58 
superhydride,58  and lithium borohydride with chlorotrimethylsilane59 all gave intractable 
mixtures of unknown byproducts. On small scale, we found that hydrogenation with 
catalytic palladium on carbon in the presence of hydrochloric acid yielded primarily 
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2.15.60 However, all attempts to perform this reaction on larger scale led to loss of the 
phenolic-TBS group.  
 
(2.2) 
 At this point, it had become clear that the phenolic-TBS group was too labile for 
the strongly reducing and/or acidic conditions necessary for b-nitrostyrene reduction. We 
decided a more robust silyl-based protecting group would be required, and thus, 
synthesized the analogous triisopropylsilyl ether. 
2.6. O-TIPS b-NITROSTYRENE SYNTHESIS 
 
 The synthesis of the triisopropylsilyl ether protected b-nitrostyrene 2.19 
proceeded in an analogous fashion to 2.14 (Scheme 2.4). From 4-bromophenol (2.10), 
silyl protection and formation of boroxime 2.17 proceeded in 98% and 89% yields, 
respectively. Subsequent Suzuki cross coupling of 2.8 and 2.17 gave the analogous O-
TIPS aldehyde 2.18 in 91% yield. Henry reaction of 2.18 formed b-nitrostyrene 2.19 in 
88% yield.  
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Scheme 2.4. Synthesis of O-TIPS protected b-nitrostyrene 2.19 
 
2.7. b-NITROSTYRENE REDUCTION: PART II. 
 
 With b-nitrostyrene 2.19 in hand, we once again turned our attention to the 
formation of the corresponding phenethylamine 2.20. Initial attempts at catalytic 
hydrogenation in various alcoholic solvents with strong Brønsted acids60,61 led to mainly 
intractable mixtures of byproducts with trace amounts of product formation. Literature 
conditions utilizing iron (0) in acidic alcoholic media also failed to yield more than trace 
amounts of 2.20.62 Finally, much to our delight, we found that dropwise addition of a 
solution of 2.19 in 1,4-dioxane into an excess of diisobutylaluminum hydride led to 
immediate formation of 2.20 in 94% yield (Equation 2.3).63 
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(2.3) 
2.8. SYNTHESIS OF 3-BENZYLOXYPROPIONALDEHYDE  
 Following the reduction of b-nitrostyrene 2.19, the next step in our synthesis was 
the Pictet-Spengler cyclization. Before any attempts at the Pictet-Spengler cyclization 
could be made, we first needed to synthesize the requisite 3-substituted propionaldehyde. 
Careful consideration as to the substituent at the 3-postion was taken. We required a 
substituent that would not only be unreactive towards our primary amine, but that we 
could also easily manipulate into a proper leaving group for the following p-phenolic C-
alkylation. We decided that a protected alcohol should fit the aforementioned 
requirements. The benzyl ether was chosen as the protecting group because it afforded us 
the ability of orthogonal deprotection, with respect to the phenolic triisopropylsilyl ether. 
From 1,3-propane diol (2.21), monobenzylation via in situ Finkelstein reaction using 
catalytic tetrabutylammonium iodide with one equivalent of benzyl chloride and sodium 
hydride, proceeded to give alcohol 2.22 in 78% yield (Scheme 2.5). Swern oxidation of 
2.22 yielded 93% of 3-benzyloxypropionaldehyde (2.23).64 
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Scheme 2.5. Synthesis of 3-benzyloxypropionaldehyde 2.23 
 
2.9. PICTET-SPENGLER CYCLIZATION: PART I.  
 The Pictet-Spengler cyclization has been utilized in a multitude of total syntheses 
and has been subject to a number of reviews.65–67 All attempts made towards the Pictet-
Spengler cyclization of 2.20 with aldehyde 2.23, failed to yield any isolable quantities of 
desired product 2.24 (Equation 2.4). Of the conditions attempted, acids including, acetic 
acid, sulfuric acid, trifluoroacetic acid, triflic acid, and titanium (IV) chloride, all failed to 
give 2.24.68,69 Attempts at an acyl-Pictet-Spengler cyclization, through in situ N-acylation 
of 2.20 via treatment with acetyl chloride or trifluoroacetic anhydride, both failed. At this 
point in time, we were inspired by a recent report in which several aliphatic aldehydes 
were cyclized onto a carbamate protected phenethylamine in a mixture of concentrated 
sulfuric acid and acetic acid at room temperature.70 
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(2.4) 
2.10. MONOARYL ETHYL CARBAMATE SYNTHESIS  
 
 We decided to initially test the recently reported carbamate cyclization conditions 
on the monoaryl carbamate 2.27 (Scheme 2.6) for two reasons. First, it is possible that the 
biaryl substituent at the 5-postion was too sterically demanding to allow for cyclization to 
occur at that position. Secondly, the monoaryl amine was easier and cheaper to 
synthesize in large quantities. Henry reaction of 5-bromoveratraldehyde (2.8) and 
subsequent diisobutylaluminum hydride reduction each proceeded in 97% yield, 
respectively, to give phenethylamine 2.26. Treatment of 2.26 with ethyl chloroformate 
gave carbamate 2.27 in 76% yield.  
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Scheme 2.6. Synthesis of monoaryl carbamate 2.27 
 
2.11. PICTET-SPENGLER CYCLIZATION: PART II. MONOARYL CARBAMATE  
 
 Representative results of the Pictet-Spengler cyclization and optimization studies 
are shown in Table 2.1. From carbamate 2.27, attempts to replicate the aforementioned 
literature procedure resulted in only trace amounts of 2.28 (entry 1). We obtained similar 
results by stirring carbamate 2.27 and aldehyde 2.23 in hexafluoroisopropanol (HFIP) at 
room temperature (entry 2). However, we found that heating a solution of 2.27 and 2.23 
in HFIP with catalytic amounts of trifluoroacetic acid led to a substantial increase in yield 
(entries 3-5). Given these results, we decided to test these conditions on the analogous 
biaryl derivative. 
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Table 2.1. Optimization of Pictet-Spengler cyclization on monoaryl carbamate 2.27 
 
Entry Acid Solvent Temperature Yield of 2.28 
1 H2SO4 AcOH rt trace 
2 - HFIP rt trace 
3 - HFIP 50 ºC 30% 
4 TFA cat. HFIP 50 ºC 50% 
5 TFA cat. HFIP 60 ºC 68% 
         (HFIP = 1,1,1,3,3,3-hexafluoroisopropanol) 
2.12. PICTET-SPENGLER CYCLIZATION: PART III. BIARYL CARBAMATE  
 
 Ethyl carbamate 2.29 was synthesized in 86% yield from 2.20 upon treatment 
with ethyl chloroformate. Following the isolation of 2.29, the previously discovered 
Pictet-Spengler cyclization conditions were attempted and gave tetrahydroisoquinoline 
2.30 in 65% yield (entry 1, Table 2.2).  In attempts to further optimize the reaction, we 
first tested to see if trifluoroacetic acid was necessary for cyclization to occur. The use of 
catalytic acetic acid, in place of trifluoroacetic acid, yielded only trace amounts of 2.30 
(entry 2). We next focused our attention on whether HFIP was necessary as the solvent. 
Given the toxicity and relatively expensive cost of HFIP, we hoped to find a safer and 
cheaper alternative. Attempts using isopropanol as the solvent gave only returned starting 
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materials 2.29 (entry 3). Finally, we found that the use of trifluoroethanol (TFE) was just 
as effective as HFIP, giving 2.30 in 85% yield (entry 4). 
Table 2.2. Pictet-Spengler cyclization of biaryl carbamate 2.29 
 
Entry Acid Solvent Temperature Yield of 2.30 
1 TFA cat. HFIP (0.2 M) 60 ºC 65% 
2 AcOH cat. HFIP (0.2 M) 60 ºC trace 
3 TFA cat. iPrOH (0.2M) 60 ºC rsm 
4 TFA cat. TFE (0.2 M) 60 ºC 85% 
5 TFA cat. HFIP (0.4 M) 60 ºC 86% 
 HFIP = 1,1,1,3,3,3-hexafluoroisopropanol, TFE = 1,1,1-trifluoroethanol. Concentrations with respect to 
carbamate 2.29  
 
2.13. P-PHENOLIC C-ALKYLATION: PART I. ETHYL CARBAMATE   
 
 To set the stage for the key p-phenolic C-alkylation, we first needed to transform 
the benzyl ether of 2.30 into an appropriate leaving group. For our initial studies, we 
chose to use the mesylate leaving group. Hydrogenolysis of benzyl ether 2.30, using 
catalytic palladium on carbon, gave alcohol 2.31 in 60% yield (Scheme 2.7). Subsequent 
treatment with mesyl chloride gave the mesyl alcohol 2.32 in 43% yield.  
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Scheme 2.7. Synthesis of p-phenolic C-alkylation substrate 2.32 
 
 
 Conditions for the p-phenolic C-alkylation were chosen based on previous studies 
from the Magnus lab.56,71 Heating a solution of 2.32 in DMF to 80 ºC followed by 
addition of flame-dried cesium fluoride, and subsequent heating to 120 ºC, led to a 
mixture of products (Figure 2.2). The desired homoproaporphine 2.33 was isolated in 
poor yield (< 20% in each attempt). 
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Figure 2.2. Initial attempt at p-phenolic C-alkylation 
 
 
 In analyzing the mixture of products and designing future experiments, we 
reasoned that the formation of dimer 2.36 could be mitigated by running the reaction 
under higher dilution. Initially, the formation of alcohol 2.35 and tetrahydrooxazinone 
2.34 was perplexing. After careful consideration, we hypothesized that the carbonyl 
oxygen atom could be displacing the mesylate to form an imidate intermediate 2.37 
(Scheme 2.8). Addition of water into 2.37 would lead to the formation of tetrahedral 
intermediate 2.38, which upon leaving of the alkoxy group (red) or ethoxy group (blue) 
would form alcohol 2.35 or tetrahydrooxazinone 2.34, respectively. 
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Scheme 2.8. Proposed mechanism of the formation of 2.34 and 2.35 
 
 
 If the given side-reaction is proceeding through the proposed mechanism, then the 
formation of byproducts 2.34 and 2.35 would be mechanistically independent from the 
desired p-phenolic C-alkylation pathway. With this in mind, we ran a control experiment 
to determine whether or not the starting material was stable to the reaction conditions. 
Heating 2.32 in DMF followed by an aqueous work-up led to the exclusive formation of 
alcohol 2.39 and tetrahydrooxazinone 2.40, thus indicating that these side reactions are 
likely happening before the desired p-phenolic C-alkylation can occur (Equation 2.5). 
Given the experimental evidence that the ethylcarbamate is likely displacing our alcohol 
before the desired transformation can occur, we decided that the N-protecting group 
needed to be changed. 
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(2.5) 
2.14. NITROGEN PROTECTING GROUP STRATEGIES  
 
In planning a new N-protecting group strategy, two possibilities immediately 
came to mind. The first idea was to perform the p-phenolic C-alkylation without a 
protecting group, i.e. from the N-H compound 2.41 (Figure 2.3). However, from our 
previous studies into the Pictet-Spengler cyclization, we know that the phenethylamine 
2.20 will not cyclize. Given that the step immediately following the Pictet-Spengler 
cyclization is a hydrogenolysis, we reasoned that the use of a Cbz N-protecting group 
would allow for the Pictet-Spengler to occur analogously to previous examples to give 
2.42. Subsequent hydrogenolysis of 2.42 would afford a tandem benzyl and Cbz 
deprotection, yielding 2.41 without any additional synthetic steps.  
 The second potential N-protecting group strategy considered, was use of the N-
tosyl sulfonamide 2.43. The oxygen atoms on the N-sulfonamide are less nucleophilic, 
and thus less likely to participate in the displacement of the leaving group during the p-
phenolic C-alkylation, as compared a carbamate oxygen atom. The biggest unknown with 
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respect to the use of the N-tosyl group in our synthesis, was whether the Pictet-Spengler 
cyclization would occur analogously to the carbamate substrates. 
Figure 2.3. Potential nitrogen-protecting group strategies 
 
2.15. P-PHENOLIC C-ALKYLATION: PART II. SECONDARY AMINE 
 
 In preparation to attempt the p-phenolic C-alkylation without a nitrogen 
protecting group, we synthesized alkyl bromide 2.48 (Scheme 2.9). Protection of 2.20 as 
the Cbz carbamate proceeded in 79% yield to give 2.45. Subsequent Pictet-Spengler 
cyclization using the dimethyl acetal 2.46 gave tetrahydroisoquinoline 2.42 in 91% yield. 
Concomitant benzyl and Cbz deprotection was achieved via hydrogenation with catalytic 
palladium on carbon to give secondary amino alcohol 2.47 in 63% yield. Given that 
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treatment of secondary amine 2.47 with methanesulfonyl chloride would likely lead to 
the N-mesyl compound, we synthesized the corresponding alkyl bromide 2.48. Heating a 
solution of 2.47 in toluene under reflux in the presence of phosphorus tribromide gave 
quantitative conversion to bromide 2.48.  
Scheme 2.9. Synthesis of secondary amine 2.48 
 
 
 With the stage set, we attempted the key p-phenolic C-alkylation on 2.48. Upon 
heating a solution of 2.48 in DMF and adding flame-dried cesium fluoride, we isolated 
80% of elimination product 2.49 (Equation 2.6).  
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(2.6) 
 We reasoned that the elimination to form 2.49 likely occurs because of the basic 
nature of the secondary amine. Heating 2.48 in DMF as a control experiment led to the 
formation of olefin 2.50, confirming that the starting material is not stable to the reaction 
conditions (Equation 2.7). Given these results, we focused our attention on synthesizing 
the corresponding N-tosyl protected amine.  
 
(2.7) 
2.16. P-PHENOLIC C-ALKYLATION: PART III. N-TOSYL SULFONAMIDE  
 
 The synthesis of N-tosyl tetrahydroisoquinoline 2.51 was accomplished 
analogously to previous examples. Treatment of phenethylamine 2.20 with tosyl chloride 
gave the N-tosyl phenethylamine 2.44 in 80% yield (Scheme 2.10). Pictet-Spengler 
cyclization of 2.44 proceeded smoothly to give tetrahydroisoquinoline 2.51 in 87% yield. 
Palladium-catalyzed transfer hydrogenolysis of 2.51 gave alcohol 2.52 in 83% yield. 
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Alcohol 2.52 was transformed into the mesylate 2.53 via treatment with methanesulfonyl 
chloride in near quantitative yield.  
Scheme 2.10. Synthesis of N-tosyl sulfonamide p-phenolic C-alkylation substrate 2.53 
 
 
 With mesylate 2.53 in hand, it was once again time to attempt the p-phenolic C-
alkylation. Upon addition of flame-dried cesium fluoride to a solution of 2.53 in DMF at 
80 ºC, followed by heating to 120 ºC, we were quite surprised to find that we not only 
isolated the desired homoproaporphine 2.54 in 22% yield, but we also isolated the 
formate ester 2.55 in 21% yield (Equation 2.8).  
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(2.8) 
 In these experiments, the formation of 2.55 coincided with the presence of trace 
amounts of the corresponding alcohol (analogous to 2.35). However, unlike the previous 
p-phenolic C-alkylation attempts with ethyl carbamate 2.32, the formation of 2.55 was a 
strong indication that the accompanying alcohol was not arising from neighboring group 
participation of the nitrogen protecting group. This led us to revise our mechanistic model 
to explain the formation of the alcohol byproduct. Given that DMF is known to act as a 
nucleophile in reactions such as the Vilsmeier-Haack,72 it is possible that DMF is 
displacing our leaving group to give intermediate 2.56 (Scheme 2.11). Subsequent 
hydrolysis upon aqueous work-up would lead to 2.55, and further hydrolysis would form 
the corresponding alcohol. 
Scheme 2.11. Mechanistic rationale for the observation of formate byproduct 2.55 
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 In order to mitigate this side reaction, we attempted the p-phenolic C-alkylation 
on substrates possessing weaker leaving groups namely, bromide 2.57 and chloride 2.58. 
We anticipated that the weaker leaving group ability would decrease the reactivity of our 
substrates towards the solvent, thus allowing intramolecular alkylation to occur. With this 
in mind, bromide 2.57 and chloride 2.58 were synthesized from an Appel reaction in 95% 
and 83% yields, respectively (Equation 2.9). 
 
(2.9) 
 From bromide 2.57, p-phenolic C-alkylation under our previously reported 
conditions gave the homoproaporphine 2.54 in 57% yield (Equation 2.10). However, 
while the use of the bromide leaving group mitigated the deleterious side reaction to a 
significant degree, trace quantities of 2.55 were still observed. Previous studies have 
shown that the bromide exhibits a weaker leaving group ability, as compared to the 
mesylate leaving group, with respect to intermolecular substitution reactions.73,74 
Therefore, we postulated that the attenuated leaving group ability of the bromide lowers 
the rate of solvolysis, relative to the rate of intramolecular alkylation, leading to an 
increased yield of 2.54. However, the 57% yield was not satisfactory for this key-step, so 
we decided to try this reaction in a number of different high-boiling aprotic solvents.  
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(2.10) 
 
(2.11) 
 
(2.12) 
 The use of 1,3-dimethyl-3,4,5,6-tetrahydro-2-pyrimidinone (DMPU) as the 
solvent in the p-phenolic C-alkylation led to exclusive formation of formate 2.55 
(Equation 2.11). The use of N-methyl pyrrolidinone (NMP) as solvent gave the desired 
homoproaporphine 2.54 in 27% yield (Equation 2.12), along with varying amounts of the 
corresponding alcohol. The quantities of byproducts formed during these reactions was 
found to be qualitatively dependent on the amount of time 2.57 was preheated at 80 ºC. 
Given our inability to completely shut down this side reaction, we considered that for 
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every substrate attempted, this side reaction occurred when heating the substrate before 
addition of the cesium fluoride. Based on previous work in our laboratory, this preheating 
was thought to be necessary for the success of the p-phenolic C-alkylation.44–46,51,71,75  
Nonetheless, we reasoned that reversing the order of addition, in adding a solution of our 
substrate to the reaction flask already containing cesium fluoride at the reaction 
temperature, would limit the amount of time that our substrate was heated before being 
able to react with the cesium fluoride, and thus minimize the formation of 2.55. 
 Our initial experiment utilizing the inverse addition procedure was met with great 
success. Cannulating a solution of 2.57 in NMP into a flask with flame-dried cesium 
fluoride at 100 ºC gave 2.54 in 79% yield (Equation 2.13), the structural assignment of 
which was confirmed by X-ray crystallography (Figure 2.4). Given this result, we ran a 
number of similar experiments and found that the inverse addition protocol was far 
superior to the previous reaction conditions for our system. Using diglyme as the solvent 
at 100 ºC and 120 ºC yielded 2.54 in 53% and 71%, respectively (Equation 2.14). We 
also found the chloride leaving group to be particularly efficient, albeit at higher 
temperatures. In NMP at 100 ºC, the chloride 2.58 was unreactive and simply yielded the 
TIPS-deprotected phenol of the starting material. However, when 2.58 was heated to 150 
ºC, we isolated the desired product 2.54 in 91% yield (Equation 2.15).  
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(2.13) 
 
(2.14) 
 
(2.15) 
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Figure 2.4. X-ray crystal structure of homoproaporphine 2.54 
  
2.17. DIENONE-PHENOL REARRANGEMENT AND N-TOSYL DEPROTECTION  
 
 Upon synthesis of the N-tosyl homoproaporphine 2.54, we next turned our 
attention towards the dienone-phenol rearrangement. The dienone-phenol rearrangement 
of a homoproaporphine to form the corresponding homoaporphine has been reported 
almost as early as the discovery of these compounds.5 We first attempted Battersby’s 
procedure by stirring 2.54 in concentrated sulfuric acid.26 However, this led to an 
intractable mixture of multiple byproducts. We then attempted a previously reported 
procedure  using boron trifluoride etherate in dichloromethane.12,76,77 This method gave 
the desired product in ~20% yield at most. We found significantly improved yields upon 
the use of Kametani’s conditions,78,79 thus stirring a solution of 2.54 in a mixture of acetic 
acid and concentrated hydrochloric acid at room temperature for two-days led to a 48% 
yield of the desired homoaporphine 2.59. Slightly modifying Kametani’s conditions, we 
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found that heating the reaction mixture to 50 ºC for 12 hours gave 2.59 in 79% yield 
(Equation 2.16), the structural assignment of which was confirmed by X-ray 
crystallography (Figure 2.5).  
 
(2.16) 
Figure 2.5. X-ray crystal structure of N-tosyl homoaporphine 2.59 
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 With the homoaporphine 2.59 in hand, we were able to deprotect our N-tosyl 
sulfonamide to access our target compound 2.1. Treatment of 2.59 with sodium 
naphthalide in dimethoxyethane gave the final homoaporphine 2.1 in 58% yield 
(Equation 2.17). Due to a lack of material and a shortage on time, these reaction 
conditions were not optimized. Further difficulty was experienced with respect to the 
purification of 2.1. Attempted purification via recrystallization failed to give satisfactory 
yields. Initial attempts at purification by column chromatography over silica gel were 
unable to yield the title compound without the presence of at least one unidentifiable 
byproduct. Finally, with material almost completely gone, the reaction was run one last 
time. Chromatography conditions previously reported by Kametani for the synthesis of an 
unnatural homoaporphine79, in which chloroform-acetone-methanol (5:4:1) was used as 
the eluent, yielded 58% of pure homoaporphine 2.1. 
 
(2.17) 
2.18. SUMMARY AND CONCLUSION 
 
 In summary, unnatural homoaporphine 2.1 was synthesized in 10-steps from 
commerically available 5-bromoveratraldehyde (2.8), with an overall yield of 15% 
(Scheme 2.12). In the final sequence, the biaryl-phenethylamine 2.20 was synthesized 
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from 2.8 through a Suzuki cross coupling, Henry reaction, and reduction of the b-
nitrostyrene proceeding in 75% over three steps. Formation of the key intermediates were 
achieved from 2.20 through a tosylation, Pictet-Spengler cyclization, hydrogenolysis, and 
Appel reactions in 55% and 48% yields over four steps to give 2.57 and 2.58, 
respectively. From these two substrates, the key p-phenolic C-alkylation afforded 
homoproaporphine 2.54 in 79% and 91% yields from 2.57 and 2.58, respectively. Finally, 
dienone-phenol rearrangement and subsequent N-tosyl deprotection gave the final 
homoaporphine 2.1 in 46% yield over two steps. The synthetic strategy of forming the 
biaryl bond through an efficient Suzuki cross coupling and subsequent formation of the 
homoproaporphine system via p-phenolic C-alkylation proceeded in high yields. This 
strategy allows access to the homoproaporphine motif in just eight steps with an overall 
yield of 33%. The use of the bromide and chloride leaving groups resulted in the same 
overall yield for each sequence.  
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Scheme 2.12. Summary of the total synthesis of homoaporphine 2.1 
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HUMAN AFRICAN TRYPANOSOMIASIS  
Chapter 3: Treating Human African Trypanosomiasis: Current and 
Future Methods 
3.1. HUMAN AFRICAN TRYPANOSOMIASIS  
 Human African trypanosomiasis (HAT), also known as African sleeping sickness, 
is a disease caused by the protozoan Trypanosoma brucei. Transmitted via the bite of the 
tsetse fly in Sub-Saharan Africa, HAT affects an estimated 10,000 - 30,000 individuals 
annually, with more than 60 million inhabitants at risk of infection.80 There are two sub-
species of the parasite that are known to infect humans, Trypanosoma brucei gambiense 
and Trypanosoma brucei rhodesiense. The former affects central and western Africa and 
accounts for between 95 - 98% of reported HAT cases.81 The disease progresses through 
two stages, and if left untreated, it is uniformly fatal. 
 The early, hemolymphatic stage, occurs when the parasite is restricted to the 
blood and lymph system, and is characterized by symptoms including, fevers, headaches, 
itching, joint pain, and swollen lymph nodes. This stage can last anywhere from months 
to years after the initial infection by T. brucei gambiense. Conversely, the first stage of 
the disease arising from the infection of T. brucei rhodesiense only lasts a couple of 
weeks before progression to the second stage occurs. The second, meningoencephalitic 
stage, results from the parasite entering the central nervous system (CNS) and crossing 
the blood brain barrier.82 This causes severe neurological symptoms including allodynia, 
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sensory-motor disruptions, sleep disturbances, and hyperalgesia. If left untreated this 
second stage will result in coma and ultimately, death.83 
3.1.1. Current HAT Treatments 
 Current drug treatments for both early and late stage HAT are problematic. Given 
that diagnosis of the disease requires the microscopic analysis of an infected fluid or 
tissue sample and that rural areas are the most heavily affected, often times the disease is 
left undiagnosed and untreated until neurological symptoms of the second stage appear.84 
Due to the fact that second stage is caused by the parasite crossing the blood brain 
barrier, drugs that do not cross the blood brain barrier are completely ineffective at 
treating this stage of the infection. Furthermore, approved drug treatments for the second 
stage of the disease are either highly toxic or very expensive.  
 One of the earliest HAT treatments, suramin (3.1) was discovered in 1922 and is 
still used to treat the first stage of T. brucei rhodesiense infections (Figure 3.1). A typical 
treatment regimen consists of slow intravenous infusion every three to seven days over a 
month’s time. Suramin (3.1) does not cross the blood brain barrier, and thus, is 
completely ineffective at treating second stage HAT infections. The mechanism of action 
towards T. brucei is currently unknown.85  
 Early stage infections due to T. brucei gambiense are most commonly treated with 
pentamidine (3.2) (Figure 3.1). Now considered to be the first line of treatment, one 
regimen of pentamidine (3.2) requires intramuscular injections once daily for 17 days. If 
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the disease is treated during the first stage, this drug is typically effective and relatively 
cheap. Notwithstanding, there are a few common side effects such as nephrotoxicity, 
hypoglycemia, hyperglycemia, and hypotension. The drug is thought to act through non-
specific binding to DNA, resulting in disruption of mitochondrial function.86 Pentamidine 
(3.1) does not cross the blood brain barrier, and thus, is ineffective for treatment of the 
disease in the second stage.  
Figure 3.1. Current HAT drugs suramin (3.1), pentamidine (3.2), melarsoprol (3.3), 
eflornithine (3.4), and nifurtimox (3.5) 
 
 
 
 Currently there are only two drugs available to treat HAT in the second stage of 
the infection. Of these two drugs, Melarsoprol (3.3) is an organoarsenical drug that was 
introduced in 1949.87 This drug is still the only treatment option for second stage HAT 
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caused by T. brucei rhodesiense. Melarsoprol (3.3) is highly toxic, with side effects 
typically mirroring that of arsenic poisoning, treatment leads to encephalopathy in 5-18% 
of patients with a mortality rate of 44-57% of said patients.80 However, due to the high 
cost and distribution challenges associated with the only alternative, melarsoprol (3.3) 
was still being used to treat as much as 88% of the gambiense HAT cases as recently as 
2003.84 The mechanism of action has been found to proceed through uptake of the drug 
via P2 transporters. Once in the parasite, melarsoprol (3.3) disrupts the trypanothione 
protein, which in turn alters the cellular redox environment, killing the parasite.88 
Recently, drug resistant T. brucei strains have led to treatment failure rates upwards of 
30% in some regions.89 
 The introduction of eflornithine (3.4) (Figure 3.1) in 1981 as a treatment for 
second stage HAT was a major breakthrough. Although eflornithine (3.4) only treats 
infections from T. brucei gambiense, it provides a much safer alternative to the arsenic 
based treatments. A repurposed drug, originally prescribed for the treatment of facial hair 
growth in women, eflornithine (3.4) acts through inhibition of ornithine decarboxylase, 
which plays an essential role in polyamine synthesis.86 The major drawback with this 
drug is the intense treatment regimen, requiring multigram injections (dosed at 100 
mg/kg) every six-hours for 14-days. This translates to roughly half a kilogram of the 
active drug per patient. Furthermore, the associated costs of a treatment regimen are very 
high, limiting availability in affected regions.90 Recently, through support from the World 
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Health Organization (WHO), kits used to treat two 40 kg individuals were made available 
at a cost of $1,420 (US).91 
 A recent advancement, that has now become the first line of defense against 
second stage T. brucei gambiense HAT cases, is the use of nifurtimox (3.5) (Figure 3.1) 
eflornithine (3.4) combination therapy (NECT). Nifurtimox (3.5) is a drug currently used 
to treat Chagas disease (Trypanosoma cruzi), that failed clinical trials as a standalone 
treatment for HAT.84 An NECT regimen consists of oral administration of nifurtimox 
(3.5) three times a day for 10-days in conjunction with intravenous eflornithine (3.4) 
administration. The major advantage to NECT is that it requires significantly smaller 
quantities of eflornithine (3.4) per regimen, only requiring IV injections every 12-hours 
for seven-days at 200 mg/kg.86 This cut the total cost of a treatment regimen roughly in 
half, kits of four treatments for individuals weighing 36 kg are available through the 
WHO at a cost of $1,440 per kit.91 The combination of these drugs toxic side effects, 
limited availability, and the ever-increasing prevalence of drug resistant parasite strains 
justify the desperate need for new, safer and cheaper HAT treatments.  
3.1.2. Current HAT Drug Candidates  
Currently, there are three drug candidates under clinical evaluation as potential 
HAT treatments. Originally discovered by Hoechst in the 1970s, fexinidazole (3.6) 
(Figure 3.2) was found to have trypanocidal activity.92 However, fexinidazole (3.6) was 
not evaluated for clinical use until a rediscovery by the Drugs for Neglected Diseases 
initiative (DNDi) in 2006. The compound exhibited in vitro activity against a number of 
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laboratory and clinical T. brucei strains with an IC50 (50% inhibition concentration) 
ranging from 0.30 to 0.93 µg/mL. Though considerably less efficacious than melarsoprol 
(3.3) (IC50 = 0.003 µg/mL), fexinidazole (3.6) displayed a significant reduction in 
toxicity. Furthermore, it cured in vivo mouse models when dosed orally at 50 mg/kg 
twice a day or at 100 mg/kg once per day.93 Fexinidazole (3.6) has since entered clinical 
trials in France, and if successful, it will become the first oral treatment for stage two 
HAT.85  
In the early 2000s, Anacor Pharmaceuticals discovered that benzoxaborole-6-
carboxamide compounds are potent inhibitors against T. brucei strains in vitro. 
Optimizing the pharmacokinetic properties through medicinal chemistry studies led to the 
discovery of SCXY-7158 (3.7) (Figure 3.2).85 Subsequent in vivo studies showed a 100% 
cure rate in mice following a seven-day regimen of i.p. injections dosed at 25 mg/kg. 
These studies found that drug concentrations in the brain remained well above the 
minimum inhibitory concentration (MIC = 0.95 µg/mL) for 24 hours, indicating that 
SCYX-7158 (3.7) could be useful towards the treatment of stage two HAT. In 2012, 
SCYX-7158 (3.7)  entered Phase II/III clinical trials, for evaluation of efficacy in 
humans.86 
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Figure 3.2. HAT treatments currently under clinical evaluation  
 
 
 Bisamidine compounds, such as pentamidine (3.2), have long been known to treat 
HAT. Recently, phase III clinical trials of the bisamidine pafuramidine (3.8) have 
concluded (Figure 3.2).94 This trial found that pafuramidine (3.8) was comparable to 
pentamidine (3.2) in treatment efficacy, curing 84% of patients, as compared to 89% 
cured for pentamidine (3.2). However, pafuramidine (3.8) exhibited lower levels of 
nephrotoxicity, with respect to pentamidine (3.2). Given the negative side-effects of 
pentamidine (3.2), pafuramidine (3.8) could provide a safer treatment alternative for first 
stage HAT infections.  
3.2. AMINOACYL-TRNA SYNTHETASES AS DRUGGABLE TARGETS  
 
 A rapidly emerging method for the treatment of infectious diseases is the design 
of drugs that inhibit aminoacyl-tRNA synthetases (aaRS) of pathogenic organism. Due to 
the important role that aaRS play in protein synthesis, their inhibition is detrimental to 
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cell viability.95 This makes aaRS enzymes particularly attractive drug targets for several 
reasons.96 
1. The evolutionary divergence between prokaryotic and eukaryotic aaRS enzymes 
has led to significant structural differences, which allows for the ability to 
selectively inhibit prokaryotic aaRS. 
2. Many aaRS enzymes are highly conserved across most pathogenic bacterial 
strains, leading to the potential design of compounds with broad-spectrum 
antibiotic activity profiles. 
3. The 20 different aaRS enzymes found within most pathogenic bacteria lead to 20 
different potentially druggable targets. 
4. Most of these enzymes are soluble, stable, and easily purified on large scale from 
recombinant expression systems, thus allowing for easy in vitro evaluation.  
5. X-ray structures for most of the aaRS enzymes have been solved, therefore 
allowing a platform for rational drug design approaches.  
This approach has been validated through the success of the antibiotic mupirocin (3.9), 
which is currently used as a topical treatment against methicillin resistant Staphylococcus 
aureus (MRSA) (Figure 3.3). Mupirocin (3.9) selectively inhibits the isoleucyl-tRNA 
synthetase (IleRS) of archaea and bacteria, resulting in prokaryotic cell death, with no 
observable effect to eukaryotic IleRS.97,98  
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Figure 3.3. Antibiotic mupirocin (3.9), a selective aaRS inhibitor  
 
3.2.1. Aminoacyl-tRNA Synthetases In Protein Translation 
 
 The major role of aaRS enzymes is to charge a specific tRNA with the respective 
amino acid for use in protein translation. This process occurs in two main steps. In the 
first step, the respective amino acid (AA) and a molecule of ATP bind to the aaRS 
(Equation 3.1). Attack of the amino acid carboxylate onto the a-phosphate of the 
proximal ATP, forms the aaRS bound amino acid-adenylate (aaRS•AA•AMP) with 
concomitant leaving of a molecule of pyrophosphate (PPi). In the second step, the 
hydroxyl group of a terminal adenosine from the respective tRNA adds into the amino 
acid, resulting in 3’-esterification of the amino acid by the tRNA, and the displacement of 
a molecule of AMP (Equation 3.2). Finally, this charged tRNAAA molecule is released 
from the aaRS and can bind to the translation elongation factor for transport to the 
ribosome for subsequent translation.99  𝑨𝑨 + 𝑨𝑻𝑷 + 𝒂𝒂𝑹𝑺	 ⇋ 𝒂𝒂𝑹𝑺 • 𝑨𝑨 • 𝑨𝑴𝑷 + 𝑷𝑷𝒊 (3.1) 𝒂𝒂𝑹𝑺 • 𝑨𝑨 • 𝑨𝑴𝑷 + 𝒕𝑹𝑵𝑨	 ⇋ 𝒂𝒂𝑹𝑺 + 𝒕𝑹𝑵𝑨𝑨𝑨 + 𝑨𝑴𝑷 (3.2) 
 
 
O
HO
OH
O
O ONa
O
O
OH
mupirocin (3.9)
 
 
 
75 
3.2.2. Previously Reported Methionyl-tRNA Synthetase Inhibitors 
 
 In the design of antibiotics that possess novel mechanisms of actions, the selective 
inhibition of bacterial methionyl-tRNA synthetase (MetRS) is particularly attractive. The 
MetRS enzyme is unique, compared to other aaRS enzymes, in that MetRS is not only 
essential for translation elongation, but is also critical for translation initiation. Given that 
methionine is the first amino acid in protein synthesis, the disruption of a cells ability to 
charge tRNAMet has the potential to completely shut down protein synthesis within the 
cell.100 
 Through a series of a high throughput screening (HTS) experiments, it has been 
shown that the 1,3-diaminoquinolinone motif is quite effective at inhibiting bacterial 
MetRS. The potential value of this structural motif for MetRS inhibition, led Lee and 
coworkers pursue structure-activity relationship (SAR) studies towards optimizing these 
compounds. They discovered that compound 3.10 (Figure 3.4) efficiently inhibited S. 
aureus MetRS, with an IC50 = 1.09 nM. Subsequent cell assays showed that this 
compound possessed in vitro activity against MRSA with a 50% effective concentration 
(EC50) of 16 nM, and was even more potent towards Enterococcus faecalis (MIC = 0.5-1 
nM).101 
 A separate HTS experiment and subsequent SAR lead optimization studies, 
identified REP8839 (3.11) (Figure 3.4) as a potent MetRS inhibitor towards gram 
positive and gram negative bacteria. Currently, REP8839 (3.11) is being prepared for 
clinical trials as a topical antibiotic with particular interest in its activity against 
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mupirocin-resistant MRSA. Preclinical evaluations have found that REP8839 (3.11) 
exhibits a very good broad spectrum antibiotic profile. The MIC values for a number of 
bacterial  strains were determined: S aureus strains ranged from 0.033 µM to 2.2 µM, a 
number of Streptococcus species (including pneumoniae) had a MIC from 0.015 µM to 
2.2 µM, and Enterococcus faecalis as well as Enterococcus faecium had MIC from 0.033 
µM to 0.26 µM.98 Following reports of MetRS inhibition in novel antibiotics, and the 
power of the 1,3-diaminoquinolinone motif in this respect, it is not surprising that studies 
of these compounds towards their use for the treatment of neglected diseases would soon 
follow. 
Figure 3.4. Examples of previous bacterial MetRS inhibitors 
 
3.2.3. Trypanosoma brucei MetRS Inhibition 
 
 Recent studies suggest that inhibition of MetRS in T. brucei could be a useful 
method to treat HAT. Shibata et. al. demonstrated, through RNAi knockdown of the 
single T. brucei methionyl-tRNA synthetase (TbMetRS) enzyme, that inhibition of 
TbMetRS is deadly to the parasite, and thus a potentially useful method to treat HAT.102 
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This group designed the first reported class of TbMetRS selective inhibitors, coined the 
aminoquinolinone-based inhibitors (ABIs), which have the general structure shown in 
Figure 3.5. The most potent of these ABIs was 3.12 with an EC50 of 4 nM in T. brucei 
cell assays.102,103 Unfortunately, due to the poor bioavailability of these ABIs, they were 
unable to cross the BBB, and would therefore be ineffective at treating late stage HAT. 
Figure 3.5. General structures of aminoquinolinone-based (ABI) and urea-based (UBI) 
TbMetRS inhibitors 
 
 
 A related class of TbMetRS inhibitors from the same group was the urea-based 
inhibitors (UBIs) (Figure 3.5). Of these inhibitors, the most efficacious was found to be 
3.13 with an EC50 = 150 nM for in vitro T. brucei assays.82,104 While the UBIs were less 
efficacious than the ABIs, with respect to TbMetRS inhibition, the UBIs possessed more 
favorable pharmacokinetic properties such as a high oral bioavailability and the ability to 
cross the BBB. Unfortunately, infected mice treated with 3.13 only survived an average 
of one day longer than control subjects.104  
 Given the recent problems with drug resistant T. brucei strains, new HAT 
treatments must mitigate the potential for the development of drug resist parasites. In a 
N
H
N
H
N
H
O
R
ABI
3.12: R = 3,5-dichloro
N
H
N
H
N
H
Ar
O
R
UBI
3.13: R = 3,5-dichloro
        Ar = 3-thiophene
 
 
 
78 
recent induced resistance study by Shibata, they found that T. brucei strains grown in 
vitro, in the presence of pentamidine (3.2), eflornithine (3.4), ABI 3.12, and UBI 3.13, 
respectively, developed resistance for pentamidine (3.2) and eflornithine (3.4) more than 
twice as quickly as 3.12 or 3.13. In fact, the T. brucei strains grown in 3.12 were unable 
to reach the experimental threshold of resistance over a 130-day period. Furthermore, 
previous studies have shown that drug resistance towards pentamidine (3.1) and 
eflornithine (3.4) arises from a mutation to the respective membrane transport protein, 
thus impeding the uptake of each drug into the parasite.105,106 However, resistance 
towards 3.12 and 3.13 was found to arise from an overexpression of TbMetRS within the 
resistant T. brucei strains. The overexpression of TbMetRS resulted in a diminished 
ability of the resistant parasite to grow in vitro, thereby greatly reducing the capability of  
these strains to infect mouse models.107 This study showed that a HAT treatment, which 
inhibits TbMetRS, could lead to the slower formation of drug resistant parasites with a 
weakened ability to infect a host, relative to the pentamidine (3.1) or eflornithine (3.4) 
resistant parasites. These findings have created an academic footrace towards the develop 
new HAT treatments targeting TbMetRS.  
3.3. MULTICOMPONENT ASSEMBLY PROCESS (MCAP): A COMBINATORIAL APPROACH 
TO DRUG DISCOVERY  
3.3.1. Diversity Oriented Synthesis 
 
 In the search for new medicines or drug lead compounds, the diversity oriented 
synthesis (DOS) approach is commonly used. In these studies, a wide range of structural 
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motifs are accessed through a short series of synthetic manipulations. Often used to 
develop libraries of structurally diverse compounds that can then undergo biological 
screening, this method has shown great utility in discovering new potential drug lead 
compounds.108–112  
 Typically, a DOS scheme will involve a reaction or sequence of reactions that can 
be used with a number of substrates tolerating a range of functional groups. Subsequent 
manipulations of these functional groups allows for the assembly of a wide range of 
different heterocyclic moieties. Finally, diversification of each unique scaffold using 
strategically placed functionalities, allows for the expedient synthesis of libraries of 
structurally diverse compounds. These synthetic strategies are referred to as “build, 
couple, pair” (Scheme 3.1).112 Namely, the starting materials are “built” by installing the 
requisite functional groups for subsequent cyclizations and derivatization. This is 
followed by “coupling” of these materials to form the cyclization precursors. Finally, the 
functional groups on these precursors are “paired” in the sense that cyclization and/or 
derivatization of the chosen functional groups will lead a diverse set of structural 
motifs.112,113  
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Scheme 3.1. Schematic illustration of the “build, couple, pair” strategy in DOS studies 
 
3.3.2. MCAP vs. MCR 
 
 In order to quickly access these chemically diverse libraries the use of 
multicomponent assembly processes (MCAP) and multicomponent reactions (MCR) is 
key. Multicomponent assembly processes (MCAP) refer to one-pot procedures in which 
three or more substrates and/or reagents are added in a specific sequence to carry out the 
given transformation(s).114–118 In contrast to the sequential nature of the MCAP, 
multicomponent reactions (MCR) require the simultaneous addition of three or more 
substrates and/or reagents to perform the given transformation(s). These types of 
reactions utilize relatively simple building blocks to facilitate cyclization reactions of the 
paired functional groups. These powerful methods can quickly access chemical libraries 
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possessing a significant degree of molecular complexity, and have been extensively 
reviewed.40–50 
3.4. PREVIOUS WORK IN THE MARTIN LAB 
3.4.1. Vinylogous Mannich Reaction: MCAP Inspiration 
 
Early work in the Martin lab, focused on the synthesis of heteroyohimbine 
alkaloids (±)-tetrahydroalstonine (3.14), (±)-cathenamine (3.15) and the corynantheioid 
alkaloid (±)-geissoschizine (3.16) (Figure 3.6), eventually led to the development of a 
highly generalizable MCAP procedure. The synthesis of these natural products revolved 
around a key MCAP involving a vinylogous Mannich reaction to form a triene that 
underwent an intramolecular Diels-Alder cycloaddition.130,131   
Figure 3.6. Natural products that inspired the Martin group MCAP procedure 
 
 
In this study, dihydro-b-carboline 3.17 was treated sequentially with trans-
crotonoyl chloride and 1-[(trimethylsilyl)oxy]butadiene to give triene 3.18 (Scheme 3.2). 
Holding a solution of 3.18 in mesitylene under reflux gave a mixture of cis:trans isomers 
(9:1, ring fusion) in 89% yield over two steps, with 3.19 as the major product. From 3.19 
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a two-step procedure previously used in the Martin laboratory132–134 installed the vinyl 
methyl ester moiety in 66% yield to give intermediate 3.20. 
Scheme 3.2. Martin synthesis of common intermediate 3.20 
 
 
The synthesis of intermediate 3.20 elegantly set the stage for quick access to the 
heteroyohimbine and corynantheioid alkaloids. Treatment of 3.20 with alane followed by 
addition of 2% methanolic acetic acid and excess sodium cyanoborohydride gave (±)-
tetrahydroalstonine (3.14) in 90% yield (Scheme 3.3). Alternatively, treatment of 3.20 
with lithium diethoxyaluminum hydride gave (±)-cathenamine (3.15) in 70% yield. 
Finally, (±)-geissoschizine (3.16) was synthesized in a two-step procedure, by treating 
3.20 with sodium amide, followed by the sequential addition of lithium 
hexamethyldisilazide, triethylaluminum, and diisobutylaluminum hydride, to give (±)-
geissoschizine (3.16) in 35% yield.  
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Scheme 3.3. Synthesis of heteroyohimbine and corynantheioid alkaloids 
 
 
 The total syntheses of the three title compounds were elegantly achieved in five- 
to six-steps from commercially available dihydro-b-carboline (3.17). The vinylogous 
Mannich reaction with trans-crotonoyl chloride and 1-[(trimethylsilyl)oxy]butadiene 
installed the requisite functionalities that underwent the intramolecular Diels-Alder 
cycloaddition, allowing access to the heteroyohimbine and corynantheioid cores in just 
two steps with high yield. This sequence was later generalized as a MCAP to synthesize a 
diverse library of small molecules with the goal of discovering new drug leads.135 
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3.4.2. MCAP and NIH Molecular Libraries Program 
Scheme 3.4. Generalized Martin MCAP strategy  
 
 
 Almost two decades after the syntheses of heteroyohimbine and corynantheioid 
natural products, the same synthetic strategy was generalized to form an extensive library 
of small molecules. These compounds were then screened in a number of cell and 
enzyme based assays to identify new potential drug lead compounds. Scheme 3.4 shows 
the generalized strategy in which arylaldehydes (R3CHO) were condensed with a primary 
amine (R1NH2) to form an imine in situ, and acylation (R2COX) led to a transient acyl-
iminium ion that was subsequently attacked by a nucleophile (Nuc). In each example of 
this MCAP procedure the substituents of each fragment were carefully selected to 
predispose the resulting motif to a variety of cyclizations and/or cycloadditions. The 
aforementioned cyclization reactions included, ring closing metathesis, intramolecular 
Heck coupling, Dieckmann condensation, intramolecular Diels-Alder cycloadditions, 
[3+2]-dipolar cycloadditions, and intramolecular Friedel-Crafts alkylations. A library of 
more than 1,000 functionalized heterocyclic compounds was synthesized throughout the 
course of this work.136–148  
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3.4.3. MCAP Leads to Trypanocidal Hit Compounds 
 
 Throughout the course of our MCAP based DOS program, a number of 
tetrahydro-b-carboline based small molecules were synthesized.135,149 In one iteration of 
this sequence, dihydro-b-carboline (3.17) was treated with trans-crotonoyl chloride and 
TBS-silyl enol ether in the presence of TMS-triflate to give 3.21 (Scheme 3.5). Crude 
3.21 was then heated with N-methylhydroxylamine hydrochloride and triethylamine in 
toluene to afford the [3+2]-dipolar cycloaddition adduct 3.22 in 60% yield over two 
steps. At this point, 3.22 was then reduced with lithium aluminum hydride to give 3.23 in 
98% yield. Both 3.22 and 3.23 were treated with nickel boride to give b-amino alcohols 
3.24 and 3.25 in 68% and 64% yields, respectively. Compounds 3.24 and 3.25 were 
further derivatized at the secondary amine position to form the corresponding amides, 
ureas, tertiary amines, and sulfonamides.  
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Scheme 3.5. Dihydro-b-carboline MCAP diversification  
 
 
 This approach provided a library of >180 of yohimbine- and corynantheioid-type 
compounds, which were screened for potential biological activities. These tests identified 
two compounds, 3.26 and 3.27, that inhibited TbMetRS in sub-micromolar concentrations 
with IC50 value of 586 nM and 297 nM, respectively (Figure 3.7). Further evaluation in T. 
brucei cell based assays, found that 3.26 and 3.27 displayed EC50 values of 2 µM and >10 
µM, respectively. Given the recent success of aaRS inhibitors in disease treatment and 
the evidence supporting TbMetRS as a viable drug target, we decided to undertake 
studies towards the optimization of 3.26 and 3.27 as potential drug leads for the treatment 
of human African trypanosomiasis.  
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Figure 3.7. Trypanocidal hit compounds from MCAP DOS 
 
 
In attempting to develop a more effective drug candidate for the treatment of 
HAT, our first objective was to design compounds with increased TbMetRS inhibition. 
This is being accomplished through the systematic design of compounds that include or 
exclude given functionalities of the hit compounds. The resulting IC50 and EC50 values of 
these new compounds will reveal which functionalities are beneficial or detrimental 
towards TbMetRS inhibition. A secondary objective is to simplify the molecular 
complexity of the new compounds, while maintaining biological activity. This will allow 
for a more efficient synthesis, thus improving the likelihood of the compound being 
economically viable for large-scale production. Given the low profit margins of drug 
candidates designed to treat neglected tropical diseases, a synthetically cheap and easy 
target is important.  
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Chapter 4: Studies Towards New Compounds with Trypanocidal 
Activity 
4.1. RATIONAL DRUG DESIGN: LEAD COMPOUND  
 
 At the onset of this project, we wanted to optimize our initial hit compounds that 
inhibited the TbMetRS enzyme as well as improve their activity towards killing the 
parasite on a cellular level. To this end, we took careful consideration of the molecular 
features from our active compounds, as well as the molecular features of structurally 
similar compounds that were inactive towards TbMetRS. We also analyzed previously 
reported crystal structures of inhibitor-bound TbMetRS to aid in the design of our new 
inhibitors.  
4.1.1. Previous Martin Group Compounds: What Works and What Doesn’t  
 
 When designing new compounds with the goal of optimizing biological activity, it 
is arguably just as important to consider the molecular functionalities of inactive 
compounds, as it is the active compounds. To this end, there were a number of 
compounds structurally similar to our hit compounds 4.1 - 4.3 (Figure 4.1), that were 
synthesized and tested during the course of our MCAP based DOS program that informed 
the current project. 
  
 
 
 
89 
Figure 4.1. Initial hit compounds and relevant inactive compounds 
 
 
 By considering the compounds shown in Figure 4.1, we started to get a 
preliminary idea of the structure activity relationship (SAR) of our scaffold relative to 
TbMetRS inhibition. Compounds 4.1, 4.2, and 4.3 displayed inhibition of TbMetRS at 
sub-micromolar concentrations. Each of these compounds possesses a 2-piperidinone 
motif with d-benzylamino alcohol functionality. Interestingly, we found a large drop in 
activity towards TbMetRS inhibition with compounds 4.4 - 4.6. Compound 4.4 was the 
only compound of these three to show any activity against TbMetRS, with an IC50 value 
N
H
N
O
H
N
OH
O
O
N
H
N
O
H
N
OH
Cl
Cl
N
H
N
O
H
N
OH
Cl
N
H
N
O
H
N
OH
NH
O
Cl
Cl
4.2
TbMetRS IC50 = 297 nM
T. brucei EC50 >10 µM
N
H
N
O
H
N
OH
N
H
N
H
N
OH
4.1
TbMetRS IC50 = 586 nM
T. brucei EC50 = 2 µM
4.3
TbMetRS IC50 = 975 nM
4.4
TbMetRS IC50 ~ 10,000 nM
4.5
TbMetRS IC50 > 12,000 nM
4.6
TbMetRS IC50 > 12,000 nM
O
Cl
Cl
Cl
Cl
 
 
 
90 
around 10 µM. Structurally, the only difference between the active compounds and 
4.4/4.5 was the N-carbonyl moiety in the D-ring. Both the urea functionality in 4.4 and 
the amide functionality of 4.5 reduce the basicity of the nitrogen substituent and led to a 
steep drop in biological activity. Conversely, when the 2-piperidinone motif was reduced 
to the basic piperidine, as in 4.6, we observed a complete loss of TbMetRS inhibition up 
to 12 µM concentration. These results led to the hypothesis that the benzyl-substituted 
tertiary amine and the 2-piperidinone moieties were required for effective inhibition of 
TbMetRS. 
 As a quick follow up to the previous set of compounds, the structurally simplified 
compounds 4.7 - 4.10 were synthesized and evaluated for inhibition of TbMetRS (Figure 
4.2). These compounds were designed to test whether a N-benzyl-4-amino-2-piperidinone 
core would retain biological activity. Unfortunately, all of these compounds were 
completely inactive towards TbMetRS. There are two key molecular differences between 
compounds 4.7 - 4.10 and our active compounds 4.1 - 4.3. The first, is that the N-
indolylethyl moiety on the 2-piperidinone core was changed to an N-benzyl group. This 
benzyl group adds hydrophobicity to the compounds and lacks a hydrogen bond donor, 
which was present in the indole moiety, and could contribute to the observed loss in 
binding towards TbMetRS. Secondly, the methylene hydroxy substituent at the a-
position of the 2-piperdinone was omitted. This also removed a potential hydrogen bond 
donor from the core and could contribute to loss in binding affinity towards TbMetRS.  
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Figure 4.2. Inactive 4-amino-2-benzylpiperidinone compounds 
 
4.1.2. Crystallographic Data in the Design of Target Compound 
 
 With our follow up compounds showing no inhibition of TbMetRS, we decided to 
look at crystallographic data from previously reported TbMetRS inhibitors. The crystal 
structure of UBI inhibitor 4.11 bound to TbMetRS is shown in Figure 4.3. The crystal 
structure shows 4.11 binding into two discrete pockets within the TbMetRS active site. 
The 3,5-dichlorobenzyl moiety occupies the methionine binding pocket and inhibits 
TbMetRS through competitive binding. Interestingly, the opposite termini of 4.11 
contains a planar heteroaromatic moiety (3-thiophene), which binds in what is referred to 
as the “auxiliary binding pocket”.103 This auxiliary binding pocket was found to form 
upon complexation of 4.11 with TbMetRS, thus leading to the proposal of an induced-fit 
mode of binding for this protein-ligand interaction. Based on the crystallographic data, 
Shibata suggested that a planar heteroaromatic moiety is required at the terminus of the 
inhibitor in order to fit into the auxiliary binding pocket. 82,103  
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Figure 4.3. X-ray crystal structure of UBI inhibitor 4.11 bound to TbMetRS (pdb: 4mvw) 
 
 
 
 In the process of designing our first target compound, we considered how the 
active compound 4.1 might be binding to TbMetRS. Given that 4.1 and 4.11 both possess 
a dichlorobenzylamine substituent on one terminus of the molecule and a heteroaromatic 
moiety at the other, we postulated that 4.1 could be binding to TbMetRS in an analogous 
fashion to 4.11. To obtain a graphical representation of how 4.1 might be binding to 
TbMetRS, colleague Lance Lepovitz performed shape complementary-based molecular 
docking studies. Even though these docking studies did not predict binding energies, they 
provided a visual representation of how 4.1 might bind to TbMetRS (A, Figure 4.4).   
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Figure 4.4. A) Shape complementary binding of 4.1 to TbMetRS. B) Overlay of 
TbMetRS bound to 4.11 (white) and predicted binding of 4.1 (pink) 
 
 
(A) 
 
 
(B) 
 
 In analyzing the graphical representation of 4.1 bound to TbMetRS, we also 
compared the predicted binding for 4.1 to the actual mode of binding for 4.11 (B, Figure 
4.4). We immediately noticed that the tetracyclic yohimbine-like core of 4.1 is quite rigid 
and contains significantly fewer degrees of rotational freedom than 4.11. With this 
notion, we hypothesized that a conceptual “opening” of the tetrahydro-b-carboline ring to 
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give the analogous tryptamine derivative (Figure 4.5), would increase the conformational 
flexibility and possibly lead to an increase in binding to TbMetRS. 
Figure 4.5. Conceptual “opening” of 4.1 to give our initial target compound 4.12 
 
 
 At this point, Lance Lepovitz performed an analogous set of docking studies to 
predict how 4.12 might bind to TbMetRS. The shape complementary predicted binding of 
4.12 to TbMetRS is shown in Figure 4.6 (A), and an overlay of predicted binding poses 
of 4.1 and 4.12 is given in Figure 4.6 (B). In comparing the overlay of the predicted 
binding of 4.1 and 4.12, it is clear that the two compounds could adopt significantly 
different conformations upon binding. Though these predicted binding modes are not 
quantitative representations, they did provide sufficient impetus to undertake studies 
towards the synthesis and evaluation of 4.12 as a new TbMetRS inhibitor. 
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Figure 4.6. A) Shape complementary binding of 4.12 to TbMetRS. B) Overlay of the 
predicted binding of 4.12 (orange) and 4.1 (pink) 
 
 
(A) 
 
 
(B) 
 
4.2. SYNTHESIS OF INITIAL TARGET COMPOUND  
4.2.1. Target Inhibitor: Retrosynthetic Analysis 
 
 The initial synthetic strategy to access our target compound 4.12 was designed to 
allow late stage functionalization of the heteroaromatic and benzylamine moieties, 
thereby allowing for easy access to diversification (Scheme 4.1). We envisioned that 4.12 
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would arise from 4.13 through nucleophilic substitution of the 2-piperidinone nitrogen 
atom, followed by reductive N-O bond cleavage and reductive amination. Condensation 
of N-methylhydroxylamine onto 4.14 and subsequent 1,3-dipolar cycloaddition would 
lead to the isoxazolidine 4.13. At this stage, we envisaged two potential routes to access 
aldehyde 4.14. 
Scheme 4.1. Retrosynthetic analysis of target compound 4.12 
 
 
 The retrosynthesis of the two proposed routes to access aldehyde 4.14 are shown 
in Scheme 4.2. In the first route (A), 4.14 would arise from an MCAP-type procedure 
utilizing crotonoyl chloride and a vinyl silyl enol ether with triazine 4.15. This route 
would lead to an N-benzyl protected amine requiring an additional deprotection step. 
Notably, this route would establish the amide moiety and the free aldehyde in one step. In 
the second route (B), amination of 3-bromopropionaldehyde dimethyl acetal (4.16), 
followed by acylation and deprotection of the aldehyde would give 4.14 in three steps.  
 
 
HN
N
O
O
N
H
O
O
N
H
N
O
N
OH
Cl
Cl
4.12 4.13 4.14
 
 
 
97 
Scheme 4.2. Retrosynthetic analysis of intermediate aldehyde 4.14 
 
4.2.2. Attempted Synthesis of Aldehyde Precursor  
 
 We first set out to synthesize aldehyde 4.14 through an MCAP-type procedure. 
Benzyl triazine 4.15 was synthesized by condensation of benzylamine and formaldehyde 
in 64% yield (Scheme 4.3). All attempts at in situ acylation of triazine 4.15 and enol ether 
addition into the resulting transient iminium ion failed to yield more than trace amounts 
of the desired product 4.17.  
Scheme 4.3. Attempted synthesis of aldehyde 4.17 
 
 
 Attempts to access cycloaddition precursor 4.14 with the other proposed route 
also faced problems. Amination of 4.16 with methanolic ammonia in a sealed tube gave 
virtually quantitative conversion to hydrobromide 4.18 (Scheme 4.4). Subsequent 
acylation attempts using either crotonoyl chloride or acryloyl chloride (not shown) were 
low yielding. This transformation was plagued by two major problems. First, the desired 
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product 4.19 was water soluble, leading to the isolation of only trace quantities of 4.19 
after aqueous work-up. Second, 4.19 was unstable to silica gel chromatography, leading 
to complex mixtures of 4.19, free aldehyde 4.14, and various aldol byproducts. After 
some experimentation, we were able to isolate 4.19 in 67% yield upon treatment of 4.18 
with crotonoyl chloride in a mixture of pyridine and dichloromethane followed 
immediately by a quick silica plug. However, despite this success, we were unable to 
cleanly isolate the aldehyde 4.14 upon treatment with acid.  
Scheme 4.4. Attempts towards the synthesis of aldehyde 4.14 
 
4.2.3. Target Inhibitor: Alternate Retrosynthetic Analysis 
 
 In the revised synthetic route towards inhibitor 4.12, we decided to introduce the 
indole moiety earlier in the synthesis. While this tactic would limit our ability to diversify 
the heteroaromatic moiety late in the synthesis, we speculated that early incorporation of 
the indole might add enough hydrophobicity to the intermediates to limit their solubility 
in water, thus allowing us to purify via aqueous extraction.  
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 In this route, 4.12 will be formed from reductive N-O bond cleavage and 
reductive alkylation of isoxazolidine 4.20. Isoxazolidine 4.20 will be accessed via the 
1,3-dipolar cycloaddition of 4.21 after aldehyde deprotection and condensation with N-
methylhydroxylamine. Finally, 4.21 will be prepared by the reductive amination of 4.22 
and 4.18. 
Scheme 4.5. Revised retrosynthetic analysis of target inhibitor 4.12 
 
4.2.4. Synthesis Indole-3-Acetaldehyde 
 
 We first needed to synthesize indole-3-acetaldehyde (4.22), because of the 
surprisingly high cost ($206 / 100 mg, Sigma-Aldrich). A Fisher-esterification of indole-
3-acetic acid (4.23) gave methyl indole-3-acetate (4.24) in essentially quantitative yield 
(Scheme 4.6). Subsequent reduction of 4.24 to indole-3-acetaldehyde (4.22) using 
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DIBAL proceeded in yields varying from 40% to 73%. We also found that the yield for 
this reaction dropped off precipitously on larger scales (>500 mg). The un-scalable and 
unpredictable nature of this reaction would lead to future studies directed towards 
circumventing this transformation. However, at the time, this reaction did provide 
sufficient quantities of 4.22 to pursue the route depicted in Scheme 4.5.  
Scheme 4.6. Synthesis of indole-3-acetaldehyde (4.22)  
 
4.2.5. Synthesis of Secondary Amide via Reductive Amination 
 
 With indole-3-acetaldehyde 4.22 and ammonium bromide 4.18 in hand, we next 
focused on the synthesis of tertiary amide 4.21. Reductive amination of 4.22 and 4.18 
proceeded with sodium cyanoborohydride to give secondary amine 4.25 in 89% yield 
(Scheme 4.7). Initially, acylation of 4.25 with crotonoyl chloride and triethylamine at 
either -78 ºC or 0 ºC gave the desired product 4.21 in 38% and 41% yields, respectively. 
However, the use of Hünig’s base in place of triethylamine at -78 ºC consistently gave 
4.21 in 71% yield.  
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Scheme 4.7. Synthesis of tertiary amide 4.21 
 
4.2.6. 1,3-Dipolar Cycloaddition 
 
 Previous attempts to remove the acetal of 4.19 revealed that the desired aliphatic 
aldehyde was likely to be unstable towards chromatographic conditions. With this in 
mind, we attempted a few procedures in which we tried to form aldehyde 4.26 in solution 
and isolate the crude material to carry onto the 1,3-dipolar cycloaddition. To this end, 
hydrochloric acid and oxalic acid in various solvents did not yield any quantifiable 
amounts of the desired aldehyde 4.26. While pondering this reaction, we realized the 
dimethyl acetal deprotection was reminiscent of the Pictet-Spengler cyclization discussed 
in Chapter 2. In the final iteration of the Pictet-Spengler reaction, catalytic trifluoroacetic 
acid in 2,2,2-trifluoroethanol (TFE) led to the deprotection of a dimethyl acetal in situ, 
which subsequently participated in cyclization. Following this idea, we tried similar 
conditions and found that treating 4.21 with catalytic trifluoroacetic acid in a mixture of 
TFE and water (3:1) gave virtually quantitative conversion to 4.26 (as judged by crude 
1H-NMR) (Scheme 4.8). Immediately following the isolation of crude 4.26, we subjected 
the material to 1,3-dipolar cycloaddition conditions. Heating a solution of crude 4.26, N-
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methylhydroxylamine hydrochloride, and triethylamine in ethanol under reflux, gave the 
desired isoxazolidine 4.20 in 30% yield.  
Scheme 4.8. Synthesis of isoxazolidine 4.20  
 
4.2.7. Synthesis of Secondary Amine via Glyoxylamide Reduction 
 
 Excited as we were to have isoxazolidine 4.20 in hand, the current synthetic route 
was not sufficiently scalable to meet our needs. In particular, the reduction of methyl 
indole-3-acetate (4.24) to indole-3-acetaldehyde (4.22) was a major bottleneck with 
respect to synthesizing gram-quantities of material. At the time, two approaches were 
attempted in parallel. First, we were attempting to synthesize 4.22 via oxidation of 
tryptophol. This transformation was only attempted twice and was quickly abandoned 
after positive results from our alternate approach (Scheme 4.9). 
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Scheme 4.9. Synthesis of amine 4.25 via glyoxylamide 4.27 reduction 
 
 
 In attempting to develop a scalable synthesis to amine 4.25, we found that the 
formation and reduction of glyoxylamide 4.27 was superior in terms of both yield and 
scalability. Treatment of indole with oxalyl chloride in ice-cold ether led to precipitation 
of the bright yellow indole-3-glyoxyl chloride. Adding a slurry of indole-3-glyoxyl 
chloride to an ice-cold solution of 4.18 and triethylamine gave clean conversion to 
glyoxylamide 4.27 in 97% yield (Scheme 4.9). Heating a solution of 4.27 and lithium 
aluminum hydride under reflux in tetrahydrofuran led to the formation of amine 4.25 in 
90% yield. Despite the fact that the previous reductive amination route was one-step to 
convert 4.18 to 4.25, this new route was far superior with respect to reproducibility, 
scalability, purification (no column chromatography required), and overall yield. 
4.2.8. Synthesis of Target Inhibitor  
 
 With a scalable route to amide 4.21 in hand, we focused on improving the yield of 
the 1,3-dipolar cycloaddition. We found that conditions previously reported for the 
synthesis of 4.1 – 4.6 worked well for our system.150,151 From amide 4.21, acetal 
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deprotection followed immediately by 1,3-dipolar cycloaddition of crude 4.26 using N-
methylhydroxylamine hydrochloride and triethylamine in toluene gave isoxazolidine 4.20 
in 85% yield over two steps (Scheme 4.10). We then used previously reported conditions 
for reductive N-O bond cleavage via in situ generation of nickel boride.140,144,150,151 
However, all attempts failed to yield anything more than trace amounts of the desired 
product 4.28. We then decided to try a more “classical” approach, and by heating a 
suspension of zinc dust and 4.20 in acetic acid, we obtained amino alcohol 4.28 in 91% 
yield. Finally, reductive alkylation of 4.28 and 3,5-dichlorobenzaldehyde with sodium 
cyanoborohydride and acetic acid gave the target compound 4.12 in 48% yield.  
Scheme 4.10. Synthesis of new inhibitor 4.12 
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4.3. BIOLOGICAL ACTIVITY: NEW INHIBITOR  
 
 Before we can comment on the biological activity of the new inhibitor 4.12, it 
must be noted that access to the previously utilized TbMetRS enzyme assay was no 
longer at our disposal. We are greatly appreciative and indebted to what became our new 
cell biology collaboration with the lab of Dr. Kojo Mensa-Wilmont of the University of 
Georgia. At the time, the Mensa-Wilmont lab was conducting T. brucei cell-based growth 
inhibition assays. This assay compared the cell densities of T. brucei cultures grown in 
the presence of inhibitors after 48 h, to that of the representative control cultures. In order 
to get a baseline of comparison for our new inhibitor, we first needed to know how 4.1 
performed in this growth inhibition assay. Compound 4.1 displayed a 50% growth 
inhibition (GI50) of 25.3 ± 0.5 µM and our target inhibitor 4.12 exhibited a GI50 of 4.3 ± 
0.4 µM (Figure 4.7). Upon determining the 5-fold increase in activity towards T. brucei 
growth inhibition of 4.12 with respect to 4.1, we immediately undertook SAR studies to 
investigate the molecular functionalities conducive to T. brucei activity, with the goal of 
improving efficacy towards T. brucei growth inhibition. 
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Figure 4.7. T. brucei growth inhibition of 4.1 and 4.12 
 
4.4. STRUCTURE ACTIVITY RELATIONSHIP  
Figure 4.8. Sites of derivatization for initial SAR study   
 
 
 
 When considering how to study the SAR of this scaffold, we first identified four 
key regions of 4.12 that could be chemically modified. After individually modifying each 
region, the resulting growth inhibition data will allow us to identify the optimal 
substituents in each region. Incorporation of these optimal substituents into future 
inhibitors would hopefully allow access to significantly more potent T. brucei inhibitors. 
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The first and easiest region to diversify was the substitution of the benzyl amine 
substituent, shown in red (Figure 4.8). By substituting various benzaldehyde derivatives 
in the last step of the synthesis, we could quickly access a diverse array of aromatic 
substitution patterns at this position. Secondly, we wanted to determine the role of the 
ethylene hydroxy side chain (blue). The alcohol functionality is a potential hydrogen 
bond donor, and we reasoned that if hydrogen bonding at this position with the protein is 
important for binding, then removing the alcohol should lead to a decrease growth 
inhibition. Next, we wanted to test the effects of the carbon linker length between the 
indole and the 2-piperidinone moieties (green) towards binding to TbMetRS. Given that 
the opposite termini of our inhibitors are possibly binding in two discrete pockets, we 
should be able to elucidate an optimal linker length to maximize binding affinity. Finally, 
we postulated that substitution of hydrogen bond donors and acceptors on the indole 
moiety (purple) might lead to increased hydrogen bonding interactions within the 
auxiliary binding pocket, which would improve binding to TbMetRS.  
4.4.1. Benzylamine Substitution: Part I. Synthesis 
 
 We first set out to synthesize a number of inhibitors with a variety of substitution 
patterns on the benzyl amine moiety. As shown in Figure 4.9, substituted benzylamine 
compounds 4.29 - 4.36 were synthesized utilizing the previous reductive alkylation 
protocol. The substituents were chosen for a few key reasons. First, we knew the 3,5-
dichloro and 3,4-methylenedioxy substitution patterns should be active based on the 
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activity of compounds 4.1 and 4.2. The unsubstituted benzylamine was chosen as a 
pseudo-negative control in that, according to previous reports,103 an electronegative atom 
in the methionine binding pocket is required for binding to the enzyme. Using the same 
logic, a 3-thiomethylbenzyl group was chosen to mimic the natural thiomethyl substituent 
of methionine. We also wanted to test a number of benzyl groups incorporating various 
methoxy and chloride substitution patterns. Accordingly, we prepared compounds 4.29 – 
4.36 for evaluation as T. brucei growth inhibitors (Figure 4.9).  
Figure 4.9. Synthesis of benzylamine substituted compounds 4.29 - 4.36 
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 The yields for this reductive alkylation step were consistently low. The major 
reason for these poor yields was due to intramolecular trapping of the iminium ion by the 
proximal alcohol. As shown in Figure 4.10, condensation of 4.28 with the given 
benzaldehyde will give the iminium ion 4.28a. The iminium ion can either be reduced to 
the desired tertiary amine 4.29 – 4.36 or the hydroxy substituent can add into the iminium 
ion to give the cyclic N-O-acetal 4.28b. All attempts to reduce N-O-acetal 4.28b failed to 
give the desired tertiary amines, thus the formation of 4.28b effectively shut down the 
desired reductive alkylation pathway.  
Figure 4.10. Reductive alkylation pathway and undesired side reaction 
 
4.4.2. Benzylamine Substitution: Part II. Biological Activity  
 
 The results of the T. brucei growth inhibition assay for compounds 4.29 – 4.36 are 
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between our initial target 4.12 and compounds 4.29 – 4.36, with most of these 
compounds exhibiting less than a 2-fold difference in GI50 values relative to 4.12. 
Compounds 4.29 and 4.35 were the two exceptions to this trend, with both compounds 
being completely inactive towards growth inhibition at the 10 µM threshold of this assay. 
Given that the 3-methoxy compound 4.32 and the 3,4,5-trimethoxy compound 4.34 were 
both single-digit micromolar growth inhibitors of T. brucei, the inactivity of the 3,5-
dimethoxy compound 4.35 was quite puzzling. Conversely, the inactivity of the 
unsubstituted analogue 4.29 was expected. From an SAR perspective, this result fit our 
hypothesis that substitution of the benzylamine moiety with an electronegative atom was 
necessary for binding. However, with most of the compounds in this series being 
equipotent to our initial compound 4.12, further conclusions about the SAR cannot be 
made.  
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Table 4.1. T. brucei growth inhibition data of substituted benzylamine derivatives 4.29 - 
4.36 
 
 
Compound Substitution (R-) GI50 (µM) 
4.12 3,5-dichloro 4.3 ± 0.4 
4.29 H > 10 
4.30 3-chloro-5-methoxy 4.8 ± 0.2 
4.31 3,4-methylenedioxy 3.9 ± 0.7 
4.32 3-methoxy 5.7 ± 0.4 
4.33 3-chloro 2.1 ± 0.2 
4.34 3,4,5-trimethoxy 8.1 ± 1.7 
4.35 3,5-dimethoxy > 10 
4.36 3-thiomethyl 2.3 ± 0.6 
 
4.4.3. Methylene Hydroxy Side Chain: Part I. Synthesis 
 
 To further understand the SAR of our compounds, we designed a set of 
derivatives to test the effects of the methylene hydroxy side chain towards T. brucei 
growth inhibition. To this end, we set out to synthesize the compounds shown in Figure 
4.10. By comparing the growth inhibition of compounds 4.37 and 4.38 to our lead 
compound 4.12, we hoped to develop an understanding of how the hydroxyl group might 
be participating in binding to TbMetRS.  
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Figure 4.11. Target methylene hydroxy side chain derivatives  
 
 
 The synthesis of methylene hydroxy inhibitor 4.37 is shown in Scheme 4.11 and 
commenced by the treatment of amine 4.25 with acryloyl chloride to give amide 4.39 in 
54% yield. Subsequent removal of the dimethyl acetal protecting group and 1,3-dipolar 
cycloaddition gave isoxazolidine 4.40 in 73% yield over two steps. Reductive N-O bond 
cleavage with zinc metal in acetic acid gave amino alcohol 4.41 in 80% yield. Finally, 
reductive alkylation of 4.41 with 3,5-dichlorobenzaldehyde gave 4.37 in 42% yield.  
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Scheme 4.11. Synthesis of methylene hydroxy inhibitor 4.37 
 
 
 Simultaneous to the synthesis of compounds 4.29 - 4.36, Lance Lepovitz 
synthesized an analogous series of nor-methylene hydroxy inhibitors, in which the a-
position of the lactam was unsubstituted. The synthesis of these inhibitors started from 
the conjugate addition of tryptamine into ethyl acrylate to give 4.42 in 90% yield 
(Scheme 4.12). Amide coupling of 4.42 with monoethyl malonate utilizing EDCI-
hydrochloride gave amide 4.43 in 88% yield. A one-pot, two-step procedure involving a 
Dieckmann cyclization and subsequent decarboxylation afforded b-keto-2-piperidinone 
4.44 in 64% yield. Finally, sequential reductive aminations with methylamine 
hydrochloride and substituted benzaldehydes led to nor-methylene hydroxy inhibitors 
4.38 and 4.45-4.51 in 50 - 80% yield.  
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Scheme 4.12. Synthesis of nor-methylene hydroxy compounds 4.38 and 4.45 – 4.51  
 
4.4.4. Methylene Hydroxy Side Chain: Part II. Biological Activity 
 
 The T. brucei growth inhibition assay results for compounds 4.37, 4.38, and 4.45 
– 4.52 are shown in Table 4.2. In comparing the analogous 3,5-dichlorobenzyl 
compounds 4.12, 4.37, and 4.38, we again found less than a two-fold difference in GI50 
values. Conversely, we did observe a decrease in growth inhibition with compounds 4.47, 
4.48, and 4.51, relative to the ethylene hydroxy analogues 4.31, 4.32, 4.36. From an SAR 
perspective, these results are inconclusive. If these compounds are indeed inhibiting T. 
brucei cell growth by inhibition of TbMetRS, then the fact that 4.12, 4.37, and 4.38 are 
equipotent would indicate that the ethylene hydroxy side-chain does not play a major role 
in protein binding. However, because compounds 4.47, 4.48, and 4.51 do not inhibit T. 
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brucei growth, whereas the analogous compounds 4.31, 4.32, and 4.36 do inhibit growth, 
might suggest that this series of compounds could be acting through an alternative 
mechanism of action.  
Table 4.2. T. brucei growth inhibition of methylene hydroxy and nor-methylene hydroxy 
analogues  
 
 
Compound Substitution (R-) GI50 (µM) 
4.12 3,5-dichloro 4.3 ± 0.4 
4.37 3,5-dichloro 5.5 ± 0.4 
4.38a 3,5-dichloro 7.1 ± 0.7 
4.45a H >10 
4.46a 3-chloro-5-methoxy 6.2 ± 0.2 
4.47a 3,4-methylenedioxy >10 
4.48a 3-methoxy >10 
4.49a 3-chloro 9.0 ± 0.4 
4.50a 3,5-dimethoxy >10 
4.51a 3-thiomethyl >10 
a Compounds synthesized by Lance Lepovitz 
4.4.5. Carbon Linker Length: Part I. Synthesis 
 
 In continuing SAR studies of our compounds as T. brucei growth inhibitors, we 
turned our attention to synthesizing compounds with the goal of optimizing the carbon 
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linker length between the indole and 2-piperdinone moieties. Given the fact that known 
TbMetRS inhibitors have been shown experimentally to bind into two distinct binding 
pockets, we designed compounds 4.52 and 4.53 to determine the optimal carbon linker 
length for binding (Figure 4.11).  
Figure 4.12. Carbon linker length analogues 4.52 and 5.53 
 
 
 The synthesis of inhibitor 4.52, which contains a three-carbon linker, was similar 
to the previous growth inhibitors. Treatment of indole-3-propionic acid (4.54) with 
thionyl chloride, followed by a reaction with amine 4.18 in the presence of triethylamine, 
gave amide 4.55 in 97% yield (Scheme 4.13). Lithium aluminum hydride reduction of 
4.55 and subsequent acylation with crotonoyl chloride gave amine 4.56 and amide 4.57 in 
87% and 62% yields, respectively. Removal of the dimethyl acetal protecting group and 
1,3-dipolar cycloaddition proceeded smoothly to give isoxazolidine 4.58 in 68% yield 
over two steps. Treatment of 4.58 with zinc metal in acetic acid afforded amino alcohol 
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4.59 in 57% yield. Finally, reductive alkylation of 4.59 with 3,5-dichlorobenzaldehyde 
yielded 4.52 in 20% yield.  
Scheme 4.13. Synthesis of three-carbon linker length inhibitor 4.52 
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 Synthesis of the one-carbon linker analogue 4.53 was achieved in an identical 
sequence to that of the three-carbon linker analogue 4.52, with one noticeable difference 
in the removal of the dimethyl acetal protecting group. Treatment of indole-3-carboxylic 
acid (4.60) with thionyl chloride, followed by addition to 4.18, gave amide 4.61 in 88% 
yield (Scheme 4.14). Upon reduction of 4.61 with lithium aluminum hydride, the 
resulting amine 4.62 was found to be unstable to silica gel column chromatography and 
aqueous acid extraction. However, when crude 4.62 was acylated, silica gel column 
chromatography provided amide 4.63 in 86% yield over two steps. When subjecting 
amide 4.63 to conditions for the removal of the dimethyl acetal protecting group in TFE, 
we were rather surprised when we exclusively isolated compound 4.66 (Scheme 4.15). 
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Scheme 4.14. Synthesis of one-carbon linked inhibitor 4.53 
 
 
 A mechanistic rationale for the formation of 4.66 is shown in Scheme 4.15. Upon 
formation of the oxonium ion 4.63a (R = Me or H), the electrophilic carbon atom is five-
atoms from the three-position of the indole. Nucleophilic attack from this position will 
form spirocyclic intermediate 4.63b. Subsequent 1,2-alkyl migration followed by 
rearomatization forms the seven-membered ring and indole moieties in 4.63c. Finally, 
acid-catalyzed elimination of methanol (or water) leads to the formation of 4.66. 
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Scheme 4.15. Proposed mechanistic rationale for byproduct 4.66 formation (R = Me or 
H) 
 
 
  To mitigate the formation of 4.66, we screened a number of solvents and found 
that a mixture of acetone and water (2:1) led to the formation of the desired aldehyde and 
only trace amounts of 4.66. The crude mixture was subjected to 1,3-dipolar cycloaddition 
conditions, leading to the formation of isoxazolidine in 4.64 in 81% yield over two steps. 
Finally, reductive N-O bond cleavage of 4.64, followed by reductive alkylation of 4.65 
proceeded in 66% and 51% yields, respectively, to give analogue 4.53. 
4.4.6. Carbon Linker Length: Part II. Biological Activity 
 The growth inhibition data for compounds 4.52 and 4.53 are shown in Figure 
4.12. We were quite surprised to find that the one-, two-, and three-carbon linked 
analogues were effectively equipotent T. brucei growth inhibitors. These results were 
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quite disconcerting. Based on our hypothesized mode of binding to TbMetRS, we 
expected the linker length to have a significant effect on biological activity. Given that 
we observed no change in growth inhibition, we reasoned that two possible scenarios 
could be taking place: either our compounds were not binding to TbMetRS or some type 
of cellular process (uptake, metabolism, ect.) was causing growth inhibition to be 
uncharacteristic of TbMetRS inhibition. In order to elucidate any meaningful conclusions 
from the growth inhibition data gathered thus far, we needed to determine the enzyme 
inhibition of our compounds. Though not available to us when we started our work in this 
area, Lance Lepovitz eventually developed an in-house TbMetRS enzyme inhibition 
assay to determine if our compounds inhibited TbMetRS. Nevertheless, we continued to 
study the developing cell-based SAR of our compounds by synthesizing analogues 
containing substitution on the indole moiety.  
Figure 4.13. Growth inhibition assay results as compared by carbon-chain linker-length 
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4.4.7. Substituted Indole Analogues: Part I. Synthesis  
 
  When designing analogues containing substituents on the indole moiety, we 
wanted to incorporate hydrogen-bond donors and acceptors. The TbMetRS inhibitors 
discussed in the preceding chapter all featured a heteroaromatic motif, namely an 
aminoquinolinone or a urea, that could act as both a hydrogen-bond donor and acceptor. 
We expected that adding the capability for hydrogen-bonding on the indole moiety would 
increase activity. To this end, we synthesized analogues containing 5-methoxyindole, 5-
benzyloxyindole, 5-hydroxyindole, and 4-benzyloxyindole motifs.  
 Synthesis of the 5-methoxyindole analogue 4.73 followed the same protocol as 
previous analogues. Treatment of 5-methoxyindole (4.67) with oxalyl chloride in ether 
led to precipitation of the corresponding glyoxyl chloride. Addition of the glyoxyl 
chloride to a solution of 4.18 and triethylamine led to nearly quantitative formation of 
glyoxylamide 4.68 (Scheme 4.16). Lithium aluminum hydride reduction of 4.68 gave 
secondary amine 4.69 in 90% yield. Acylation of 4.69 with crotonoyl chloride proceeded 
smoothly to give crotyl amide 4.70 in 71% yield. Removal of the dimethyl acetal 
protecting group and subsequent 1,3-dipolar cycloaddition led to the formation of 
isoxazolidine 4.71 in 85% yield over two steps. Reductive N-O bond cleavage of 4.71 
gave amino alcohol 4.72 in 85% yield. Finally, reductive alkylation of 4.72 gave the 5-
methoxyindole analogue 4.73 in 89% yield.  
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Scheme 4.16. Synthesis of 5-methoxyindole inhibitor 4.73 
 
 
 Synthesis of the 5-benzyloxyindole 4.80 and 5-hydroxyindole 4.81 analogues, 
started with the treatment of 5-benzyloxyindole (4.74) with oxalyl chloride to give the 
corresponding glyoxyl chloride (Scheme 4.17). Addition of the glyoxyl chloride to a 
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solution of 4.18 and triethylamine gave the glyoxylamide 4.75 in 95% yield. Reduction of 
4.75 to the corresponding amine 4.76 was achieved in 94% yield. Treatment of 4.76 with 
crotonoyl chloride led to the formation of amide 4.77 in 61% yield. Removal of the 
dimethyl acetal protecting group and 1,3-dipolar cycloaddition of 4.77 proceeded to give 
isoxazolidine 4.78 in 68% yield over two steps. Treatment of 4.78 with zinc metal 
afforded N-O bond cleavage to give aminoalcohol 4.79 in 85% yield. The ensuing 
reductive alkylation of 4.79 with 3,5-dichlorobenzaldehyde gave the 5-benzyloxyindole 
analogue 4.80 in 37% yield. The 5-hydroxyindole analogue 4.81 was synthesized from 
4.78 in two steps (Equation 4.1). First, palladium-catalyzed hydrogenolysis in acidic 
ethanol of 4.78 effected benzyl deprotection and N-O bond cleavage to give the crude 5-
hydroxyindole amino alcohol (not shown), which was unstable. However, subjecting the 
crude 5-hydroxyindole amino alcohol directly to reductive alkylation conditions led to 
the formation of 5-hydroxyindole analogue 4.81 in 28% yield over two steps.  
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Scheme 4.17. Synthesis of 5-benzyloxyindole inhibitor 4.80  
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(4.1) 
 We next focused on the synthesis of the 4-benzyloxyindole analogue 4.89, which 
was the most troublesome inhibitor to prepare. In contrast to every previous example, 
treatment of 4-benzyloxyindole (4.82) with oxalyl chloride did not lead to precipitation of 
the corresponding glyoxyl chloride. Rather a dark red solution formed, and over a 
relatively short period of time, the solution turned dark green. Even more frustrating was 
the fact that addition of either this red or green solution to 4.18 led to complex mixtures 
of starting material 4.82, desired product 4.83, and oxalyl-amide 4.84 (Equation 4.2). To 
further compound the problems with this reaction, we found that 4.82, 4.83, and 4.84 
were inseparable by acid/base extraction and unstable to chromatography conditions, 
resulting in an intractable mixture of unidentifiable degradation products.  
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 Given the large number of problems with the formation and isolation of 
glyoxylamide 4.83, an astonishingly simple solution was devised. We discovered that 
cannulating an ice-cold solution of a large excess of the glyoxyl chloride, which was 
formed using an equimolar ratio of 4.82 and oxalyl chloride, into an ice-cold solution of 
4.18 with excess triethylamine minimized the formation of 4.84.  Upon a quick aqueous 
workup, the crude mixture was immediately subjected to a lithium aluminum hydride 
reduction, which enabled purification of the desired product by a simple acid/base 
extraction, to give pure 4.85 in 67% yield over two steps (Scheme 4.18). Acylation of 
4.85 with crotonoyl chloride gave amide 4.86 in 86% yield. Unmasking of the aldehyde 
in 4.86 and subsequent 1,3-dipolar cycloaddition gave isoxazolidine 4.87 in 93% over 
two steps. Treatment of 4.87 with zinc metal afforded amino alcohol 4.88 in 57% yield. 
Finally, reductive alkylation of 4.88 with 3,5-dichlorobenzaldehyde gave the 4-
benzyloxyindole analogue 4.89 in 19% yield. It should be noted that all attempts at 
benzyl deprotection of 4.87, 4.88, and 4.89 led to complex mixtures that quickly 
decomposed to unspecified byproducts.  
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Scheme 4.18. Synthesis of 4-benzyloxyindole inhibitor 4.89 
 
4.4.8. Substituted Indole Analogues: Part II. Biological Activity  
 
 Growth inhibition data for compounds 4.73, 4.80, 4.81, and 4.89 are shown in 
Table 4.3. We were elated to find that the 5-methoxyindole analogue 4.73 exhibited sub-
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micromolar growth inhibition of T. brucei (GI50 = 0.95 ± 0.04 µM), which to this day, is 
our most potent growth inhibitor. The benzyloxyindole and hydroxyindole compounds 
4.80, 4.81, and 4.89 exhibited less than a two-fold difference in growth inhibition, with 
respect to compound 4.12. As excited as we were to have finally achieved a significant 
increase in biological activity in compound 4.73, it was undeniable that our library of 
compounds displayed a relatively flat SAR.  
Table 4.3. T. brucei growth inhibition data of substituted indole derivatives  
 
 
Compound Substituent (R) GI50 (µM) 
4.12 H 4.3 ± 0.4 
4.73 5-methoxy 0.95 ± 0.04 
4.80 5-benzyloxy 2.1 ± 0.4 
4.81 5-hydroxy 5.5 ± 0.6 
4.89 4-benzyloxy 2.0 ± 0.2 
 
4.5. TBMETRS ENZYME ASSAY RESULTS   
 
 After some experimentation Lance Lepovitz developed an in-house TbMetRS 
enzyme inhibition assay. This assay utilized a colorimetric method to determine 
inhibition of the enzyme. This method is less sensitive than the radiolabeled l-methionine 
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competitive binding enzyme assay that was previously used to determine the IC50 values 
of compounds 4.1 – 4.6. For this reason, we first obtained a baseline for comparison by 
determining the IC50 value of 4.1 in our enzyme assay. We found that 4.1 exhibited an 
IC50 value of 4.9 ± 1.5 µM, which is roughly an eight-fold decrease in value, as compared 
to of the radiolabeled l-methionine-based TbMetRS inhibition assay (IC50 = 586 nm). 
With a proper baseline for comparing with 4.1, we assayed our new compounds using 
this protocol, and the results are shown in Table 4.4. We were surprised to find that all of 
our new analogues were completely inactive towards inhibition of TbMetRS at 
concentrations up to 200 µM. Hence, each new compound has an IC50 value greater than 
200 µM. These results show that our new analogues, though better growth inhibitors of 
the parasite than 4.1 and 4.2, are not acting through inhibition of TbMetRS, but rather by 
some different mechanism of action. 
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4.6. BIOLOGICAL ACTIVITY  
Table 4.4. Summary of the biological activity of 4-amino-2-piperidinone analogues 
towards T. brucei and TbMetRS. 
 
Compound R1 R2 R3 n GI50 (µM) TbMetRS 
Inhib. (%)a 
4.1 3,5-diCl CH2OH H 2 25.3 ± 0.5  4.9 ± 1.5 µMc 
4.12 3,5-diCl CH(OH)CH3 H 2 4.3 ± 0.4 28 ± 10 
4.29 H CH(OH)CH3 H 2 >10 17 ± 3 
4.30 3-Cl-5-OMe CH(OH)CH3 H 2 4.8 ± 0.2 17 ± 3 
4.31 3,4-O2CH2 CH(OH)CH3 H 2 3.9 ± 0.7 0 
4.32 3-OMe CH(OH)CH3 H 2 5.7 ± 0.4 0 
4.33 3-Cl CH(OH)CH3 H 2 2.1 ± 0.2 n/a 
4.34 3,4,5-triOMe CH(OH)CH3 H 2 8.1 ± 1.7 10 ± 1 
4.35 3,5-diOMe CH(OH)CH3 H 2 >10 0 
4.36 3-SMe CH(OH)CH3 H 2 2.3 ± 0.6 0 
4.37 3,5-diCl CH2OH H 2 5.5 ± 0.4 0 
4.38b 3,5-diCl H H 2 7.1 ± 0.7 17 ± 15 
4.45b H H H 2 >10  0 
4.46b 3-Cl-5-OMe H H 2 6.2 ± 0.2 9 ± 7 
4.47b 3,4-O2CH2 H H 2 >10 0 
4.48b 3-OMe H H 2 >10 7 ± 5 
4.49b 3-Cl H H 2 9.0 ± 0.4 0 
4.50b 3,5-diOMe H H 2 >10 4 ± 1 
4.51b 3-SMe H H 2 >10 10 ± 1 
4.52 3,5-diCl CH(OH)CH3 H 3 5.5 ± 0.2 n/a 
4.53 3,5-diCl CH(OH)CH3 H 1 4.1 ± 0.6 n/a 
4.73 3,5-diCl CH(OH)CH3 5-OMe 2 0.95 ± 0.04 0 
4.80 3,5-diCl CH(OH)CH3 5-OBn 2 2.1 ± 0.4 0 
4.81 3,5-diCl CH(OH)CH3 5-OH 2 5.5 ± 0.6 27 ± 4 
4.89 3,5-diCl CH(OH)CH3 4-OBn 2 2.0 ± 0.2 0 
a Percentage of TbMetRS deactivation at 200 µM concentration. b Compounds synthesized by L. Lepovitz.  
c Given value is the TbMetRS inhibition constant (IC50) using the in-house colorimetric enzyme assay. 
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4.7. SUMMARY 
 The synthetic efforts resulted in the synthesis of a library of indole containing 4-
amino-2-piperidinone compounds. The generalized synthetic route developed, which is 
shown in Scheme 4.19, depicts the methods used to make the aforementioned library. 
This route allows access to these structural motifs in seven steps from amine 4.18 and 
indole (eight steps total). A major benefit of this route was the use of simple reaction 
protocols. Additionally, the purification of these reactions was quite simple. With the 
exception of the acylation and the final reductive alkylation step, these procedures did not 
require chromatography to afford material of >95% purity. 
Scheme 4.19. Generalized synthetic scheme of 4-amino-2-piperidinone compounds 
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 To summarize, we sought to develop an SAR that correlated specific molecular 
functionalities of our scaffold with the activity towards growth inhibition of T. brucei. 
We synthesized a library of analogues of our initial inhibitor 4.12 that were designed to 
test the effects upon inhibiting growth of T. brucei by varying the benzylamine 
substituent (shown in red, Figure 4.14), the ethylene hydroxy side-chain (shown in blue), 
the length of the carbon linker (shown in green), and substitution on the indole moiety 
(shown in purple). We thus discovered a very flat SAR between these sites of derivation 
and growth inhibition.  
Figure 4.14.  Inhibitor scaffold and derivatized functionalities  
 
 
 We originally thought the observed T. brucei growth inhibition of our compounds 
was due to the inhibition of TbMetRS. This assumption was based upon the structural 
similarities between our compounds and the known TbMetRS inhibitors 4.1 - 4.3. 
However, during the course of our studies we discovered that the changes made to our 
scaffold, which we predicted would affect binding to TbMetRS, did not lead to 
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appreciable changes in growth inhibition. For this reason, we undertook studies to 
develop an in-house TbMetRS enzyme inhibition assay.  
 The entire collection of biological data for the compounds described is shown in 
Table 4.4. As previously described, our tryptamine-based analogues are generally more 
efficacious T. brucei growth inhibitors than the initial hit compound 4.1. However, this 
increased activity at the cellular level is no longer acting through inhibition of TbMetRS, 
as demonstrated by the lack of TbMetRS inhibition in our in-house enzyme assay. 
4.8. CONCLUSION  
 
 We have learned that our initial hypothesis that the flexible tryptamine analogues 
of our previous tetrahydro-b-carboline compounds 4.1 – 4.3 would be better TbMetRS 
inhibitors was incorrect. When this study was initiated, access to a TbMetRS enzyme 
inhibition assay was not available in our labs so we had to operate under the assumption 
that growth inhibition of T. brucei reflected TbMetRS inhibition. In fact, the in-house 
enzyme assays of our tryptamine analogues surprisingly showed that these compounds 
did not inhibit the activity of TbMetRS at all. 
 Though the exact reason why our tryptamine analogues no longer bind to 
TbMetRS is unclear, it is possible that the tetrahydro-b-carboline scaffold is preorganized 
into a conformation that positions the indole moiety, relative to the 2-piperidinone 
moiety, in an ideal orientation for binding to TbMetRS. Conversely, even though the 
tryptamine analogues possess greater conformational flexibility, the indole moiety in this 
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scaffold physically cannot adopt the same conformation as in 4.1, because of the steric 
repulsion that would develop between the hydrogen atom at the two-position of the 
indole and the hydrogen atoms in the three-position of the 2-piperidinone moieties.  
 Nevertheless, upon analyzing the enzyme inhibition assay data, the observed lack 
of an SAR between our analogues and growth inhibition of T. brucei is no longer 
surprising. With the knowledge that our compounds do not bind to TbMetRS, there is no 
longer a logical argument for why the molecular changes made would lead to a change in 
biological activity.  
 Using a rational drug design approach, we synthesized a number of compounds 
that exhibited enhanced efficacy on a cellular level towards growth inhibition of the T. 
brucei parasite. However, we found that this enhanced activity on a cellular level was 
through a new mode of action relative to compounds 4.1 – 4.3. These studies substantiate 
the importance of verifying the activity towards a proposed biochemical target when 
undertaking a rational drug design approach in drug discovery. Even though our 
tryptamine based analogues were no longer inhibiting the TbMetRS enzyme, the 
increased efficacy towards T. brucei growth inhibition is intriguing. Future collaborative 
efforts to elucidate the new mechanism of action for these compounds is currently being 
considered. Nevertheless, the compounds described in this chapter add to the growing 
body of research towards finding a more effective cure for HAT.   
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NEURONS THAT MATTER:  USING LIGHT TO TAG NEURONAL 
ENSEMBLES BASED ON FUNCTION  
Chapter 5: Photolabile Protecting Groups 
 5.1. PHOTOLABILE PROTECTING GROUPS: GENERAL  
 
 Photolabile protecting groups (PPGs) are light reactive moieties that can render a 
given functional group chemically inert. Much like traditional protecting groups, the 
utility of a PPG is inherently tied to the ability to efficiently install/remove the group as 
well as the chemical stability towards various conditions. Unlike traditional protecting 
groups, the removal of PPGs is accomplished using light as the sole input, thus negating 
the need for chemical reagents. This characteristic of PPGs often translates to their utility 
within sensitive systems, especially in biological settings. While originally designed by 
synthetic chemists, the use of PPGs in chemical synthesis has been minimal.152 However, 
the use of PPGs to study and manipulate biological systems has grown consistently since 
their early discovery. Often referred to as “cages” or “photocages”, biological 
applications using photocaged compounds have found use in controlling protein 
functions, cellular stimulation, control over gene silencing, and neuronal stimulation or 
inhibition. These applications have been the subject of a multiple of reviews.153–161 
 When determining the photochemical efficiency of deprotection, quantum yield is 
often used as a quantitative metric. The quantum yield of substrate release (Fr) is equal to 
the rate constant of substrate release from the excited state (kr) divided by the sum of all 
rate constants for every possible photochemical pathway from the excited state (Equation 
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5.1). To simplify, the quantum yield is the probability of substrate release upon 
promotion of a PPG-protected compound to the excited state upon irradiation of a given 
wavelength.  
Φ0 = 	 𝑘0𝑘 (5.1) 
 When considering absorption of light, the probability of a compound absorbing a 
photon is a function of molar absorptivity (e). If we consider a compound with a quantum 
yield of unity (Fr = 1), then every photon absorbed will lead to release of the given 
substrate. However, if this compound has a very low molar absorptivity at a given 
wavelength, it will require longer irradiation times (more photons) to be promoted to the 
excited state. This leads to the product of quantum yield and molar absorptivity (Fr•e) 
being a better representative metric of photochemical efficiency of deprotection. This is 
especially true for visible light absorbing PPGs, where large absorptivities in the visible 
region are often attributed to the availability of multiple unproductive photochemical 
pathways.162  
 The first reported use of PPGs started to appear in the literature in the early 
1960’s. Early publications by Barltrop,163 Barton,164,165 Patchornik and Woodward166 set 
the stage for what continues to be a large area of research today. In his seminal report, 
Barltrop described the first use of a photo-removable group as a new protecting group 
strategy. In this study, irradiation of Cbz-glycine (5.1) with UV-light (254 nm, mercury 
lamp) led to the isolation of benzyl alcohol (5.2) and glycine (5.3) in up to 75% yield 
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(Equation 5.2). Though unbeknownst at the time, the use of PPG-protected carbamates 
and carbonates to release free amines and alcohols upon decarboxylation, is still 
commonplace in PPG strategies today.167,168 
 
(5.2) 
 Though each individual application will necessitate a specific set of requirements, 
a general set of criteria should be met in the design of a useful PPG.161  
1. The PPG-protected compound needs to be chemically and biologically inert to the 
system under investigation.  
2. Photodeprotection should occur cleanly, in high chemical and quantum yields. 
With respect to biological systems, caging groups should decage at wavelengths > 
350 nm to minimize cellular damage.  
3. The photochemical byproducts should be inert within the system being studied. In 
the case of biological systems, these byproducts must also be non-toxic to 
mitigate potential interference with the given study.  
4. The protected compound must be soluble in the target media. Given the 
prominent use of PPGs within biological studies, this often means the protected 
compounds must soluble in aqueous media. 
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5. The observed release rate of the target compound must exceed that of the 
response under investigation. This is particularly important for biological studies 
of very fast physiological events, such as electrophysiology.  
A major reason for the continued development of novel PPGs is that no one group 
currently fulfills all of these given requirements for all potential applications. With 
literally hundreds of PPGs reported in the literature, we will highlight the most 
commonly used PPGs, grouped by common structural features. 
5.2. O-NITROBENZYL-BASED PHOTOLABILE PROTECTING GROUPS  
 
 
 By far the most commonly used class of PPGs and photocages is the o-
nitrobenzyl based family. One of the oldest known groups of PPGs, this class of 
compounds was pioneered by Barltrop169 and Patchornik.166 Over four decades of 
research has led to a profound understanding of how these groups react photochemically. 
However, despite their wide-spread use in biological and chemical applications, there are 
a number of disadvantages to the NB-based PPGs. These disadvantages can be 
understood by considering the mechanism of deprotection of NB groups. 
o-nitrobenzyl (NB)
NO2
LG
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5.2.1. o-Nitrobenzyl Mechanism of Deprotection 
 
 The mechanism of deprotection of o-nitrobenzyl PPG is shown in Scheme 
5.1.161,170 Upon irradiation, a molecule of NB will enter the exited state 5.4. An 
intramolecular 1,5-hydrogen abstraction from the excited nitro group leads to the 
formation of the aci-nitro intermediate 5.5. In aqueous media, the reactive (E)-aci-
intermediate 5.5 is in rapid equilibrium with the unproductive (Z)-aci-intermediate (not 
shown). The irreversible cyclization of 5.5 to 5.6 occurs with a rate constant on the order 
of 102 - 104 s-1. For moderate to good leaving groups, the decay of 5.5 is rate limiting. 
Ring opening of 5.6 leads to the formation of 5.7. Hydrolysis of hemiacetal 5.7, which 
can be rate-limiting for poor leaving groups or basic media, releases the leaving group 
and forms 2-nitrosobenzaldehyde (5.8).  
Scheme 5.1. o-Nitrobenzyl PPG mechanism of deprotection 
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 In considering the mechanism shown in Scheme 5.1, a number of problems arise 
from the use of these PPGs. First and foremost, is the formation of a 2-
nitrosobenzaldehyde byproduct as 5.8. Far from chemically inert, 5.8 can participate in a 
number side-reactions, the most troublesome of which is the condensation with primary 
amines.171,172 Given that deprotection of an amino-containing compound generates 
equimolar amounts 5.8 and the released amine, subsequent condensation of 5.8 and the 
released amine will inhibit the amine from participating in the desired response, thus 
effectively diminishing the efficiency of deprotection. Additionally, Bayley and Givens 
found that 5.8 reacted with thiophosphotyrosine in photoreleased peptides, which 
inhibited the released peptide from binding to the respective protein.173,174 Furthermore, 
the 2-nitrosobenzaldehyde byproducts can be toxic towards biological systems.162 
Finally, these byproducts exhibit a stronger absorbance of light at similar wavelengths to 
the parent o-nitrobenzyl protected compound, leading to the formation of dark colored 
solutions. This absorbance acts as an internal UV-filter, thus decreasing the rate of 
deprotection as a function of reaction progress. 
 An issue that is commonplace amongst many types of PPGs, including NBs, is the 
inability to efficiently release poor leaving groups, such as alcohols and amines (Equation 
5.3). A common method used to circumvent this problem is to protect the given alcohol 
or amine as the PPG-carbonate or –carbamate 5.9, respectively (Equation 5.4). In general, 
the carbonates and carbamates are good leaving groups and will lead to efficient 
deprotection. Upon departure of the carbonate or carbamate 5.10, subsequent 
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decarboxylation will yield the free alcohol or amine (H-LG). As for NB specifically, the 
decarboxylation step often becomes rate limiting. This relatively slow effective rate of 
release largely negates the utility of these PPGs towards fast physiological 
applications.162 
 
(5.3) 
 
(5.4) 
5.2.2. o-Nitrobenzyl-Based PPG Derivatives   
 
 Over the years, a plethora of NB derivatives have been designed with the goal of 
increasing the utility of these compounds as PPGs and caging groups. In order to 
circumvent the formation of 5.8, early nitrobenzyl derivatives focused on substitution at 
the benzylic carbon. Patchornik demonstrated that the use of the 1-(2-nitrophenyl)ethyl 
group (NPE) (Figure 5.1) led to quantitative release of amino acids.166 The addition of 
the methyl group at the benzylic position leads to the formation of the corresponding 2-
nitrosoacetophenone, which is significantly less prone to imine formation than 5.8. 
However, substitution at the a-substitution of these PPGs creates a new stereogenic 
center that can lead to the formation of diastereomers during synthesis, which can 
significantly complicate the synthesis of chiral and biological compounds. 
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 An early PPG that was designed to increase efficiency of deprotection was the 
2,6-dinitrobenzyl group (DNB) (Figure 5.1). It was found that the second nitro group on 
the aromatic ring led to an increase in quantum yield upon irradiation at 248, 254, and 
313 nm relative to the analogous NB derivatives.175,176 The rationale behind the observed 
increase in quantum efficiency was that, upon absorption of a photon, the second o-nitro 
group led to a statistical increase in the probability of 1,5-hydrogen abstraction to form 
the aci-intermediate analogous to 5.5 in the rate determining step. The DNB group was 
shown to release amino acids, as carbamates, in higher chemical yields, as compared to 
the NB counterpart.175,177 However, later studies found that this increase in efficiency was 
not due to the additional hydrogen-abstracting group, but instead due to the resulting 
ketone byproduct being less prone to imine formation of the released amino acid.178,179 
Figure 5.1. o-Nitrobenzyl photolabile protecting group derivatives  
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nitropiperonyl (NP) are amongst the most common PPGs and photocages in modern 
science.162,170 The electron donating groups lead to a significant bathochromic shift and 
hyperchromic effect, which increased absorptivity at longer wavelengths. Interestingly, 
the NB group actually deprotects more efficiently than the NV group at 254 nm and is 
comparable in efficiency at 350-420 nm.180 It is believed that the increased absorbance of 
the NV group is due to the availability of several new excited states that proceed through 
unproductive photochemical pathways.179  
 A recent example of an o-nitrobenzyl-based PPG that has found quick use in a 
variety of biological applications is the nitrodibenzofuran group (NDBF). Originally 
synthesized by Ellis-Davies for the photochemical release of calcium ions, NDBF 
undergoes photolysis between 16 – 160 times faster and more efficiently than previous 
NB derivatives.181 With a very high molar absorptivity at 330 nm (e = 18,400 M-1 cm-1) 
and 350 nm (e = 15,300 M-1 cm-1), this group has quickly found use as a caging group in 
a number of biological applications, including cellular activation, peptide activation, and 
photoregulation of siRNA.182–184 
5.3. NITROPHENPROPYL PHOTOLABILE PROTECTING GROUPS 
 
 First reported by Hasan in the late 1990s, the nitrophenpropyl PPG (NPP) is 
closely related to the NB PPG, although considerably fewer studies have been conducted 
using NPP.177 The mechanism of deprotection of the NPP-based PPGs is shown in 
Scheme 5.2. Similar to the NB-based PPG, the first step upon excitation to 5.11 is a 1,5-
 
 
 
145 
hydrogen abstraction to form the aci-nitro-intermediate 5.12. Decomposition of the aci-
intermediate occurs through elimination of the leaving group and formation of the 2-
nitrostyrene byproduct 5.13. 
Scheme 5.2. Nitrophenpropyl PPG deprotection mechanism 
 
 
 The NPP-based PPGs possess a few notable advantages over the NB-PPGs. First, 
NPP has been shown to release 5’-O-nucleoside carbonates about twice as fast as the 
analogous NB-caged nucleosides.185 Furthermore, the MNPPOC (Figure 5.2) released 
carbonates at 365 nm with a five-fold increase in rate (t1/2 = 11 s) relative to the 
analogous aMe-NP (t1/2 = 54 s) and 20-fold faster than the NV group (t1/2 = 216 s).186 In 
addition to the increased photolysis efficiency, the NPP-based PPGs are also more 
suitable for the release of amine containing compounds, with respect to NB PPGs, 
because the photochemical byproduct 5.13 is unreactive towards amines. 
 Recently, a number of reports on the design and use of nitrobiphenyl compounds 
as efficient PPGs have been published.162 The ANBP and EANBP groups (Figure 5.2) 
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have been shown to exhibit a strong absorbance in the visible region (lmax = 400 nm, e = 
7,500 M-1cm-1).187 These compounds have been used in a number of interesting 
applications including, live-cell fluorescence imaging, release of neurotransmitters, and 
photochemical DNA synthesis.188–191 
Figure 5.2. o-Nitrophenpropyl PPG derivatives  
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Section 5.7.1). The deprotection of carboxylates and phosphates proceeds very quickly 
and cleanly to quantitatively yield the desired product and 2-phenyl-5,7-
dimethoxybenzofuran (DMBF, 5.17) (Scheme 5.3).193 These reactions take place readily 
in both polar and nonpolar solvents. The photochemical mechanism of deprotection was 
found to be virtually independent of the identity of the leaving group, thus allowing for 
direct release of poor leaving groups such as amines.168,194  
 The DMB mechanism of deprotection has been subject to extensive studies and is 
shown in Scheme 5.3.195–199 A number of time-resolved studies have shown that 
excitation of the parent DMB-protected compound yields a short-lived excited singlet 
state 5.14. Initial studies suggested that the cyclohexadienyl cation 5.16 was formed 
directly from 5.14. However, more recent pump-probe experiments with picosecond time 
resolution found that the preoxetane biradical 5.15 was formed with a rate constant (k = 6 
x 1010 s-1) from the excited singlet state, and decayed into 5.6 within 1-2 ns. 
Deprotonation of 5.16 yields the final protonated leaving group and DMBF.198  
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Scheme 5.3. 3,5-Dimethoxybenzoin (DMB) mechanism of deprotection 
 
 
 A major issue that has limited the use of DMB for protecting amines and alcohols 
as carbamates and carbonates are the potential side reactions that can occur during 
synthesis. Reacting 5.18 with phosgene or CDI leads to the formation of 5.19 (Scheme 
5.4). Compound 5.19 can undergo an intramolecular cyclization to give 5.22, which is 
unproductive towards PPG use. Furthermore, reacting 5.19 with a primary amine will 
give carbamate 5.20, which can undergo a similar cyclization to give the photochemically 
inert 5.21.167 With respect to biological studies, the poor water solubility of DMB-caged 
compounds also limits the utility of this caging group. 162 
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Scheme 5.4. Side-reactions upon DMB-protected substrate synthesis 
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HYDROXYPHENACYL  
 
 Since the discovery of the p-hydroxyphenacyl PPG (pHP) (Scheme 5.5) a little 
over two decades ago, this group has since proven to be useful in numerous applications 
such as neurobiology and enzyme catalysis.161,200,201 The pHP group has a number of 
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pHP-protected compounds proceeds with comparable efficiencies to that of the neutral 
pHP species. In contrast to many other types of PPGs, there is no chiral center on the 
pHP chromophore, thus allowing for easier preparation and purification of chiral 
protected compounds. 
Scheme 5.5. p-Hydroxyphenacyl PPG (pHP) mechanism of deprotection 
 
 
 The mechanism of deprotection of pHP is unique and has been the focus of a 
number of studies.202 As shown in Scheme 5.5, deprotection of pHP occurs via 
photochemical formation of the cyclopropanone intermediate 5.23 with simultaneous 
release of the leaving group.203,204 Due to the structural similarity of 5.23 to that of the 
intermediate in the Favorskii rearrangement, this mechanism has been coined the photo-
Favorskii rearrangement. The exact nature of the excited state formation of 5.23 has been 
subject to debate. Both excited singlet and short-lived excited triplet state pathways have 
been proposed.205,206 Addition of water into 5.23 gives the sole photochemical byproduct, 
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does not interfere with parent pHP absorption.153 Adding to the utility of the pHP group 
as a photocage in biological studies, 5.23 is biologically inert and photochemically 
stable.207 The photochemical efficiency of deprotection is highly dependent on the 
identity of the leaving group. Good leaving groups, such as phosphates or sulfonates, 
typically release with quantum yields near unity and poor leaving groups, like phenolates, 
often proceed with low quantum yields (Fr < 0.1).208,209  
5.6. PHOTOENOLIZATION-BASED PHOTOLABILE PROTECTING GROUPS  
 
 Despite the structural similarities between DMB and pHP PPGs, the 
photoenolization PPGs are grouped based on their similar mechanism of deprotection. A 
number of interesting modifications to the photoenolization mechanism have led to the 
development of numerous photoenolization-based PPGs that will be discussed in the 
following sections. 
5.6.1. 2-Methyl-Substituted Acetophenones 
 
 The most basic of the photoenolization-based PPGs is the 2-methylacetophenone 
PPG 5.25 (Scheme 5.6).210–212 Upon irradiation, 5.25 is promoted to the singlet excited 
state 5.26. Intersystem crossing (ISC) to the excited triplet state 5.27 allows for homolytic 
1,5-hydrogen abstraction, leading to the triplet 1,4-diradical 5.28. Biradical 5.28 will then 
form two isomeric photoenols (Z)-photoenol 5.29 and (E)-photoenol 5.30. However, 
direct enolization from the singlet excited state 5.26 leads to the sole formation of the (Z)-
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photoenol 5.29, which is short lived and quickly undergoes a 1,5-sigmatropic 
rearrangement to give the parent compound 5.25. The (E)-photoenol 5.30, however, 
requires intermolecular hydrogen transfer to quench, and therefore persists long enough 
to undergo nucleophilic attack at the a-carbon to release the leaving group and form 1-
indanone (5.31). Given that the leaving group is released through an SN2 displacement, 
the efficiency of deprotection is directly correlated to the leaving group ability. 
Consequently, 5.25 is unsuitable for protection of poor leaving groups like phenols, 
thiols, alcohols, and amines. 
Scheme 5.6. 2-Methylacetophenone PPG 5.25 mechanism of deprotection 
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  The 2-methyl-substituted acetophenones 5.25 release good leaving groups such 
as phosphates, carboxylates, and sulfonates.170 However, there are numerous 
disadvantages of this PPG that have limited its application to a few examples of 
photoresponsive polymers.213,214 The first of these disadvantages, is the poor 
photochemical efficiency of deprotection. Quantum yields and rates of release are 
typically very low for 5.25-protected compounds relative to other PPGs. Furthermore, 
deprotection only occurs upon irradiation of UV-light, typically l = 250 – 300 nm. In 
addition to the requirement of UV-light, the utility of 5.25-caged compounds for 
biological applications is further hampered by the hydrophobicity of 5.25, resulting in 
poor aqueous solubility.  
 Interestingly, the photochemical reactivity of this group was utilized in the 
syntheses of 1-indanone containing compounds, such as the Alzheimer’s drug donepezil 
(5.34), pterosine B (5.37), and pterosine C (5.40), were achieved (Scheme 5.7). Benzoyl 
ester 5.32 was irradiated with a medium pressure mercury lamp to give 1-indanone 5.33 
in 90% yield, thereby completing a formal synthesis of the acetylcholinesterase inhibitor 
donepezil (5.34) (A, Scheme 5.7).215,216 In a separate study, Wessig irradiated a-
mesylates 5.35 and 5.38 to form the 1-indanones 5.36 and 5.39 in 19% and 31% yield, 
respectively. Hydrolysis and a-methylation of 5.36 and 5.39 gave the natural products 
pterosine B (5.37) and pterosine C (5.40), respectively (C and D, Scheme 5.7).217,218  
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Scheme 5.7. 1-Indanone compounds accessed via photoenolization 
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deprotection of 5.41-protected compounds is shown in Scheme 5.8. Excitation of 5.41 
leads to the formation of (E)-photoenol 5.42, which can undergo ketonization to eliminate 
the leaving the group and form the 2-styrene byproduct 5.43. Due to the fact that 
protonation of 5.42 to reform the parent compound 5.41 is faster than elimination, these 
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PPGs release leaving groups with poor photochemical efficiency. Consequently, the use 
of these groups has been minimal since their initial discovery.162 
Scheme 5.8. 2-Ethylene-substituted aryl ketone mechanism of deprotection 
 
5.6.3. Intramolecular Lactonization 
 
 A very interesting application of these reactive photoenols was reported by 
Gudmundsdottir in 2005.222,223 In this report, excitation of protected alcohol 5.44 
produced photoenol 5.45 via the triplet excited state (Scheme 5.9). Photoenol 5.45 then 
undergoes an electrocyclization to give benzocyclobutanol 5.46, which positions the 
hydroxyl group proximal to the ester carbonyl. Subsequent lactonization of 5.46 leads to 
5.47 and simultaneous release of the leaving group. In this report free alcohols were 
released in high chemical yields (90%).224,225  
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Scheme 5.9. Photodeprotection of 5.44 via lactone formation 
 
 
 The direct release of free alcohols is a desired feature in PPGs. However, the low 
quantum yields of release and slow reaction rates of 5.44, is likely the reason this group 
has not been utilized in any biological applications.  
5.7. BENZYL BASED PHOTOLABILE PROTECTING GROUPS 
 
 A large class of PPGs is based on the photosolvolysis of benzyl substituted 
compounds. To generalize, a leaving group is attached to the benzylic carbon of an 
aromatic or heteroaromatic chromophore (ArCH2LG) (Equation 5.5). Upon irradiation, 
excitation leads to heterolytic bond cleavage, or homolytic bond cleavage followed by 
immediate electron transfer, to give a benzyl cation (ArCH2+) and leaving group anion 
(LG-) ion pair.162 Trapping of the benzyl cation with a nucleophile, generally solvent 
(ROH), leads to the release of the leaving group. Given the necessity of a nucleophile, 
these photosolvolysis reactions are most efficient in polar protic solvents. In the absence 
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of nucleophilic trapping of the benzyl cation, recombination of the ion pair results in the 
formation of the original starting material.  
 
(5.5) 
5.7.1. The Meta Effect 
 As mentioned in the discussion of the DMB, it is commonplace in PPG design to 
incorporate electron donating groups meta to the benzylic position. The rationale behind 
these substitution patterns is based on what is known as the meta effect.  
 In what is now considered a historic series of papers in photochemistry, 
Zimmerman discovered that electron donating groups in the meta-position actually 
stabilize benzylic carbocations in their excited states.226–231 Through molecular orbital 
calculations of the excited state, he found that there is significant orbital overlap between 
the meta-positions within excited states of aromatic compounds. Experimental evidence 
was obtained through the photolysis of 4-methoxybenzylacetate (5.48) and 3-
methoxybenzylacetate (5.52). Upon photolysis in aqueous dioxane, 5.48 gave 5.49 – 
5.51, the products of homolytic bond cleavage and subsequent radical chain reactions 
(Equation 5.6). However, upon photolysis of 5.52 in aqueous dioxane, the 
photosolvolysis product 5.53 was obtained as the major product, and radical byproducts 
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analogous to 5.49 – 5.51 were only observed in trace amounts (Equation 5.7). 
Furthermore, photolysis of 3,5-dimethoxybenzyl acetate (5.54) (Scheme 5.10) led to 
exclusive formation of the corresponding benzyl alcohol.   
 
(5.6) 
 
(5.7) 
 Based on molecular orbital calculations of the excited state of 5.54, Zimmerman 
describes the reaction mechanism shown in Scheme 5.10. Upon excitation of 5.54, a π  ® 
π* transition leads to an excited state that is best depicted as 5.54a. Upon ionization of the 
acetate, the resulting excited state benzyl cation can be depicted as resonance structures 
5.55a and 5.55b. The interconversion between 5.55a and 5.55b illustrates the 
stabilization of the excited-state benzyl cation by the meta effect.  
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Scheme 5.10. Mechanistic representation of the meta effect from M.O. calculations 
 
5.7.2. Benzyl Based PPG Examples 
 
 A select number of benzyl-based PPGs are shown in Figure 5.3. For this class of 
PPGs, release of the leaving group is dependent on nucleophilic capture of the resulting 
benzyl cation, thus weaker leaving groups tend to lead to faster rates of recombination, 
reducing the efficiency of deprotection.  The 9-phenylxanthyl PPG (Px) has been shown 
to release alcohols directly upon irradiation of light at 254 – 300 nm in yields ranging 
from 78-97%.232 Further improvements to Px led to the development of the 9-
phenylthioxanthyl group (S-Px) and the corresponding meta-methoxy derivatives. In 
some of these examples, primary alcohols were released upon irradiation of light with 
wavelengths as long as 350 nm in varied yields (75-97%).233  
 The anthraquinone-2-yleth-2-yl (Aqe) group has also been shown to release 
alcohols, as the carbonate, and carboxylic acids. Applications in releasing carbohydrates 
and nucleosides upon irradiation at 350 nm has also been demonstrated.234,235 While the 
yields of the Aqe deprotection again vary depending on the leaving group, this PPG has a 
distinct advantage within biological studies in that deprotection can occur with irradiation 
of visible light. Finally, the 3-(dimethylamino)trityl group (DMATr) was first reported 
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by Wang.170,236 The DMATr PPG releases primary alcohols upon irradiation at 254 nm 
in good yields. Secondary alcohols as leaving groups led poor yields upon synthesis of 
the DMATr-protected compounds. Given that the trityl group has traditionally been used 
as an acid-labile protecting group in organic synthesis, the main concern with DMATr 
PPGs was their stability in acid. Wang demonstrated orthogonal deprotection between a 
standard trityl protected alcohol and a DMATr-protected alcohol.237  In continuing their 
studies with trityl-based PPGs, Wang developed 5.56 for protection of ketones and 
aldehydes. Irradiation of various aldehydes and ketones with light (l < 320 nm) led to 
efficient release of the corresponding aldehydes and ketones.238,239 This class of PPGs has 
been used for a number of biological applications including, neural activation and 
photogeneration of bases for cellular imaging.170,240,241 
Figure 5.3. Selected examples of benzyl-based photolabile protecting groups 
 
5.8. COUMARIN-BASED PHOTOLABILE PROTECTING GROUPS  
 
 Arguably, one of the most useful classes of PPGs are the coumarin-based PPGs. 
First discovered by Givens, who showed that phosphate esters were efficiently and 
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quickly released from the methoxycoumarin PPG (MCM) (Figure 5.4), this class of 
compounds has since been broadly investigated.242 The coumarin-based PPGs have a 
number of distinct advantages over some of the previously discussed PPGs. First the 
coumarin chromophore has a very large absorption coefficient at longer wavelengths 
(lmax = 350 – 475 nm), allowing derivatives to be reactive in visible light. Second, the 
coumarin chromophore is a strong fluorophore as well, allowing for the ability to monitor 
reaction progress through changes in fluorescence.162 Finally, for good leaving groups, 
such as, phosphates, sulfonates, and carboxylates, this class of PPGs has some of the 
fastest rates of release for a PPG, making these PPGs useful for monitoring very fast 
physiological events, such as in electrophysiology studies.152 However, due to the 
photosolvolytic mechanism of deprotection (Scheme 5.11), these groups do not 
efficiently release poor leaving groups like phenols, thiols, alcohols, or amines. 
Furthermore, decarboxylation becomes the rate limiting step in the release of carbonates 
and carbamates, which significantly reduces the apparent rates of release for alcohols and 
amines.243–245  
 
 
 
 
 
 
 
 
162 
Figure 5.4. Select coumarin photolabile protecting group examples 
 
 
 In recent years, a large number of coumarin PPG derivatives have been described, 
and reviews on the subject have been published.200 An interesting development within the 
“first-generation” of coumarin-based PPGs was the 6-bromo-7-hydroxycoumarin-4-
methyl group (BHCM) (Figure 5.4). The bromide substituent lowered the pKa of the 
proximal phenol by two-units, thus allowing full deprotonation of the phenol at 
physiological pH. Deprotonation of BHCM dramatically increased the aqueous solubility 
of BHCM-protected derivatives, and also resulted in a 50 nm redshift of the maximum 
absorbance (lmax = 370 nm), as compared to MCM (lmax = 320 nm).246,247  
 The “second-generation” coumarin PPGs are groups containing a 7-amino 
substituent, such as diethylaminocoumarin (DEAC). Addition of the 7-amino-substiuent 
was found to improve the efficiency of deprotection and further red shift the maximum 
absorbance (lmax = 390 nm).248,249 Shortly after the discovery of the improved 
O O
LG
MeO O O
LG
HO O O
LG
Et2N
Br
MCM BHCM DEAC
O O
LG
Et2N
DEAC450
NH
O
O O
LG
N
BCMAC
HO2C
HO2C
O S
LG
Et2N
thio-DEAC
CO2H
CO2H
 
 
 
163 
photochemical properties of DEAC, Ellis-Davis reported the synthesis of DEAC450, 
which has a maximum absorbance well into the visible region (lmax = 450 nm), due to the 
extended conjugation of the enone moiety.250,251 Finally, thio-DEAC has recently been 
reported and shown to possess a very high absorptivity in the visible region as well (lmax 
= 470 nm). Furthermore, upon irradiation of green light (l = 500 nm), the thio-DEAC 
group efficiently released a small molecule transcription inducer, cyclofen, in zebra fish 
embryos to induce protein expression.252  
 A major drawback to the coumarin-based PPGs is the hydrophobicity of the 
protected compounds. Given that most biological systems require aqueous media, this 
creates problems when attempting to use coumarin based cages for biological 
applications. To address this problem a number of coumarin-based PPGs containing polar 
functionalities have been designed, including BCMAC and DEAC450. Though the 
concentration of saturated aqueous solutions of BCMAC- and DEAC450-protected 
compounds were not given in these reports, biological studies were conducted at 1 mM 
concentrations without the addition of an organic co-solvent. 
5.8.1. Coumarin Mechanism of Deprotection 
 
 Using MCM as an illustrative example, the mechanism of deprotection for the 
coumarin-based PPGs is shown in Scheme 5.11.253–256 Upon irradiation, the parent 
compound is promoted to the excited singlet state, which is represented by the resonance 
structures 5.57a and 5.57b. From this excited singlet state, loss of a photon results in 
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fluorescence and gives the parent compound MCM. Alternatively, heterolytic bond 
cleavage of 5.57 leads to the formation of a tight ion pair 5.58, which comprises the 
leaving group anion and the coumarin cation. This tight ion pair can either undergo 
recombination to give the parent compound MCM, or it can form a solvent-separated ion 
pair. From the solvent separated ion pair a nucleophile, typically solvent, can react with 
the cation to form 5.59, and subsequent protonation of the leaving group anion gives the 
deprotected compound. It is worth noting that time-resolved absorption studies have 
shown the rate of heterolysis (for phosphate esters) is about 2 x 1010 s-1, making this 
amongst the fastest measured photolysis rates for any PPG. However, due to the fact that 
the rate of recombination is about 10-fold faster than that of nucleophilic trapping, the 
actual observed rate of product formation is much lower.257  
 Coumarin-based PPGs and photocages have been extensively utilized in a range 
of biological applications, including small molecule gene regulation, siRNA gene 
regulation, small molecule neural activation, photochemical peptide synthesis, and 
embryonic cellular signal transduction.153,162,243,248,250–252,258 
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Scheme 5.11. Coumarin mechanism of deprotection 
 
5.9. PHOTOCAGING: BIOLOGICAL APPLICATIONS OF PPGS 
 Though originally designed by synthetic chemists, the use of PPGs in biological 
settings has become a fertile field of research. One of the earliest examples of the use of a 
PPG-protected compound in biology was in 1977 by Engels, who synthesized NB-cAMP 
(Figure 5.5) and demonstrated in vitro decaging through activation of the cAMP-
dependent protein kinase in rat glioma cells.259 Shortly thereafter, Hoffman reported the 
use of NB-ATP to study Na/K ion pumps through the decaging of ATP in human red 
blood cells.260 In this paper, Hoffman refers to the NB-ATP compound as “caged ATP”. 
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From that point on, the use of PPGs to inactivate biological compounds has been known 
as “caging”.  
Figure 5.5. First examples of photocaged biological compounds 
 
 
 Though the term has stuck for nearly half-century, the use of “caging” to denote 
PPG-protected biological compounds has been met with scrutiny.160 The term “caging” is 
often misinterpreted to mean a biological compound that is completely encompassed by a 
photoreactive molecule, which physically opens upon irradiation of light.160 
Consequently, over the past 40 years, a number of terms such as, photoactivatable, light-
triggered, or photocaged, have been used interchangeably with the term “caged”. 
Nonetheless, an immense amount of research using photocaged compounds to study 
biological processes including, the control of gene expression, inhibition of mRNA, 
protein synthesis/folding, neuronal activation/inhibition, and cellular imaging, have been 
reported since the seminal report by Engles. In the following section, we will highlight a 
few examples that are directly applicable to the research at hand. A number of reviews 
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have previously covered the applications of photocaged compounds across multiple 
divisions of biology.153–162,200,261 
5.9.1. Induced Gene Expression via Photocaged Small Molecules 
 
A common application of photocaged small molecules, is the photochemical 
control of gene expression. Inducible heterologous gene expression is a fundamental 
process in synthetic biology.262 Heterologous transgene expression systems, consisting of 
a specific group of genes (operon) that allows for the ability to “turn on” or “turn off” 
expression of a gene of interest, are activated by a specific small molecule. Commonly, 
these small molecules consist of clinically approved antibiotics, such as erythromycin A, 
doxycycline, or rapamycin.154,263 Therefore, in these studies, control over when and for 
how long the small molecule is present, leads to the temporal control of gene expression. 
Recently, to increase the temporal resolution within these expression systems, the use of 
photocaged small molecules has allowed for control over gene expression through 
irradiation of light.156,264 By releasing these small molecules in vitro or in vivo via 
decaging, temporal resolution on the order of the rate of deprotection is achievable. 
In one example of the photochemical control of gene expression, Deiters used the 
nitropiperonyl-protected erythromycin-9-oxime (NP-ERY) (Figure 5.6) to induce 
expression of a fluorescent protein in bacteria.265 In this study, the macrolide-inducible 
transgene expression system (EON), which activates transgene expression in the presence 
of erythromycin A, was utilized.266 Unable to directly photocage erythromycin A (ERY), 
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Deiters first ran a positive control experiment to confirm that erythromycin-9-oxime 
initiated transcription of the fluorescent reporter. After confirmation, he demonstrated 
that irradiation of NP-ERY with UV-light (365 nm, 25 W) for five minutes, induced the 
same level of fluorescent protein expression as the positive control. Deiters further 
demonstrated spatial control over gene expression by seeding the bacterial cells onto an 
agar plate and covering half of the plate. Subsequent irradiation with UV light for five 
minutes led to fluorescent protein expression of only the exposed portion of the plate. 
While this study was an elegant demonstration of spatial resolution of bacterial gene 
expression, the use of UV-light was taxing on cell viability, leading to a decrease in 
fluorescence response with irradiation times greater than five minutes.  
Figure 5.6. Erythromycin A (ERY) and nitropiperonyl-caged erythromycin-9-oxime 
(NP-ERY)  
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 Another exciting advance in the field was reported by Cambridge in 2009. In this 
study, a nitroveratryl photocaged doxycycline derivative (NV-DOX) was used to induce 
the expression of a fluorescent reporter in vivo (Figure 5.7).267 In this report, Cambridge 
used the tetracycline-inducible expression system (TetON), which induces heterologous 
gene expression in the presence of tetracycline derivatives, like doxycycline (DOX).268,269 
Upon irradiation of transduced rat hippocampal brain slices at 330 – 350 nm for 15 
seconds, they observed expression of the fluorescent reporter. Furthermore, an impressive 
degree of spatial resolution was achieved, demonstrating the ability to induce a 
fluorescence response in individual cells. Comically, this spatial resolution was also 
demonstrated by the creation of a fluorescent “smiley face” in one brain slice.  
 Furthering the potential applicability of light-dependent gene control methods, 
Cambridge also demonstrated photoactivated gene expression in live mouse embryos. 
Using a mouse whole-embryo culture system,270,271 they infected mice embryos with the 
TetON expression system. After 10.5 days, the embryos were removed, incubated with 
NV-DOX, and irradiated with light (330 nm, 15 s). They observed a fluorescence 
response in the irradiated embryos, thus demonstrating photoactivation of gene 
expression in vivo.    
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Figure 5.7. Doxycycline (DOX) and nitroveratryl caged doxycycline (NV-DOX) 
 
5.9.2. Photoinduced Muscle Contraction via Calcium Ion Release  
Since the first reported use of a photocage in 1977, the overwhelming majority of 
in vitro studies have utilized the NB or NV caging groups, which require UVA-light for 
one-photon decaging and high-intensity near IR-light for two-photon decaging.162 
Consequently, the light required for these decaging processes can be damaging to cells 
and can also bleach endogenous chromophores, thus restricting these photocages from 
use in vivo. In addressing these shortcomings, Ellis-Davis designed the NDBF photocage, 
which improved photochemical properties such as, larger molar absorptivities, faster rates 
of release, and better quantum yields of release, with respect to the NB and NV 
photocages (Figure 5.8).183  
For this study, Ellis-Davis designed NDBF-EGTA to photochemically release 
Ca2+ ions and demonstrated the efficient release of Ca2+ in vitro.183 They found that the 
parent NDBF-EGTA was a strong binder of Ca2+ (kd = 1.4 x 10-8), and upon photolysis, 
underwent a 140,000-fold decrease in binding to Ca2+ (kd = 10-3). Decaging in guinea pig 
cardiac muscle, via irradiation with a UV-laser at a power of 70 mJ, produced the 
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maximum force of muscle contraction. By comparison, under the same conditions, the 
NB-EGTA analogue produced < 10% of the maximum force of muscle contraction, due 
to the poor photochemical release of Ca2+ by NB-EGTA. Furthermore, decaging was 
found to be very efficient, proceeding with a rate constant of kr = 2 x 104 and a quantum 
yield of 0.7 (Fr•e = 1.8 x 104). Since this initial report of the NDBF cage, multiple 
studies have demonstrated the fast release of nucleotides,184 thiols,183 and amides.181 
Figure 5.8. Structures of NDBF-EGTA and NDBF 
 
5.9.3. Photoactivation and Photoinhibition of Neurons 
One of the most potentially impactful applications of photocaged small 
molecules, is the release of neurotransmitters to enable photoactivation or photoinhibition 
of neurons. The decaging of neurotransmitters such as, glutamate or GABA, allows for 
precise spatial and temporal control of neuron activation/inhibition using light. 
Furthermore, three-dimensional spatial resolution has been demonstrated through two-
photon uncaging in living organisms.208,244 However, the poor photochemical efficiencies 
of traditional nitrobenzyl-based caging groups has limited the in vivo applications of this 
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technique. To address these shortcomings, recent studies have focused on the design of 
novel caging compounds with better two-photon efficiencies  
In 2012, Goeldner and Specht reported the use of ANBP-GABA to effect the 
photoactivation of neurons (Figure 5.9).187 In these studies, they found that ANBP-
GABA possessed a number of advantageous properties, compared to previous 
photocaged GABA examples. First, ANBP-GABA was found to be soluble in phosphate 
buffer up to 10 mM and hydrolytically stable at room temperature for 24 hours. 
Furthermore, the ANBP cage absorbed light in the visible region (lmax = 397 nm) and 
displayed decent one-photon decaging efficiency (Fr•e = 1.1 x 103 M-1 cm-1). However, 
the ANBP cage displayed an impressive two-photon rate of release, with a single 
nanosecond laser pulse leading to nearly complete photolysis in under 5 µs. Subsequent 
in vitro studies found that isolated rat cortical brain slices, incubated in a 1 mM solution 
of ANBP-GABA, quickly underwent two-photon decaging when irradiated at 800 nm, 
and showed almost immediate dendritic current spikes. The efficiency of two-photon 
decaging of ANBP-GABA in vitro, has sparked interest in the potential use of ANBP-
caged neurotransmitters for in vivo photoactivation of neurons. 
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Figure 5.9. Examples of photocaged GABA and cAMP 
 
 
 More recently, the ability to selectively excite and inhibit neurons, through the 
orthogonal decaging of DEAC450-cAMP and CDNI-GABA has been reported (Figure 
5.9).251 In designing the DEAC450 photocage, Ellis-Davis discovered that DEAC450 not 
only exhibited a large absorbance in the visible region (lmax = 450 nm, e = 43,000 M-1 
cm-1), but also displayed a relative minimum in absorbance at wavelengths commonly 
used for decaging (lmin = 350 nm). He demonstrated orthogonal deprotection of 
DEAC450-cAMP and CDNI-GABA in striatal cholinergic interneurons, isolated from 
mouse brain slices. These neurons are known to spontaneously fire at a given 
frequency.272 The firing rate is known to be upregulated in response to stimuli that 
produce cAMP, thus the presence of cAMP increases the frequency of action potential 
firing.273 Conversely, action potential firing is inhibited by GABA, and thus the 
frequency of action potential firing decreases in response to the presence of GABA.274 In 
this assay, a solution of DEAC450-cAMP (25 – 75 µM) and CDNI-GABA (1 mM) was 
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added to the cholinergic interneurons, which resulted in no change of the action potential 
frequency. Upon irradiation at 473 nm for 100 - 200 ms, a dramatic increase in action 
potential frequency that lasted for tens of seconds was observed. In the same solution, 
irradiation at 355 nm for 2 ms, led to an immediate decrease in the frequency of neuron 
firing. The design of new visible light reactive caging groups has allowed for the ability 
to orthogonally deprotect two photocaged compounds, which will undoubtedly lead to 
entirely new applications of photocaged compounds.   
5.10. SUMMARY OF PHOTOLABILE PROTECTING GROUPS AND THE FUTURE OF 
PHOTOCAGING  
 
 Since the first report of the photolytic deprotection of Cbz-glycine, the field of 
photolabile protecting groups has grown dramatically.153 To reiterate, a successful PPG 
must meet the five criteria discussed. The protected compounds must be inert to the 
system under investigation. Deprotection should proceed quickly and efficiently upon 
irradiation. Photochemical byproducts must be inert and non-toxic to the system at hand. 
The protected compounds must be soluble in the target media. The observed rate of 
release must be faster than the response under investigation (biological studies). Since no 
one PPG meets all of these criteria for every potential application, selection of an 
appropriate PPG is paramount to the success of a given application. 
 A wide variety of PPGs featuring unique structural and mechanistic properties 
have been reported over the past half-century. Some of the most commonly used PPGs, 
or photocages, are shown in Figure 5.10. By far the most commonly used groups for 
 
 
 
175 
photocaging applications are the NV and NP cages. Though the photochemical 
efficiencies of these groups are less than ideal, the ability to reliably uncage a wide range 
of functionalities, combined with the simple synthesis of caged substrates from 
commercially available materials, has led to the wide-spread use of the NV and NP 
caging groups.170 New ortho-nitrobenzyl photocages, such as NDBF, have dramatically 
increased the photochemical efficiencies of decaging and will certainly be applied to 
future applications.183  
 The arylcarbonylmethyl photocages, namely, DMB and pHP, are especially 
useful in photochemical electrophysiology studies.194,201 Due to the fast rates of release 
and the formation of biologically inert photochemical byproducts, DMB and pHP caged 
neurotransmitters have been extensively utilized to study photoactivation and 
photoinhibition of neurons. Unfortunately, despite many efforts, the design of new 
photocages related to DMB and pHP that decage in visible light, have not been 
successful.    
 Though mechanistically related to the ortho-nitrobenzyl photocages, the ortho-
nitrophenpropyl photocages are particularly effective at two-photon decaging. One of the 
original ortho-nitrophenpropyl photocages, the NPP cage has been extensively used in 
photochemical gene silencing and photochemical activation/inhibition of enzymes, via 
the use of NPP-caged siRNA and peptides, respectively.275 Red-shifting the wavelengths 
of decaging into the visible region, the ANBP photocage is remarkably efficient at two-
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photon decaging, which will allow for unprecedented levels of spatial and temporal 
control in photocaging applications within living organisms.187   
Figure 5.10. Summary of the most commonly used and advantageous PPGs 
 
 
 Finally, the coumarin-based cages are one of the most promising classes of new 
photocages is the coumarin-based cages. With fast rates of decaging, large absorbance in 
the visible region, and advantageous fluorescent properties, coumarin-based photocages 
are quickly becoming a favorite choice for many in vitro applications.250 However, due to 
the photosolvolysis mechanism of deprotection, the coumarin caging groups are only 
applicable for the photocaging of good leaving groups. Nonetheless, many coumarin-
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based derivatives have been designed for photocaging applications. As demonstrated by 
Ellis-Davis, the large absorbance at long wavelengths of DEAC450, allows for 
orthogonal deprotection between traditional photocages, like the ortho-nitrobenzyl cages.  
 To this day, research continues towards the development of novel photocages to 
further meet the needs of current applications. There is currently a need for better caging 
groups that fulfill the criteria previously discussed. Currently, we are conducting research 
into the design of new caging groups that can release poor leaving groups, like alcohols 
and amines, upon irradiation with visible light. The unique and advantageous properties 
of the most recent photocages, has instigated a paradigm shift in what is now believed to 
be possible through the application of photoactivated compounds. Research into novel 
applications of photocages will lead to exciting advances in the fields of drug delivery, 
molecular biology, synthetic biology, and neurobiology. In the latter field, we have 
commenced a chemical, genetic, and neurobiological collaborative effort to develop a 
functional neuronal tagging method that, if successful, will lead to an unprecedented 
understanding of how the brain functions on a cellular level.  
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Chapter 6: Studies Towards Neuronal Tagging Through Caged Small 
Molecule Repressor Ligands. 
6.1. STUDYING BRAIN FUNCTION  
 In 1861, the French physiologist Paul Broca used the brain of Louis Leborgne, 
known in science folklore simply as “tan”, to show that a small section in the frontal lobe 
of the human brain was responsible for speech production. The patient, who could only 
speak the syllable “tan” with altered volume and inflection, was found post-mortem to 
have damage to the ventral frontal lobe of the left hemisphere of his brain.276 By 
correlating physiological symptoms to physical damage of the brain, Broca made an 
inference that this area of the brain, now known as Broca’s area, is crucial in speech 
production. At the time, this pioneering work launched what is known today within 
neurobiology as the lesion method.277 
 The lesion method of studying the brain is the practice of observing symptoms of 
a subject upon, removal or damage to a given area of their brain. Correlations between 
damaged sections of the brain and the corresponding physiological consequences, allows 
one to infer the function of a given area of the brain. While seemingly archaic and 
arguably outdated, this method of neurobiological research has led to a great deal of 
knowledge on brain function in the areas of language comprehension,278 long-term 
memory formation,279 processing of emotions,280,281 and visual perception.282 However, 
this method has a number of limitations.  
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 A major problem with lesion studies, is that this method inherently requires the 
destruction of neuronal circuitry, which means that conclusions based on this method are 
drawn from the lack of connectivity within the brain, as opposed to the study of a healthy 
intact brain. This relationship between a lack of function and the disruption of 
connectivity is further complicated by the ability of certain sections of the brain to change 
function in response to damaged circuitry.283 Second, the lesion method lacks the 
capability for an experimental control. The inference of brain function, based on the 
location of a lesion and the resulting physiological symptoms assumes these functional 
areas of the brain are localized to the exact same position for all individuals. However, it 
has been well documented that the brain shows a relatively large degree of anatomical 
diversity between individuals.284 Therefore, without proper experimental control subjects 
and a representative sample size, the results from an individual cannot be assumed to 
hold true for an entire population. Finally, this method assumes discrete anatomical 
modulation of cognitive function, also known as the “modularity” or “localization” 
assumption.277 This assumption has proven problematic because it has been shown that 
many brain functions are distributed between a number of localities.285 Though rich in 
history, many conclusions drawn from lesion studies have since been modified or 
disproven with the advent of modern functional brain imaging techniques, most notably 
functional magnetic resonance imaging (fMRI).  
 Since the discovery of functional magnetic resonance imaging (fMRI) in the early 
1990’s, this technique has revolutionized neurobiological research.286,287 Most 
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commonly, blood-oxygen-level dependent (BOLD) contrast is utilized. This method 
takes advantage of the fact that oxygenated and deoxygenated blood have different 
magnetic properties,288 which allows for images based on oxygenated blood flow within 
the brain to be produced. Since there is a direct relationship between blood flow within 
the brain and neural activity, these images have been shown to reflect brain activity.289 
This technique has led to remarkable gains in the understanding of how the human brain 
functions. However, there are also limitations to this technique, one of which is that the 
results are purely correlational. Because this method does not provide any information on 
brain function, it cannot be known if an activated area of the brain is necessary or even 
participates in a given task.277 Furthermore, the spatial resolution is limited to about 1 
mm3. While this resolution has allowed researchers to learn a great deal about what areas 
of the brain are active during a given function, it provides little or no insight into how 
specific neuronal pathways are interconnected, nor how these pathways contribute to a 
given function.  
6.2. NEW METHOD FOR FUNCTION-BASED NEURONAL TAGGING  
 
 In addressing the shortcomings of these previous techniques, we are developing a 
novel method to tag or label neurons based on function. While early attempts to develop 
this method will focus on fluorescently labeling activated neurons within a live mouse 
host, successive iterations will feature the expression of cellular actuators within these 
activated neurons. This will allow for experimental manipulation of the given subsets of 
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neurons that have been identified based on function, thus allowing the ability to probe 
neuronal circuitry on a cellular level.  
 The genetic construct to achieve this neuronal labeling method is currently being 
designed and developed in the laboratory of Dr. Boris Zemelman. For in vivo studies, we 
plan to install the genetic sequence via transduction of a viral vector. The three main 
components of this construct are Promoter X, Operator X, and the reporter (A, Figure 
6.1). Promoter X is a DNA sequence that acts as a binding site for a specific transcription 
factor (TF). The transcription factor responds to neuron activation by binding to the 
promoter and initiating transcription of downstream genes. For the purpose of this work, 
the reporter is green fluorescent protein (GFP). Operator X is a DNA sequence that acts 
as a binding site for the respective repressor protein. When bound to Operator X, the 
repressor protein blocks transcription downstream of Operator X, thus for a transduced 
neuron in the presence of the repressor, expression of the reporter is blocked or repressed 
irrespective of neuron activation (B, Figure 6.1). Finally, the repressor ligand is a small 
molecule with high-affinity for the repressor protein. When the repressor ligand is 
introduced, it binds to the repressor protein and the resulting protein-ligand complex 
detaches from Operator X. This allows for the reporter to be expressed whenever the 
transcription factor responds to neuron activation (C, Figure 6.1). 
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Figure 6.1. Proposed genetic construct to functionally tag activated neuronsa 
 
 
aA) Schematic representation of each component within the proposed genetic construct. B) In the absence 
of the repressor ligand, the repressor protein binds to the operator, thereby repressing expression of the 
reporter. Therefore, a transduced neuron will remain unlabeled irrespective of transcription factor 
activation due to neuron firing. C) Upon introduction of the repressor ligand, the repressor protein-ligand 
complex will dissociate from Operator X. Upon dissociation, neuron action potential will provoke a 
response from the transcription factor, which will initiate transcription of the reporter and lead to labeling 
of the neuron.  
6.2.1. Promoter X 
 
 An elegant feature of the proposed genetic construct is the inherent modularity of 
the genetic components. While the basic nature of Promoter X, Operator X, and the 
reporter will fundamentally remain the same, we have the ability to use any number of 
specific genes for each component to best fit our goal. For instance, promoter X can be a 
number of different DNA sequences, or response elements, that act as binding sites for 
transcription factors, which respond to neuron activation. Previous studies have reported 
the use of transcription factors that respond to immediate early genes (IEGs), such as c-
fos or arc, to induce gene expression reflective of neuronal activation.290–295 However, for 
Promoter X Operator X Reporter Repressor
Protein
Repressor 
Ligand
A.
B.
Unlabeled Neuron
C.
Labeled Neuron
TF
Transcription
Factor
TF
TF
Transcription
No Transcription
 
 
 
183 
our initial studies we plan to use the cAMP response element binding protein (CREB) as 
the transcription factor and the cAMP response element (CRE) as Promoter X. CREB is 
naturally found in all neurons and regulates gene expression, including IEG expression, 
based on neural activity. In the neuron signaling pathway, CREB-mediated gene 
expression occurs prior to the expression of IEGs, thus its use as the transcription factor 
should allow for a more responsive signaling method. 
 In nature, CREB activates gene transcription in response to a number of cellular 
signals, such as cAMP or Ca2+, that arise from neuron activation. Found in all neurons 
and a near universal indicator of neuronal activation, CREB has been previously used to 
control exogenous expression in neurons.296,297 The neuron signaling pathway for CREB-
mediated gene expression is shown in Figure 6.2. Binding of a ligand (L), or 
neurotransmitter, to the G protein-coupled receptor (GPCR) activates G protein (G), 
which in turn induces adenylyl cyclase (AC) mediated cAMP production. The secondary 
messenger, cAMP, promotes the dissociation of the heterotetrameric protein kinase A 
(PKA), which consists of two pairs of catalytic- (C) and regulatory-subunits (R). Through 
passive diffusion, the catalytic subunit (C) will enter the nucleus and phosphorylate (p) 
CREB at a single serine residue (Ser133). The phosphorylated-CREB binds to the cAMP 
response element (CRE), which is a repeating palindromic DNA sequence 
(TGACGTCA) and CREB binding site. Upon binding to CRE, the phosphorylated-CREB 
associates with the co-activator, CREB-binding protein (CBP), which in turn coordinates 
with RNA polymerase II (POL II) and initiates transcription.298 CREB-mediated gene 
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expression generally peaks about 30 min after neuronal stimulation, and subsequently 
decreases over the ensuing two – four hours, due to CREB dephosphorylation by the 
serine/threonine phosphatases PP-1 and PP-2A. 
Figure 6.2. Neuron signaling pathway leading to CREB-mediated gene transcriptiona 
 
 
aLigand (L) binding to G protein-coupled receptor (GPCR) activates the G protein (G), which induces 
adenylyl cyclase (AC) mediated cAMP production. cAMP promoted dissociation of protein kinase A 
(PKA) releases the catalytic-subunit (C), which enters the nucleus through passive diffusion. The catalytic-
subunit phosphorylates CREB, which in turn binds to the response element CRE. Upon binding to CRE, 
phosphorylated CREB initiates transcription through the association of CREB binding protein (CBP), 
which coordinates with RNA polymerase II (POL II).  
6.2.2. Operator/Repressor Systems 
 
 In order to label neurons based on function, during a given physiological event or 
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timeframe. Without this control, preliminary results have shown that over time, every 
transduced neuron will inevitably activate and express the reporter. Control of gene 
expression will be achieved through the inclusion of a heterologous transgene expression 
system. To date, a large number of eukaryotic transgene expression systems have been 
reported.299 
 Most heterologous transgene expression systems have been modified to both 
expression-ON and expression-OFF variants.266,299 Although mechanisms can vary 
between specific expression systems, typically in an expression-ON system, the 
respective repressor protein binds directly to the operator DNA sequence. Since the 
operator is downstream of the promoter, this binding interaction sterically blocks RNA 
polymerase (RNA-Pol) from binding to the protomer, thereby repressing transcription (A, 
Figure 6.3). Introduction of the repressor ligand leads to a protein-ligand interaction 
between the repressor protein and the repressor ligand that causes the ligand-bound 
repressor to dissociate from the operator, known as derepression, thus allowing RNA 
polymerase to bind to the promoter and initiate transcription.   
 Conversely, expression-OFF systems are designed so that introduction of the 
repressor ligand leads to repression of gene transcription. In these systems, generally a 
reverse ligand-dependent transactivator (Activator) is expressed (B, Figure 6.3).266,299 
This transactivator contains a repressor protein domain and when this domain is unbound, 
the transactivator coordinates with RNA polymerase and binds to the operator, thus 
promoting gene expression. When the repressor ligand is introduced, the ligand binds to 
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the repressor protein domain of the transactivator. This binding interaction causes the 
transactivator and RNA polymerase to dissociate from the operator, thus repressing 
transcription.  
Figure 6.3. Generalized heterologous gene expression schematic diagramsa  
 
 
aA) Expression-ON: in the absence of the repressor ligand, gene expression is repressed. Upon addition of 
the repressor ligand, derepression allows for gene transcription. B) Expression-OFF: in the absence of the 
repressor ligand a transactivator (Activator) promotes the binding of RNA polymerase (RNA-pol) to the 
promoter and leads to gene expression. Addition of the repressor ligand leads to dissociation of the 
transactivator and RNA polymerase to represses gene expression. 
 
 Gene regulation systems that utilize clinically approved small molecules 
including, erythromycin A, tetracycline, pristinamycin, and rapamycin as repressor 
ligands have been previously described.262,299 We have chosen the erythromycin-
dependent inducible expression regulation system (EON), which has been modified from 
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the macrolide 2’-phosphotransfersae I (mph(A)) protein, the protein responsible for 
inactivation of macrolide antibiotics and consequently, macrolide antibiotic resistance in 
E. coli.300 The expression of mph(A) in E. coli is regulated by the presence of the 
macrolide 2’-phosphotransferase repressor protein (MphR).266 MphR binds to a 35-base 
pair operator sequence (ETR) and overlaps with the mph(A) promoter, sterically blocking 
RNA polymerase from binding to the promoter, thus repressing gene expression (A, 
Figure 6.3, left side). Binding of erythromycin A to MphR leads to derepression of 
mph(A) and concomitant inactivation of erythromycin A (A, Figure 6.3, right side).  
6.2.3. Illustrative Example of the Proposed Method 
The genetic construct described currently has two requirements for the tagging of 
transduced neurons. First, since CRE (Promoter X) is upstream of ETR (Operator X) in 
our construct, erythromycin A (repressor ligand) must be present to induce derepression. 
Second, during derepression, the neuron must fire to phosphorylate CREB, which will 
then bind to CRE and lead the expression of GFP.  
A hypothetical example using this method to study the neuronal circuitry 
responsible for the feeling of hunger in mice, is given in Figure 6.4. Experimentally, we 
would first install our genetic construct into the brain of the mouse, via transduction of a 
viral vector. Upon transduction, we would expose the subjects to the physiological state 
or event under investigation, in this example, hunger. Administration of erythromycin A 
to both the hungry mice and a set of sated mice (control subjects) will induce 
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derepression, which will allow for CREB-mediated expression of GFP in neurons that are 
activated during this time. We would then maintain these physiological states for amount 
of time required to achieve quantifiable levels of reporter expression. At which point, ex 
vivo imaging of the brain will allow for a comparison of the neuronal ensembles that 
were active in both the experimental and control subjects. By comparing the neuronal 
ensembles activated in the hungry subjects to that of the control subjects, we can identify 
the ensembles responsible for the hunger signal. Once we have identified the neuronal 
ensembles that are potentially responsible for hunger, subsequent studies can target these 
ensembles through the expression of molecular actuators. This will allow us to 
independently manipulate these subsets of neurons in order to validate that stimulation or 
inhibition of these ensembles leads to the observed hunger signal. 
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Figure 6.4. Illustrative example of the proposed methoda  
 aThe comparison of tagged neurons in the hungry mice to the tagged neurons in the control mice will allow 
identification of the neurons responsible for the hunger signal. 
 
 Though the methods described are well suited to study physiological events that 
can be maintained over a long period of time, such as hunger or addiction, the methods 
described will not allow for the study of very fast physiological events like memory 
formation or fear response. The major limitation in applying this method to very fast 
physiological events is that administration of erythromycin A, either orally or via 
injection, leads to the presence of the drug, and thus derepression, on the timescale of 
hours. To achieve the temporal resolution necessary for the study of fast physiological 
events, we will use light to quickly release erythromycin A in the brain from a 
photocaged-erythromycin derivative.   
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6.2.4. Proposed Method to Tag Neuronal Ensembles Based on Function 
 A summary of the proposed biochemical methods that will be used to achieve 
neuronal tagging are shown in Figure 6.5. First two expression cassettes will be 
transduced in vivo via a viral vector (A, Figure 6.5). Cassette (1) consists of the mouse 
synapsin promoter (mSyn promoter), which promotes constitutive transcription of 
downstream genes in mouse neurons, MphR will be continuously expressed. The second 
expression cassette (2) contains CRE, which is multimerized to adjust the sensitivity of 
gene expression, the ETR operator, and GFP. The expressed MphR protein will bind to 
ETR and repress transcription of GFP. Initially, administration of the photocaged 
erythromycin (caged-ERY) will not affect gene expression. However, following 
irradiation with visible light, released ERY will bind to MphR, and the MphR-ERY 
complex will dissociate from ETR (B, Figure 6.5). At this point, neuron action potential 
will lead to the phosphorylation of CREB, which will bind to CRE and initiate 
transcription of the reporter. By releasing erythromycin A from a photocage via 
irradiation with visible light, this system will achieve temporal resolution on the order of 
the rate of decaging. If decaging can be accomplished on the timescale of seconds to 
minutes, this method will be able to identify neuronal ensembles responsible for fast 
neurological events such as, memory formation or fear response. 
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Figure 6.5. The proposed biochemical construct and mechanism to effect tagging of 
activated neurons using visible lighta 
 
aA) Expression cassettes that will be transduced to install the genetic construct into mouse models. B) 
Irradiation of visible light will lead to the release of erythromycin, which will bind too and remove the 
MphR protein from the ETR operator. Subsequent phosphorylation of CREB, due to neural activity, will 
lead to the expression of the fluorescent reporter GFP. C) In summary, for a transduced neuron to express 
GFP as an output, neural activity and irradiation of light are required as inputs.  
 
6.3. VISIBLE LIGHT PHOTOCAGED ERYTHROMYCIN A  
 The ultimate goal of this project, is to develop a method to tag or label activated 
neurons within a living organism, and this necessitates that the caged-ERY derivative 
meets a strict set of criteria. Four requirements were identified in designing the caged-
ERY derivative.  
1. The caged-ERY must be water soluble. Given that we ultimately are 
developing a method to be used in the brain of a living organism, aqueous 
solubility is a necessity. 
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2. The caged compound must be inert in the biological system in the absence of 
light.  
3. The caged-ERY needs to decage using visible light. The use of UV-light in 
decaging is commonplace in many applications, but UV-light damages living 
tissue. In our studies, neuronal damage will inherently disrupt the natural 
neuronal circuitry that we are attempting to study.  
4. The caged-ERY derivative must decage on a timescale of seconds to minutes. 
The irradiation times required to decage ERY in suitable quantities, will 
directly affect the temporal resolution attainable with this method. Irradiation 
times greater than a few minutes will lead higher levels of neuron labeling due 
to background brain activity.  
With the aforementioned requirements, we set out to design and validate a novel caged-
ERY derivative that fit these criteria.  
6.3.1. Erythromycin A Derivatives and Caging Groups 
 
 When considering how to photocage ERY (6.1) (Figure 6.6) with a suitable 
caging group, two factors were considered. First, we needed to use an ERY derivative 
that contained a suitable functional handle to append the photocage. Second, we needed 
to validate that this ERY derivative retains a high binding affinity to MphR. As 
mentioned previously (Chapter 5.9.1), Deiters had demonstrated that decaging of 
erythromycin A-9-oxime (ERY-9-OX, 6.2) allows for photoactivated derepression of 
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gene transcription using the EON expression system.265 Furthermore, previous reports 
have shown that ERY-9-OX retains biological activity with respect to ERY.301,302 
Figure 6.6. Erythromycin A (ERY, 6.1) and erythromycin A-9-oxime (ERY-9-OX, 6.2) 
 
 
 In view of the aforementioned precedent, it remained to determine which visible 
light caging group is best suited for our system. As described in Chapter 5, there are 
many potential caging groups. Based on the previously described criteria, we narrowed 
the number of options to two potential caging groups, the nitrodibenzofuran (NDBF, 6.3) 
and diethylaminocoumarin 450 (DEAC450, 6.4) groups (Figure 6.7). These groups stood 
out as promising caging candidates for ERY-9-OX based on previous reports of fast 
release rates and the successful applications of these caging groups in biological 
studies.183,250,251 
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Figure 6.7. Caging groups chosen for this study, NDBF (6.3) and DEAC450 (6.4) 
 
 
 As discussed in the preceding chapter (Section 5.9.2), the NDBF photocage has 
previously demonstrated efficient release of nucleotides,181,184 peptides,183 and calcium 
ions.183 Notably, it was possible to quickly decage NDBF substrates with poor leaving 
groups like thiols183 and amides.181 Although the maximum absorbance is not in the 
visible region, the relatively large absorbance and efficient quantum yields of release 
(lmax = 330 nm, e = 18,400 M-1 cm-1, e•F = 12,880)183 provided promise for success of 
this caging group for our studies.  
 With a large absorbance well into the visible region (lmax = 450 nm, e = 43,000 
M-1 cm-1), the DEAC450 photocage is also an attractive option for the caging of ERY-9-
OX.250 Furthermore, in vitro studies found that the decaging of cAMP from DEAC450 
proceeded in an impressive quantum yield of 0.78 (e•F = 33,500).251 Though the 
decaging of coumarin-caged compounds with poor leaving is known to be inefficient, we 
anticipated that the low concentrations necessary for ERY induced gene expression (~1 
µM),266 would allow for the release of sufficient quantities of ERY-9-OX. With this in 
mind, we commenced studies towards the synthesis and evaluation of NDBF-ERY and 
DEAC450-ERY. 
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6.4. SYNTHESIS OF ERYTHROMYCIN A-9-OXIME   
 
 The synthesis of ERY-9-OX proceeded smoothly according to literature 
precedent.301 Stirring ERY at room temperature in pyridine with an excess of 
hydroxylamine hydrochloride for 72 hours, followed by extraction and recrystallization 
from ethanol gave ERY-9-OX in 74% yield on multi-gram scale (Equation 6.1).  
 
(6.1) 
6.5. SYNTHESIS OF NDBF CAGING GROUP  
 
 The NDBF photocage was prepared according to previously reported methods.181 
However, our synthesis proceeded with higher yields for most steps and an overall yield 
of 31%, as compared to 19% overall yield in the previous report. Starting from 4-fluoro-
2-nitrobenzaldehyde (6.5), an Ullman coupling with 2-iodophenol (6.6) gave biaryl ether 
6.7 in 86% yield (Scheme 6.1). Allowing 6.7 to react with neat trimethylaluminum 
formed biaryl-alcohol 6.8 in nearly quantitative yield. Palladium-catalyzed arylation of 
6.8 proceeded in 51% yield to give dibenzofuran 6.9. Attempts to optimize this reaction 
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met with limited success. The use of different solvents, temperatures, reaction times, 
bases, and the addition of ligands failed to provide any appreciable gains in chemical 
yield. The major byproduct from this reaction was the dehalogenation of 6.8. The poor 
reactivity of 6.8 towards palladium-catalyzed arylation is thought to arise from the poor 
reactivity of intermediate 6.10, which is formed upon oxidative addition of palladium 
(0).303,304 Intermediate 6.10 must undergo an electrophilic aromatic substitution onto the 
palladium center, which is followed by rearomatization and reductive elimination to give 
6.9. However, in this system the nitro substituent strongly deactivates that aromatic ring 
towards attack of the palladium center.  
Scheme 6.1. Synthesis of nitrodibenzofuran alcohol 6.9 
 
 
 Synthesis of the NDBF caging group 6.12 from dibenzofuran 6.9 was completed 
in two additional steps (Scheme 6.2). Oxidation of dimethylsulfide led to the in situ 
formation of a Pummerer-type intermediate, and subsequent addition of 6.9 gave the 
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thioacetal 6.11 in 74% yield. Finally, allowing 6.11 to react with sulfuryl chloride gave 
the chloro-acetal 6.12 in nearly quantitative yield. It is worth noting that while compound 
6.11 was benchtop stable, the alkylating agent 6.12 was quite unstable. Compound 6.12 is 
effectively an NDBF-caged chloride ion (good leaving group), so the reaction and work-
up to isolate 6.12 needed to be carried out in the dark to avoid photochemical release of 
the chloride ion.  
Scheme 6.2. Synthesis of NDBF caging group 6.12 
 
6.6. SYNTHESIS OF DEAC450 CAGING GROUP 
 
 Synthesis of a DEAC450 caging group commenced with the allylic oxidation of 
7-diethylamino-4-methylcoumarin (6.13) to give the alcohol 6.14 in 29% yield (Scheme 
6.3).305 Though low yielding, this reaction was easily scaled to provide sufficient 
amounts of material to complete the synthesis. Protecting the alcohol 6.14 as the TBS 
silyl ether provided 6.15 in 77% yield. Ammonium acetate catalyzed aromatic 
bromination of 6.15 cleanly gave the bromide 6.16 in 86% yield. Heck cross coupling of 
6.16 and tert-butyl acrylate gave 6.17 in 41% yield. All attempts to reproduce the 
literature yield (85%) and optimize this reaction failed to improve the isolated yield.250 
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Additionally, we were unable to replicate the literature yield (85%) for the TBS 
deprotection.250 Using the reported protocol, treatment of 6.17 with TBAF consistently 
gave 6.18 in 30-40% yield. However, we found that the use of a 3HF•Et3N solution in 
dichloromethane buffered with two equivalents of triethylamine afforded the free alcohol 
6.18 in 92% yield. Finally, the transformation of 6.18 to the corresponding mesylate 
proceeded in nearly quantitative yield to give 6.19.  
Scheme 6.3. Synthesis of DEAC450 caging group 6.19 
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6.7. SYNTHESIS OF NDBF-ERY AND DEAC450-ERY  
 
 The final step in synthesizing our caged-ERY derivatives was the alkylation of 
ERY-9-OX with the respective caging group. We initially attempted this reaction by 
heating a solution of ERY-9-OX, 6.12, and potassium carbonate in acetone under reflux, 
which consistently gave returned starting materials. We then found that treatment of 
ERY-9-OX with sodium hydride in a mixture of DMF and THF (1:1), followed by the 
addition of a solution of the respective alkylating agents, gave NDBF-ERY and 
DEAC450-ERY in 78% and 39% yields, respectively (Equation 6.2, 6.3). With NDBF-
ERY and DEAC450-ERY in hand, we focused our attention on determining whether 
these compounds met the criteria necessary for the neuronal imaging studies. 
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6.8. EVALUATING THE CAGED-ERY CRITERIA 
 
 As a quick summary, the criteria that our caged-ERY derivatives must fit are:  
1. Water solubility. 
2. Inert towards the biological system in the absence of light. 
3. Uncaging with visible light. 
4. Uncaging must occur on a timescale of seconds to minutes.  
In evaluating the water solubility of NDBF-ERY and DEAC450-ERY, we utilized 
Beer’s law to determine the concentration of a saturated solution of each compound. UV-
vis spectroscopy was used with aqueous solutions of the caged-ERY derivatives to plot 
the absorbance at lmax against concentration.  
 The Beer’s law plots for NDBF-ERY and DEAC450-ERY are shown in Figure 
6.8 and 6.9, respectively. We were pleased to find a linear relationship between 
absorbance and concentration in both cases at concentrations between ~10 – 100 µM. For 
NDBF-ERY, we found lmax at 350 nm and determined the concentration of a saturated 
aqueous solution to be 115 µM. Although, the maximum absorbance occurs outside of 
the visible region, this does not innately mean that this compound is unsuitable for our 
purposes. In the UV-Vis plots (see S.I.) there is a trailing absorbance past 400 nm, which 
means that this compound could decage using visible light. Conversely, DEAC450-ERY 
displayed a strong absorbance between 440 – 470 nm with a lmax at 460 nm. The Beer’s 
law plot shows a near perfect linear relationship between absorbance at 461 nm and 
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concentrations from 8 to 100 µM. We determined the concentration of a saturated 
aqueous solution to be 100 µM.  
Figure 6.8. Beer’s law plot of NDBF-ERY at 350 nm 
 
Figure 6.9. Beer’s law plot of DEAC450-ERY at 461 nm 
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 At this point, it was necessary to determine whether concentrations of 100 µM fit 
our criteria of water solubility. From a synthetic chemist perspective, these 
concentrations might not suggest that these molecules are “water soluble”, because the 
saturated solutions equate to about 0.1 mg/mL. However, when reviewing previously 
reported literature on the use of MphR, we find that the Eon systems display induced gene 
expression with ERY concentrations ranging from 10 – 2,000 ng/mL, which equates to 
0.013 – 2.7 µM.266 This means, dependent on the yield of decaging, achieving final 
concentrations of ERY within a neuron at single or low double digit micromolar 
concentrations is feasible from a 100 µM solution of caged-ERY.  
 To determine the extent of decaging of NDBF-ERY and DEAC450-ERY with 
respect to time and wavelength, two key issues needed to be addressed. First, we needed 
to develop a method to quantitate micromolar concentrations of released ERY-9-OX in 
an aqueous solution. Typically, photolysis studies involve irradiation of the samples, 
followed by HPLC separation and quantitation using a UV detector. Because ERY-9-OX 
lacks a strongly absorbing chromophore this is challenging, and thus, ERY-9-OX is 
indiscernible on HPLC chromatograms with UV-vis detectors. Second, we needed to 
develop a method to irradiate our samples with discrete wavelengths of light at powers 
that were comparable to the fiber optics that will be used in the in vivo studies. Previous 
studies often relied on the use of lasers or powerful mercury lamps (~200-500 W) with a 
UV-filter to achieve irradiation at selected wavelengths. However, both methods provide 
light with a much greater intensity than the fiber optics.  
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 We initially focused our attention towards developing an ERY-9-OX quantitation 
method. Initial attempts to quantify ERY-9-OX via HPLC chromatography were quickly 
found to be ineffective. The lack of an appreciable chromophore on ERY-9-OX meant 
that the micromolar concentrations used in these experiments were well below the 
instrumental detection limit. We next turned to the use of mass spectrometry as a method 
of quantitation. Subjection of a number of solutions of ERY-9-OX in concentrations 
ranging from 0.25 – 100 µM to LC/MS and subsequent plotting of concentration against 
a number of different signals (ion count, peak height, peak area), gave the data shown in 
Figure 6.10. We found a linear relationship between the mass spectrum peak area and 
ERY-9-OX concentrations from 6 – 100 µM. We observed that concentrations below 6 
µM diverged from a linear relationship and approached zero in an exponential decay. The 
use of LC/MS, as opposed to direct injection MS, was chosen because the 
chromatographic separation will be advantageous when analyzing irradiated NDBF-ERY 
and DEAC450-ERY samples. This separation will allow us to not only determine the 
concentration of released ERY-9-OX, but also allow us to analyze the amounts of 
unreacted starting material and any potential photochemical decomposition byproducts.  
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Figure 6.10. LC/MS quantitation of ERY-9-OX 
 
 
  In the initial decaging studies, irradiation time was set as the variable. The 
purpose of this time-course study was to determine the feasibility of inducing ERY-9-OX 
release on a timescale of seconds to minutes. The following experiment was conducted 
using a UV-laser (l = 340 nm, P = 100 mW). In this study, saturated aqueous solutions of 
NDBF-ERY in a vial were positioned directly beneath the laser. Each sample was 
irradiated for the given amount of time and immediately analyzed by the LC/MS 
quantitation method. The results are shown below (Figure 6.11). 
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Figure 6.11. Time-course decaging of NDBF-ERY 
 
 
 The results from this decaging study were encouraging. Decaging started rapidly 
(10% at 1 min) and proceeded to release ERY-9-OX in 30% yield after five minutes. 
Attempts to effect complete decaging of ERY-9-OX (15 min and 30 min) were 
unsuccessful. We postulated that that the inability to achieve complete decaging upon 
irradiation for 30 minutes, was in part due to the fact that the diameter of the laser beam 
was smaller than that of the vial used. Since that the samples were not irradiated 
homogenously, a fraction of the sample remained unreacted. Nonetheless, we were 
delighted to find that appreciable quantities of decaging (30%) were obtained after a 
reasonable amount of time (5 min). Under these conditions the concentration of ERY-9-
OX is roughly 35 µM, which is well above the threshold necessary for induced 
transcription in the EON expression system found in previous studies.266 
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  Though encouraged by these early results, there were multiple reasons for 
abandoning this decaging study. First, the laser used in this experiment was much more 
powerful than the light that would be available using fiber optics for the in vivo studies. 
Hence, these results were not a direct representation of the photochemical reactivity of 
NDBF-ERY within the in vivo system that would be used.   
 At this stage, we considered different ways we could select for specific 
wavelengths of light to irradiate our caged compounds. We decided a fluorometer could 
be an effective method to select specific wavelengths. Using a QuantaMaster 
Spectrofluorometer (PTI inc.), we irradiated saturated solutions of NDBF-ERY and 
DEAC450-ERY at wavelengths between 300 and 500 nm. The results from these 
wavelength-dependence decaging studies were both promising and disappointing.  
 Results of the wavelength-dependence decaging study of NDBF-ERY are shown 
below (Figure 6.12). In this study, 100 µL samples of aqueous NDBF-ERY solutions 
were irradiated for five minutes at the specified wavelength and analyzed by the LC/MS 
quantitation method discussed previously. Importantly, the dark control sample (l = 0), 
which was keep in the dark for the entirety of the study, displayed no trace of ERY-9-
OX. This indicates that NDBF-ERY is stable in an aqueous solution at room temperature 
for at least three hours. To avoid unwanted derepression in our biological studies, the 
stability of the caged-ERY compounds in aqueous media is paramount. Furthermore, we 
found that decaging was quite efficient at 325 nm, proceeding in an 80% yield of decaged 
ERY-9-OX. Though the yields of decaging declined as a function of wavelength, the 
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observed 37% yield at 400 nm demonstrated that NDBF-ERY meets the criteria for 
decaging under visible light on the order of seconds to minutes.  
Figure 6.12. Wavelength-dependent decaging of NDBF-ERY (irradiation time = 5 min)   
 
 
 In almost direct contrast to the NDBF-ERY results, decaging of DEAC450-ERY 
was quite inefficient (Figure 6.13). Using the same protocol, we found that these 
conditions did not lead to an appreciable release of ERY-9-OX. At best, ERY-9-OX was 
released from DEAC450-ERY in 12% yield, upon irradiation at 400 nm. Furthermore, 
the dark control sample gave 2% decaging (or hydrolysis), which indicates that 
DEAC450-ERY is not stable in aqueous media at room temperature and could 
potentially be problematic. These results clearly indicate that, for the purposes of our 
studies, DEAC450-ERY does not fit the criteria of decaging using visible light on a 
timescale of seconds to minutes.  
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Figure 6.13. Wavelength-dependent decaging of DEAC450-ERY 
 
 
 The slow decaging of DEAC450-ERY can likely be explained by considering the 
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However, the pKa values of alkyl-oximes have been reported and found to range from 
~24-29 as exemplified by propanal oxime (pKa = 28.5 in DMSO).306 For comparison 
sake, poor leaving groups, such as alcohols, exhibit similar pKa values (methanol, pKa = 
0
10
20
30
40
50
0 350 400 450 500
D
ec
ag
in
g 
(%
)
Wavelength (nm)
DEAC450-ERY Decaging
 
 
 
210 
29.0 in DMSO).307 These relatively high pKa values indicate that the oxime functionality 
and by extension, ERY-9-OX, is not a satisfactory leaving group for the DEAC450 
caging group. 
6.9. PENDING EXPERIMENTS: IN VITRO PROOF OF PRINCIPLE 
 A number of in vitro experiments are currently being conducted to establish proof 
of principle that our genetic construct will lead to the labeling activated neurons. First, we 
have to establish the optimal parameters for the neuron cell assay and tune the sensitivity 
of reporter response. In doing so, we are considering three variables namely, the number 
of repeating CRE sequences, the levels of MphR expression, and the concentration of 
ERY-9-OX. To determine the optimal number of CRE multimers, isolated mouse 
hippocampal neurons are being transduced with iterations of the genetic construct that not 
only omit the gene coding for MphR, but also vary in the number of CRE repeats. Upon 
chemical stimulation of the neurons using forskolin, we will determine the number of 
CRE repeats necessary for reporter expression.308  
 A second set of experiments is being performed to determine the required levels 
of MphR expression for full repression of the reporter, as well as the concentrations of 
ERY-9-OX required to achieve derepression. In these experiments, which are illustrated 
in Figure 6.14, transduced hippocampal mouse neurons are placed in each well of a 
microtiter plate. Expression levels of the MphR protein is increased in wells along the X-
axis and concentration of ERY-9-OX was increased in wells along the Y-axis of the 
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plate. The first column the plate does not express any MphR and is thus a positive control 
to compare levels of reporter expression. Conversely, the bottom row, which contains no 
ERY-9-OX, is as a negative control to determine the minimum level of MphR expression 
required to achieve full repression of the reporter. By comparing the fluorescence 
intensity of each well to that of the positive control, we can determine the concentrations 
of ERY-9-OX required for derepression of a given level of MphR expression. 
Figure 6.14. Illustrative representation of in vitro titration of MphR expression against 
ERY-9-OX concentration  
 
 
 Once optimal cell assay parameters are established, in vitro studies will focus on 
demonstrating the utility of NDBF-ERY in the current system. First, transduced neurons 
will be incubated with increasing concentrations of NDBF-ERY to establish that NDBF-
ERY is inert towards the biological system. Upon determining the concentrations at 
which NDBF-ERY is inert, neuron cultures containing NDBF-ERY will be irradiated 
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with visible light (l ~ 400 nm), which will ideally lead to expression of the fluorescent 
reporter. If successful, these experiments will provide an adequate proof of principle to 
continue further studies in live mouse models. 
6.10. SUMMARY AND FUTURE DIRECTIONS  
 
 We have synthesized two novel caged analogues of ERY-9-OX, although the 
caging groups themselves are known. To our knowledge, the use of visible-light caging 
groups on a molecule possessing the chemical complexity of ERY-9-OX has not been 
reported. We have demonstrated that irradiation of NDBF-ERY under a relatively low 
power of visible light (5-6 mW) efficiently releases ERY-9-OX. Conversely, we also 
found that the DEAC450 caging group does not release ERY-9-OX under the same 
conditions.  
 Once the efficacy of NDBF-ERY towards the labeling of activated neurons in 
vitro is established, future studies will focus on two goals. The first goal will be to 
implement this method in live mouse models. Viral transduction of our genetic construct 
will circumvent the necessity for time-intensive transgenic animal models. Upon 
transduction, surgically implanted microsyringes flanked by fiber optic filaments will 
allow us to inject and irradiate NDBF-ERY inside of the brains of live mice. We 
anticipate that the release of ERY-9-OX in the brain will lead to expression of the 
fluorescent reporter in neurons that were activated during this time. Once this method has 
been established in mouse models, we can begin to expose the mouse subjects to 
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experimentally controlled physiological stimuli or conditioned responses and visualize 
the neural activity responsible for the given event.  
 The second aim of our future studies, is to introduce bidirectionality within our 
expression system. Given that the response element CRE is a palindromic DNA 
sequence, transcription of the antisense 3’ to 5’ direction will allow for the expression of 
a second reporter (Reporter Y) (Figure 6.15). Using a different operator/repressor pair 
(Operator Y and Repressor Y), we can then develop a caged derivative of the new 
repressor ligand (Ligand-PPG). One such possibility, is the use of the TetON expression 
systems, for which the repressor protein (TetR) responds to the presence of tetracycline 
or doxycycline.268,309 Photocaging of this ligand with an appropriate caging group could 
allow for orthogonal decaging between NDBF-ERY and new caged-ligand.  
  This bidirectional reporter system will allow for numerous experimental 
capabilities. First, in the absence of Repressor Y, the expression of Reporter Y will act as 
a positive internal standard to visualize transduced neurons. Secondly, the bidirectional 
reporter system will allow for the labeling of two distinct states of neuronal activation, 
thus allowing us to confirm that the same contextual stimuli leads to the activation of the 
same neuronal ensembles. Conversely, the bidirectional system will allow us to visualize 
the similarities and differences of neuronal ensembles activated by different contextual 
stimuli.   
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Figure 6.15. Future genetic construct to afford bidirectional neuronal tagging 
 
 
 The potential applications of this function-based neuronal tagging technique are 
multifold. First, this method could allow for functional brain imaging with spatial 
resolution on the cellular level. This resolution would lead to tremendous gains in 
understanding what areas of the brain are responsible for given functions. Second, this 
tagging method could be used to express molecular actuators, such as channelrhodopsins, 
in subsets of neurons that have been specified based on neural function. By selecting for 
specific neuron populations by irradiating with light and subsequent neural activity, 
neurobiologists will have an unprecedented ability to experimentally target specific areas 
of the brain involved in a given physiological event. Finally, the use of this technique will 
have a profound impact on the medical community, specifically in the study of 
neurological disorders. Many neurological disorders are poorly understood and often 
difficult to treat. The use of this technique as an imaging method would not only permit 
studies of the neurological mechanisms responsible for these diseases, but could also lead 
to new diagnostic tools. Finally, the neurologist’s holy grail, would be a method that 
could be used to treat neurological disorders by targeting, controlling, or manipulating 
selected populations of neurons that are responsible for the given disorder.   
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Chapter 7: Experimental Procedures 
7.1. GENERAL EXPERIMENTAL METHODS 
 Tetrahydrofuran and diethyl ether were dried by filtration through two columns of 
activated, neutral alumina according to the procedure described by Grubbs.310 Methanol, 
acetonitrile and dimethylformamide were dried by filtration through two columns of 
activated molecular sieves, and toluene was dried by filtration through one column of 
activated, neutral alumina followed by one column of Q5 reactant. Benzene was distilled 
from sodium and benzophenone. Methylene chloride, diisopropylamine, triethylamine, 
and diisopropylethylamine were distilled from calcium hydride immediately prior to use. 
Pyridine was distilled from potassium hydroxide (KOH) and calcium hydride and stored 
over KOH pellets. All other reagents and solvents were reagent grade and were purchased 
and used as received unless otherwise noted. Reactions were performed under a nitrogen 
or argon atmosphere in round-bottom flasks sealed under rubber septa with magnetic 
stirring, unless otherwise noted. Water sensitive reactions were performed with flame- or 
oven-dried glassware, stir-bars, and steel needles. Reaction temperatures are reported as 
the temperatures of the bath surrounding the vessel. Sensitive reagents and solvents were 
transferred using plastic syringes and steel needles using standard techniques. 
 Proton nuclear magnetic resonance (1H NMR) and carbon nuclear magnetic 
resonance (13C NMR) spectra were acquired in CDCl3 unless otherwise noted. Chemical 
shifts are reported in parts per million (ppm, δ), downfield from tetramethylsilane (TMS, 
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δ = 0.00 ppm) and are referenced to residual solvent (CDCl3, δ = 7.26 ppm (
1H) and 
77.16 ppm (13C)). Coupling constants (J) are reported in hertz (Hz) and the resonance 
multiplicity abbreviations used are: s, singlet; d, doublet; t, triplet; q, quartet; p, pentet; 
sex, sextet; sep, septet; dt, doublet of triplets; dd, doublet of doublets; ddd, doublet of 
doublet of doublets; dddd, doublet of doublet of doublet of doublets; m, multiplet; comp, 
overlapping multiplets of magnetically non-equivalent protons. The abbreviations br and 
app stand for broad and apparent, respectively. Infrared (IR) spectra were obtained with a 
Thermo Scientific Nicolet IR-100 FT-IR series spectrometer as thin films on sodium 
chloride plates. Melting points were determined using a Thomas-Hoover Uni-melt 
capillary melting point apparatus. Thin-layer chromatography (TLC) was performed on 
EMD 60 F254 glass- backed pre-coated silica gel plates and were visualized using one or 
more of the following methods: UV light (254 nm) and staining with basic potassium 
permanganate (KMnO4) or acidic p-anisaldehyde (PAA). Flash chromatography was 
performed using glass columns and with Silicycle
® 
SiliaFlash F60
® 
(40-63 µm) silica 
gel eluting with the solvents indicated according to the procedure of Still. 
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7.2. EXPERIMENTAL PROCEDURES 
 
 3-Bromo-4,5-dimethoxybenzaldehyde (2.8). ARMI23. Bromine (3.7 mL, 72.3 
mmol) was added dropwise over 5 min to a solution of vanillin (10.0 g, 65.7 mmol) in 
acetic acid (100 mL), and the reaction was stirred at room temperature for 3 h. The 
mixture was poured over crushed ice (~200 g), and the solid was collected by filtration. 
Iodomethane (4.5 mL, 72.3 mmol) was added dropwise over 10 min to a solution of the 
isolated solid and K3PO4 (22.7 g, 164 mmol) in DMF (330 mL). The mixture was stirred 
for 14 h at room temperature, then diluted with water (300 mL), and extracted with t-
butylmethyl ether (3 x 300 mL). The combined organic fractions were washed with brine 
(1 x 300 mL), dried (Na2SO4), filtered, and concentrated in vacuo to give crude 2.8 as an 
amorphous solid. Crystallization from boiling hexanes afforded 13.0 g (81%) of 2.8 as 
white crystals: M.p. 59-60 ºC. IR (thin film) 2945, 92836, 1692, 1587, 1566, 1486, 1281 
cm-1. 1H NMR (400 MHz) d 9.85 (s, 1 H), 7.66 (d, J = 2.0 Hz, 1 H), 7.39 (d, J = 2.0 Hz, 1 
H), 3.95 (s, 3 H), 3.93 (s, 3 H). 13C NMR (100 MHz) d 189.9, 154.2, 151.8, 133.0, 128.8, 
117.9, 110.0, 60.8, 56.2. HRMS calculated for C9H9BrO3 (MH+) 244.9813 and 246.9793 
found 244.9815 and 246.9793. 
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 NMR Assignment. 1H NMR (400 MHz) d 9.85 (s, 1 H, CHO), 7.66 (d, J = 2.0 Hz, 
1 H, C2-H), 7.39 (d, J = 2.0 Hz, 1 H, C1-H), 3.95 (s, 3 H, OCH3), 3.93 (s, 3 H, OCH3). 
 
 
 (4-Bromophenoxy)(tert-butyl)dimethylsilane (2.11). ARMVI21. A solution of 
4-bromophenol (10.0 g, 57.8 mmol), TBSCl (9.5 g, 63.6 mmol), and imidazole (5.9 g, 
86.7 mmol) in CH2Cl2 (150 mL) was stirred for 2.5 h at room temperature. the mixture 
was diluted with CH2Cl2 (100 mL), and washed successively with saturated aqueous 
NH4Cl (100 mL) and water (100 mL). The organic fraction was dried (Na2SO4), filtered, 
and concentrated in vacuo to give crude 2.11 as a colorless oil. The crude material was 
purified via silica gel plug eluting with hexanes, to afford 15.28 g (92%) of 2.11 as a 
colorless oil: 1H NMR (400 MHz) d 7.33 (d, J = 8.8 Hz, 2 H), 6.73 (d, J = 8.8 Hz, 2 H), 
1.00 (s, 9 H), 0.21 (s, 6 H). 
 NMR Assignment. 1H NMR (400 MHz) d 7.33 (d, J = 8.8 Hz, 2 H, C1-H), 6.73 
(d, J = 8.8 Hz, 2 H, C2-H), 1.00 (s, 9 H, TBS), 0.21 (s, 6 H, TBS). 
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 2,4,6-Tris(4-((tert-butyldimethylsilyl)oxy)phenyl)-1,3,5,2,4,6-
trioxatriborinane (2.12). ARMI17. A solution of n-butyllithium (2.3 M, 3.7 mL, 8.7 
mmol) was added dropwise to a solution of 2.11 (1.0 g, 3.5 mmol) in THF (8 mL) at -78 
ºC, and stirred for 5 min at -78 ºC. Triisopropyl borate (3.3 g, 17.4 mmol) was added in 
one portion, and the reaction was slowly warmed to room temperature overnight. The 
mixture was diluted with water (50 mL) and saturated aqueous NH4Cl (10 mL), and 
extracted with ethyl acetate (3 x 50 mL). The combined organic fractions were 
concentrated in vacuo to a total volume of roughly 20 mL, and refrigerated overnight. A 
white solid crashed out of solution, which was isolated by filtration to give 0.71 g (81%) 
of 2.12 as an amorphous white solid: 1H NMR (400 MHz) d 8.13 – 8.10 (m, 6 H), 6.97 – 
6.94 (m, 6 H), 1.01 (s, 27 H), 0.26 (s, 18 H) 
 NMR Assignment. 1H NMR (400 MHz) d 8.13 – 8.10 (m, 6 H, C1-H), 6.97 – 
6.94 (m, 6 H, C2-H), 1.01 (s, 27 H, TBS), 0.26 (s, 18 H, TBS) 
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 4'-((tert-Butyldimethylsilyl)oxy)-5,6-dimethoxy-[1,1'-biphenyl]-3-
carbaldehyde (2.13). ARMI29. Solid Pd(dppf)Cl2•CH2Cl2 (0.45 g, 0.5 mmol) was added 
to a degassed solution of K3PO4 (6.96 g, 32.8 mmol), 2.8 (2.67 g, 10.9 mmol), and 2.12 
(3.31 g, 13.1 mmol) in 1,4-dioxane/water (4 : 1, 55 mL), and the heated to 80 ºC for 2.5 
h. The reaction was cooled to room temperature, diluted with water (100 mL), and 
extracted with ethyl acetate (3 x 100 mL). The combined organic fractions were dried 
(Na2SO4), filtered, and concentrated in vacuo to give crude 2.13. The crude material was 
purified via silica gel flash column chromatography eluting with hexanes : ethyl acetate 
(1 : 0 → 9 : 1 along a gradient) to give 3.9 g (96%) of 2.13 as an opaque oil: 1H NMR 
(400 MHz) d 9.98 (s, 1 H), 7.52 – 7.47 (comp, 4 H), 6.96 (d, J = 9.2 Hz, 2 H), 4.02 (s, 3 
H), 3.72 (s, 3 H), 1.06 (s, 9 H), 0.29 (s, 6 H) 
 NMR Assignment. 1H NMR (400 MHz) d 9.98 (s, 1 H, CHO), 7.52 – 7.47 
(comp, 4 H, C3-H, C2-H, C1-H), 6.96 (d, J = 9.2 Hz, 2 H, C4-H), 4.02 (s, 3 H, OCH3), 
3.72 (s, 3 H, OCH3), 1.06 (s, 9 H, TBS), 0.29 (s, 6 H, TBS) 
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 (E)-tert-Butyl((2',3'-dimethoxy-5'-(2-nitrovinyl)-[1,1'-biphenyl]-4-
yl)oxy)dimethylsilane (2.14). ARMI33. A solution of 2.13 (3.60 g, 9.7 mmol) and 
ammonium acetate (0.55 g, 7.2 mmol) in nitromethane (74 mL) was heated for 12 h 
under reflux, with removal of water via Dean-Stark trap. The reaction was cooled to room 
temperature and the solvent removed in vacuo. The resulting residue was partitioned 
between ethyl acetate (100 mL) and water (100 mL). The layers were separated, and the 
aqueous layer was extracted with ethyl acetate (2 x 100 mL). The combined organic 
fractions were dried (Na2SO4), filtered, and concentrated in vacuo to give crude 2.14 as a 
viscous yellow oil. The crude material was purified via silica gel flash column 
chromatography eluting with hexanes : ethyl acetate (19 : 1) to give 3.11 g (77%) of 2.14 
as a viscous yellow oil that slowly formed canary yellow crystals upon standing: 1H 
NMR (400 MHz) d 7.97 (d, J = 13.6 Hz, 1 H), 7.57 (d, J = 13.6 Hz, 1 H), 7.39 (d, J = 8.8 
Hz, 2 H), 7.16 (d, J = 2.0 Hz, 1 H), 7.02 (d, J = 2.0 Hz, 1 H), 6.90 (d, J = 8.8 Hz, 2 H), 
3.94 (s, 3 H), 3.64 (s, 3 H), 1.01 (s, 9 H), 0.25 (s, 6 H). 
 NMR Assignment. 1H NMR (400 MHz) d 7.97 (d, J = 13.6 Hz, 1 H, C2-H), 7.57 
(d, J = 13.6 Hz, 1 H, C1-H), 7.39 (d, J = 8.8 Hz, 2 H, C5-H), 7.16 (d, J = 2.0 Hz, 1 H, 
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C4-H), 7.02 (d, J = 2.0 Hz, 1 H, C3-H), 6.90 (d, J = 8.8 Hz, 2 H, C6-H), 3.94 (s, 3 H, 
OCH3), 3.64 (s, 3 H, OCH3), 1.01 (s, 9 H, TBS), 0.25 (s, 6 H, TBS). 
 
 
 (4-Bromophenoxy)triisopropylsilane (2.16). ARMI59. A solution of 4-
bromophenol (10.0 g, 57.8 mmol), TIPSCl (12.3 g, 63.6 mmol), and imidazole (5.9 g, 
86.7 mmol) in CH2Cl2 (150 mL) was stirred for 2.5 h at room temperature. The mixture 
was diluted with CH2Cl2 (100 mL), and washed successively with saturated aqueous 
NH4Cl (100 mL), and water (100 mL). The organic fraction was dried (Na2SO4), filtered, 
and concentrated in vacuo to give crude 2.16 as a colorless oil. The crude material was 
purified via silica gel plug eluting with hexanes to give 18.6 g (98%) of 2.16 as a 
colorless oil: 1H NMR (400 MHz) d 7.33 (d, J = 8.8 Hz, 2 H), 6.78 (d, J = 8.8 Hz, 2 H), 
1.27 (sep, J = 6.8 Hz, 3 H), 1.12 (d, J = 6.8 Hz, 18 H). 
 NMR Assignment. 1H NMR (400 MHz) d 7.33 (d, J = 8.8 Hz, 2 H, C1-H), 6.78 
(d, J = 8.8 Hz, 2 H, C2-H), 1.27 (sep, J = 6.8 Hz, 3 H, TIPS), 1.12 (d, J = 6.8 Hz, 18 H, 
TIPS). 
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 2,4,6-Tris(4-((triisopropylsilyl)oxy)phenyl)-1,3,5,2,4,6-trioxatriborinane 
(2.17). ARMI117. A solution of n-butyllithium (1.5 M, 50 mL, 75 mmol) was added 
dropwise to a solution of 2.16 (10.0 g, 30 mmol) in THF (100 mL) at -78 ºC. The reaction 
was stirred for 5 min at -78 ºC, whereupon triisopropyl borate (28.6 g, 150 mmol) was 
added in one portion, and the reaction was slowly warmed to room temperature 
overnight. The mixture was diluted with water (300 mL) and saturated aqueous NH4Cl 
(100 mL), and extracted with ethyl acetate (3 x 300 mL). The combined organic fractions 
were dried (Na2SO4), filtered, and concentrated in vacuo to give crude 2.17 as a white 
paste. The crude material was purified via silica gel flash column chromatography eluting 
with hexanes : ethyl acetate (1 : 0 → 4 : 1 along a gradient) to give 7.99 g (89%) of 2.17 
as a white amorphous solid: 1H NMR (400 MHz) d 8.10 (d, J = 8.8 Hz, 6 H), 6.98 (d, J = 
8.8 Hz, 6 H), 1.31 (sep, J = 7.2 Hz, 9 H), 1.12 (d, J = 7.2 Hz, 54 H). 
 NMR Assignment. 1H NMR (400 MHz) d 8.10 (d, J = 8.8 Hz, 6 H, C1-H), 6.98 
(d, J = 8.8 Hz, 6 H, C2-H), 1.31 (sep, J = 7.2 Hz, 9 H, TIPS), 1.12 (d, J = 7.2 Hz, 54 H, 
TIPS). 
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 5,6-Dimethoxy-4'-((triisopropylsilyl)oxy)-[1,1'-biphenyl]-3-carbaldehyde 
(2.18). ARMII103. A solution of K3PO4 (16.1 g, 75.8 mmol), 2.17 (6.20 g, 25.3 mmol), 
2.8 (8.38 g, 10.1 mmol) and Pd(dppf)Cl2•CH2Cl2 (0.103 g, 0.13 mmol) in a degassed 
mixture of 1,4-dioxane/water (4 : 1, 125 mL) was heated to 80 ºC for 3 h. The reaction 
was cooled to room temperature, diluted with water (100 mL), and extracted with ethyl 
acetate (3 x 100 mL). The combined organic fractions were washed with brine (1 x 100 
mL), dried (Na2SO4), and concentrated in vacuo to give crude 2.18 as a viscous oil. The 
crude material was purified via silica gel flash chromatography eluting with hexanes : 
ethyl acetate (1 : 0 → 85 : 15 along a gradient) to give 8.60 g (91%) of 2.18 as a white 
solid. Crystallization from methanol gave white needles: M.p. 75-76 ºC. IR (thin film) 
2944, 2867, 2360, 1695, 1513, 1464, 1382, 1265 cm-1. 1H NMR (400 MHz) d 9.92 (s, 1 
H), 7.47 (d, J = 2.0 Hz, 1 H), 7.44 - 7.40 (m, 3 H), 6.65 (dt, J = 8.4, 2.0 Hz, 2 H), 3.96 (s, 
3 H), 3.64 (s, 3 H), 1.29 (sep, J = 7.6 Hz, 3 H), 1.12 (d, J = 7.2 Hz, 18 H). 13C NMR (100 
MHz) d 191.3, 155.9, 153.8, 151.9, 135.8, 132.3, 130.2, 129.6, 127.3, 119.8, 108.9, 60.5, 
56.1, 17.9, 12.7. HRMS calculated for C24H34O4Si (MH+) 415.2305, found 415.2305. 
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 NMR Assignment. 1H NMR (400 MHz) d 9.92 (s, 1 H, CHO), 7.47 (d, J = 2.0 
Hz, 1 H, C2-H), 7.44 - 7.40 (comp, 3 H, C1-H and C3-H), 6.65 (dt, J = 8.4, 2.0 Hz, 2 H, 
C4-H), 3.96 (s, 3 H, OCH3), 3.64 (s, 3 H, OCH3), 1.29 (sep, J = 7.6 Hz, 3 H, TIPS), 1.12 
(d, J = 7.2 Hz, 18 H, TIPS). 
 
 
 (E)-((2',3'-Dimethoxy-5'-(2-nitrovinyl)-[1,1'-biphenyl]-4-
yl)oxy)triisopropylsilane (2.19). ARMIII41. A solution of 2.18 (3.08 g, 7.43 mmol) and 
ammonium acetate (0.43 g, 5.57 mmol) in nitromethane (56 mL) was heated under reflux 
for 12 h with removal of water via Dean-Stark trap. The reaction was cooled to room 
temperature, and concentrated in vacuo to give crude 2.19 as a viscous orange oil. The 
crude material was purified by silica gel column chromatography eluting with hexanes : 
ethyl acetate (19 : 1) to give 3.00 g (88%) of 2.19 as a viscous yellow oil that formed 
canary yellow crystals upon standing: M.p. 65-67 ºC. IR (thin film) 2944, 2867, 1512, 
1335, 1264. 1H NMR (400 MHz) d 7.98 (d, J = 13.6 Hz, 1 H), 7.56 (d, J = 13.6 Hz, 1 H), 
7.38 (d, J = 8.8 Hz, 2 H), 7.17 (d, J = 2.0 Hz, 1 H), 7.01 (d, J = 2.0 Hz, 1 H), 6.95 (d, J = 
8.8 Hz, 2 H), 3.94 (s, 3 H), 3.61 (s, 3 H), 1.28 (sep, J = 7.2 Hz, 3 H), 1.13, (d, J = 7.2 Hz, 
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18 H). 13C NMR (100 MHz) d 155.9, 153.6, 150.1, 139.1, 136.5, 136.3, 130.1, 129.4, 
125.6, 124.9, 119.8, 110.5, 60.6, 59.1, 17.9, 12.7. HRMS calculated for C25H35NO5Si 
(M+Na)+ 480.21770, found 480.21750.  
 NMR Assignment. 1H NMR (400 MHz) d 7.98 (d, J = 13.6 Hz, 1 H, C2-H), 7.56 
(d, J = 13.6 Hz, 1 H, C1-H), 7.38 (d, J = 8.8 Hz, 2 H, C5-H), 7.17 (d, J = 2.0 Hz, 1 H, 
C4-H), 7.01 (d, J = 2.0 Hz, 1 H, C3-H), 6.95 (d, J = 8.8 Hz, 2 H, C6-H), 3.94 (s, 3 H, 
OCH3), 3.61 (s, 3 H, OCH3), 1.28 (sep, J = 7.2 Hz, 3 H, TIPS), 1.13, (d, J = 7.2 Hz, 18 H, 
TIPS). 
 
 
 2-(5,6-Dimethoxy-4'-((triisopropylsilyl)oxy)-[1,1'-biphenyl]-3-yl)ethanamine 
(2.20). ARMI95. A solution of 2.19 (50 mg, 0.10 mmol) in 1,4-dioxane (1 mL, dried 
over 4Å mol sieves) was added dropwise to a solution of DIBAL-H (1 M in hexanes, 3 
mL, 3.0 mmol) in 1,4-dioxane (1 mL) at room temperature. The reaction was stirred for 
0.5 h at room temperature. The mixture was cooled to 0 ºC in an ice bath, and ethyl 
acetate (2 mL) followed by Rochelle’s salt (3 mL) was carefully added. The mixture was 
stirred for 2 h at room temperature, whereupon layers were separated and the aqueous 
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layer was extracted with ethyl acetate (3 x 10 mL). The combined organic fractions were 
dried (Na2SO4), filtered, and concentrated in vacuo to give crude 2.20 as a viscous oil. 
The crude material was purified via silica gel column chromatography eluting with 
CH2Cl2 : methanol (1 : 0 → 9 : 1 along a gradient) to give 44 mg (94%) of 2.20 as a clear 
viscous oil: IR (thin film) 2944, 2867, 1607, 1512, 1263 cm-1. 1H NMR (400 MHz) d 
7.41 (d, J = 8.8 Hz, 2 H), 6.91, (d, J = 8.8 Hz, 2 H), 6.77 (d, J = 2.0 Hz, 1 H), 6.72 (d, J = 
2.0 Hz, 1 H), 3.88 (s, 3 H), 3.50 (s, 3 H), 3.03 – 2.95 (comp, 4 H), 2.71 (t, J = 7.6 Hz, 2 
H) 1.28 (sep, J = 8.0 Hz, 3 H), 1.12 (d, J = 7.2 Hz, 18 H). 13C NMR (100 MHz) d 155.3, 
153.0, 144.9, 135.3, 134.8, 130.7, 130.2, 122.6, 119.6, 111.5, 60.3, 56.0, 43.0, 38.8, 17.9, 
12.7. HRMS calculated for C25H39NO3Si (M+Na)+ 452.24910 found 452.25840. 
 NMR Assignment. 1H NMR (400 MHz) d 7.41 (d, J = 8.8 Hz, 2 H, C5-H), 6.91, 
(d, J = 8.8 Hz, 2 H, C6-H), 6.77 (d, J = 2.0 Hz, 1 H, C4-H), 6.72 (d, J = 2.0 Hz, 1 H, C3-
H), 3.88 (s, 3 H, OCH3), 3.50 (s, 3 H, OCH3), 3.03 – 2.95 (comp, 4 H, C1-H and NH2), 
2.71 (t, J = 7.6 Hz, 2 H, C2-H) 1.28 (sep, J = 8.0 Hz, 3 H, TIPS), 1.12 (d, J = 7.2 Hz, 18 
H, TIPS). 
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 (E)-1-Bromo-2,3-dimethoxy-5-(2-nitrovinyl)benzene (2.25). ARMII23. A 
solution of 2.8 (3.00 g, 12.3 mmol) and ammonium acetate (0.72 g, 9.3 mmol) in 
nitromethane (98 mL) heated under reflux for 12 h, with removal of water via Dean-Stark 
trap. The reaction was cooled to room temperature and the solvent was removed in vacuo. 
The resulting residue was partitioned between ethyl acetate (100 mL) and water (100 
mL), the layers were separated, and the aqueous layer was extracted with ethyl acetate (2 
x 100 mL). The combined organic fractions were dried (Na2SO4), filtered, and 
concentrated in vacuo to give crude 2.25 as a viscous yellow oil. The crude material was 
purified via silica gel flash column chromatography eluting with hexanes : ethyl acetate 
(19 : 1) to give 3.42 g (97%) of 2.25 as a viscous yellow oil that slowly formed canary 
yellow crystals upon standing: 1H NMR (400 MHz) d 7.89 (d, J = 13.6 Hz, 1 H), 7.51 (d, 
J = 13.6 Hz, 1 H), 7.37 (d, J = 2.0 Hz, 1 H), 6.97 (d, J = 2.0 Hz, 1 H), 3.920 (s, 3 H), 
3.917 (s, 3 H). 
 NMR Assignment. 1H NMR (400 MHz) d 7.89 (d, J = 13.6 Hz, 1 H, C2-H), 7.51 
(d, J = 13.6 Hz, 1 H, C1-H), 7.37 (d, J = 2.0 Hz, 1 H, C4-H), 6.97 (d, J = 2.0 Hz, 1 H, 
C3-H), 3.920 (s, 3 H, OCH3), 3.917 (s, 3 H, OCH3). 
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 2-(3-Bromo-4,5-dimethoxyphenyl)ethan-1-amine (2.26). ARMII47. A solution 
of 2.25 (1.0 g, 3.4 mmol) in 1,4-dioxane (15 mL, dried over 4 Å MS) was added to a 
solution DIBAL-H (1 M in hexanes, 52 mL, 52 mmol) in 1,4-dioxane (15 mL). The 
reaction was warmed to room temperature, and stirred for 12 h. The reaction was cooled 
to 0 ºC, and excess DIBAL-H was quenched via slow addition of methanal (5 mL), 
followed by addition of Rochelle’s salt (50 mL). The mixture was stirred at room 
temperature for 1 h, then extracted with ethyl acetate (3 x 50 mL). The combined organic 
fractions were washed with brine (1 x 100 mL), dried (Na2SO4), filtered, and 
concentrated in vacuo to give crude 2.26 as a viscous oil. The crude material was purified 
via silica gel flash column chromatography eluting with CH2Cl2 : methanol (1 : 0 → 9 : 1 
along a gradient) to give 0.87 g (97%) of 2.26 as a viscous oil: 1H NMR (400 MHz) d 
6.90 (d, J = 2.0 Hz, 1 H), 6.62 (d, J = 2.0 Hz, 1 H), 3.78 (s, 3 H), 3.75 (s, 3 H), 2.87 (t, J 
= 7.2 Hz, 2 H), 2.59 (t, J = 7.2 Hz, 2 H), 1.00 (brs, 2 H).  
 NMR Assignment. 1H NMR (400 MHz) d 6.90 (d, J = 2.0 Hz, 1 H, C4-H), 6.62 
(d, J = 2.0 Hz, 1 H, C3-H), 3.78 (s, 3 H, OCH3), 3.75 (s, 3 H, OCH3), 2.87 (t, J = 7.2 Hz, 
2 H, C1-H), 2.59 (t, J = 7.2 Hz, 2 H, C2-H), 1.00 (brs, 2 H, NH2). 
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 Ethyl (3-bromo-4,5-dimethoxyphenethyl)carbamate (2.27). ARMII33. Ethyl 
chloroformate (0.12 g, 1.1 mmol) was added to a solution of 2.26 (0.27 g, 1.0 mmol) and 
triethylamine (0.11 g, 1.1 mmol) in CH2Cl2 (3 mL) at 0 ºC. The reaction was stirred for 
12 h, and warmed to room temperature. The reaction mixture was diluted with CH2Cl2 
(50 mL), washed with water (50 mL), dried (Na2SO4), filtered, and concentrated in vacuo 
to give crude 2.27 as a viscous oil. The crude material was purified via silica gel flash 
column chromatography eluting with hexanes : ethyl acetate (7 : 3) to give 0.26 g (76%) 
of 2.27 as a viscous oil: 1H NMR (400 MHz) d 6.89 (d, J = 2.0 Hz, 1 H), 6.63 (d, J = 2.0 
Hz, 1 H), 4.93 (brs, 1 H), 4.04 (q, J = 7.2 Hz, 2 H), 3.79 (s, 3 H), 3.76 (s, 3 H), 3.33 (q, J 
= 6.8 Hz, 2 H), 2.68 (t, J = 6.8 Hz, 2 H), 1.17 (t, J = 7.2 Hz, 3 H). 13C NMR (100 MHz) d 
171.1, 156.5, 153.6, 144.9, 136.0, 124.6, 117.6, 112.2, 60.5, 56.1, 41.9, 35.7, 14.6. 
 NMR Assignment. 1H NMR (400 MHz) d 6.89 (d, J = 2.0 Hz, 1 H, C6-H), 6.63 
(d, J = 2.0 Hz, 1 H, C5-H), 4.93 (brs, 1 H, NH), 4.04 (q, J = 7.2 Hz, 2 H, C2-H), 3.79 (s, 
3 H, OCH3), 3.76 (s, 3 H, OCH3), 3.33 (q, J = 6.8 Hz, 2 H, C3-H), 2.68 (t, J = 6.8 Hz, 2 
H, C4-H), 1.17 (t, J = 7.2 Hz, 3 H, C1-H). 
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 Ethyl 1-(2-(benzyloxy)ethyl)-8-bromo-6,7-dimethoxy-3,4-
dihydroisoquinoline-2(1H)-carboxylate (2.28). ARMII125. A solution of 2.27 (66 mg, 
0.2 mmol), 2.23 (66 mg, 0.4 mmol), and TFA (2 drops) in HFIP (1 mL) was heated to 60 
ºC for 12 h, whereupon the solvent was removed in vacuo to give crude 2.28. The crude 
mixture was purified via silica gel flash column chromatography eluting with CH2Cl2 
with triethylamine (1%) to give 65 mg (68%) of 2.28 as a viscous oil: 1H NMR (400 
MHz) (rotamers 1 : 1) d 7.27 – 7. 18 (comp, 5 H), 6.56 (s, 0.5 H), 6.54 (s, 0.5 H), 5.41 
(dd, J = 10.4, 2.8 Hz, 0.5 H), 5.34 (dd, J = 10.4, 2.8 Hz, 0.5 H), 4.44 (s, 2 H), 4.12 – 3.99 
(comp, 2.5 H), 3.94 – 3.88 (m, 0.5 H), 3.77 – 3.73 (comp, 6 H), 3.65 – 3.63 (m, 0.5 H), 
3.58 – 3.54 (m, 1 H), 3.51 – 3.46 (m, 0.5 H), 3.38 – 3.31 (m, 0.5 H), 3.28 – 3.20 (m, 0.5 
H), 2.90 – 2.78 (m, 1 H), 2.69 – 2.65 (m, 1 H), 2.24 (dtd, J = 14.8, 7.2, 3.2 Hz, 1 H), 1.91 
– 1.80 (m, 1 H), 1.19 – 1.13 (comp, 3 H). 13C NMR (100 MHz) (rotamers 1 : 1) d 162.5, 
155.7, 155.6, 152.0, 151.9, 145.0, 144.9, 138.6, 138.5, 131.4, 131.2, 130.0, 129.7, 128.3, 
128.2, 127.5, 127.44, 127.36, 118.3, 118.0, 112.1, 111.8, 73.0, 68.2, 67.7, 61.6, 61.4, 
60.5, 56.0, 52.2, 52.0, 37.6, 36.8, 33.9, 33.8, 28.2, 27.9, 14.7, 14.6. 
 NMR Assignment. 1H NMR (400 MHz) (rotamers 1 : 1) d 7.27 – 7. 18 (comp, 5 
H, OBn), 6.56 (s, 0.5 H, C1-H), 6.54 (s, 0.5 H, C1-H), 5.41 (dd, J = 10.4, 2.8 Hz, 0.5 H, 
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C4-H), 5.34 (dd, J = 10.4, 2.8 Hz, 0.5 H, C4-H), 4.44 (s, 2 H, OBn), 4.12 – 3.99 (comp, 
2.5 H, C7-H and C6-H), 3.94 – 3.88 (m, 0.5 H, C6-H), 3.77 – 3.73 (comp, 6 H, OCH3 and 
OCH3), 3.65 – 3.63 (m, 0.5 H, C6-H), 3.58 – 3.54 (m, 1 H, C3-H), 3.51 – 3.46 (m, 0.5 H, 
C6-H), 3.38 – 3.31 (m, 0.5 H, C3-H), 3.28 – 3.20 (m, 0.5 H, C3-H), 2.90 – 2.78 (m, 1 H, 
C2-H), 2.69 – 2.65 (m, 1 H, C2-H), 2.24 (dtd, J = 14.8, 7.2, 3.2 Hz, 1 H, C5-H), 1.91 – 
1.80 (m, 1 H, C5-H), 1.19 – 1.13 (comp, 3 H, C8-H). 
 
 
 Ethyl (2-(5,6-dimethoxy-4'-((triisopropylsilyl)oxy)-[1,1'-biphenyl]-3-
yl)ethyl)carbamate (2.29). ARMII131. Ethyl chloroformate (1.68 g, 15.5 mmol) was 
added over 20 min to a solution of 2.20 (4.43 g, 10.3 mmol) and triethylamine (1.57 g, 
15.5 mmol) in CH2Cl2 (30 mL) at 0 ºC. The reaction was stirred for 12 h at 0 ºC, then 
warmed to room temperature. Water (50 mL) was added to the mixture, the two phases 
were separated, and the aqueous phase was extracted with CH2Cl2 (3 x 50 mL). The 
combined organic fractions were dried (Na2SO4), filtered, and concentrated in vacuo to 
give crude 2.29 as an opaque oil. The crude material was purified via silica gel column 
chromatography eluting with CH2Cl2 to give 4.47 g (86%) of 2.29 as a clear viscous oil: 
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1H NMR (400 MHz) d 7.41 (d, J = 8.8 Hz, 2 H), 6.91 (d, J = 8.8 Hz, 2 H), 6.76 (d, J = 
2.0 Hz, 1 H), 6.70 (brs, 1 H), 4.71 (brs, 1 H), 4.11 (q, J = 7.2 Hz, 2 H), 3.89 (s, 3 H), 3.51 
(s, 3 H), 3.45 (q, J = 6.8 Hz, 2 H), 2.79 (t, J = 6.8 Hz, 2 H), 1.38 – 1.21 (comp, 6 H), 1.12 
(d, J = 7.2 Hz, 18 H). 
 NMR Assignment. 1H NMR (400 MHz) d 7.41 (d, J = 8.8 Hz, 2 H, C7-H), 6.91 
(d, J = 8.8 Hz, 2 H, C8-H), 6.76 (d, J = 2.0 Hz, 1 H, C6-H), 6.70 (brs, 1 H, C1-H), 4.71 
(brs, 1 H, NH), 4.11 (q, J = 7.2 Hz, 2 H, C4-H), 3.89 (s, 3 H, OCH3), 3.51 (s, 3 H, 
OCH3), 3.45 (q, J = 6.8 Hz, 2 H, C3-H), 2.79 (t, J = 6.8 Hz, 2 H, C2-H), 1.38 – 1.21 
(comp, 6 H, C5-H and TIPS), 1.12 (d, J = 7.2 Hz, 18 H, TIPS). 
 
 
 Ethyl 1-(2-(benzyloxy)ethyl)-6,7-dimethoxy-8-(4-
((triisopropylsilyl)oxy)phenyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (2.30). 
ARMII145.  A solution of 2.29 (200 mg, 0.40 mmol), 2.23 (131 mg, 0.80 mmol), and 
TFA (2 drops) in HFIP (1 mL) was heated to 60 ºC for 12 h. The reaction was cooled to 
room temperature, and the solvent removed in vacuo to give crude 2.30. The crude 
material was purified via silica gel column chromatography eluting with hexanes : ethyl 
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acetate (1 : 0 → 9 :1 along a gradient) to give 223 mg (86%) of 2.30 as a clear viscous 
oil: 1H NMR (400 MHz) (rotamers 1 : 1) d 7.33 – 7.28 (comp, 2 H), 7.27 – 7.10 (comp, 5 
H), 7.00 – 6.96 (comp, 2 H), 6.69 (s, 0.5 H), 6.66 (s, 0.5 H), 5.38 (dd, J = 10.8, 3.6 Hz, 
0.5 H), 5.22 (dd, J = 10.8, 3.6 Hz, 0.5 H), 4.26 (s, 2 H), 4.15 – 4.02 (comp, 3 H), 3.87 (s, 
1.5 H), 3.86 (s, 1.5 H), 3.43 – 3.37 (comp, 4 H), 3.28 – 3.19 (m, 1 H), 3.16 – 3.10 (m, 1 
H), 3.04 – 2.93 (m, 1 H), 2.87 – 2.76 (m, 1 H), 1.87 – 1.77 (m, 1 H), 1.71 – 1.64 (m, 1 H), 
1.34 – 1.23 (comp, 4.5 H), 1.19 – 1.12 (comp, 19.5 H). 
 NMR Assignment. 1H NMR (400 MHz) (rotamers 1 : 1) d 7.33 – 7.28 (comp, 2 
H, C9-H), 7.27 – 7.10 (comp, 5 H, OBn), 7.00 – 6.96 (comp, 2 H, C9-H), 6.69 (s, 0.5 H, 
C1-H), 6.66 (s, 0.5 H, C1-H), 5.38 (dd, J = 10.8, 3.6 Hz, 0.5 H, C6-H), 5.22 (dd, J = 10.8, 
3.6 Hz, 0.5 H, C6-H), 4.26 (s, 2 H, OBn), 4.15 – 4.02 (comp, 3 H, C5-H and C8-H), 3.87 
(s, 1.5 H, OCH3), 3.86 (s, 1.5 H, OCH3), 3.43 – 3.37 (comp, 4 H, OCH3 and C8-H), 3.28 
– 3.19 (m, 1 H, C3-H), 3.16 – 3.10 (m, 1 H, C3-H), 3.04 – 2.93 (m, 1 H, C2-H), 2.87 – 
2.76 (m, 1 H, C2-H), 1.87 – 1.77 (m, 1 H, C7-H), 1.71 – 1.64 (m, 1 H, C7-H), 1.34 – 1.23 
(comp, 4.5 H, C4-H and TIPS), 1.19 – 1.12 (comp, 19.5 H, C4-H and TIPS). 
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 Ethyl 1-(2-hydroxyethyl)-6,7-dimethoxy-8-(4-((triisopropylsilyl)oxy)phenyl)-
3,4-dihydroisoquinoline-2(1H)-carboxylate (2.31). ARMIII11. A solution of 2.30 (468 
mg, 0.72 mmol) in 2-propanol (1 mL) was added to a suspension of Pd/C (10% w/w, 90 
mg) in 2-propanol (15 mL) under a balloon of H2 at 50 ºC. The reaction was stirred for 5 
h at 50 ºC, whereupon the suspension was filtered through a pad of Celite and washed 
with methanol. The solution was concentrated in vacuo to give crude 2.31 as an opaque 
oil. The crude material was purified via silica gel flash column chromatography eluting 
with hexanes : ethyl acetate (9 : 1 → 3 : 1 along a gradient) to yield 240 mg (60%) of 
2.31 as a clear viscous oil: 1H NMR (400 MHz) d 6.96 – 6.86 (comp, 2 H), 6.75 – 6.69 
(comp, 2 H), 6.47 (s, 1 H), 5.06 – 5.02 (m, 1 H), 3.95 – 3.89 (comp, 2 H), 3.64 (s, 3 H), 
3.61 – 3.55 (m, 1 H), 3.22 – 3.19 (comp, 4 H), 3.08 – 3.05 (comp, 2 H), 2.77 – 2.63 
(comp, 2 H), 1.40 – 1.30 (comp, 2 H), 1.08 – 1.02 (comp, 6 H), 0.90 (d, J = 7.2 Hz, 18 
H). 
 NMR Assignment. 1H NMR (400 MHz) d 6.96 – 6.86 (comp, 2 H, C9-H), 6.75 – 
6.69 (comp, 2 H, C10-H), 6.47 (s, 1 H, C1-H), 5.06 – 5.02 (m, 1 H, C6-H), 3.95 – 3.89 
(comp, 2 H, C5-H), 3.64 (s, 3 H, OCH3), 3.61 – 3.55 (m, 1 H, C8-H), 3.22 – 3.19 (comp, 
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4 H, C8-H and OCH3), 3.08 – 3.05 (comp, 2 H, C3-H), 2.77 – 2.63 (comp, 2 H, C2-H), 
1.40 – 1.30 (comp, 2 H, C7-H), 1.08 – 1.02 (comp, 6 H, C4-H and TIPS), 0.90 (d, J = 7.2 
Hz, 18 H, TIPS). 
 
 
 Ethyl 6,7-dimethoxy-1-(2-((methylsulfonyl)oxy)ethyl)-8-(4-
((triisopropylsilyl)oxy)phenyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (2.32). 
ARMIII13. Mesyl chloride (23 mg, 0.20 mmol) was added to a solution of 2.31 (100 mg, 
0.18 mmol) and triethylamine (27 mg, 0.27 mmol) in CH2Cl2 (1 mL) at 0 ºC, and the 
reaction was stirred for 0.5 h. The reaction was warmed to room temperature, and stirred 
for an additional 2.5 h. The mixture was diluted with CH2Cl2 (20 mL), and successively 
washed with water (10 mL), aqueous HCl (1 M, 10 mL), saturated aqueous NaHCO3 (10 
mL), and brine (10 mL). The combined organic fractions were dried (Na2SO4), filtered, 
and concentrated in vacuo to give crude 2.32 as an oil. The crude material was purified 
via silica gel flash column chromatography to give 49 mg (43%) of 2.32 as an oil: 1H 
NMR (400 MHz)(rotamers 1 : 1) d 6.96 – 6.85 (comp, 2 H), 6.75 (d, J = 8.4 Hz, 1 H), 
6.70 (d, J = 8.4 Hz, 1H), 6.46 (s, 0.5 H), 6.44 (s, 0.5 H), 5.13 (td, J = 10.8, 2.8 Hz, 0.5 H), 
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5.01 (dd, J = 10.8, 2.8 Hz, 0.5 H), 3.93 – 3.85 (comp, 2.5 H), 3.78 – 3.74 (m, 0.5 H), 3.74 
– 3.67 (m, 1 H), 3.63 (s, 3 H), 3.60 – 3.58 (m, 1 H), 3.23 – 3.17 (comp, 4 H), 3.12 – 3.06 
(m, 1 H), 2.81 – 2.67 (m, 1 H), 2.62 – 2.59 (comp, 3 H), 1.73 – 1.64 (m, 1 H), 1.51 – 1.44 
(m, 1 H), 1.08 – 1.01 (comp, 6 H), 0.89 (d, J = 7.2 Hz, 18 H). 
 NMR Assignment. 1H NMR (400 MHz)(rotamers 1 : 1) d 6.96 – 6.85 (comp, 2 
H, C9-H), 6.75 (d, J = 8.4 Hz, 1 H, C10-H), 6.70 (d, J = 8.4 Hz, 1H, C10-H), 6.46 (s, 0.5 
H, C1-H), 6.44 (s, 0.5 H, C1-H), 5.13 (td, J = 10.8, 2.8 Hz, 0.5 H, C6-H), 5.01 (dd, J = 
10.8, 2.8 Hz, 0.5 H, C6-H), 3.93 – 3.85 (comp, 2.5 H, C5-H and C8-H), 3.78 – 3.74 (m, 
0.5 H, C8-H), 3.74 – 3.67 (m, 1 H, C3-H), 3.63 (s, 3 H, OCH3), 3.60 – 3.58 (m, 1 H, C3-
H), 3.23 – 3.17 (comp, 3 H, OCH3), 3.12 – 3.06 (m, 1 H, C2-H), 2.81 – 2.67 (m, 1 H, C2-
H), 2.62 – 2.59 (comp, 3 H, OMs), 1.73 – 1.64 (m, 1 H, C7-H), 1.51 – 1.44 (m, 1 H, C7-
H), 1.08 – 1.01 (comp, 6 H, C4-H and TIPS), 0.89 (d, J = 7.2 Hz, 18 H, TIPS). 
 
 
 Benzyl (2-(5,6-dimethoxy-4'-((triisopropylsilyl)oxy)-[1,1'-biphenyl]-3-
yl)ethyl)carbamate (2.45). ARMIII65. CbzCl (0.44 g, 2.59 mmol) was added dropwise 
over 5 min to a suspension of 2.20 (1.01 g, 2.35 mmol) and K2CO3 (0.39 g, 2.80 mmol) 
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in THF (15 mL). The reaction was stirred for 2 h at room temperature, at which point 
CbzCl (0.22 g, 1.80 mmol) was added. The reaction was stirred for an additional 2 h at 
room temperature, then diluted with CH2Cl2 (50 mL), and washed with saturated aqueous 
Na2CO3 (3 x 20 mL). The organic fraction was dried (Na2SO4), filtered, and concentrated 
in vacuo to give crude 2.45 as an oil. The crude material was purified via silica gel flash 
column chromatography eluting with CH2Cl2 to give 1.05 g (79%) of 2.45 as an oil: 1H 
NMR (400 MHz) d 7.41 (d, J = 8.0 Hz, 2 H), 7.35 – 7.29 (comp, 5 H), 6.92 (d, J = 8.0 
Hz, 2 H), 6.76 (s, 1 H), 6.69 (s, 1 H), 5.10 (s, 2 H), 4.95 (brs, 1 H), 3.85 (s, 3 H), 3.52 (s, 
3 H), 3.47 (q, J = 7.2 Hz, 2 H), 2.80 (t, J = 7.2 Hz, 2 H), 1.32 – 1.24 (sep, J = 7.2 Hz, 3 
H), 1.13 (d, J = 7.2 Hz, 18 H). 
 NMR Assignment. 1H NMR (400 MHz) d 7.41 (d, J = 8.0 Hz, 2 H, C5-H), 7.35 – 
7.29 (comp, 5 H, Cbz), 6.92 (d, J = 8.0 Hz, 2 H, C6-H), 6.76 (s, 1 H, C4-H), 6.69 (s, 1 H, 
C3-H), 5.10 (s, 2 H, Cbz), 4.95 (brs, 1 H, NH), 3.85 (s, 3 H, OCH3), 3.52 (s, 3 H, OCH3), 
3.47 (q, J = 7.2 Hz, 2 H, C1-H), 2.80 (t, J = 7.2 Hz, 2 H, C2-H), 1.32 – 1.24 (sep, J = 7.2 
Hz, 3 H, TIPS), 1.13 (d, J = 7.2 Hz, 18 H, TIPS). 
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 Benzyl 1-(2-(benzyloxy)ethyl)-6,7-dimethoxy-8-(4-
((triisopropylsilyl)oxy)phenyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (2.42). 
ARMIII95. A solution of 2.45 (0.81 g, 1.40 mmol), 2.46 (0.61 g, 2.90 mmol), and TFA 
(0.25 g, 2.20 mmol) in TFE (17 mL) were heated to 60 ºC for 12 h, whereupon the 
solvent was removed in vacuo to give crude 2.42. The crude material was purified via 
silica gel column chromatography eluting with hexanes : ethyl acetate (19 : 1 → 9 : 1 
along a gradient) to give 0.94 g (91%) of 2.42 as an oil: 1H NMR (400 MHz) (rotamers 3 
: 7)  d 7.34 – 7.12 (comp, 11.7 H), 7.00 – 6.93 (comp, 2 H), 6.71 (dd, J = 8.4, 2.8 Hz, 0.7 
H), 6.67 (s, 0.7 H), 6.65 (s, 0.3 H), 5.38 (dd, J = 10.8, 3.6 Hz, 0.3 H), 5.32 – 5.29 (comp, 
1 H), 5.14 – 5.11 (comp, 1.3 H), 4.97 (d, J = 12.4 Hz, 0.7 H), 4.23 (s, 0.7 H), 4.15 (s, 1.3 
H), 4.13 – 4.10 (m, 0.7 H), 4.06 – 4.01 (m, 0.3 H), 3.86 (s, 3 H), 3.45 – 3.35 (comp, 4 H), 
3.24 – 2.92 (comp, 3 H), 2.80 (tt, J = 16.8, 4.8 Hz, 1 H), 1.85 – 1.60 (comp, 2 H), 1.31 – 
1.23 (comp, 3 H), 1.13 – 1.10 (comp, 18 H). 
 NMR Assignment. 1H NMR (400 MHz) (rotamers 3 : 7)  d 7.34 – 7.12 (comp, 
11.3 H, Cbz and OBn), 7.00 – 6.93 (comp, 2 H, C8-H and OBn), 6.71 (dd, J = 8.4, 2.8 
Hz, 0.7 H, OBn), 6.67 (s, 0.7 H, C3-H), 6.65 (s, 0.3 H, C3-H), 5.38 (dd, J = 10.8, 3.6 Hz, 
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0.3 H, C4-H), 5.32 – 5.29 (comp, 1 H, C4-H and Cbz), 5.14 – 5.11 (comp, 1.3 H, Cbz), 
4.97 (d, J = 12.4 Hz, 0.7 H, Cbz), 4.23 (s, 0.7 H, OBn), 4.15 (s, 1.3 H, OBn), 4.13 – 4.10 
(m, 0.7 H, C6-H), 4.06 – 4.01 (m, 0.3 H, C6-H), 3.86 (s, 3 H, OCH3), 3.45 – 3.35 (comp, 
4 H, C6-H and OCH3), 3.24 – 2.92 (comp, 3 H, C1-H and C2-H), 2.80 (tt, J = 16.8, 4.8 
Hz, 1 H, C2-H), 1.85 – 1.60 (comp, 2 H, C5-H), 1.31 – 1.23 (comp, 3 H, TIPS), 1.13 – 
1.10 (comp, 18 H, TIPS). 
 
 
 2-(6,7-Dimethoxy-8-(4-((triisopropylsilyl)oxy)phenyl)-1,2,3,4-
tetrahydroisoquinolin-1-yl)ethan-1-ol (2.47). ARMIII87. A solution of 2.42 (227 mg, 
0.32 mmol) in Methanol (1 mL) was added to a suspension of Pd/C (10% w/w, 320 mg) 
in degassed Methanol (10 mL) under a balloon of H2 gas. The reaction was heated to 50 
ºC for 3 h, whereupon the suspension was filtered through a pad of Celite, and washed 
with methanol. The crude reaction mixture was concentrated in vacuo to give crude 2.47 
as a cloudy oil. The crude material was purified via silica gel flash column 
chromatography eluting with CH2Cl2 : methanol (1 : 0 → 19 : 1 along a gradient) to give 
98 mg (63%) of 2.47 as an oil: 1H NMR (400 MHz) d 7.11 – 7. 05 (comp, 2 H), 6.97 – 
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6.91 (comp, 2 H), 6.64 (s, 1 H), 6.04 (brs, 1 H), 4.20 (d, J = 11.6, 1 H), 3.87 (s, 3 H), 3.50 
(d, J = 5.6 Hz, 2 H), 3.43 (s, 3 H), 3.25 -3.21 (m, 1 H), 3.10 – 3.05 (m, 1 H), 2.82 – 2.71 
(comp, 2 H), 1.83 – 1.75 (comp, 2 H), 1.31 – 1.21 (comp, 3 H), 1.12 (app dd, J = 7.2, 1.2 
Hz, 18 H). 
 NMR Assignment. 1H NMR (400 MHz) d 7.11 – 7. 05 (comp, 2 H, C7-H), 6.97 
– 6.91 (comp, 2 H, C8-H), 6.64 (s, 1 H, C6-H), 6.04 (brs, 1 H, NH), 4.20 (d, J = 11.6, 1 
H, C3-H), 3.87 (s, 3 H, OCH3), 3.50 (d, J = 5.6 Hz, 2 H, C1-H), 3.43 (s, 3 H, OCH3), 
3.25 -3.21 (m, 1 H, C4-H), 3.10 – 3.05 (m, 1 H, C4-H), 2.82 – 2.71 (comp, 2 H, C5-H), 
1.83 – 1.75 (comp, 2 H, C2-H), 1.31 – 1.21 (comp, 3 H, TIPS), 1.12 (app dd, J = 7.2, 1.2 
Hz, 18 H, TIPS). 
 
 
 1-(2-Bromoethyl)-6,7-dimethoxy-8-(4-((triisopropylsilyl)oxy)phenyl)-1,2,3,4-
tetrahydroisoquinoline (2.48). ARMIII99. Phosphorus tribromide (418 mg, 1.50 mmol) 
was added dropwise to a solution of 2.47 (75 mg, 0.15 mmol) in toluene (7.5 mL), and 
the reaction was heated under reflux for 3 h. The reaction was cooled to room 
temperature, followed by careful addition of methanol (1 mL) and water (2 mL). The 
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mixture was diluted with water (20 mL), and extracted with ether (3 x 20 mL). The 
combined organic fractions were successively washed with saturated aqueous NaHCO3 
(30 mL), water (30 mL), and brine (30 mL). The solution was dried (Na2SO4), filtered, 
and concentrated in vacuo to give crude 2.48 as an oil. The crude material was purified 
via silica gel flash column chromatography eluting with CH2Cl2 : methanol (1 : 0 → 19 : 
1 along a gradient) to give 85 mg (quant.) of 2.48 as an oil: 1H NMR (400 MHz) d 7.01 
(dd, J = 8.2, 2.0 Hz, 1 H), 6.91 – 6.85 (comp, 3 H), 6.68 (s, 1 H), 5.47 (q, J = 8.4 Hz, 1 
H), 4.34 (pent, J = 8.4 Hz, 1 H), 3.84 (s, 3 H), 3.51 – 3.47 (m, 1 H), 3.40 (s, 3 H), 3.36 – 
3.24 (comp, 2 H), 3.15 – 3.12 (comp, 2 H), 2.98 – 2.91 (m, 1 H), 2.25 – 2.14 (m, 1 H), 
2.08 – 2.02 (m, 1 H), 1.23 (sept, J = 7.2 Hz, 3 H), 1.06 (d, J = 7.2 Hz, 18 H). 
 NMR Assignment. 1H NMR (400 MHz) d 7.01 (dd, J = 8.2, 2.0 Hz, 1 H, C7-H), 
6.91 – 6.85 (comp, 3 H, C7-H and C8-H), 6.68 (s, 1 H, C6-H), 5.47 (q, J = 8.4 Hz, 1 H, 
C3-H), 4.34 (pent, J = 8.4 Hz, 1 H, NH), 3.84 (s, 3 H, OCH3), 3.51 – 3.47 (m, 1 H, C4-
H), 3.40 (s, 3 H, OCH3), 3.36 – 3.24 (comp, 2 H, C4-H and C1-H), 3.15 – 3.12 (comp, 2 
H, C1-H and C5-H), 2.98 – 2.91 (m, 1 H, C5-H), 2.25 – 2.14 (m, 1 H, C2-H), 2.08 – 2.02 
(m, 1 H, C2-H), 1.23 (sept, J = 7.2 Hz, 3 H, TIPS), 1.06 (d, J = 7.2 Hz, 18 H, TIPS). 
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 N-(2-(5,6-Dimethoxy-4'-((triisopropylsilyl)oxy)-[1,1'-biphenyl]-3-yl)ethyl)-4-
methylbenzenesulfonamide (2.44). ARMVIII97. A solution of 2.20 (0.687 g, 1.6 
mmol), TsCl (0.366 g, 1.9 mmol), and TBAI (spatula tip), in THF (5 mL) and H2O (15 
mL) was stirred for 6 h at room temperature. The mixture was extracted with ethyl 
acetate (3 x 20 mL). The combined organic fractions were washed with brine (30 mL), 
dried (Na2SO4), and concentrated in vacuo to give crude 2.44 as an amorphous solid. The 
crude material was purified via silica gel flash column chromatography eluting with 
hexanes : ethyl acetate (19 : 1 → 9 : 1 along a gradient) to give 0.751 g (80%) of 2.44 as 
an off white solid: M.p. 99-100 ºC. IR (thin film) 2944, 2866, 1512, 1262. 1H NMR (400 
MHz) d 7.68 (d, J = 8.4 Hz, 2 H), 7.36 (d, J = 8.4 Hz, 2 H), 7.26 (d, J = 8.0 Hz, 2 H), 
6.91 (d, J = 8.8 Hz, 2 H), 6.59 (d, J = 4.8 Hz, 2 H), 4.39 (t, J = 6.0 Hz, 1 H), 3.84 (s, 3 H), 
3.51 (s, 3 H), 3.24 (q, J = 6.8 Hz, 2 H), 2.74 (t, J = 6.8 Hz, 2 H), 2.41 (s, 3 H), 1.27 (sept, 
J = 6.8 Hz, 3 H), 1.13 (d, J = 6.8Hz, 18 H). 13C NMR (100 MHz) 
d 155.5, 153.2, 145.3, 143.4, 136.9, 135.7, 133.2, 130.5, 130.2, 129.7, 127.1, 122.4, 
119.6, 111.3, 60.3, 55.9, 44.1, 35.6, 21.5, 17.9, 12.7. HRMS calculated for C32H45NO5SSi 
(M)+ 583.2788 found 583.2795. 
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 NMR Assignment. 1H NMR (400 MHz) d 7.68 (d, J = 8.4 Hz, 2 H, NTs), 7.36 
(d, J = 8.4 Hz, 2 H, NTs), 7.26 (d, J = 8.8 Hz, 2 H, C4-H), 6.91 (d, J = 8.8 Hz, 2 H, C5-
H), 6.59 (app d, J = 4.8 Hz, 2 H, C3-H and C4-H), 4.39 (t, J = 6.0 Hz, 1 H, NH), 3.84 (s, 
3 H, OCH3), 3.51 (s, 3 H, OCH3), 3.24 (q, J = 6.8 Hz, 2 H, C1-H), 2.74 (t, J = 6.8 Hz, 2 
H, C2-H), 2.41 (s, 3 H, NTs), 1.27 (sept, J = 6.8 Hz, 3 H, TIPS), 1.13 (d, J = 6.8Hz, 18 H, 
TIPS). 
 
 
 1-(2-(Benzyloxy)ethyl)-6,7-dimethoxy-2-tosyl-8-(4-
((triisopropylsilyl)oxy)phenyl)-1,2,3,4-tetrahydroisoquinoline (2.51). ARM107. A 
solution of 2.44 (0.732 g, 1.25 mmol), 2.46 (0.395 g, 1.88 mmol), and TFA (0.14 mL, 
1.88 mmol), in TFE (15 mL) was heated to 60 ºC for 24 h. The reaction was cooled to 
room temperature, and concentrated in vacuo to give crude 2.51. The crude mixture was 
purified via silica gel flash column chromatography eluting with hexanes : ethyl acetate 
(19: 1 → 9 : 1 along a gradient) to 0.794 g (87%) of 2.51 as a clear viscous oil: IR (thin 
film) 2944, 2866, 1511, 1464, 1262 cm-1. 1H NMR (400 MHz) d 7.60 (d, J = 8.0 Hz, 2 
H), 7.32 - 6.95 (comp, 11 H), 6.51 (s, 1 H), 4.87 (dd, J = 10.4, 4.0 Hz, 1 H), 4.22 (s, 2 H), 
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3.89 - 3.80 (comp, 4 H), 3.61 - 3.53 (m, 1 H), 3.42 (s, 3 H), 3.26 (td, J = 9.2, 5.2 Hz, 1 
H), 3.15 - 3.04 (m, 1 H), 2.95 - 2.81 (m, 1 H), 2.70 (dt, J = 16.8, 4.4 Hz, 1 H), 2.34 (s, 3 
H), 1.85 – 1.69 (comp, 2 H), 1.30 (sept, J = 7.6 Hz, 3 H), 1.14 (d, J = 7.6 Hz, 18 H). 13C 
NMR (100 MHz) d 155.4, 151.4, 145.3, 143.0, 138.5, 137.3, 134.2, 131.8, 130.2, 129.2, 
128.8, 128.2, 127.4, 127.3,120.1, 120.0, 111.7, 72.6, 67.7, 60.4, 55.7, 51.2, 38.8, 35.2, 
27.0, 21.5, 17.9, 12.6. HRMS calculated for C42H55NO6SSi (M+Na)+ 752.34120 found 
752.33890. 
 NMR Assignment. 1H NMR (400 MHz) d 7.60 (d, J = 8.0 Hz, 2 H, NTs), 7.32 - 
6.95 (comp, 11 H, OBn, NTs, C7-H, C8-H), 6.51 (s, 1 H, C6-H), 4.87 (dd, J = 10.4, 4.0 
Hz, 1 H, C3-H), 4.22 (s, 2 H, OBn), 3.89 - 3.80 (comp, 4 H, OCH3 and C1-H), 3.61 - 3.53 
(m, 1 H, C1-H), 3.42 (s, 3 H, OCH3), 3.26 (td, J = 9.2, 5.2 Hz, 1 H, C4-H), 3.15 - 3.04 
(m, 1 H, C4-H), 2.95 - 2.81 (m, 1 H, C5-H), 2.70 (dt, J = 16.8, 4.4 Hz, 1 H, C5-H), 2.34 
(s, 3 H, NTs), 1.85 – 1.69 (comp, 2 H, C2-H), 1.30 (sept, J = 7.6 Hz, 3 H, TIPS), 1.14 (d, 
J = 7.6 Hz, 18 H, TIPS). 
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 2-(6,7-Dimethoxy-2-tosyl-8-(4-((triisopropylsilyl)oxy)phenyl)-1,2,3,4-
tetrahydroisoquinolin-1-yl)ethanol (2.52). ARMIII105. A suspension of 2.51 (0.396 g, 
0.54 mmol), ammonium formate (0.171 g, 2.71 mmol) and Pd/C (10% w/w, 0.30 g) in 
methanol (20 mL) was heated to 50 ºC for 6 h. The suspension was filtered through a pad 
of Celite, washed with copious amounts of methanol, and concentrated in vacuo to give 
crude 2.52. The crude material was purified via silica gel flash column chromatography 
eluting with hexanes : ethyl acetate (19 : 1 → 3 : 1 along a gradient) to give 0.287 g 
(83%) of 2.52 as a white solid. Recrystallization from methanol afforded white crystals: 
M.p. 105-107 ºC. IR (thin film) 3545, 2944, 2866, 2361, 2340, 1606, 1511, 1464, 1261 
cm-1. 1H NMR (400 MHz) d 7.53 (d, J = 7.6 Hz, 2 H), 7.18 (d, J = 8.2 Hz, 2 H), 7.12 (d, J 
= 7.6 Hz, 1 H), 6.99 (d, J = 8.2 Hz, 2 H), 6.86 (d, J = 7.2 Hz, 1 H), 6.53 (s, 1 H), 4.83 
(dd, J = 8.4, 8 Hz, 1 H), 3.81 (s, 3 H), 3.62 – 3.50 (comp, 3 H), 3.47 - 3.41 (comp, 4 H), 
2.70 - 2.78 (comp, 2 H), 2.37 (s, 3 H), 2.19 (t, J = 7.6 Hz, 1 H), 1.68 – 1.60 (comp, 2 H), 
1.31 (sept, J = 7.6 Hz, 3 H), 1.14 (d, J = 7.6 Hz, 18 H). 13C NMR (100 MHz) d 155.6, 
151.5, 145.4, 143.3, 136.3, 134.2, 131.4, 130.4, 129.4, 129.2, 128.3, 127.7, 127.3, 120.1, 
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119.9, 111.5, 60.5, 59.0, 55.7, 51.1, 40.5, 39.0, 27.3, 21.5, 17.9, 12.6. HRMS calculated 
for C35H49NO6SSi (M+H)+ 640.3128 found 640.3107. 
 NMR Assignment. 1H NMR (400 MHz) d 7.53 (d, J = 7.6 Hz, 2 H, C7-H), 7.18 
(d, J = 8.2 Hz, 2 H, NTs), 7.12 (d, J = 7.6 Hz, 1 H, C8-H), 6.99 (d, J = 8.2 Hz, 2 H, NTs), 
6.86 (d, J = 7.6 Hz, 1 H, C8-H), 6.53 (s, 1 H, C6-H), 4.83 (dd, J = 8.4, 8 Hz, 1 H, C3-H), 
3.81 (s, 3 H, OCH3), 3.62 – 3.50 (comp, 3 H, C1-H and C4-H), 3.47 - 3.41 (comp, 4 H, 
OCH3 and C4-H), 2.70 - 2.78 (comp, 2 H, C5-H), 2.37 (s, 3 H, NTs), 2.19 (t, J = 7.6 Hz, 
1 H, OH), 1.68 – 1.60 (comp, 2 H, C2-H), 1.31 (sept, J = 7.6 Hz, 3 H, TIPS), 1.14 (d, J = 
7.6 Hz, 18 H, TIPS). 
 
 
 1-(2-Bromoethyl)-6,7-dimethoxy-2-tosyl-8-(4-((triisopropylsilyl)oxy)phenyl)-
1,2,3,4-tetrahydroisoquinoline (2.57). ARMIV43. Triphenylphosphine (0.50 g, 1.92 
mmol) was added to a solution of 2.52 (0.61 g, 0.96 mmol) and CBr4 (0.64 g, 1.92 mmol) 
in CH2Cl2 (25 mL) at 0 ºC. The reaction was stirred for 15 min at 0 ºC, whereupon the 
cold bath was removed and the reaction stirred for 3 h at room temperature. The mixture 
was diluted with ether (100 mL), filtered, and concentrated in vacuo to give crude 2.57. 
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The crude material was purified via silica gel flash column chromatography eluting with 
hexanes : ethyl acetate (9 : 1) to give 0.641 g (95%) of 2.57 as a white solid. The pure 
material was recrystallized from methanol to give white crystals: M.p. 112-113 ºC. IR 
(thin film) 2944, 2866, 1512, 1463, 1262 cm-1. 1H NMR (400 MHz) d 7.62 (d, J = 8.0 Hz, 
2 H), 7.19 (d, J = 8.0 Hz, 2 H), 7.15 - 7.05 (m, 1 H), 7.01 - 6.98 (comp, 3 H), 6.49 (s, 1 
H), 4.80 (dd, J = 10.4, 3.2 Hz, 1 H), 3.81 – 3.74 (comp, 4 H), 3.48 (ddd, J = 15.6, 10.0, 
5.6 Hz, 1 H), 3.42 (s, 3 H), 3.14 (td, J = 10.0, 4.4 Hz, 1 H), 2.90 - 2.77 (comp, 2 H), 2.67 
(dt, J = 16.4, 5.2 Hz, 1 H), 2.37 (s, 3 H), 2.02 – 1.94 (m, 1 H), 1.87 – 1.79 (m, 1 H), 1.30 
(sept, J = 6.8 Hz, 3 H), 1.14 (d, J = 6.8 Hz, 18 H). 13C NMR (100 MHz) d 155.5, 151.7, 
145.4, 143.3, 137.0, 134.3, 131.6, 130.1, 129.4, 128.8, 127.7, 127.3, 127.1, 120.3, 120.0, 
111.7, 105.0, 60.5, 55.7, 52.9, 39.0, 28.8, 27.0, 21.5, 17.9, 12.7. HRMS calculated for 
C35H48BrNO5SSi 724.20980 and 726.20840 found 724.20680 and 726.20690. 
 NMR Assignment. 1H NMR (400 MHz) d 7.62 (d, J = 8.0 Hz, 2 H, NTs), 7.19 
(d, J = 8.0 Hz, 2 H, NTs), 7.15 - 7.05 (m, 1 H, C7-H), 7.01 - 6.98 (comp, 3 H, C7-H and 
C8-H), 6.49 (s, 1 H, C6-H), 4.80 (dd, J = 10.4, 3.2 Hz, 1 H, C3-H), 3.81 – 3.74 (comp, 4 
H, OCH3 and C4-H), 3.48 (ddd, J = 15.6, 10.0, 5.6 Hz, 1 H, C4-H), 3.42 (s, 3 H, OCH3), 
3.14 (td, J = 10.0, 4.4 Hz, 1 H, C1-H), 2.90 - 2.77 (comp, 2 H, C1-H and C5-H), 2.67 (dt, 
J = 16.4, 5.2 Hz, 1 H, C5-H), 2.37 (s, 3 H, NTs), 2.02 – 1.94 (m, 1 H, C2-H), 1.87 – 1.79 
(m, 1 H, C2-H), 1.30 (sept, J = 6.8 Hz, 3 H, TIPS), 1.14 (d, J = 6.8 Hz, 18 H, TIPS). 
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 1-(2-Chloroethyl)-6,7-dimethoxy-2-tosyl-8-(4-((triisopropylsilyl)oxy)phenyl)-
1,2,3,4-tetrahydroisoquinoline (2.58). ARMIV97. Triphenylphosphine (0.128 g, 0.49 
mmol) was added to a solution of 2.52 (0.104 g, 0.16 mmol) and CCl4 (0.075 g, 0.49 
mmol) in CH2Cl2 (5 mL) at 0 ºC, and stirred for 15 min. The reaction was warmed to 
room temperature and stirred for an additional 5 h. The mixture was diluted with ether 
(30 mL), filtered, and concentrated in vacuo to give crude 2.58. The crude material was 
purified via silica gel flash column chromatography eluting with hexanes : ethyl acetate 
(9 : 1) to give 0.088 g (83%) of 2.58 as a white solid. The purified material can be 
recrystallized from methanol to give white crystals: M.p. 115-118 ºC. IR (thin film) 2944, 
2867, 1606, 1511, 1464, 1339,1263 cm-1. 1H NMR (400 MHz) d 7.55 (d, J = 8.4 Hz, 2 
H), 7.24 (d, J = 7.2 Hz, 1 H), 7.19 (d, J = 8.0 Hz, 2 H), 7.10 (d, J = 9.2 Hz, 1 H), 7.01 – 
6.92 (comp, 2 H), 6.50 (s, 1 H), 4.77 (dd, J = 10.4, 3.2 Hz, 1 H), 3.73 (comp, 4 H), 3.49 
(ddd, J = 15.2, 10.0, 5.6 Hz, 1 H), 3.42 (s, 3 H), 3.27 (ddd, J = 10.8, 9.6, 4.8 Hz, 1 H), 
2.96 – 2.89 (m, 1 H), 2.82 – 2.74 (m, 1 H), 2.68 (dt, J = 15.2, 4.0 Hz, 1 H), 2.30 (s, 3 H), 
1.92 – 1.85 (m, 1 H), 1.78 – 1.69 (m, 1 H), 1.31 (sept, J = 7.6 Hz, 3 H), 1.14 (d, J = 7.6 
Hz, 18 Hz). 13C NMR (100 MHz) d 155.5, 151.6, 145.4, 143.3, 137.0, 134.3, 131.6, 
N
MeO
MeO
Cl
OTIPS
Ts
1
2
3
4
56
7
8
2.58
 
 
 
250 
130.1, 129.4, 128.8, 127.7, 127.3, 127.2, 120.2, 120.0, 111.7, 60.5, 55.7, 51.8, 41.0, 39.0, 
38.5, 27.0, 21.5, 17.9, 12.7. HRMS calculated for C35H48ClNO5SSi (M+Na)+ 680.26030 
found 680.25790.  
 NMR Assignment. 1H NMR (400 MHz) d 7.55 (d, J = 8.4 Hz, 2 H, NTs), 7.24 
(d, J = 7.2 Hz, 1 H, C7-H), 7.19 (d, J = 8.4 Hz, 2 H, NTs), 7.10 (d, J = 7.2 Hz, 1 H, C7-
H), 7.01 – 6.92 (comp, 2 H, C8-H), 6.50 (s, 1 H, C6-H), 4.77 (dd, J = 10.4, 3.2 Hz, 1 H, 
C3-H), 3.73 (comp, 4 H, OCH3 and C4-H), 3.49 (ddd, J = 15.2, 10.0, 5.6 Hz, 1 H, C4-H), 
3.42 (s, 3 H, OCH3), 3.27 (ddd, J = 10.8, 9.6, 4.8 Hz, 1 H, C1-H), 2.96 – 2.89 (m, 1 H, 
C1-H), 2.82 – 2.74 (m, 1 H, C5-H), 2.68 (dt, J = 15.2, 4.0 Hz, 1 H, C5-H), 2.30 (s, 3 H, 
NTs), 1.92 – 1.85 (m, 1 H, C2-H), 1.78 – 1.69 (m, 1 H, C2-H), 1.31 (sept, J = 7.6 Hz, 3 
H, TIPS), 1.14 (d, J = 7.6 Hz, 18 Hz, TIPS). 
 
 
 5,6-Dimethoxy-1-tosyl-1,2,3,8,9,9a-hexahydrospiro[benzo[de]quinoline-7,1'-
cyclohexa[2,5]dien]-4'-one (2.54). ARMIV53. A solution of 2.57 (50 mg, 0.071 mmol) 
in NMP (14 mL) was added dropwise over 10 min via cannula, to flame-dried CsF (32 
mg, 0.31 mmol) at 100 ºC. The resulting suspension was stirred for 2 h at 100 ºC. The 
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reaction was cooled to room temperature, diluted with water (30 mL), and extracted with 
toluene (4 x 30 mL). The combined organic fractions were washed with water (30 mL), 
brine (30 mL), dried (MgSO4), and concentrated in vacuo to give crude 2.54. The crude 
material was purified via silica gel flash column chromatography eluting with hexanes : 
ethyl acetate (4 : 1) to give 26 mg (79%) of 2.54 as a white solid. Crystals suitable for x-
ray diffraction were grown via slow diffusion of hexanes into ethyl acetate: M.p. 174-175 
ºC. IR (thin film) 2939, 2360, 2340, 1659, 1620, 1597, 1477, 1337, 1316. 1H NMR (400 
MHz) d 7.75 (d, J = 8.0 Hz, 2 H), 7.31 (d, J = 8.0 Hz, 2 H), 7.02 (dd, J = 10.0, 3.2 Hz, 1 
H), 6.92 (dd, J = 10.0, 3.2 Hz, 2 H), 6.52 (s, 1 H), 6.32 (dd, J = 10.0, 2.0 Hz, 1 H), 6.22 
(dd, J = 10.0, 2.0 Hz, 1 H), 4.50 (dd, J = 11.6, 4.0 Hz, 1 H), 3.97 (dt, J = 13.6, 4.0 Hz, 1 
H), 3.76 (s, 3 H), 3.58 (s, 3 H), 3.15 (ddd, J = 14.0, 11.6, 2.8 Hz, 1 H), 2.59 (dq, J = 12.8, 
3.2 Hz, 1 H), 2.48 (dt, J = 15.6, 2.8 Hz, 1 H), 2.42 (s, 3 H), 2.33 (ddd, J = 15.2, 11.2, 4.0 
Hz, 1 H), 2.20 (td, J = 14.0, 2.8 Hz, 1 H), 1.99 – 1.83 (m, 1 H), 1.79 (ddd, J = 14.0, 4.4, 
2.8 Hz, 1 H). 13C NMR (100 MHz) d 186.0, 156.5, 153.5, 151.4, 143.6, 137.5, 131.4, 
129.9, 129.1, 127.2, 126.4, 126.3, 124.4, 112.1, 105.0, 60.9, 55.6, 54.8, 43.7, 42.7, 35.7, 
30.2, 29.3, 21.5. HRMS calculated C26H27NO5S (M+H)+ 466.1688 found 466.1685. 
 NMR Assignment. 1H NMR (400 MHz) d 7.75 (d, J = 8.0 Hz, 2 H, NTs), 7.31 
(d, J = 8.0 Hz, 2 H, NTs), 7.02 (dd, J = 10.0, 3.2 Hz, 1 H, C6-H), 6.92 (dd, J = 10.0, 3.2 
Hz, 2 H, C6-H), 6.52 (s, 1 H, C1-H), 6.32 (dd, J = 10.0, 2.0 Hz, 1 H, C8-H), 6.22 (dd, J = 
10.0, 2.0 Hz, 1 H, C8-H), 4.50 (dd, J = 11.6, 4.0 Hz, 1 H, C4-H), 3.97 (dt, J = 13.6, 4.0 
Hz, 1 H, C3-H), 3.76 (s, 3 H, OCH3), 3.58 (s, 3 H, OCH3), 3.15 (ddd, J = 14.0, 11.6, 2.8 
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Hz, 1 H, C3-H), 2.59 (dq, J = 12.8, 3.2 Hz, 1 H, C2-H), 2.48 (dt, J = 15.6, 2.8 Hz, 1 H, 
C2-H), 2.42 (s, 3 H, NTs), 2.33 (ddd, J = 15.2, 11.2, 4.0 Hz, 1 H, C5-H), 2.20 (td, J = 
14.0, 2.8 Hz, 1 H, C5-H), 1.99 – 1.83 (m, 1 H, C6-H), 1.79 (ddd, J = 14.0, 4.4, 2.8 Hz, 1 
H, C6-H). 
 
 
 10,11-Dimethoxy-3-tosyl-1,2,3,3a,4,5-hexahydrobenzo[6,7]cyclohepta[1,2,3-
ij]isoquinolin-7-ol (2.55). ARMIV87. Concentrated HCl (10 mL) was added dropwise to 
a solution of 2.54 (192 mg, 0.41 mmol) in glacial acetic acid (200 mL) at room 
temperature. The solution was heated to 50 ºC for 18 h, whereupon the reaction was 
cooled to room temperature, and the majority of solvent was removed in vacuo at 40 ºC 
(water bath). The resulting residue was diluted with CH2Cl2 (300 mL), and washed with 
water (2 x 200 mL), saturated aqueous NaHCO3 (200 mL), brine (200 mL), dried 
(MgSO4), and concentrated in vacuo to give crude 2.55. The crude material was purified 
via silica gel flash column chromatography eluting with hexanes : ethyl acetate (9 : 1 → 
82 : 18 along a gradient) to afford 152 mg (79%) of 2.55 as a white solid. 
Recrystallization by slow evaporation of methanol afforded x-ray quality crystals: M.p. 
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160 ºC. IR (thin film) 3418, 2937, 1597, 1452, 1245. 1H NMR (400 MHz) d 7.48 (d, J = 
8.0 Hz, 2 H), 7.36 (d, J = 8.4 Hz, 1 H), 7.10 (d, J = 8.0 Hz, 2 H), 6.79 (dd, J = 8.4, 2.6 
Hz, 1 H), 6.74 (d, J = 2.6 Hz, 1 H), 6.46 (s, 1 H), 5.12 (brs, 1 H), 4.58 (dd, J = 10.4, 6.4 
Hz, 1 H), 3.95 (dd, J = 14.0, 6.4 Hz, 1 H), 3.82 (s, 3 H), 3.42 – 3.36 (comp, 4 H), 2.66 
(td, J = 12.0, 6.8 Hz, 1 H), 2.56 (dd, J = 16.8, 3.6 Hz, 1 H), 2.45 – 2.40 (m, 1 H), 2.31- 
2.19 (comp, 5 H), 2.15 – 2.03 (m, 1 H). 13C NMR (100 MHz) 155.4, 151.7, 144.2, 142.9, 
140.3, 137.9, 131.7, 131.7, 129.3, 127.7, 126.8, 126.4, 125.6, 114.9, 113.4, 111.1, 60.3, 
55.8, 52.4, 38.6, 37.7, 30.5, 27.5, 21.4. HRMS calculated for C26H27NO5S (M+Na)+ 
488.15020 found 488.14 
 NMR Assignment. 1H NMR (400 MHz) d 7.48 (d, J = 8.0 Hz, 2 H, NTs), 7.36 
(d, J = 8.4 Hz, 1 H, C9-H), 7.10 (d, J = 8.0 Hz, 2 H, NTs), 6.79 (dd, J = 8.4, 2.6 Hz, 1 H, 
C8-H), 6.74 (d, J = 2.6 Hz, 1 H, C7-H), 6.46 (s, 1 H, C1-H), 5.12 (brs, 1 H, OH), 4.58 
(dd, J = 10.4, 6.4 Hz, 1 H, C4-H), 3.95 (dd, J = 14.0, 6.4 Hz, 1 H, C3-H), 3.82 (s, 3 H, 
OCH3), 3.42 – 3.36 (comp, 4 H, OCH3 and C3-H), 2.66 (td, J = 12.0, 6.8 Hz, 1 H, C2-H), 
2.56 (dd, J = 16.8, 3.6 Hz, 1 H, C2-H), 2.45 – 2.40 (m, 1 H, C5-H), 2.31- 2.19 (comp, 5 
H, OCH3, C5-H, and C6-H), 2.15 – 2.03 (m, 1 H, C6-H). 
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 10,11-Dimethoxy-1,2,3,3a,4,5-hexahydrobenzo[6,7]cyclohepta[1,2,3-
ij]isoquinolin-7-ol (2.1). ARMIV105. Sodium naphthalide was prepared by the addition 
of sodium metal (64 mg, 2.81 mmol), portionwise over 10 min, to a solution of 
naphthalene (458 mg, 3.58 mmol) in dry DME (2.5 mL), and stirring for 1 h at room 
temperature. The sodium naphthalide solution was added dropwise to a solution of 2.55 
(119 mg, 0.26 mmol) in DME (10.4 mL) at -50 ºC, until a green color persisted. Water (1 
mL) was added to the reaction, and the mixture was diluted with aqueous HCl (1 M, 80 
mL), washed with ether (2 x 40 mL), and neutralized with solid NaHCO3. The neutral 
aqueous solution was extracted with ether (4 x 100 mL), and the combined organic 
fractions were washed with brine (100 mL), dried (MgSO4), and concentrated in vacuo to 
give crude 2.1. The crude material was purified via silica gel flash column 
chromatography eluting with CH2Cl2 : acetone : methanol (5 : 4 : 1) to afford 46 mg 
(58%) of 2.1 as a white solid. Homoaporphine 2.1 is not bench-top stable, turning brown 
within hours, and must be stored in a freezer: M.p. 189-191 ºC. IR (thin film) 2917, 2849, 
1454, 1427, 1243 cm-1. 1H NMR (400 MHz, CD3OD) d 7.20 (d, J = 9.2 Hz, 1 H), 6.76 (s, 
1 H), 6.70 – 6.62 (comp, 2 H), 3.86 (s, 3 H), 3.53 (dd, J = 11.2, 6.8 Hz, 1 H), 3.41 (s, 3 
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H), 3.16 (td, J = 12.0, 4.4 Hz, 1 H), 3.00 (dd, J = 13.2, 6.4 Hz, 1 H), 2.88 (ddd, J = 17.6, 
12.0, 6.4 Hz, 1 H), 2.74 (dd, J = 16.4, 2.4 Hz, 1 H), 2.48 (dd, J = 12.8, 6.0 Hz, 1 H), 2.35 
(td, J = 12.8, 7.2 Hz, 1 H), 2.25 – 2.18 (m, 1 H), 2.11 – 2.01 (m, 1 H). 13C NMR (125 
MHz, (CD3)2SO) d 156.5, 150.8, 143.3, 140.6, 131.2, 130.9, 129.7, 128.7, 125.4, 114.3, 
112.5, 111.8, 59.7, 55.5, 50.2, 37.4, 30.5, 29.1. HRMS calculated for C19H21NO3 (M+H)+ 
312.15940 found 312.15950. 
 NMR Assignment. 1H NMR (400 MHz, CD3OD) d 7.20 (d, J = 9.2 Hz, 1 H, C9-
H), 6.76 (s, 1 H, C1-H), 6.70 – 6.62 (comp, 2 H, C8-H and C7-H), 3.86 (s, 3 H, OCH3), 
3.53 (dd, J = 11.2, 6.8 Hz, 1 H, C4-H), 3.41 (s, 3 H, OCH3), 3.16 (td, J = 12.0, 4.4 Hz, 1 
H, C3-H), 3.00 (dd, J = 13.2, 6.4 Hz, 1 H, C3-H), 2.88 (ddd, J = 17.6, 12.0, 6.4 Hz, 1 H, 
C2-H), 2.74 (dd, J = 16.4, 2.4 Hz, 1 H, C2-H), 2.48 (dd, J = 12.8, 6.0 Hz, 1 H, C5-H), 
2.35 (td, J = 12.8, 7.2 Hz, 1 H, C5-H), 2.25 – 2.18 (m, 1 H, C6-H), 2.11 – 2.01 (m, 1 H, 
C6-H). 
 
 
1,3,5-Tribenzyl-1,3,5-triazinane (4.11). Prepared according to previous literature 
reports.311,312 
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3,3-Dimethoxypropan-1-ammonium bromide (4.18). ARMV93. 3-
Bromopropionaldehyde dimethyl acetal (1.34 g, 7.33 mmol) was added to a solution of 
methanolic ammonia (7 N, 100 mL) in a glass pressure vessel. The vessel was sealed and 
the reaction was heated at 85 ºC overnight. The reaction was cooled to room temperature, 
the pressure was carefully released, and the solvent was removed in vacuo to give 1.42 g 
(98%) of 4.18 as a white crystalline solid that formed an orange gum upon exposure to 
air; 1H NMR (400 MHz, CD3CN) d 4.54 (t, J = 5.2 Hz, 1 H), 3.36 (s, 6 H), 3.05 (t, J = 5.2 
Hz, 2 H), 2.41 (brs, 3 H), 2.04 (q, J = 5.2 Hz, 2 H); 13C NMR (100 MHz, CD3CN) d 
104.3, 54.5, 36.7, 30.4; IR (thin film) 2915, 2025, 1628 cm-1; HRMS (ESI) m/z calcd for 
C5H13NO2 (M+1)+, 120.1019; found, 120.1018 
NMR Assignments. 1H NMR (400 MHz, CD3OD) d 4.54 (t, J = 5.2 Hz, 1 H, C3-
H), 3.36 (s, 6 H, C4-H), 3.05 (t, J = 5.2 Hz, 2 H, C1-H), 2.41 (brs, 3 H, N-H), 2.04 (q, J = 
5.2 Hz, 2 H, C2-H) 
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(E)-N-(3,3-Dimethoxypropyl)but-2-enamide (4.19). ARMV65. A solution of crotonoyl 
chloride (709 mg, 2.0 mmol) in pyridine (5 mL) was added dropwise over 10 min to a 
solution of 4.18 (200 mg, 1.0 mmol) in pyridine (5 mL) at 0 ºC. The reaction was stirred 
for 3 h at 0 ºC, whereupon the solvent was removed in vacuo to give crude 4.19. The 
crude material was purified via silica gel plug eluting with ether to give 125 mg (67%) of 
4.19 as an oil: 1H NMR (400 MHz) d 6.78 (qd, J = 15.2, 6.8 Hz, 1 H), 6.14 (brs, 1 H), 
5.75 (dq, J = 15.2, 1.6 Hz, 1 H), 4.41 (t, J = 5.2 Hz, 1 H), 3.36 (q, J = 5.2 Hz, 2 H), 3.32 
(s, 6 H), 1.83 – 1.78 (comp, 5 H). 
 NMR Assignment. 1H NMR (400 MHz) d 6.78 (qd, J = 15.2, 6.8 Hz, 1 H, C6-H), 
6.14 (brs, 1 H, NH), 5.75 (dq, J = 15.2, 1.6 Hz, 1 H, C5-H), 4.41 (t, J = 5.2 Hz, 1 H, C2-
H), 3.36 (q, J = 5.2 Hz, 2 H, C4-H), 3.32 (s, 6 H, C1-H), 1.83 – 1.78 (comp, 5 H, C3-H 
and C7-H). 
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 Methyl indole-3-ethanoate (4.24). Synthesized according to previous literature 
procedure.313 
 
 Indole-3-acetaldehyde (4.22). Synthesized according to previous literature 
procedure.313 
 
 
N-(2-(1H-Indol-3-yl)ethyl)-3,3-dimethoxypropan-1-amine (4.25). ARMV77. 
Sodium cyanoborohydride (84 mg, 1.34 mmol) was added to a solution of 4.22 (170 mg, 
1.07 mmol) and 4.18 (178 mg, 0.89 mmol) in methanol (5 mL). The reaction was stirred 
overnight at room temperature, whereupon the solvent was removed in vacuo, and the 
resulting residue was purified via silica gel flash column chromatography eluting with 
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CH2Cl2 : methanol (99 : 1 → 19 : 1 along a gradient) to give 208 mg (89%) of 4.25 as an 
off white oil: 1H NMR (400 MHz) d 8.61 (brs, 1 H), 7.57 (d, J = 7.2 Hz, 1 H), 7.42 (dt, J 
= 8.0, 1.2 Hz, 1 H), 7.27 – 7.20 (m, 1 H), 7.17 (dd, J = 8.0, 1.2 Hz, 1 H), 7.14 (ddd, J = 
8.0, 7.2, 1.2 Hz, 1 H), 4.25 (t, J = 4.0 Hz, 1 H), 3.20 - 3.18 (comp, 4 H), 3.03 (t, J = 5.6 
Hz, 2 H), 3.00 (s, 6 H), 1.88 (tt, J = 7.2, 4.0 Hz, 2 H). 13C NMR (100 MHz) d 134.0, 
123.8, 121.5, 120.0, 117.4, 115.6, 109.2, 105.8, 101.3, 52.3, 45.6, 41.1, 25.8, 19.6. IR 
(neat) 3411, 2337, 2173, 1640, 1458 cm-1; HRMS (CI) m/z calcd for C15H23N2O2 (M+1)+, 
263.1760; found, 263.1760. 
 NMR Assignment. 1H NMR (400 MHz) d 8.61 (brs, 1 H, N10-H), 7.57 (d, J = 
7.2 Hz, 1 H, C13-H), 7.42 (dt, J = 8.0, 1.2 Hz, 1 H, C16-H), 7.27 – 7.20 (m, 1 H, C15-H), 
7.17 (dd, J = 8.0, 1.2 Hz, 1 H, C14-H), 7.14 (ddd, J = 8.0, 7.2, 1.2 Hz, 1 H, C9-H), 4.25 
(t, J = 4.0 Hz, 1 H, C2-H), 3.20-3.18 (comp, 4 H, C4-H and C6-H), 3.03 (t, J = 5.6 Hz, 2 
H, C7-H), 3.00 (s, 6 H, C1-H), 1.88 (tt, J = 7.2, 4.0 Hz, 2 H, C3-H) 
 
 
 (E)-N-(2-(1H-Indol-3-yl)ethyl)-N-(3,3-dimethoxypropyl)but-2-enamide 
(4.21). ARMV95. A solution of crotonoyl chloride (51 mg, 0.48 mmol) in CH2Cl2 (1 
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mL) was added dropwise to a solution of triethylamine (82 mg, 0.81 mmol) and 4.25 (106 
mg, 0.40 mmol) in CH2Cl2 (1 mL) at – 78 ºC. The reaction was stirred for 2 h at –78 ºC, 
whereupon saturated aqueous NaHCO3 (5 mL) was added. The phases were separated, 
and the aqueous phase was extracted with CH2Cl2 (3 x 10 mL). The combined organic 
fractions were dried (Na2SO4), filtered, and the was solvent removed in vacuo. The 
resulting residue was purified via silica gel flash column chromatography eluting with 
CH2Cl2 : methanol (99 : 1 → 97 : 1 along a gradient) to give 94 mg (71%) of 4.21 as a 
clear oil: 1H NMR (400 MHz) (1 : 1 rotamer mixture) d 9.24 (brs, 0.5 H), 9.20 (brs, 0.5 
H), 7.65 (d, J = 8.0 Hz, 0.5 H), 7.58 (d, J = 8.0 Hz, 0.5 H), 7.42 (d, J = 3.6 Hz, 0.5 H), 
7.40 (d, J = 3.6 Hz, 0.5 H), 7.17 – 7.14 (comp, 1 H), 7.10 – 7.06 (comp, 2 H), 6.87 (dq, J 
= 14.8, 7.2 Hz, 0.5 H), 6.64 (dq, J = 14.8, 7.2 Hz, 0.5 H), 6.40 (dd, J = 14.8, 1.6 Hz, 0.5 
H), 6.16 (dd, J = 14.8, 1.6 Hz, 0.5 H), 4.38 – 4.34 (comp, 1 H), 3.63 (t, J = 6.4 Hz, 1 H), 
3.61 (t, J = 6.4 Hz, 1 H), 3.39 – 3.35 (comp, 2 H), 3.27 (s, 6 H), 3.00 (t, J = 8.0 Hz, 1 H), 
2.98 (t, J = 8.0 Hz, 1 H), 1.99 (dd, J = 6.8, 1.6 Hz, 1.5 H), 1.83 – 1.79 (comp, 2 H), 1.69 
(dd, J = 6.8, 1.6 Hz, 1.5 H); 13C NMR (1:1 rotamer mixture) (100 MHz, CD3CN) 
d 166.2, 166.0, 140.9, 140.1, 136.8, 127.8, 127.7, 123.4, 122.7, 122.6, 122.6, 121.8, 
121.7, 119.1, 119.0, 118.9, 118.5, 112.9, 111.9, 111.7, 111.6, 103.1, 102.6, 52.8, 52.5, 
48.8, 47.5, 44.0, 42.5, 32.7, 31.1, 25.3, 23.7, 17.5, 17.3; HRMS (ESI) m/z calcd for 
C19H26N2O3 (M+Na)+, 353.1836; found, 353.1836. 
 NMR Assignment. 1H NMR (400 MHz) (1 : 1 rotamer mixture) d 9.24 (brs, 0.5 
H, N2-H), 9.20 (brs, 0.5 H, N2-H), 7.65 (d, J = 8.0 Hz, 0.5 H, C6-H), 7.58 (d, J = 8.0 Hz, 
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0.5 H, C6-H), 7.42 (d, J = 3.6 Hz, 0.5 H, C3-H), 7.40 (d, J = 3.6 Hz, 0.5 H, C3-H), 7.17 – 
7.14 (comp, 1 H, C4-H), 7.10 – 7.06 (comp, 2 H, C5-H and C1-H), 6.87 (dq, J = 14.8, 7.2 
Hz, 0.5 H, C10-H), 6.64 (dq, J = 14.8, 7.2 Hz, 0.5 H, C10-H), 6.40 (dd, J = 14.8, 1.6 Hz, 
0.5 H, C9-H), 6.16 (dd, J = 14.8, 1.6 Hz, 0.5 H, C9-H), 4.38 – 4.34 (comp, 1 H, C14-H), 
3.63 (t, J = 6.4 Hz, 1 H, C8-H), 3.61 (t, J = 6.4 Hz, 1 H, C8-H), 3.39 – 3.35 (comp, 2 H 
C12-H), 3.27 (s, 6 H, C15-H), 3.00 (t, J = 8.0 Hz, 1 H, C7-H), 2.98 (t, J = 8.0 Hz, 1 H, 
C7-H), 1.99 (dd, J = 6.8, 1.6 Hz, 1.5 H, C11-H), 1.83 – 1.79 (comp, 2 H, C13-H), 1.69 
(dd, J = 6.8, 1.6 Hz, 1.5 H, C11-H). 
 
 
(3S,3aR,7aS)-5-(2-(1H-Indol-3-yl)ethyl)-1,3-dimethylhexahydroisoxazolo[4,3-
c]pyridin-4(1H)-one (4.20). ARMV88/ARMV89. A solution of trifluoroacetic acid (230 
mg, 2.02 mmol) and 4.21 (65 mg, 0.20 mmol) in trifluoroethanol/water (3 : 1, 2 mL) was 
stirred for 1.5 h at room temperature, whereupon saturated aqueous NaHCO3 (5 mL) was 
added. The layers were separated, and the aqueous layer was extracted with CH2Cl2 (3 x 
10 mL). The combined organic fractions were dried (Na2SO4), filtered, and the solvent 
was removed in vacuo. The resulting residue was dissolved in ethanol (4 mL). N-
methylhydroxylamine hydrochloride (18 mg, 0.22 mmol) and triethylamine (22 mg, 0.22 
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mmol) were added to the mixture, and the reaction was heated under reflux for 48 h. the 
reaction was cooled to room temperature, the solvent was removed in vacuo, and the 
crude mixture was purified via silica gel flash column chromatography eluting with 
CH2Cl2 : methanol (97 : 3) to give 19 mg (30%) of 4.20 as a clear oil: 1H NMR (500 
MHz) d 8.26 (brs, 1 H), 6.62 (d, J = 8.1 Hz, 1 H), 7.32 (d, J = 8.1 Hz, 1 H), 7.16 (t, J = 
7.1 Hz, 1 H), 7.09 (t, J = 7.1 Hz, 1 H), 6.99 (d, J = 1.7 Hz, 1 H), 3.89 (pent, J = 6.1 Hz, 1 
H), 3.73 – 3.68 (m, 1 H), 3.64 – 3.58 (m, 1 H), 3.53 (td, J = 12.0, 2.9 Hz, 1 H), 2.99 - 
2.95 (comp, 3 H), 2.81 – 2.76 (comp, 2 H), 2.63 (s, 3 H), 1.75 (ddt, J = 14.5, 11.2, 4.1 
Hz, 1 H) 1.59 (dq, J = 14.5, 3.2 Hz, 1 H), 1.44 (d, J = 5.9 Hz, 3 H); 13C NMR (125 MHz) 
d 169.0, 136.3, 127.4, 122.0, 121.9, 119.3, 118.7, 112.8, 111.2, 77.4, 66.1, 55.3, 48.5, 
44.0, 43.1, 25.2, 23.4, 19.2; HRMS (CI) m/z calcd for C18H23N3O2  (M+1)+, 314.1869; 
found, 314.1867. 
NMR Assignment. 1H NMR (500 MHz) d 8.26 (brs, 1 H, N10-H), 6.62 (d, J = 
8.1 Hz, 1 H, C14-H), 7.32 (d, J = 8.1 Hz, 1 H, C11-H), 7.16 (t, J = 7.1 Hz, 1 H, C12-H), 
7.09 (t, J = 7.1 Hz, 1 H, C13-H), 6.99 (d, J = 1.7 Hz, 1 H, C9-H), 3.89 (pent, J = 6.1 Hz, 
1 H, C2-H), 3.73 – 3.68 (m, 1 H, C7-H), 3.64 – 3.58 (m, 1 H, C7-H), 3.53 (td, J = 12.0, 
2.9 Hz, 1 H, C6-H), 2.99 - 2.95 (comp, 3 H, C8-H and C6-H), 2.81 – 2.76 (comp, 2 H, 
C3-H and C4-H), 2.63 (s, 3 H, N-CH3), 1.75 (ddt, J = 14.5, 11.2, 4.1 Hz, 1 H, C5-H) 1.59 
(dq, J = 14.5, 3.2 Hz, 1 H, C5-H), 1.44 (d, J = 5.9 Hz, 3 H, C1-H). 
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 N-(3,3-Dimethoxypropyl)-2-(1H-indol-3-yl)-2-oxoacetamide (4.27). 
ARMVII132-ARMVII133. A solution of oxalyl chloride (1.52 g, 12.0 mmol) in ether (1 
mL) was added dropwise over 5 min to a solution of indole (1.41 g, 12.0 mmol) in ether 
(24 mL) at 0 ºC. The reaction was stirred at 0 ºC for 1 h, then warmed to room 
temperature, and stirred for an additional 1 h. The yellow precipitate was collected via 
vacuum filtration and dried in vacuo to give 2.28 g (87%) of indole-3-glyoxal chloride. A 
suspension of indole-3-glyoxal chloride (1.91 g, 8.7 mmol) in CH2Cl2 (20 mL) was added 
dropwise over 30 min to a solution of 4.18 (1.47 g, 7.3 mmol) and triethylamine (3.70 g, 
36.5 mmol) in CH2Cl2 (75 mL) at 0 ºC. The reaction was stirred at 0 ºC for 0.5 h, then 
warmed to room temperature and stirred for an additional 1 h. Saturated aqueous 
NaHCO3 (100 mL) was added to the reaction and stirred for 15 min. The mixture was 
extracted with CH2Cl2 (3 x 100 mL), and the combined organic extracts were washed 
with aqueous NaOH (1 M, 2 x 100 mL), water (100 mL), and brine (100 mL), dried 
(Na2SO4), filtered, and concentrated in vacuo to give 2.23 g (97%) of crude 4.27. The 
crude material was >90% purity, and was further purified by dissolving in CH2Cl2 (300 
N
H
O HN
O
O
O
1
2
3
4 5
6
7
8
9 10
11
4.27
 
 
 
264 
mL) and successively with saturated aqueous NH4Cl (200 mL), saturated aqueous 
NaHCO3 (200 mL), water (200 mL), and brine (200 mL). The organic fraction was dried 
(Na2SO4), and concentrated in vacuo to give 1.91 g (90%) of 4.27 as a pale yellow solid ( 
>95% purity, 1H NMR): 1H NMR (400 MHz) d 9.99 (brs, 1 H), 9.01 (d, J = 3.2 Hz, 1 H), 
8.41 (d, J = 7.2 Hz, 1 H), 7.97 (t, J = 6.0 Hz, 1 H), 7.40 – 7.38 (m, 1 H), 7.31 (ddd, J = 
8.4, 7.2, 1.2 Hz, 1 H), 7.25 (ddd, J = 8.4, 7.2, 1.2 Hz, 1 H), 4.48 (t, J = 6.4 Hz, 1 H), 3.47 
(q, J = 6.4 Hz, 2 H), 3.36 (s, 6 H), 1.91 (q, J = 6.4 Hz, 2 H). 13C NMR (100 MHz, 
CD3CN) d 181.6, 163.0, 139.1, 136.5, 126.9, 124.0, 123.1, 121.9, 112.8, 112.5, 103.7, 
53.1, 35.1, 32.3. HRMS (ESI) m/z calcd for C15H18N2O4 (M+Na)+, 313.1159; found, 
313.1166. 
 NMR Assignment. 1H NMR (400 MHz) d 9.99 (brs, 1 H, N5-H), 9.01 (d, J = 3.2 
Hz, 1 H, C6-H), 8.41 (d, J = 7.2 Hz, 1 H, C1-H), 7.97 (t, J = 6.0 Hz, 1 H, N7-H), 7.40 – 
7.38 (m, 1 H, C4-H), 7.31 (ddd, J = 8.4, 7.2, 1.2 Hz, 1 H, C3-H), 7.25 (ddd, J = 8.4, 7.2, 
1.2 Hz, 1 H, C2-H), 4.48 (t, J = 6.4 Hz, 1 H, C10-H), 3.47 (q, J = 6.4 Hz, 2 H, C8-H), 
3.36 (s, 6 H, C11-H), 1.91 (q, J = 6.4 Hz, 2 H, C9-H). 
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 N-(2-(1H-Indol-3-yl)ethyl)-3,3-dimethoxypropan-1-amine (4.25).  
ARMVII137. A solution of 4.27 (0.50 g, 1.70 mmol) in THF (5 mL) was added dropwise 
over 15 min to a stirred suspension of lithium aluminum hydride (0.65 g, 17.0 mmol) in 
THF (40 mL) at 0 ºC. The reaction was heated at 65 ºC for 14 h. The reaction was cooled 
to 0 ºC and the Fieser work-up was carefully performed by successive addition of water 
(0.6 mL), aqueous sodium hydroxide (15% w/v, 0.6 mL), and water (3 mL). The 
suspension was warmed to room temperature and MgSO4 was added. The solution was 
filtered through a fritted funnel, and the solids were washed with excess CH2Cl2. The 
filtrate was concentrated in vacuo to give crude 4.25 as an opaque viscous oil. The crude 
material was taken up in aqueous HCl (0.2 M, 150 mL) and washed with ether (2 x 100 
mL). The aqueous fraction was basified with aqueous NaOH (40% w/v) to pH 12-14, as 
judged by pH paper. The basic solution was extracted with CH2Cl2 (3 x 200 mL). The 
combined organic extracts were dried (Na2SO4), filtered, and concentrated to give 0.41 g 
(90%) of 4.25 as a viscos oil (>95% purity, 1H NMR); 1H NMR (400 MHz) d 8.61 (brs, 1 
H), 7.57 (d, J = 7.2 Hz, 1 H), 7.42 (dt, J = 8.0, 1.2 Hz, 1 H), 7.27 – 7.20 (m, 1 H), 7.17 
(dd, J = 8.0, 1.2 Hz, 1 H), 7.14 (ddd, J = 8.0, 7.2, 1.2 Hz, 1 H), 4.25 (t, J = 4.0 Hz, 1 H), 
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3.20 - 3.18 (comp, 4 H), 3.03 (t, J = 5.6 Hz, 2 H), 3.00 (s, 6 H), 1.88 (tt, J = 7.2, 4.0 Hz, 2 
H); 13C NMR (100 MHz) d 134.0, 123.8, 121.5, 120.0, 117.4, 115.6, 109.2, 105.8, 101.3, 
52.3, 45.6, 41.1, 25.8, 19.6; IR (neat) 3411, 2337, 2173, 1640, 1458 cm-1; HRMS (CI) 
m/z calcd for C15H23N2O2 (M+1)+, 263.1760; found, 263.1760. 
 NMR Assignment. 1H NMR (400 MHz) d 8.61 (brs, 1 H, N10-H), 7.57 (d, J = 
7.2 Hz, 1 H, C13-H), 7.42 (dt, J = 8.0, 1.2 Hz, 1 H, C16-H), 7.27 – 7.20 (m, 1 H, C15-H), 
7.17 (dd, J = 8.0, 1.2 Hz, 1 H, C14-H), 7.14 (ddd, J = 8.0, 7.2, 1.2 Hz, 1 H, C9-H), 4.25 
(t, J = 4.0 Hz, 1 H, C2-H), 3.20-3.18 (comp, 4 H, C4-H and C6-H), 3.03 (t, J = 5.6 Hz, 2 
H, C7-H), 3.00 (s, 6 H, C1-H), 1.88 (tt, J = 7.2, 4.0 Hz, 2 H, C3-H) 
 
 
(3S,3aR,7aS)-5-(2-(1H-Indol-3-yl)ethyl)-1,3-dimethylhexahydroisoxazolo[4,3-
c]pyridin-4(1H)-one (4.20). ARMVII146-ARMVII147. A solution of trifluoroacetic 
acid (5 drops) and 4.21 (110 mg, 0.33 mmol) in TFE/water (3 : 1, 7 mL) was stirred for 1 
h at room temperature. Saturated aqueous NaHCO3 (20 mL) was added, and the aqueous 
layer extracted with CH2Cl2 (3 x 20 mL). The combined organic fractions were dried 
(Na2SO4), filtered, and concentrated in vacuo. The crude mixture was dissolved in 
toluene (5 mL), followed by addition of N-methylhydroxylamine hydrochloride (41 mg, 
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0.50 mmol) and triethylamine (83 mg, 0.83 mmol). The reaction was heated under reflux 
for 1 h, then cooled to room temperature, and partitioned between saturated aqueous 
NaHCO3 (20 mL), ethyl acetate (20 mL), and methanol (2 mL). The layers were 
separated, and the aqueous layer was extracted with ethyl acetate (3 x 20 mL). The 
combined organic fractions were washed with water (30 mL), brine (30 mL), dried 
(Na2SO4), filtered, and concentrated in vacuo to give 88 mg (85%) of 4.20 as an oil 
(>90% purity, 1H NMR); 1H NMR (500 MHz) d 8.26 (brs, 1 H), 6.62 (d, J = 8.1 Hz, 1 
H), 7.32 (d, J = 8.1 Hz, 1 H), 7.16 (t, J = 7.1 Hz, 1 H), 7.09 (t, J = 7.1 Hz, 1 H), 6.99 (d, J 
= 1.7 Hz, 1 H), 3.89 (p, J = 6.1 Hz, 1 H), 3.73 (m, 1 H), 3.64 (m, 1 H), 3.53 (td, J = 12.0, 
2.9 Hz, 1 H), 2.99 - 2.95 (comp, 3 H), 2.81 – 2.76 (comp, 2 H), 2.63 (s, 3 H), 1.75 (ddt, J 
= 14.5, 11.2, 4.1 Hz, 1 H) 1.59 (dq, J = 14.5, 3.2 Hz, 1 H), 1.44 (d, J = 5.9 Hz, 3 H); 13C 
NMR (125 MHz) d 169.0, 136.3, 127.4, 122.0, 121.9, 119.3, 118.7, 112.8, 111.2, 77.4, 
66.1, 55.3, 48.5, 44.0, 43.1, 25.2, 23.4, 19.2; HRMS (CI) m/z calcd for C18H23N3O2  
(M+1)+, 314.1869; found, 314.1867. 
NMR Assignment. 1H NMR (500 MHz) d 8.26 (brs, 1 H, N10-H), 6.62 (d, J = 
8.1 Hz, 1 H, C14-H), 7.32 (d, J = 8.1 Hz, 1 H, C11-H), 7.16 (t, J = 7.1 Hz, 1 H, C12-H), 
7.09 (t, J = 7.1 Hz, 1 H, C13-H), 6.99 (d, J = 1.7 Hz, 1 H, C9-H), 3.89 (p, J = 6.1 Hz, 1 
H, C2-H), 3.73 (m, 1 H, C7-H), 3.64 (m, 1 H, C7-H), 3.53 (td, J = 12.0, 2.9 Hz, 1 H, C6-
H), 2.99 - 2.95 (comp, 3 H, C8-H and C6-H), 2.81 – 2.76 (comp, 2 H, C3-H and C4-H), 
2.63 (s, 3 H, N-CH3), 1.75 (ddt, J = 14.5, 11.2, 4.1 Hz, 1 H, C5-H) 1.59 (dq, J = 14.5, 3.2 
Hz, 1 H, C5-H), 1.44 (d, J = 5.9 Hz, 3 H, C1-H) 
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 (±)-(3R,4S)-1-(2-(1H-Indol-3-yl)ethyl)-3-((R)-1-hydroxyethyl)-4-
(methylamino)piperidin-2-one (4.28). ARMVII152. Zinc (powder, 530 mg, 8.14 
mmol) was added in three portions over 1.5 h to a solution of 4.20 (85 mg, 0.27 mmol) in 
acetic acid (aq 80%, 20 mL) at 60 ºC, and stirred at 60 ºC for an additional 1 h. The 
reaction was cooled to room temperature, whereupon excess zinc was filtered and washed 
with ethyl acetate. Ethyl acetate (100 mL) was added to the filtrate and zinc acetate 
immediately precipitated out of solution as a fluffy white solid. The zinc acetate was 
filtered, and washed with excess ethyl acetate. The solvent was removed in vacuo to give 
crude 4.28. the crude material was taken up in aqueous HCl (1 M, 30 mL) and washed 
with ether (2 x 30 mL). The aqueous fraction was basified with aqueous NaOH (40% 
w/v) to pH ~ 14. The basic solution was extracted with CH2Cl2 (4 x 50 mL). The 
combined organic fractions were washed with saturated aqueous NaHCO3 (100 mL), 
water (100 mL),  brine (1 x 100 mL), dried (Na2SO4), filtered, and concentrated in vacuo 
to give 78 mg (91%) of 4.28 as an oil (>95% purity, 1H NMR); 1H NMR (500 MHz, 
CD3OD) d 7.58 (dt, J = 7.8, 0.7 Hz, 1 H), 7.32 (dt, J = 7.8, 0.7 Hz, 1 H), 7.09 – 7.05 
(comp, 2 H), 7.00 (td, J = 7.1, 1.0 Hz, 1 H), 4.37 (pent, J = 6.3 Hz, 1 H), 3.67 – 3.60 (m, 
1 H), 3.56 – 3.49 (m, 1 H), 3.33 – 3.17 (comp, 1 H), 3.15 (pent, J = 3.9 Hz, 1 H), 3.11 – 
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3.04 (comp, 3 H), 2.40 (dd, J = 6.1, 4.2 Hz, 1 H), 2.34 (s, 3 H), 1.97 (app sex, J = 7.8 Hz, 
1 H), 1.74 (dtd, J = 13.9, 7.1, 3.2 Hz, 1 H), 1.23 (d, J = 6.4 Hz, 3 H); 13C NMR (125 
MHz, CD3OD) d 171.0, 138.1, 128.9, 123.6, 122.4, 119.7, 119.3, 113.1, 112.3, 67.5, 
56.1, 51.4, 45.7, 33.5, 30.8, 24.8, 23.7, 22.5; HRMS (ESI) m/z calcd for C18H25N3O2 
(M+1)+, 316.2020; found, 316.2024. 
 NMR Assignment. 1H NMR (500 MHz, CD3OD) d 7.58 (dt, J = 7.8, 0.7 Hz, 1 H, 
C15-H), 7.32 (dt, J = 7.8, 0.7 Hz, 1 H, C18-H), 7.09 – 7.05 (comp, 2 H, C17-H and C12-
H), 7.00 (td, J = 7.1, 1.0 Hz, 1 H, C16-H), 4.37 (pent, J = 6.3 Hz, 1 H, C2-H), 3.67 – 3.60 
(m, 1 H, C-9H), 3.56 – 3.49 (m, 1 H, C9-H), 3.33 – 3.17 (comp, 1 H, C7-H and solvent), 
3.15 (pent, J = 3.9 Hz, 1 H, C4-H), 3.11 – 3.04 (comp, 3 H, C7-H and C10-H), 2.40 (dd, 
J = 6.1, 4.2 Hz, 1 H, C3-H), 2.34 (s, 3 H, C5-H), 1.97 (app sex, J = 7.8 Hz, 1 H, C6-H), 
1.74 (dtd, J = 13.9, 7.1, 3.2 Hz, 1 H, C6-H), 1.23 (d, J = 6.4 Hz, 3 H, C1-H); 13C NMR 
(125 MHz, CD3OD) d 171.0 (C8), 138.1 (C13), 128.9 (C14), 123.6 (C12), 122.4 (C17), 
119.7 (C16), 119.3 (C15), 113.1 (C11), 112.3 (C18), 67.5 (C2), 56.1 (C4), 51.4 (C3), 
45.7 (C9), 33.5 (C7), 30.8 (C5), 24.8 (C6), 23.7 (C10), 22.5 (C1). 
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Representative Procedure for the Reductive Amination of Amino-Alcohols 
 
(3R,4S)-1-(2-(1H-Indol-3-yl)ethyl)-4-((3,5-dichlorobenzyl)(methyl)amino)-3-
((R)-1-hydroxyethyl)piperidin-2-one (4.12). ARMV171. A solution of 4.28 (50 mg, 
0.16 mmol) and 3,5-dichlorobenzaldehyde (45 mg, 0.26 mmol) in acetonitrile (1 mL) was 
heated under reflux for 2 h. The reaction was cooled to room temperature, at which time 
NaBH3CN (22 mg, 0.35 mmol) and acetic acid (53 µL, 0.89 mmol) were added. The 
reaction was stirred at room temperature for 20 h. The mixture was partitioned between 
saturated aqueous NaHCO3 (6.5 mL), ethyl acetate (6.5 mL), and methanol (0.5 mL). The 
two phases were separated, and the aqueous phase was extracted with ethyl acetate (2 x 
6.5 mL). The combined organic fractions were washed with brine (6.5 mL), dried 
(Na2SO4), filtered, and concentrated in vacuo to give crude 4.12 as an opaque viscous oil. 
The crude material was purified via flash column chromatography eluting with a gradient 
of hexanes : ethyl acetate (1 : 1) → ethyl acetate : methanol (20 : 1), to give 36 mg (48%) 
of 4.12 as a white solid; 1H NMR (600 MHz) d 8.15 (d, J = 1.9 Hz, 1 H), 7.55 (d, J = 8.2 
Hz, 1 H), 7.34 (dt, J = 8.1, 0.8 Hz, 1 H), 7.27 (t, J = 1.9 Hz, 1 H), 7.18 (ddd, J = 8.1, 7.1, 
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1.1 Hz, 1 H), 7.12 – 7.08 (comp, 3 H), 7.02 (d, J = 1.9 Hz, 1 H), 4.35 (dq, J = 6.5, 6.2 Hz, 
1 H), 3.74 - 3.78 (m, 1 H), 3.64 - 3.69 (m, 1 H), 3.41 - 3.26 (comp, 3 H), 3.24 (dt, J = 
13.4, 5.4 Hz, 1 H), 3.12 (dt, J = 16.9, 9.2 Hz, 1 H), 3.04 - 2.99 (m, 1 H), 2.97 - 2.92 (m, 1 
H), 2.31 (t, J = 5.2 Hz, 1H), 2.03 (s, 3 H), 1.83 - 1.87 (comp, 3 H), 1.15 (d, J = 6.5 Hz, 3 
H); 13C NMR (150 MHz) d 171.7, 140.6, 136.3, 135.2, 128.1, 127.6, 127.3, 122.4, 122.1, 
119.4, 118.4, 112.3, 111.5, 66.2, 58.9, 48.0, 47.4, 44.9, 37.3, 29.7, 23.2, 21.7, 20.1; 
HRMS (ESI) m/z calcd for C25H29Cl2N3O2 (M+1)+, 474.1710 and 476.1686; found, 
474.1712 and 476.1690. 
 NMR Assignment. 1H NMR (600 MHz) d 8.15 (d, J = 1.9 Hz, 1 H, NH), 7.55 (d, 
J = 8.2 Hz, 1 H, C17-H), 7.34 (dt, J = 8.1, 0.8 Hz, 1 H, C14-H), 7.27 (t, J = 1.9 Hz, 1 H, 
C1-H), 7.18 (ddd, J = 8.1, 7.1, 1.1 Hz, 1 H, C15-H), 7.12 – 7.08 (comp, 3 H, C16-H and 
C2-H), 7.02 (d, J = 1.9 Hz, 1 H, C13-H), 4.35 (dq, J = 6.5, 6.2 Hz, 1 H, C7-H), 3.75 – 
3.70 (m, 1 H, C11-H), 3.66 – 3.60 (m, 1 H, C11-H), 3.41 - 3.26 (comp, 3 H, C3-H and 
C5-H), 3.24 (dt, J = 13.4, 5.4 Hz, 1 H, C10-H), 3.12 (dt, J = 16.9, 9.2 Hz, 1 H, C10-H), 
3.09 – 2.99 (m, 1 H, C12-H), 2.95 – 2.86 (m, 1 H, C12-H), 2.31 (t, J = 5.2 Hz, 1 H, C6-
H), 2.03 (s, 3 H, C4-H), 1.93 – 1.80 (comp, 3 H, C9-H and OH), 1.15 (d, J = 6.5 Hz, 3 H, 
C8-H). 
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 (±)-(3R,4S)-1-(2-(1H-Indol-3-yl)ethyl)-4-(benzyl(methyl)amino)-3-((R)-1-
hydroxyethyl)piperidin-2-one (4.29). ARMV174. Prepared according to representative 
procedure for compound 4.12. The crude material was purified via flash column 
chromatography eluting with a gradient with hexanes : ethyl acetate (1 : 1) → ethyl 
acetate : methanol (20 : 1). To give 31 mg (48%) of 4.29 as an off white solid; 1H NMR 
(500 MHz) d 8.13 (brs, 1 H), 7.58 (d, J = 7.9 Hz, 1 H), 7.35 (d, J = 7.9 Hz, 1 H), 7.33 – 
7.26 (comp, 3 H), 7.21 (d, J = 6.6 Hz, 2 H), 7.19 (t, J = 7.1 Hz, 1 H), 7.11 (t, J = 7.1 Hz, 
1 H), 7.03 (d, J = 2.2 Hz, 1 H), 4.34 (p, J = 6.1 Hz, 1 H), 3.76 (p, J = 7.6 Hz, 1 H), 3.64 
(p, J = 6.4 Hz, 1 H), 3.52, 3.47 (ABq, JAB = 12.7 Hz, 2 H), 3.42 (q, J = 7.6 Hz, 1 H), 3.26 
(ddd, J = 13.7, 6.6, 3.4 Hz, 1 H), 3.16 - 3.10 (m, 1 H), 3.04 - 2.93 (comp, 2 H), 2.35 (t, J 
= 5.6 Hz, 1 H), 2.06 (s, 3 H), 1.96 - 1.90 (comp, 2 H), 1.16 (d, J = 6.4 Hz, 3 H); 13C NMR 
(125 MHz) d 171.7, 136.7, 136.3, 129.3, 128.7, 127.9, 127.3, 122.3, 122.1, 119.4, 118.4, 
112.4, 111.4, 66.4, 60.0, 48.3, 47.4, 45.1, 37.2, 29.7, 23.2, 21.9, 20.1; HRMS (ESI) m/z 
calcd for C25H31N3O2 (M+1)+, 406.2489; found, 406.2490. 
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 NMR Assignment. 1H NMR (500 MHz) d 8.13 (brs, 1 H, N18-H), 7.58 (d, J = 
7.9 Hz, 1 H, C23-H), 7.35 (d, J = 7.9 Hz, 1 H, C20-H), 7.33 – 7.26 (comp, 3 H, C1-H and 
C2-H), 7.21 (d, J = 6.6 Hz, 2 H, C3-H), 7.19 (t, J = 7.1 Hz, 1 H, C21-H), 7.11 (t, J = 7.1 
Hz, 1 H, C22-H), 7.03 (d, J = 2.2 Hz, 1 H, C17-H), 4.34 (p, J = 6.1 Hz, 1 H, C12-H), 
3.76 (p, J = 7.6 Hz, 1 H, C14-H), 3.64 (p, J = 6.4 Hz, 1 H, C14-H), 3.52, 3.47 (ABq, JAB 
= 12.7 Hz, 2 H, C5-H), 3.42 (q, J = 7.6 Hz, 1 H, C7-H), 3.26 (ddd, J = 13.7, 6.6, 3.4 Hz, 
1 H, C10-H), 3.16 – 3.10 (m, 1 H, C10-H), 3.04 – 2.93 (m, 2 H, C15-H), 2.35 (t, J = 5.6 
Hz, 1 H, C8-H), 2.06 (s, 3 H, C6-H), 1.96 – 1.90 (comp, 2 H, C11-H), 1.16 (d, J = 6.4 
Hz, 3 H, C13-H). 
 
 
 (±)-(3R,4S)-1-(2-(1H-Indol-3-yl)ethyl)-4-((3-chloro-5-
methoxybenzyl)(methyl)amino)-3-((R)-1-hydroxyethyl)piperidin-2-one (4.30). 
ARMV175. Prepared according to representative procedure for compound 4.12. The 
crude material was purified via flash column chromatography eluting with a gradient with 
hexanes : ethyl acetate (1 : 1) → ethyl acetate : methanol (20 : 1). To give 30 mg (27%) 
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of 4.30 as a white solid: 1H NMR (400 MHz) d 8.24 (s, 1 H), 7.57 (d, J = 7.6 Hz, 1 H), 
7.33 (d, J = 7.6 Hz, 1 H), 7.18 (td, J = 7.2, 1.2 Hz, 1 H), 7.10 (td, J = 8.0, 1.2 Hz, 1 H), 
7.01 (d, J = 2.4 Hz, 1 H), 6.80 (t, J = 1.6 Hz, 1 H), 6.78 (t, J = 1.6 Hz, 1 H), 6.67 (t, J = 
1.6 Hz, 1 H), 4.33 (p, J = 6.4 Hz, 1 H), 3.79 - 3.72 (comp, 4 H), 3.61 (p, J = 6.4 Hz, 1 H), 
3.47 – 3.30 (comp, 3 H), 3.23 (dt, J = 12.4, 4.8 Hz, 1 H), 3.10 (dt, J = 12.4, 9.2 Hz, 1 H), 
3.02 - 2.90 (comp, 2 H), 2.38 (t, J = 6.0 Hz, 1 H), 2.06 (s, 3 H), 1.91 - 1.85 (comp, 2 H), 
1.18 (d, J = 6.4 Hz, 3 H); 13C NMR (100 MHz) d 170.9, 160.5, 139.6, 136.2, 135.0, 
127.3, 122.3, 122.1, 121.4, 119.3, 118.4, 113.6, 113.4, 112.4, 111.4, 66.3, 59.0, 58.0, 
55.6, 48.5, 47.4, 45.0, 37.5, 23.1, 22.1, 20.5; HRMS (ESI) m/z calcd for C26H32ClN3O3 
(M+1)+, 470.2205; found, 470.2207. 
NMR Assignment. 1H NMR (400 MHz) d 8.24 (s, 1 H, N18-H), 7.57 (d, J = 7.6 
Hz, 1 H, C23-H), 7.33 (d, J = 7.6 Hz, 1 H, C20-H), 7.18 (td, J = 7.2, 1.2 Hz, 1 H, C21-
H), 7.10 (td, J = 8.0, 1.2 Hz, 1 H, C22-H), 7.01 (d, J = 2.4 Hz, 1 H, C17-H), 6.80 (t, J = 
1.6 Hz, 1 H, C4-H), 6.78 (t, J = 1.6 Hz, 1 H, C3-H), 6.67 (t, J = 1.6 Hz, 1 H, C1-H), 4.33 
(p, J = 6.4 Hz, 1 H, C12-H), 3.79 – 3.72 (comp, 4 H, C2-H and C14-H), 3.61 (p, J = 6.4 
Hz, 1 H, C14-H), 3.47 – 3.30 (comp, 3 H, C5-H and C7-H), 3.23 (dt, J = 12.4, 4.8 Hz, 1 
H, C10-H), 3.10 (dt, J = 12.4, 9.2 Hz, 1 H, C10-H), 3.02 – 2.90 (comp, 2 H, C15-H), 2.38 
(t, J = 6.0 Hz, 1 H, C8-H), 2.06 (s, 3 H, C6-H), 1.91 – 1.85 (comp, 2 H, C11-H), 1.18 (d, 
J = 6.4 Hz, 3 H, C13-H). 
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 (3R,4S)-1-(2-(1H-Indol-3-yl)ethyl)-4-((benzo[d][1,3]dioxol-5-
ylmethyl)(methyl)amino)-3-((R)-1-hydroxyethyl)piperidin-2-one (4.31). ARMV184. 
Prepared according to representative procedure for compound 4.12. The crude material 
was purified via flash column chromatography eluting with a gradient with hexanes : 
ethyl acetate (3 : 1 → 0 : 1) to give 30 mg (28%) of 4.31 as an off white solid; 1H NMR 
(400 MHz) d 8.35 (s, 1 H), 7.63 (d, J = 7.6 Hz, 1 H), 7.35 (d, J = 8.0 Hz, 1 H), 7.19 (t, J = 
7.2 Hz, 1 H), 7.12 (t, J = 7.6 Hz, 1 H), 7.02 (d, J = 2.0 Hz, 1 H), 6.74 – 6.72 (comp, 2 H), 
6.67 (d, J = 8.0 Hz, 1 H), 4.28 (dq J = 6.4, 6.0 Hz, 1 H), 3.81 (p, J = 7.6 Hz, 1 H), 3.54 
(p, J = 6.4 Hz, 1 H), 3.48, 3.37 (ABq, JAB = 12.4 Hz, 2 H), 3.28 - 3.23 (m, 1 H), 3.16 - 
3.10 (comp, 2 H), 3.07 - 2.98 (comp, 2 H), 2.65 (dd, J = 8.8, 5.2 Hz, 1 H), 2.10 (s, 3 H), 
1.99 - 1.96 (comp, 2 H), 1.32 (d, J = 6.0 Hz, 3 H); 13C NMR (100 MHz) d 170.1, 148.0, 
147.1, 136.4, 131.2, 127.5, 122.4, 122.2, 122.1, 119.4, 118.7, 112.8, 111.4, 109.4, 108.3, 
101.1, 66.8, 59.8, 58.6, 50.1, 47.6, 45.6, 38.0, 23.3, 22.8, 21.6; HRMS (ESI) m/z calcd for 
C26H31N3O4 (M+1)+, 450.2387; found, 450.2394. 
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 NMR Assignment. 1H NMR (400 MHz) d 8.35 (s, 1 H, N18-H), 7.63 (d, J = 7.6 
Hz, 1 H, C23-H), 7.35 (d, J = 8.0 Hz, 1 H, C20-H), 7.19 (t, J = 7.2 Hz, 1 H, C21-H), 7.12 
(t, J = 7.6 Hz, 1 H, C22-H), 7.02 (d, J = 2.0 Hz, 1 H, C17-H), 6.74 – 6.72 (comp, 2 H, 
C3-H and C4-H), 6.67 (d, J = 8.0 Hz, 1 H, C2-H), 4.28 (dq J = 6.4, 6.0 Hz, 1 H, C12-H), 
3.81 (p, J = 7.6 Hz, 1 H, C14-H), 3.54 (p, J = 6.4 Hz, 1 H, C14-H), 3.48, 3.37 (ABq, JAB 
= 12.4 Hz, 2 H, C5-H), 3.28 – 3.23 (m, 1 H, C7-H), 3.16 – 3.10 (comp, 2 H, C10-H), 3.07 
– 2.98 (comp, 2 H, C15-H), 2.65 (dd, J = 8.8, 5.2 Hz, 1 H, C8-H), 2.10 (s, 3 H, C6-H), 
1.99 – 1.96 (comp, 2 H, C11-H), 1.32 (d, J = 6.0 Hz, 3 H, C13-H). 
 
 
(3R,4S)-1-(2-(1H-Indol-3-yl)ethyl)-3-((R)-1-hydroxyethyl)-4-((3-
methoxybenzyl)(methyl)amino)piperidin-2-one (4.32). ARMV198. Prepared 
according to representative procedure for compound 4.12. The crude material was 
purified via flash column chromatography eluting with a gradient with hexanes : ethyl 
acetate (1 : 1) → ethyl acetate : methanol (20 : 1) to give 18 mg (26%) of 4.32 as an off 
white solid; 1H NMR (400 MHz) d 8.19 (s, 1 H), 7.58 (d, J = 8.0 Hz, 1 H), 7.34 (d, J = 
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8.0 Hz, 1 H), 7.24 – 7.16 (comp, 2 H), 7.10 (td, J = 8.0, 1.2 Hz, 1 H), 7.03 (d, J = 2.4 Hz, 
1 H), 6.82 (d, J = 2.0 Hz, 1 H), 6.80 (d, J = 2.0 Hz, 1 H), 6.77 (t, J = 2.0 Hz, 1 H), 4.33 
(p, J = 6.4 Hz, 1 H), 3.81 - 3.74 (comp, 4 H), 3.60 (p, J = 6.4 Hz, 1 H), 3.50, 3.43 (ABq, 
JAB = 12.8 Hz, 2 H), 3.37 - 3.32 (m, 1 H), 3.24 (dt, J = 12.0, 4.4 Hz, 1 H), 3.11 (dt, J = 
12.0, 8.0 Hz, 1 H), 3.04 - 2.92 (comp, 2 H), 2.41 (t, J = 7.2 Hz, 1 H), 2.07 (s, 3 H), 1.95 - 
1.89 (comp, 2 H), 1.19 (d, J = 6.4 Hz, 3 H); 13C NMR (100 MHz, CD3OD) d 171.8, 
161.4, 140.3, 137.6, 130.6, 128.9, 123.7, 122.4, 122.3, 119.7, 119.3, 115.5, 114.2, 112.8, 
112.3, 68.0, 61.2, 59.6, 55.6, 50.9, 46.6, 38.3, 24.0, 22.9, 22.3; HRMS (ESI) m/z calcd for 
C26H33N3O3 (M+1)+, 436.2595; found, 436.2599. 
NMR Assignment. 1H NMR (400 MHz) d 8.19 (s, 1 H, N18-H), 7.58 (d, J = 8.0 
Hz, 1 H, C23-H), 7.34 (d, J = 8.0 Hz, 1 H, C20-H), 7.24 – 7.16 (comp, 2 H, C3-H and 
C21-H), 7.10 (td, J = 8.0, 1.2 Hz, 1 H, C22-H), 7.03 (d, J = 2.4 Hz, 1 H, C17-H), 6.82 (d, 
J = 2.0 Hz, 1 H, C4-H), 6.80 (d, J = 2.0 Hz, 1 H, C2-H), 6.77 (t, J = 2.0 Hz, 1 H, C5-H), 
4.33 (p, J = 6.4 Hz, 1 H, C12-H), 3.81 – 3.74 (comp, 4 H, C1-H and C14-H), 3.60 (p, J = 
6.4 Hz, 1 H, C14-H), 3.50, 3.43 (ABq, JAB = 12.8 Hz, 2 H, C6-H), 3.37 – 3.32 (m, 1 H, 
C7-H), 3.24 (dt, J = 12.0, 4.4 Hz, 1 H, C10-H), 3.11 (dt, J = 12.0, 8.0 Hz, 1 H, C10-H), 
3.04 – 2.92 (comp, 2 H, C15-H), 2.41 (t, J = 7.2 Hz, 1 H, C8-H), 2.07 (s, 3 H, NCH3), 
1.95 – 1.89 (comp, 2 H, C11-H), 1.19 (d, J = 6.4 Hz, 3 H, C13-H). 
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(3R,4S)-1-(2-(1H-Indol-3-yl)ethyl)-4-((3-chlorobenzyl)(methyl)amino)-3-((R)-
1-hydroxyethyl)piperidin-2-one (4.33). ARMV199. Prepared according to 
representative procedure for compound 4.12. The crude material was purified via flash 
column chromatography eluting along a gradient with hexanes : ethyl acetate (3 : 1 → 0 : 
1) to give 26 mg (37%) of 4.33 as a white solid; 1H NMR (400 MHz, CD3OD) d 7.58 (d, 
J = 7.6 Hz, 1 H), 7.33 (d, J = 7.4 Hz, 1 H), 7.31 – 7.26 (comp, 3 H), 7.18 (dt, J = 6.8, 1.6 
Hz, 1 H), 7.11 – 7.07 (comp, 2 H), 7.02 (ddd, J = 7.6, 6.8, 0.8 Hz, 1 H), 4.22 (dq, J = 8.8, 
6.0 Hz, 1 H), 3.77 (dt, J = 13.2, 7.2 Hz, 1 H), 3.57 – 3.51 (comp, 2 H), 3.44 (d, J = 12.8 
Hz, 1 H), 3.35 - 3.32 (m, 1 H), 3.18 – 2.90 (comp, 4 H), 2.59 (dd, J = 8.4, 5.2 Hz, 1 H), 
2.07 (s, 3 H), 2.04 - 1.98 (m, 1 H), 1.94 - 1.87 (m, 1 H), 1.20 (d, J = 6.4 Hz, 3 H); 13C 
NMR (100 MHz, CD3OD) d 171.8, 141.6, 138.1, 135.5, 131.1, 130.0, 128.9, 128.5, 
123.7, 122.4, 119.7, 119.3, 112.8, 112.3, 67.9, 61.2, 58.9, 51.0, 46.6, 38.3, 24.0, 22.8, 
22.4; HRMS (ESI) m/z calcd for C25H30ClN3O2 (M+1)+, 440.2099; found, 440.2099. 
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 NMR Assignment. 1H NMR (400 MHz, CD3OD) d 7.58 (d, J = 7.6 Hz, 1 H, 
C23-H), 7.33 (d, J = 7.4 Hz, 1 H, C20-H), 7.31 – 7.26 (comp, 3 H, C1-H, C3-H, C4-H), 
7.18 (dt, J = 6.8, 1.6 Hz, 1 H, C2-H), 7.11 – 7.07 (comp, 2 H, C17-H and C21-H), 7.02 
(ddd, J = 7.6, 6.8, 0.8 Hz, 1 H, C22-H), 4.22 (dq, J = 8.8, 6.0 Hz, 1 H, C12-H), 3.77 (dt, J 
= 13.2, 7.2 Hz, 1 H, C14-H), 3.57 – 3.51 (comp, 2 H, C5-H and C14-H), 3.44 (d, J = 12.8 
Hz, 1 H, C5-H), 3.35 – 3.32 (m, 1 H, C7-H), 3.18 – 2.90 (comp, 4 H, C10-H, C15-H), 
2.59 (dd, J = 8.4, 5.2 Hz, 1 H, C8-H), 2.07 (s, 3 H, C6-H), 2.04 – 1.98 (m, 1 H, C11-H), 
1.94 – 1.87 (m, 1 H, C11-H), 1.20 (d, J = 6.4 Hz, 3 H, C13-H) 
 
 
 (3R,4S)-1-(2-(1H-Indol-3-yl)ethyl)-3-((R)-1-hydroxyethyl)-4-(methyl(3,4,5-
trimethoxybenzyl)amino)piperidin-2-one (4.34). ARMV202. Prepared according to 
representative procedure for compound 4.12. The crude material was purified via flash 
column chromatography eluting with a gradient with hexanes : ethyl acetate (1 : 1 → 0 : 
1) to give 26 mg (33%) of 4.34 as a an off white solid; 1H NMR (400 MHz, CD3OD) 
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d 7.59 (dt, J = 8.0, 1.2 Hz, 1 H), 7.33 (dt, J = 8.4, 1.2 Hz, 1 H), 7.11 – 7.07 (comp, 2 H), 
7.02 (ddd, J = 8.0, 7.2, 1.2 Hz, 1 H), 6.58 (s, 2 H), 4.23 (dq, J = 9.2, 6.4 Hz, 1 H), 3.82 (s, 
6 H), 3.81 - 3.76 (m, 1 H), 3.75 (s, 3 H), 3.64 – 3.54 (comp, 3 H), 3.59 - 3.49 (m, 1 H), 
3.22 – 3.14 (comp, 2 H), 3.10 – 2.92 (comp, 2 H), 2.61 (dd, J = 9.2, 5.6 Hz, 1 H), 2.16 (s, 
3 H), 2.10 - 2.04 (m, 1 H), 2.00 - 1.93 (m, 1 H), 1.20 (d, J = 6.0 Hz, 3 H); 13C NMR (125 
MHz, CD3OD) d 169.8, 152.7, 136.7, 136.2, 127.0, 121.8, 120.5, 117.8, 117.3, 110.9, 
110.4, 105.4, 66.0, 59.2, 59.1, 57.9, 54.7, 48.9, 44.6, 36.4, 22.0, 21.0, 20.3; HRMS (ESI) 
m/z calcd for C28H37N3O5 (M+1)+, 496.2806; found, 496.2803 
NMR Assignment. 1H NMR (400 MHz, CD3OD) d 7.59 (dt, J = 8.0, 1.2 Hz, 1 H, 
C18-H), 7.33 (dt, J = 8.4, 1.2 Hz, 1 H, C15-H), 7.11 – 7.07 (comp, 2 H, C16-H and C14-
H), 7.02 (ddd, J = 8.0, 7.2, 1.2 Hz, 1 H, C17-H), 6.58 (s, 2 H, C3-H), 4.23 (dq, J = 9.2, 
6.4 Hz, 1 H, C10-H), 3.82 (s, 6 H, C2-H), 3.81 – 3.76 (m, 1 H, C12-H), 3.75 (s, 3 H, C1-
H), 3.64 – 3.45 (comp, 3 H, C12-H and C4-H), 3.59 – 3.49 (m, 1 H, C6-H), 3.22 – 3.14 
(comp, 2 H, C8-H), 3.10 – 2.92 (comp, 2 H, C13-H), 2.61 (dd, J = 9.2, 5.6 Hz, 1 H, C7-
H), 2.16 (s, 3 H, C5-H), 2.10 – 2.04 (m, 1 H, C9-H), 2.00 – 1.93 (m, 1 H, C9-H), 1.20 (d, 
J = 6.0 Hz, 3 H, C11-H) 
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(3R,4S)-1-(2-(1H-Indol-3-yl)ethyl)-4-((3,5-dimethoxybenzyl)(methyl)amino)-
3-((R)-1-hydroxyethyl)piperidin-2-one (4.35). ARMV203. Prepared according to 
representative procedure for compound 4.12. The crude material was purified via flash 
column chromatography eluting with a gradient with hexanes : ethyl acetate (1 : 1 → 0 : 
1) to give 37 mg (50%) of 4.35 as a white solid; 1H NMR (400 MHz, CD3OD) d 7.58 (dt, 
J = 8.0, 0.8 Hz, 1 H), 7.33 (dt, J = 8.0, 0.8 Hz, 1 H), 7.11 - 7.07 (comp, 2 H), 7.01 (td, J = 
8.0, 6.8, 1.2 Hz, 1 H), 6.42 (d, J = 2.4 Hz, 2 H), 6.38 (t, J = 2.4 Hz, 1 H), 4.23 (dq, J = 
14.0, 6.0 Hz, 1 H), 3.81 - 3.71 (comp, 7 H), 3.57 - 3.51 (m, 1 H), 3.47, 3.41 (ABq, JAB = 
12.8 Hz, 2 H), 3.34 - 3.30 (m, 1 H), 3.17 - 2.93 (comp, 4 H), 2.58 (dd, J = 8.8, 5.6 Hz, 1 
H), 2.09 (s, 3 H), 2.04 - 1.98 (m, 1 H), 1.95 - 1.85 (m, 1 H), 1.19 (d, J = 6.0 Hz, 3 H); 13C 
NMR (100 MHz, CD3OD) d 171.9, 162.5, 141.4, 138.1, 128.9, 123.7, 122.4, 119.7, 
119.3, 112.8, 112.3, 107.8, 100.3, 68.0, 61.0, 59.8, 55.7, 50.9, 46.7, 38.4, 24.0, 22.8, 
22.3; HRMS (ESI) m/z calcd for C27H35N3O4 (M+1)+, 466.2700; found, 466.2701. 
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 NMR Assignment. 1H NMR (400 MHz, CD3OD) d 7.58 (dt, J = 8.0, 0.8 
Hz, 1 H, C18-H), 7.33 (dt, J = 8.0, 0.8 Hz, 1 H, C15-H), 7.11 – 7.07 (comp, 2 H, C14-H 
and C16-H), 7.01 (td, J = 8.0, 6.8, 1.2 Hz, 1 H, C17-H), 6.42 (d, J = 2.4 Hz, 2 H, C3-H), 
6.38 (t, J = 2.4 Hz, 1 H, C2-H), 4.23 (dq, J = 14.0, 6.0 Hz, 1 H, C10-H), 3.81 – 3.71 
(comp, 7 H, C1-H and C12-H), 3.57 – 3.51 (m, 1 H, C12-H), 3.47, 3.41 (ABq, JAB = 12.8 
Hz, 2 H, C4-H), 3.34 – 3.30 (m, 1 H, C6-H), 3.17 – 2.93 (comp, 4 H, C8-H and C13-H), 
2.58 (dd, J = 8.8, 5.6 Hz, 1 H, C7-H), 2.09 (s, 3 H, C5-H), 2.04 – 1.98 (m, 1 H, C9-H), 
1.95 – 1.85 (m,  1 H, C9-H), 1.19 (d, J = 6.0 Hz, 3H, C11-H). 
 
 
 (3R,4S)-1-(2-(1H-Indol-3-yl)ethyl)-3-((R)-1-hydroxyethyl)-4-(methyl(3-
(methylthio)benzyl)amino)piperidin-2-one (4.36). ARMV214. Prepared according to 
representative procedure for compound 4.12. The crude material was purified via flash 
column chromatography eluting with a gradient with hexanes : ethyl acetate (1 : 1 → 0 : 
1) to give 45 mg (49%) of 4.36 as a fluffy white solid; 1H NMR (400 MHz, CD3OD) 
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d 7.58 (d, J = 7.6 Hz, 1 H), 7.33 (d, J = 8.0 Hz, 1 H), 7.26 (td, J = 7.6, 0.8 Hz, 1 H), 7.17 
- 7.15 (comp, 2 H), 7.09 (ddd, J = 8.0, 7.6, 0.8 Hz, 1 H), 7.07 (s, 1 H), 7.03 - 6.99 (comp, 
2 H), 4.22 (dq, J = 8.8, 6.0 Hz, 1 H), 3.77 (dt, J = 13.2, 7.6 Hz, 1 H), 3.56 - 3.49 (comp, 2 
H), 3.43 (d, J = 12.8, 1 H), 3.34 - 3.28 (m, 1 H), 3.17 - 2.92 (comp, 4 H), 2.58 (dd, J = 
8.8, 5.6 Hz, 1 H), 2.45 (s, 3 H), 2.07 (s, 3 H), 2.02 - 1.86 (comp, 2 H), 1.19 (d, J = 6.4 Hz, 
3 H); 13C NMR (100 MHz, CD3OD) d 171.8, 140.6, 139.7, 138.1, 130.0, 128.8, 127.8, 
126.7, 125.4, 123.7, 122.4, 119.7, 119.3, 112.8, 112.3, 67.9, 61.1, 59.4, 50.9, 46.5, 38.3, 
24.0, 22.9, 22.3, 15.5; HRMS (ESI) m/z calcd for C26H33N3O2S (M+Na)+, 474.2186; 
found, 474.2187. 
NMR Assignment. 1H NMR (400 MHz, CD3OD) d 7.58 (d, J = 7.6 Hz, 1 H, 
C20-H), 7.33 (d, J = 8.0 Hz, 1 H, C17-H), 7.26 (td, J = 7.6, 0.8 Hz, 1 H, C18-H), 7.17 – 
7.15 (comp, 2 H, C2-H and C5-H), 7.09 (ddd, J = 8.0, 7.6, 0.8 Hz, 1 H, C19-H), 7.07 (s, 
1 H, C16-H), 7.03 – 6.99 (comp, 2 H, C3-H and C4-H), 4.22 (dq, J = 8.8, 6.0 Hz, 1 H, 
C12-H), 3.77 (dt, J = 13.2, 7.6 Hz, 1 H, C14-H), 3.56 – 3.49 (comp, 2 H, C6-H and C14-
H), 3.43 (d, J = 12.8, 1 H, C6-H), 3.34 – 3.28 (m, 1 H, C7-H), 3.17 – 2.92 (comp, 4 H, 
C9-H and C15-H), 2.58 (dd, J = 8.8, 5.6 Hz, 1 H, C8-H), 2.45 (s, 3 H, C1-H), 2.07 (s, 3 
H, C11-H), 2.02 – 1.86 (comp, 2 H, C10-H), 1.19 (d, J = 6.4 Hz, 3 H, C13-H). 
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 N-(2-(1H-Indol-3-yl)ethyl)-N-(3,3-dimethoxypropyl)acrylamide (4.39). 
ARMV217. Acryloyl chloride (0.42 g, 4.7 mmol) was added dropwise over 5 min to a 
solution of 4.25 (0.94 g, 3.6 mmol) and Hünig’s base (1.20 g, 9.3 mmol) in CH2Cl2 (40 
mL) at -78 ºC. The solution was stirred for 2 h at -78 ºC, then partitioned between 
saturated aqueous NaHCO3 (40 mL) and CH2Cl2 (40 mL). The two phases were 
separated, and the aqueous phase was extracted with CH2Cl2 (3 x 40 mL). The combined 
organic fractions were washed with water (40 mL), brine (40 mL), dried (Na2SO4), 
filtered, and concentrated in vacuo to give crude 4.39 as a clear oil. The crude material 
was purified via silica gel flash column chromatography eluting with hexanes : ethyl 
acetate (3 : 1 → 1 : 1 along a gradient) to give 0.63 g (54%) of 4.39 as a clear oil; 1H 
NMR (500 MHz) (1 : 1 rotamer mixture) d 8.76 (brs, 0.5 H), 8.63 (brs, 0.5 H), 7.70 (d, J 
= 6.4 Hz, 0.5 H), 7.56 (d, J = 8.0 Hz, 0.5 H), 7.35 (app t, J = 8.0 Hz, 1 H), 7.21 – 7.01 
(comp, 2 H), 6.98 (d, J = 2.5 Hz, 0.5 H), 6.92 (d, J = 2.5 Hz, 0.5 H), 6.64 (dd, J = 16.7, 
10.4 Hz, 0.5 H), 6.45 (dd, J = 16.7, 2.0 Hz, 0.5 H), 6.40 (dd, J = 16.7, 10.4 Hz, 0.5 H), 
6.27 (dd, J = 16.7, 2.0 Hz, 0.5 H), 5.73 (dd, J = 10.4, 2.0 Hz, 0.5 H), 5.52 (dd, J = 10.4, 
2.0 Hz, 0.5 H), 4.42 (t, J = 5.6 Hz, 0.5 H), 4.32 (t, J = 5.6 Hz, 0.5 H), 3.71 (app t, J = 7.2 
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Hz, 1 H), 3.64 (app t, J = 7.2 Hz, 1 H), 3.49 (t, J = 7.2 Hz, 0.5 H), 3.39 (t, J = 7.2 Hz, 0.5 
H), 3.33 (s, 3 H), 3.30 (s, 3 H), 3.08 (t, J = 7.2 Hz, 1 H), 3.02 (t, J = 7.2 Hz, 1 H), 1.97 – 
1.93 (m, 1 H), 1.83 (dt, J = 7.2, 5.6 Hz, 1 H); 13C NMR (125 MHz) (1 : 1 rotamer 
mixture) d 166.5, 166.3, 136.43, 136.39, 128.2, 127.7, 127.6, 127.5, 127.4, 127.1, 122.5, 
122.2, 122.1, 121.9, 119.4, 119.2, 118.8, 118.1, 112.9, 111.6, 111.5, 111.3, 102.9, 102.1, 
53.3, 53.1, 49.0, 47.9, 44.2, 43.0, 32.5, 30.9, 25.5, 23.7; HRMS (ESI) m/z calcd for 
C18H24N2O3 (M+Na)+, 339.1679; found, 339.1662. 
 NMR Assignment. 1H NMR (500 MHz) (1 : 1 rotamer mixture) d 8.76 (brs, 0.5 
H, NH), 8.63 (brs, 0.5 H, NH), 7.70 (d, J = 6.4 Hz, 0.5 H, C1-H), 7.56 (d, J = 8.0 Hz, 0.5 
H, C1-H), 7.35 (app t, J = 8.0 Hz, 1 H, C4-H), 7.21 – 7.01 (comp, 2 H, C2-H and C3-H), 
6.98 (d, J = 2.5 Hz, 0.5 H, C5-H), 6.92 (d, J = 2.5 Hz, 0.5 H, C5-H), 6.64 (dd, J = 16.7, 
10.4 Hz, 0.5 H, C12-H), 6.45 (dd, J = 16.7, 2.0 Hz, 0.5 H, H-14), 6.40 (dd, J = 16.7, 10.4 
Hz, 0.5 H, C12-H), 6.27 (dd, J = 16.7, 2.0 Hz, 0.5 H, H-14), 5.73 (dd, J = 10.4, 2.0 Hz, 
0.5 H, H-13), 5.52 (dd, J = 10.4, 2.0 Hz, 0.5 H, H-13), 4.42 (t, J = 5.6 Hz, 0.5 H, C10-H), 
4.32 (t, J = 5.6 Hz, 0.5 H, C10-H), 3.71 (app t, J = 7.2 Hz, 1 H, C8-H), 3.64 (app t, J = 
7.2 Hz, 1 H, C8-H), 3.49 (t, J = 7.9 Hz, 1 H, C7-H), 3.39 (t, J = 7.9 Hz, 1 H, C7-H), 3.33 
(s, 3 H, C11-H), 3.30 (s, 3 H, C11-H), 3.08 (t, J = 7.9 Hz, 1 H, C6-H), 3.02 (t, J = 7.9 Hz, 
1 H, C6-H), 1.97 – 1.93 (m, 1 H, C9-H), 1.83 (dt, J = 7.2, 5.6 Hz, 1 H, C9-H). 
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(3aR,7aS)-5-(2-(1H-Indol-3-yl)ethyl)-1-methylhexahydroisoxazolo[4,3-
c]pyridin-4(1H)-one (4.40). ARMVII92/ARMVII93. A solution of trifluoroacetic acid 
(45 mg, 0.40 mmol) and 4.39 (250 mg, 0.79 mmol) in TFE/water (3 : 1, 16 mL) was 
stirred for 1 h at room temperature. Saturated aqueous NaHCO3 (20 mL) was added and 
the aqueous layer was extracted with CH2Cl2 (3 x 20mL). The combined organic 
fractions were dried (Na2SO4), filtered, and concentrated in vacuo. The crude mixture 
was dissolved in toluene (12 mL). N-Methylhydroxylamine hydrochloride (99 mg, 1.19 
mmol) and triethylamine (200 mg, 1.98 mmol) were added to the reaction mixture, and 
the reaction was heated at reflux for 1.5 h. The reaction was cooled to room temperature, 
and partitioned between saturated aqueous NaHCO3 (20 mL), ethyl acetate (20 mL), and 
methanol (2 mL). The layers were separated, and the aqueous layer was extracted with 
ethyl acetate (3 x 20 mL). The combined organic fractions were washed with water (40 
mL), brine (40 mL), dried (Na2SO4), filtered, and concentrated in vacuo to give 173 mg 
(73%) of 4.40 as a clear oil (>95% purity, by 1H NMR); 1H NMR (500 MHz) d 8.29 (s, 1 
H), 7.64 (d, J = 7.8 Hz, 1 H), 7.36 (d, J = 8.0 Hz, 1 H), 7.18 (td, J = 8.0, 1.0 Hz, 1 H), 
7.11 (td, J = 7.8, 1.0 Hz, 1 H), 7.02 (d, J = 2.2 Hz, 1 H), 4.34 (t, J = 9.0 Hz, 1 H), 3.80 (t, 
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J = 8.0 Hz, 1 H), 3.69 - 3.65 (comp, 2 H), 3.45 (td, J = 12.9, 3.4 Hz, 1 H), 3.39 (td, J = 
9.0, 6.8 Hz, 1 H), 3.07 – 3.00 (comp, 3 H), 2.86 (s, 1 H), 2.66 (s, 3 H), 1.83 (ddt, J = 
13.9, 9.8, 4.1 Hz, 1 H), 1.65 (dq, J = 13.9, 5.1 Hz, 1 H); 13C NMR (125 MHz) d 169.3, 
136.3, 127.4, 122.1, 122.0, 119.3, 118.7, 112.9, 111.3, 69.3, 65.2, 48.8, 48.6, 44.3, 43.2, 
25.4, 23.4; HRMS (ESI) m/z calcd for C17H21N3O2 (M+Na)+, 322.1526; found, 322.1529. 
NMR Assignment. 1H NMR (500 MHz) d 8.29 (s, 1 H, N-H), 7.64 (d, J = 7.8 Hz, 
1 H, C13-H), 7.36 (d, J = 8.0 Hz, 1 H, C10-H), 7.18 (td, J = 8.0, 1.0 Hz, 1 H, C11-H), 
7.11 (td, J = 7.8, 1.0 Hz, 1 H, C12-H), 7.02 (d, J = 2.2 Hz, 1 H, C9-H), 4.34 (t, J = 9.0 
Hz, 1 H, C2-H), 3.80 (t, J = 8.0 Hz, 1 H, C2-H), 3.69 – 3.65 (comp, 2 H, C7-H), 3.45 (td, 
J = 12.9, 3.4 Hz, 1 H, C6-H), 3.39 (td, J = 9.0, 6.8 Hz, 1 H, C3-H), 3.07 – 3.00 (comp, 3 
H, C6-H and C8-H), 2.86 (brs, 1 H, C4-H), 2.66 (s, 3 H, N-CH3), 1.83 (ddt, J = 13.9, 9.8, 
4.1 Hz, 1 H, C5-H), 1.65 (dq, J = 13.9, 5.1 Hz, 1 H, C5-H). 
 
 
(3R,4S)-1-(2-(1H-Indol-3-yl)ethyl)-3-(hydroxymethyl)-4-
(methylamino)piperidin-2-one (4.41). ARMV229. Zinc (dust, 2.00 g, 30 mmol) was 
added in three portions over 1 h to a solution of 4.40 (293 mg, 1.0 mmol) in acetic acid 
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(aq 80%, 60 mL) at 65 ºC, and stirred for an additional 1 h. The reaction was cooled to 
room temperature, excess zinc was filtered and washed with ethyl acetate. Hexanes (100 
mL) was added to the filtrate, whereupon zinc acetate immediately precipitated out of 
solution as a fluffy white solid. The zinc acetate was removed by vacuum filtration and 
washed with excess ethyl acetate. The combined filtrate and washes were concentrated in 
vacuo. The resulting residue was taken up in HCl (aq 1 M, 100 mL), and washed with 
ether (100 mL). The aqueous fraction was basified to pH ~14 with solid NaOH. The 
resulting basic solution was extracted with CH2Cl2 (3 x 150 mL). The combined organic 
fractions were washed with brine (200 mL), dried (Na2SO4), filtered, and concentrated in 
vacuo. The crude mixture was purified via flash column chromatography eluting with 
CH2Cl2 : methanol (98 : 2 → 9 : 1 along a gradient) to give 240 mg (80%) of 4.41 as a 
yellow oil; 1H NMR (600 MHz, CD3OD) d 7.57 (dt, J = 7.9, 1.0 Hz, 1 H), 7.33 (dt, J = 
8.1, 0.9 Hz, 1 H), 7.10 – 7.07 (comp, 2 H), 7.01 (ddd, J = 8.0, 7.0, 1.0 Hz, 1 H), 3.95 (qd, 
J = 11.3, 7.7 Hz, 2 H), 3.66 (ddd, J = 13.3, 7.2, 6.2 Hz, 1 H), 3.54 (ddd, J = 13.3, 8.0, 6.7 
Hz, 1 H), 3.24 (ddd, J = 10.2, 5.2, 3.3 Hz, 1 H), 3.16 - 3.10 (m, 1 H), 3.09 - 3.02 (m, 1 
H), 3.01 - 2.90 (comp, 2 H), 2.87 (dt, J = 7.7, 4.3 Hz, 1 H), 2.54 (s, 3 H), 2.02 – 1.96 (m, 
1 H), 1.90 - 1.84 (m, 1 H); 13C NMR (150 MHz, CD3OD) d 169.8, 138.1, 128.9, 123.7, 
122.4, 119.7, 119.25, 113.0, 112.4, 61.4, 57.1, 50.0, 47.2, 46.4, 32.8, 23.7, 23.4; HRMS 
(ESI) m/z calcd for C17H23N3O2 (M+1)+, 302.1863; found, 302.1864. 
NMR Assignment. 1H NMR (600 MHz, CD3OD) d 7.57 (dt, J = 7.9, 1.0 Hz, 1 H, 
C14-H), 7.33 (dt, J = 8.1, 0.9 Hz, 1 H, C11-H), 7.10 – 7.07 (comp, 2 H, C10-H and C12-
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H), 7.01 (ddd, J = 8.0, 7.0, 1.0 Hz, 1 H, C13-H), 3.95 (qd, J = 11.3, 7.7 Hz, 2 H, C3-H), 
3.66 (ddd, J = 13.3, 7.2, 6.2 Hz, 1 H, C8-H), 3.54 (ddd, J = 13.3, 8.0, 6.7 Hz, 1 H, C8-H), 
3.24 (ddd, J = 10.2, 5.2, 3.3 Hz, 1 H, C5-H), 3.16 – 3.10 (m, 1 H, C7-H), 3.09 – 3.02 (m, 
1 H, C7-H), 3.01 – 2.90 (comp, 2 H, C9-H), 2.87 (dt, J = 7.7, 4.3 Hz, 1 H, C4-H), 2.54 (s, 
3 H, C1-H), 2.02 – 1.96 (m, 1 H, C6-H), 1.90 – 1.84 (m, 1 H, C6-H). 
 
 
(3R,4S)-1-(2-(1H-Indol-3-yl)ethyl)-4-((3,5-dichlorobenzyl)(methyl)amino)-3-
(hydroxymethyl)piperidin-2-one (4.37). ARMV250. A solution of 4.41 (50 mg, 0.17 
mmol) and 3,5-dichlorobenzaldehyde (87 mg, 0.50 mmol) in acetonitrile (1 mL) was 
heated under reflux for 2 h. The solution was cooled to room temperature, at which time 
NaBH3CN (31 mg, 0.5 mmol) and acetic acid (glacial, 58 µL, 1.0 mmol) were added. The 
reaction was stirred for 20 h at room temperature, then partitioned between aqueous 
NaOH (1 M, 10 mL) and CH2Cl2 (10 mL). The two phases were separated, and the 
aqueous phase extracted with CH2Cl2 (2 x 10 mL). The combined organic fractions were 
washed with brine (10 mL) and dried (Na2SO4), filtered, and concentrated in vacuo to 
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give crude 4.37 as an opaque viscous oil. The crude material was purified via silica gel 
flash column chromatography eluting with a gradient of hexanes : ethyl acetate (1 : 1) → 
ethyl acetate : methanol (20 : 1). To give 32 mg (42%) of 4.37 as a white solid: 1H NMR 
(500 MHz, CD3OD) d 7.57 (d, J = 7.8 Hz, 1 H), 7.32 (dt, J = 8.3, 0.7 Hz, 1 H), 7.28 (t, J 
= 2.0 Hz, 1 H), 7.23 (s, 2 H), 7.09 - 7.06 (comp, 2 H), 6.99 (ddd, J = 8.1, 7.1, 1.0 Hz, 1 
H), 3.98 (d, J = 5.9 Hz, 2 H), 3.68 - 3.64 (comp, 2 H), 3.46 (d, J = 14.2 Hz, 1 H), 3.40 (d, 
J = 14.2 Hz, 1 H), 3.23 - 3.02 (comp, 3 H), 2.98 (p, J = 7.1 Hz, 2 H), 2.74 (brs, 1 H), 2.04 
(s, 3 H), 1.86 - 1.81 (comp, 2 H); 13C NMR (125 MHz, CD3OD) d 173.5, 145.0, 138.1, 
136.0, 128.8, 128.0, 128.0, 123.7, 122.4, 119.7, 119.3, 112.9, 112.4, 61.3, 60.4, 58.4, 
47.5, 38.7, 24.0, 23.2; HRMS (ESI) m/z calcd for C24H27Cl2N3O2 (M+Na)+, 482.1373 and 
484.1348; found, 482.1379 and 484.1354. 
 NMR Assignment. 1H NMR (500 MHz, CD3OD) d 7.57 (d, J = 7.8 Hz, 1 H, 
C15-H), 7.32 (dt, J = 8.3, 0.7 Hz, 1 H, C12-H), 7.28 (t, J = 2.0 Hz, 1 H, C1-H), 7.23 (s, 2 
H, C2-H), 7.09 - 7.06 (comp, 2 H, C14-H and C11-H), 6.99 (ddd, J = 8.1, 7.1, 1.0 Hz, 1 
H, C13-H), 3.98 (d, J = 5.9 Hz, 2 H, C8-H), 3.68 - 3.64 (comp, 2 H, C9-H), 3.46 (d, J = 
14.2 Hz, 1 H, C3-H), 3.40 (d, J = 14.2 Hz, 1 H, C3-H), 3.23 - 3.02 (comp, 3 H, C4-H and 
C6-H), 2.98 (p, J = 7.1 Hz, 2 H, C10-H), 2.74 (brs, 1 H, C7-H), 2.04 (s, 3 H, N-CH3), 
1.86 - 1.81 (comp, 2 H, C5-H). 
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N-(3,3-Dimethoxypropyl)-3-(1H-indol-3-yl)propanamide (4.55).  
ARMVI45-ARMVI46. Thionyl chloride (1.14 g, 9.6 mmol) was added dropwise over 10 
min to a solution of indole-3-propionic acid (1.51 g, 8.0 mmol) and DMF (3 drops) in 
THF (40 mL) at 0 ºC. The reaction was stirred for 2 h at 0 ºC, whereupon all volatiles 
were removed in vacuo. The crude material was dissolved in CH2Cl2 (20 mL) and added 
dropwise over 20 min to a solution of 4.18 (1.46 g, 7.3 mmol) and triethylamine (3.30 g, 
32.8 mmol) in CH2Cl2 (120 mL) at 0 ºC. The reaction was stirred for 1 h at 0 ºC, 
followed by stirring for 2 h at room temperature. The solution was diluted with CH2Cl2 
(300 mL) and washed successively with saturated aqueous NH4Cl (150 mL), aqueous 
Na2CO3 (5% w/v, 150 mL), and brine (150 mL). The organic fraction was dried 
(Na2SO4), filtered, and concentrated in vacuo to give crude 4.55 as a viscous yellow oil. 
The crude material was purified via silica gel flash column chromatography eluting with 
hexanes : ethyl acetate (1 : 1 → 1 : 3 along a gradient) to give 2.05 g (97%) of 4.55 as a 
viscous yellow oil: 1H NMR (400 MHz) d 8.42 (brs, 1 H), 7.59 (d, J = 8.0 Hz, 1 H), 7.33 
(d, J  = 8.0 Hz, 1 H), 7.18 (td, J = 8.0, 1.2 Hz, 1 H), 7.11 (ddd, J = 8.0, 7.2, 0.8 Hz, 1 H), 
6.96 (d, J = 2.4 Hz, 1 H), 5.94 (brs, 1 H), 4.26 (t, J = 5.2 Hz, 1 H), 3.30 - 3.25 (comp, 8 
H), 3.10 (t, J = 7.2 Hz, 2 H), 2.55 (t, J = 7.2 Hz, 2 H), 1.69 (q, J = 7.2 Hz, 2H); 13C NMR 
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(100 MHz) d 172.7, 136.4, 127.1, 121.9, 121.8, 119.2, 118.6, 114.7, 111.3, 103.9, 53.3, 
37.4, 35.3, 31.9, 21.4; HRMS (ESI) m/z calcd for C16H22N2O3 (M+Na)+, 313.1523; 
found, 313.1524. 
 NMR Assignment. 1H NMR (400 MHz) d 8.42 (brs, 1 H, N2-H), 7.59 (d, J = 8.0 
Hz, 1 H, C6-H), 7.33 (d, J  = 8.0 Hz, 1 H, C3-H), 7.18 (td, J = 8.0, 1.2 Hz, 1 H, C4-H), 
7.11 (ddd, J = 8.0, 7.2, 0.8 Hz, 1 H, C5-H), 6.96 (d, J = 2.4 Hz, 1 H, C1-H), 5.94 (brs, 1 
H, N9-H), 4.26 (t, J = 5.2 Hz, 1 H, C12-H), 3.30 - 3.25 (comp, 8 H, C10-H and C13-H), 
3.10 (t, J = 7.2 Hz, 2 H, C7-H), 2.55 (t, J = 7.2 Hz, 2 H, C8-H), 1.69 (q, J = 7.2 Hz, 2H, 
C11-H). 
 
 
N-(3-(1H-Indol-3-yl)propyl)-3,3-dimethoxypropan-1-amine (4.56). 
ARMVII150. A solution of 4.55 (400 mg, 1.4 mmol) in THF (5 mL) was added 
dropwise over 15 min to a suspension of lithium aluminum hydride (115 mg, 3.0 mmol) 
in THF (30 mL) at 0 ºC. The reaction was heated at 65 ºC for 14 h, at which point the 
reaction was cooled to 0 ºC, and the Fieser work-up was carefully performed by 
successive addition of water (0.1 mL), aqueous NaOH (15% w/v, 0.1 mL), and water (1 
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mL). The suspension was warmed to room temperature and MgSO4 was added. The 
solids were removed by filtration through a fritted funnel, and washed with copious 
amounts of CH2Cl2. The filtrate was concentrated in vacuo to give crude 4.56 as an 
opaque viscous oil. The crude material was taken up into aqueous HCl (0.2 M, 150 mL) 
and washed with ether (2 x 100 mL). The aqueous fraction was basified to pH ~ 12-14 by 
dropwise addition of aqueous NaOH (40% w/v), and extracted with CH2Cl2 (4 x 150 
mL). The combined organic fractions were successively washed with saturated aqueous 
NaHCO3 (200 mL), water (200 mL), and brine (200 mL). The organic fraction was dried 
(Na2SO4), filtered, and concentrated in vacuo to give 331 mg (87%) of 4.56 as an oil 
(>95% purity, by 1H NMR): 1H NMR (400 MHz) d 8.43 (brs, 1 H), 7.60 (d, J = 7.6 Hz, 1 
H), 7.33 (dt, J = 8.0, 1.2 Hz, 1 H), 7.18 (td, J = 6.8, 1.2 Hz, 1 H), 7.10 (td, J = 6.8, 1.2 
Hz, 1 H), 6.94 (d, J = 2.0 Hz, 1 H), 4.46 (t, J = 5.6 Hz, 1 H), 3.33 (s, 6 H), 2.80 (t, J = 7.6 
Hz, 2 H), 2.72 - 2.68 (comp, 4 H), 1.92 (p, J = 7.6 Hz, 2 H), 1.82 (q, J = 6.0 Hz, 2 H); 13C 
NMR (100 MHz) d 136.4, 127.5, 121.8, 121.2, 119.0, 118.8, 116.1, 111.1, 103.6, 52.9, 
49.9, 45.5, 32.8, 30.4, 22.9; HRMS (ESI) m/z calcd for C16H24N2O2 (M+1)+, 277.1911; 
found 277.1912. 
NMR Assignment. 1H NMR (400 MHz) d 8.43 (brs, 1 H, N2-H), 7.60 (d, J = 7.6 
Hz, 1 H, C6-H), 7.33 (dt, J = 8.0, 1.2 Hz, 1 H, C3-H), 7.18 (td, J = 6.8, 1.2 Hz, 1 H, C4-
H), 7.10 (td, J = 6.8, 1.2 Hz, 1 H, C5-H), 6.94 (d, J = 2.0 Hz, 1 H, C1-H), 4.46 (t, J = 5.6 
Hz, 1 H, C13-H), 3.33 (s, 6 H, C14-H), 2.80 (t, J = 7.6 Hz, 2 H, C9-H), 2.72 - 2.68 
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(comp, 4 H, C7-H and C11-H), 1.92 (p, J = 7.6 Hz, 2 H, C8-H), 1.82 (q, J = 6.0 Hz, 2 H, 
C12-H). 
 
 
(E)-N-(3-(1H-Indol-3-yl)propyl)-N-(3,3-dimethoxypropyl)but-2-enamide 
(4.57). ARMV257. Crotonoyl chloride (200 mg, 1.9 mmol) was added dropwise over 10 
min to a stirred solution of 4.56 (440 mg, 1.6 mmol) and Hünig’s base (496 mg, 3.8 
mmol) in CH2Cl2 (16 mL) at -78 ºC. The solution was stirred for 2 h at -78 ºC, then 
partitioned between saturated aqueous NaHCO3 solution (50 mL) and CH2Cl2 (50 mL). 
The two phases were separated and the aqueous phase extracted with CH2Cl2 (2 x 50 
mL). The combined organic fractions were successively washed with water (50 mL), 
brine (50 mL), dried (Na2SO4), filtered, and concentrated in vacuo to give crude 4.57 as a 
colorless oil. The crude material was purified via silica gel flash column chromatography 
eluting with a gradient hexanes : ethyl acetate (3 : 1 → 1 : 1 along a gradient) to give 
340 mg (62%) of 4.57 as an opaque viscous oil: 1H NMR (400 MHz) (1:1 rotamer 
mixture) d 8.69 (brs, 0.5 H), 8.54 (brs, 0.5 H), 7.57 (dd, J = 8.0, 0.4 Hz, 1 H), 7.35 (d, J = 
8.0 Hz, 0.5 H), 7.32 (d, J = 8.0 Hz, 0.5 H), 7.20 - 7.06 (comp, 2 H), 7.00 - 6.95 (comp, 
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1.5 H), 6.85 (dq, J = 14.2, 6.8 Hz, 0.5 H), 6.32 (dd, J = 14.2, 1.6 Hz, 0.5 H), 5.98 (dd, J = 
14.2, 1.6 Hz, 0.5 H), 4.38 (t, J = 6.0 Hz, 0.5 H), 4.33 (t, J = 6.0 Hz, 0.5 H), 3.50 - 3.39 
(comp, 3 H), 3.36 - 3.28 (comp, 7 H), 2.77 (app q, J = 7.2 Hz, 2 H), 2.01 (q, J = 7.2 Hz, 2 
H), 1.90 - 1.83 (comp, 3.5 H), 1.68 (dd, J = 6.8, 1.6 Hz, 1.5 H); 13C NMR (400 MHz) 
(1:1 rotamer mixture) d 166.5, 166.4, 141.8, 141.5, 136.6, 136.4, 127.4, 127.2, 121.9, 
121.8, 121.6, 121.5, 119.1, 118.9, 118.7, 118.6, 115.3, 114.6, 111.3, 111.2, 102.9, 102.2, 
53.2, 53.0, 48.0, 46.5, 43.6, 42.3, 32.5, 31.0, 29.6, 28.0, 22.6, 22.3, 18.3, 18.0; HRMS 
(ESI) m/z calcd for C20H28N2O2 (M+Na)+, 367.1992; found, 367.1994. 
NMR Assignment. 1H NMR (400 MHz) (1:1 rotamer mixture) d 8.69 (brs, 0.5 H, 
N2-H), 8.54 (brs, 0.5 H, N2-H), 7.57 (dd, J = 8.0, 0.4 Hz, 1 H, C6-H), 7.35 (d, J = 8.0 
Hz, 0.5 H, C3-H), 7.32 (d, J = 8.0 Hz, 0.5 H, C3-H), 7.20 - 7.06 (comp, 2 H, C5-H and 
C4-H), 7.00 - 6.95 (comp, 1.5 H, C11-H and C1-H), 6.85 (dq, J = 14.2, 6.8 Hz, 0.5 H, 
C11-H), 6.32 (dd, J = 14.2, 1.6 Hz, 0.5 H, C10-H), 5.98 (dd, J = 14.2, 1.6 Hz, 0.5 H, 
C10-H), 4.38 (t, J = 6.0 Hz, 0.5 H, C15-H), 4.33 (t, J = 6.0 Hz, 0.5 H, C15-H), 3.50 - 
3.39 (comp, 3 H, C13-H and C9-H), 3.36 - 3.28 (comp, 7 H, C16-H and C13-H), 2.77 
(app q, J = 7.2 Hz, 2 H, C7-H), 2.01 (q, J = 7.2 Hz, 2 H, C14-H), 1.90 - 1.83 (comp, 3.5 
H, C12-H and C8-H), 1.68 (dd, J = 6.8, 1.6 Hz, 1.5 H, C12-H). 
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 (3R,3aR,7aS)-5-(3-(1H-Indol-3-yl)propyl)-1,3-
dimethylhexahydroisoxazolo[4,3-c]pyridin-4(1H)-one (4.58). ARMVII156-
ARMVII157. A solution of trifluoroacetic acid (5 drops) and 4.57 (50 mg, 0.14 mmol) in 
TFE/water (3 : 1, 4 mL) was stirred for 1 h at room temperature. Saturated aqueous 
NaHCO3 (10 mL) was added, the layers were separated, and the aqueous layer was 
extracted with CH2Cl2 (3 x 20 mL). The combined organic fractions were dried 
(Na2SO4), filtered, and concentrated in vacuo. The crude mixture was dissolved in 
toluene (2 mL), followed by the addition of N-methylhydroxylamine hydrochloride (18 
mg, 0.22 mmol) and triethylamine (37 mg, 0.36 mmol). The reaction was heated under 
reflux for 1.5 h. After cooling the to room temperature, the reaction was partitioned 
between saturated aqueous NaHCO3 (10 mL), ethyl acetate (20 mL), and methanol (1 
mL). The layers were separated, and the aqueous layer was extracted with ethyl acetate (3 
x 20 mL). The combined organic fractions were washed successively with water (40 mL) 
and brine (40 mL), dried (Na2SO4), filtered, and concentrated in vacuo to give 49 mg 
(quant) of 4.58 as an oil of ~80 - 90% purity, as judged by 1H NMR. The crude material 
was taken up in aqueous HCl (1 M, 10 mL), and washed with ether (2 x 10 mL). The 
aqueous fraction was basified to pH 12-14 by dropwise addition of aqueous NaOH (40% 
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w/v), as judged by pH paper. The basic solution was extracted with CH2Cl2 (2 x 30 mL) 
and ethyl acetate (2 x 30 mL). The combined organic fractions were dried (Na2SO4), 
filtered, and concentrated in vacuo to give 33 mg (68%) of 4.58 as a colorless oil: 1H 
NMR (400 MHz) d 8.24 (brs, 1 H), 7.57 (d, J = 7.6 Hz, 1 H), 7.35 (dt, J = 8.4, 1.2 Hz, 1 
H), 7.18 (ddd, J = 8.4, 7.2, 1.2, 1 H), 7.10 (ddd, J = 8.0, 7.2, 1.2 Hz, 1 H), 7.03 (d, J = 2.0 
Hz, 1 H), 3.94 (dq, J = 7.2, 6.0 Hz, 1 H), 3.68 - 3.55 (comp, 2 H), 3.44 - 3.37 (m, 1 H), 
3.07 (dt, J = 12.4, 4.0 Hz, 1 H), 2.91 - 2.87 (m, 1 H), 2.84 - 2.70 (comp, 3 H), 2.69 (s, 3 
H), 2.00 - 1.85 (comp, 3 H), 1.71 (dq, J = 14.4, 3.6 Hz, 1 H), 1.47 (d, J = 6.0 Hz, 3 H); 
13C NMR (100 MHz) d 169.0, 136.4, 127.3, 121.8, 121.5, 119.1, 118.7, 115.4, 111.1, 
77.6, 66.1, 55.4, 47.3, 46.0, 43.2, 27.6, 25.2, 22.4, 19.2; HRMS (ESI) m/z calcd for 
C19H25N3O2 (M+Na)+, 350.1839; found, 350.1845. 
 NMR Assignment. 1H NMR (400 MHz) d 8.24 (brs, 1 H, N2-H), 7.57 (d, J = 7.6 
Hz, 1 H, C6-H), 7.35 (dt, J = 8.4, 1.2 Hz, 1 H, C3-H), 7.18 (ddd, J = 8.4, 7.2, 1.2, 1 H, 
C4-H), 7.10 (ddd, J = 8.0, 7.2, 1.2 Hz, 1 H, C5-H), 7.03 (d, J = 2.0 Hz, 1 H, C1-H), 3.94 
(dq, J = 7.2, 6.0 Hz, 1 H, C15-H), 3.68 - 3.55 (comp, 2 H, C9-H), 3.44 - 3.37 (m, 1 H, 
C10-H), 3.07 (dt, J = 12.4, 4.0 Hz, 1 H, C10-H), 2.91 - 2.87 (m, 1 H, C12-H), 2.84 - 2.70 
(comp, 3 H, C13-H and C7-H), 2.69 (s, 3 H, C16-H), 2.00 - 1.85 (comp, 3 H, C11-H and 
C8-H), 1.71 (dq, J = 14.4, 3.6 Hz, 1 H, C11-H), 1.47 (d, J = 6.0 Hz, 3 H, C14-H). 
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(3R,4S)-1-(3-(1H-Indol-3-yl)propyl)-3-((R)-1-hydroxyethyl)-4-
(methylamino)piperidin-2-one (4.59). ARMVI55. A suspension of zinc (dust, 7.0 g, 84 
mmol) and 4.58 (1.37 g, 4.2 mmol) in acetic acid (aq 80%, 200 mL) was stirred for 3 h at 
65 ºC, at which point the reaction was cooled to room temperature. Excess zinc was 
removed via vacuum filtration and washed with ethyl acetate (200 mL), whereupon zinc 
acetate immediately precipitated out of solution as a fluffy white solid. The zinc acetate 
was removed by vacuum filtration and washed with ethyl acetate. The combined filtrate 
and washes were concentrated in vacuo. The resulting residue was dissolved in aqueous 
HCl (1 M, 300 mL), and washed with ether (150 mL). The aqueous fraction was carefully 
basified to pH ~14 with solid NaOH, and extracted with CH2Cl2 (3 x 300 mL). The 
combined organic fractions were washed with brine (200 mL), dried (Na2SO4), filtered, 
and concentrated in vacuo to give crude 4.59. The crude mixture was purified via silica 
gel flash column chromatography eluting with CH2Cl2 : methanol (98 : 2 → 9 : 1 along a 
gradient) to give 791 mg (57%) of 4.59 as a yellow oil: 1H NMR (500 MHz, CD3OD) d 
7.51 (dt, J =  8.0, 1.5 Hz, 1 H), 7.30 (dt, J = 8.5, 1.0 Hz, 1 H), 7.06 (ddd, J = 8.5, 7.0, 1.5 
Hz, 1 H), 7.03 (s, 1 H), 6.97 (ddd, J = 8.0, 7.0, 1.5 Hz, 1 H), 4.41 (t, J = 6.2 Hz, 1 H), 
3.54 (ddd, J = 13.4, 8.4, 6.8 Hz, 1 H), 3.38 (ddd, J = 12.7, 7.5, 6.3 Hz, 1 H), 3.28 - 3.20 
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(comp, 2 H), 3.16 (p, J = 3.8 Hz, 1 H), 2.75 (t, J = 7.4 Hz, 2 H), 2.37 (s, 3 H), 2.34 (dd, J 
= 5.9, 4.1 Hz, 1 H), 2.09 - 2.02 (m, 1 H), 1.99 - 1.93 (comp, 2 H), 1.79 (dtd, J = 14.3, 7.4, 
3.6 Hz, 1 H), 1.25 (d, J = 6.2 Hz, 3 H); 13C NMR (125 MHz, CD3OD) d 171.2, 138.2, 
128.7, 122.8, 122.2, 119.4, 119.3, 115.7, 112.2, 67.4, 56.1, 51.4, 48.3, 45.0, 33.7, 28.4, 
25.2, 23.7, 22.3; HRMS (ESI) m/z calcd for C19H27N3O2 (M+Na)+, 352.1995; found, 
352.2000. 
 NMR Assignment. 1H NMR (500 MHz, CD3OD) d 7.51 (dt, J =  8.0, 1.5 Hz, 1 
H, C5-H), 7.30 (dt, J = 8.5, 1.0 Hz, 1 H, C2-H), 7.06 (ddd, J = 8.5, 7.0, 1.5 Hz, 1 H, C3-
H), 7.03 (s, 1 H, C1-H), 6.97 (ddd, J = 8.0, 7.0, 1.5 Hz, 1 H, C4-H), 4.41 (t, J = 6.2 Hz, 1 
H, C13-H), 3.54 (ddd, J = 13.4, 8.4, 6.8 Hz, 1 H, C8-H), 3.38 (ddd, J = 12.7, 7.5, 6.3 Hz, 
1 H, C9-H), 3.28 - 3.20 (comp, 2 H, C9-H and C8-H), 3.16 (p, J = 3.8 Hz, 1 H, C11-H), 
2.75 (t, J = 7.4 Hz, 2 H, C6-H), 2.37 (s, 3 H, C15-H), 2.34 (dd, J = 5.9, 4.1 Hz, 1 H, C12-
H), 2.09 - 2.02 (m, 1 H, C10-H), 1.99 - 1.93 (comp, 2 H, C7-H), 1.79 (dtd, J = 14.3, 7.4, 
3.6 Hz, 1 H, C10-H), 1.25 (d, J = 6.2 Hz, 3 H, C14-H). 
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(3R,4S)-1-(3-(1H-Indol-3-yl)propyl)-4-((3,5-dichlorobenzyl)(methyl)amino)-3-
((R)-1-hydroxyethyl)piperidin-2-one (4.52). ARMVI56. A solution of 4.56 (100 mg, 
0.30 mmol) and 3,5-dichlorobenzaldehyde (159 mg, 0.91 mmol) in acetonitrile (2 mL) 
was heated under reflux for 2 h. The reaction was cooled to room temperature, at which 
time NaBH3CN (22 mg, 0.35 mmol) and acetic acid (glacial, 53 µL, 0.89 mmol) were 
added. The reaction was stirred for 20 h at room temperature, then partitioned between 
aqueous NaOH (1 M, 15 mL) and CH2Cl2 (30 mL). The two phases were separated, and 
the aqueous phase was extracted with CH2Cl2 (2 x 15 mL). The combined organic 
fractions were washed with brine (15 mL), dried (Na2SO4), filtered, and concentrated in 
vacuo to give crude 4.52 as an opaque viscous oil. The crude material was purified via 
silica gel flash column chromatography eluting with hexanes : ethyl acetate (1 : 1 → 0 : 1 
along a gradient) to give 30 mg (20%) of 4.52 as a white solid: 1H NMR (400 MHz) d 
8.10 (brs, 1 H), 7.57 (d, J = 7.6 Hz, 1 H), 7.36 (dt, J = 8.4, 0.8 Hz, 1 H), 7.27 (t, J = 2.0 
Hz, 1 H), 7.21 - 7.17 (m, 1 H), 7.14 (d, J = 2.0 Hz, 2 H), 7.11 (ddd, J = 8.0, 7.2, 0.8 Hz, 1 
H), 7.04 (d, J = 2.0 Hz, 1 H), 7.33 (dq, J = 8.8, 6.4 Hz, 1 H), 3.62 - 3.55 (comp, 2 H), 
3.45 (d, J = 13.2 Hz, 1 H), 3.39 - 3.24 (comp, 3 H), 3.14 (dt, J = 10.4, 5.6 Hz, 1 H), 2.77 
N
O
N
OH
Cl
Cl
N
H
1
2
3
4
5 6 7
8
9
10
11 12
13 14
15
16
17
18 19
4.52
 
 
 
301 
(t, J = 7.2 Hz, 2 H), 2.70 (dd, J = 8.4, 5.6 Hz, 1 H), 2.16 (s, 3 H), 2.13 - 2.05 (comp, 2 H), 
1.99 - 1.92 (comp, 2 H), 1.34 (d, J = 6.0 Hz, 3 H); 13C NMR (100 MHz, CDCl3) d 169.9, 
141.2, 136.3, 135.2, 127.8, 127.3, 127.1, 121.9, 121.4, 119.2, 118.7, 115.4, 111.2, 66.5, 
60.3, 57.9, 50.2, 46.6, 44.9, 39.5, 27.5, 22.5, 22.5, 21.8; HRMS (ESI) m/z calcd for 
C26H31Cl2N3O2 (M+Na)+, 510.1686 and 512.1662; found, 510.1690 and 512.1695. 
 NMR Assignment. 1H NMR (400 MHz) d 8.10 (brs, 1 H, N2-H), 7.57 (d, J = 7.6 
Hz, 1 H, C6-H), 7.36 (d, J = 8.4 Hz, 1 H, C3-H), 7.27 (t, J = 2.0 Hz, 1 H, C19-H), 7.19 
(dt, J = 7.2, 1.2 Hz, 1 H, C4-H), 7.14 (d, J = 2.0 Hz, 2 H, C18-H), 7.11 (ddd, J = 8.0, 7.2, 
0.8 Hz, 1 H, C5-H), 7.04 (d, J = 2.0 Hz, 1 H, C1-H), 4.33 (dq, J = 8.8, 6.4 Hz, 1 H, C14-
H), 3.62 - 3.55 (comp, 2 H, C17-H and C12-H), 3.45 (d, J = 13.2 Hz, 1 H, C17-H), 3.39 - 
3.24 (comp, 3 H, C10-H and C9-H), 3.14 (dt, J = 10.4, 5.6 Hz, 1 H, C10-H), 2.77 (t, J = 
7.2 Hz, 2 H, C7-H), 2.70 (dd, J = 8.4, 5.6 Hz, 1 H, C13-H), 2.16 (s, 3H, C16-H), 2.13 - 
2.05 (comp, 2 H, C11-H), 1.99 - 1.92 (comp, 2 H, C8-H), 1.34 (d, J = 6.0 Hz, 3 H, C15-
H). 
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N-(3,3-Dimethoxypropyl)-1H-indole-3-carboxamide (4.61). ARMVII143. 
Freshly distilled thionyl chloride (0.37 g, 3.2 mmol) was added dropwise over 10 min, 
followed by addition of DMF (3 drops), to a solution of indole-3-carboxylic acid (0.42 g, 
2.6 mmol) in THF (13 mL) at 0 ºC. The reaction was stirred for 1.5 h at 0 ºC and for an 
additional 0.5 h at room temperature. The solvent was removed in vacuo, whereupon the 
crude material was taken up in CH2Cl2 (5 mL), and added dropwise over 10 min to a 
solution of 4.18 (0.52 g, 2.6 mmol) and triethylamine (0.79 g, 7.8 mmol) in CH2Cl2 (50 
mL) at 0 ºC. The reaction was stirred for 1 h at 0 ºC, then warmed to room temperature 
and stirred for an additional 1 h. The mixture was diluted with CH2Cl2 (100 mL), and 
successively washed with saturated aqueous NH4Cl (100 mL), saturated aqueous Na2CO3 
(100 mL), water (100 mL) and brine (100 mL). The organic fraction was dried (Na2SO4), 
filtered, and concentrated in vacuo to give 0.60 g (88%) of 4.61 as a viscous oil (>95% 
purity, by 1H NMR): 1H NMR (400 MHz) d 9.94 (brs, 1 H), 7.95 - 7.93 (m, 1 H), 7.72 (d, 
J = 2.9 Hz, 1 H), 7.44 - 7.42 (m, 1 H), 7.25 - 7.20 (comp, 2 H), 6.85 (t, J = 4.9 Hz, 1 H), 
4.54 (t, J = 5.4 Hz, 1 H), 3.64 (q, J = 5.4 Hz, 2 H), 3.40 (s, 6 H), 1.98 (q, J = 5.4 Hz, 2 
H); 13C NMR (100 MHz) d 165.7, 136.8, 128.9, 124.5, 122.7, 121.5, 119.5, 112.4, 112.2, 
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104.9, 53.8, 35.6, 32.2; HRMS (ESI) m/z calcd for C14H18N2O3 (M+Na)+, 285.1210; 
found, 285.1212. 
 NMR Assignment. 1H NMR (400 MHz) d 9.94 (brs, 1 H, N2-H), 7.95 - 7.93 (m, 
1 H, C3-H), 7.72 (d, J = 2.9 Hz, 1 H, C1-H), 7.44 - 7.42 (m, 1 H, C6-H), 7.25 - 7.20 
(comp, 2 H, C5-H and C4-H), 6.85 (t, J = 4.9 Hz, 1 H, N7-H), 4.54 (t, J = 5.4 Hz, 1 H, 
C10-H), 3.64 (q, J = 5.4 Hz, 2 H, C8-H), 3.40 (s, 6 H, C11-H), 1.98 (q, J = 5.4 Hz, 2 H, 
C9-H) 
 
 
(E)-N-((1H-Indol-3-yl)methyl)-N-(3,3-dimethoxypropyl)but-2-enamide (4.63). 
ARMV255/ARMV260. A solution of 4.61 (140 mg, 0.53 mmol) in THF (3 mL) was 
added dropwise over 10 min to a stirred suspension of lithium aluminum hydride (101 
mg, 2.7 mmol) in THF (10 mL) at 0 ºC. The reaction heated to 65 ºC for 48 h, then 
cooled to 0 ºC, and the Fieser work-up was carefully performed by successive addition of 
water (0.1 mL), aqueous NaOH (15%, 0.1 mL), and water (1 mL). The suspension was 
warmed to room temperature and MgSO4 was added, followed by removal of solids by 
vacuum filtration through a fritted funnel, and washing with copious amounts of ether 
and CH2Cl2. The filtrate was concentrated in vacuo to give 132 mg (quant.) of crude 4.62 
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as an opaque viscous oil. Due to the instability of 4.62 towards acid/base extraction and 
chromatographic conditions, the crude material was immediately carried on to the next 
step without further purification.  
  Crotonoyl chloride (66 mg, 0.64 mmol) was added dropwise over 5 min to a 
stirred solution of crude 4.62 (132 mg, 0.53 mmol) and Hünig’s base (165 mg, 1.28 
mmol) in CH2Cl2 (5 mL) at -78 ºC. The solution was stirred for 2 h at -78 ºC, then 
partitioned between saturated aqueous NaHCO3 (10 mL) and CH2Cl2 (10 mL). The 
phases were separated, and the aqueous phase extracted with CH2Cl2 (2 x 10 mL). The 
combined organic fractions were successively washed with water (10 mL) and brine (10 
mL), dried (Na2SO4), filtered, and concentrated in vacuo to give crude 4.63 as a viscous 
yellow oil. The crude material was purified via silica gel flash column chromatography 
eluting with hexanes : ethyl acetate (2 : 1 → 1 : 1 along a gradient) to give 141 mg 
(86%, two-steps) of 4.63 as a yellow solid: 1H NMR (400 MHz)  (1:1 rotamer mixture) d 
9.04 (brs, 0.5 H), 8.85 (brs, 0.5 H), 7.69 (d, J = 7.8 Hz, 0.5 H), 7.53 (d, J = 7.8 Hz, 0.5 
H), 7.38 (d, J = 8.1 Hz, 0.5 H), 7.34 (d, J = 8.1 Hz, 0.5 H), 7.23 - 6.96 (comp, 4 H), 6.41 
(dd, J = 14.9, 1.2 Hz, 0.5 H), 6.34 (dd, J = 14.9, 1.2 Hz, 0.5 H), 4.85 (s, 1 H), 4.75 (s, 1 
H), 4.40 (t, J = 5.5 Hz, 0.5 H), 4.30 (t, J = 5.5 Hz, 0.5 H), 3.53 (t, J = 7.4 Hz, 1 H), 3.40 
(t, J = 7.4 Hz, 1 H) 3.28 (s, 6 H), 1.97 - 1.81 (comp, 5 H); 13C NMR (100 MHz) (1 : 1 
rotamer mixture) d 166.0, 165.4, 141.0, 140.9, 135.7, 135.3, 125.9, 124.9, 123.2, 121.5, 
121.3, 121.1, 121.1, 120.9, 118.6, 118.2, 117.3, 111.0, 110.6, 110.2, 101.9, 101.3, 52.2, 
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51.9, 43.5, 41.5, 41.0, 38.9, 31.1, 29.8, 17.3, 17.2; HRMS (ESI) m/z calcd for 
C18H24N2O3 (M+Na)+, 339.1679; found, 339.1680. 
 NMR Assignment. 1H NMR (400 MHz)  (1:1 rotamer mixture) d 9.04 (brs, 0.5 
H, N2-H), 8.85 (brs, 0.5 H, N2-H), 7.69 (d, J = 7.8 Hz, 0.5 H, C6-H), 7.53 (d, J = 7.8 Hz, 
0.5 H, C6-H), 7.38 (d, J = 8.1 Hz, 0.5 H, C3-H), 7.34 (d, J = 8.1 Hz, 0.5 H, C3-H), 7.23 - 
6.96 (comp, 4 H, C9-H, C5-H, C4-H, and C1-H), 6.41 (dd, J = 14.9, 1.2 Hz, 0.5 H, C8-
H), 6.34 (dd, J = 14.9, 1.2 Hz, 0.5 H, C8-H), 4.85 (s, 1 H, C7-H), 4.75 (s, 1 H, C7-H), 
4.40 (t, J = 5.5 Hz, 0.5 H, C13-H), 4.30 (t, J = 5.5 Hz, 0.5 H, C13-H), 3.53 (t, J = 7.4 Hz, 
1 H, C11-H), 3.40 (t, J = 7.4 Hz, 1 H, C11-H) 3.28 (s, 6 H, C14-H), 1.97 - 1.81 (comp, 5 
H, C12-H and C10-H) 
 
 
 (3R,3aR,7aS)-5-((1H-Indol-3-yl)methyl)-1,3-dimethylhexahydroisoxazolo[4,3-
c]pyridin-4(1H)-one (4.64). ARMV285/ARMV287. A solution of trifluoroacetic acid 
(36 mg, 0.32 mmol) and 4.63 (100 mg, 0.32 mmol) in a mixture of acetone/water (2 : 1, 6 
mL) was stirred for 3 h at room temperature. Saturated aqueous NaHCO3 (20 mL) was 
added, the layers were separated, and the aqueous layer was extracted with CH2Cl2 (3 x 
30 mL). The combined organic fractions were dried (Na2SO4), filtered, and concentrated 
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in vacuo. The resulting residue was dissolved in toluene (5 mL), followed by the addition 
of N-methylhydroxylamine hydrochloride (40 mg, 0.47 mmol) and triethylamine (81 mg, 
0.80 mmol). The resulting solution was heated under reflux for 1 h, at which point the 
solution was cooled to room temperature, and partitioned between saturated aqueous 
NaHCO3 (20 mL), ethyl acetate (20 mL) and methanol (1 mL). The phases were 
separated, and the aqueous phase was extracted with ethyl acetate (3 x 20 mL). The 
combined organic fractions were washed successively with water (50 mL) and brine (50 
mL), dried (Na2SO4), filtered, and concentrated in vacuo to give 76 mg (81%, two-steps) 
of 4.64 as a colorless oil (>95% purity, by 1H NMR): 1H NMR (400 MHz, CD3OD) 
d 7.57 (dt, J = 8.0, 1.0 Hz, 1 H), 7.35 (dt, J = 8.2, 0.8 Hz, 1 H), 7.26 (s, 1 H), 7.11 (ddd, J 
= 8.2, 7.1, 1.2 Hz, 1 H), 7.00 (ddd, J = 8.0, 7.1, 1.0 Hz, 1 H), 4.78 (s, 2 H), 3.93 - 3.87 
(m, 1 H), 3.40 - 3.33 (m, 1 H), 3.20 (dt, J = 12.8, 4.3 Hz, 1 H), 2.97 - 2.88 (comp, 2 H), 
2.62 (s, 3 H), 1.79 (tt, J = 14.4, 4.0 Hz, 1 H), 1.63 (dq, J = 14.4, 3.9 Hz, 1 H), 1.45 (d, J = 
6.0 Hz, 3 H); 13C NMR (100 MHz, CD3OD) d 169.2, 136.9, 126.5, 124.5, 121.4, 118.7, 
118.4, 111.0, 109.8, 77.3, 66.2, 54.9, 41.4, 41.1, 24.1, 24.1, 18.1; HRMS (ESI) m/z calcd 
for C17H21N3O2 (M+Na)+, 322.1526; found, 322.1529. 
 NMR Assignment. 1H NMR (400 MHz, CD3OD) d 7.57 (dt, J = 8.0, 1.0 Hz, 1 H, 
C6-H), 7.35 (dt, J = 8.2, 0.8 Hz, 1 H, C3-H), 7.26 (s, 1 H, C1-H), 7.11 (ddd, J = 8.2, 7.1, 
1.2 Hz, 1 H, C4-H), 7.00 (ddd, J = 8.0, 7.1, 1.0 Hz, 1 H, C5-H), 4.78 (s, 2 H, C7-H), 3.93 
- 3.87 (m, 1 H, C12-H), 3.40 - 3.33 (m, 1 H, C10-H), 3.20 (dt, J = 12.8, 4.3 Hz, 1 H, C8-
H), 2.97 - 2.88 (comp, 2 H, C11-H and C8-H), 2.62 (s, 3 H, C14-H), 1.79 (tt, J = 14.4, 
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4.0 Hz, 1 H, C9-H), 1.63 (dq, J = 14.4, 3.9 Hz, 1 H, C9-H), 1.45 (d, J = 6.0 Hz, 3 H, C13-
H). 
 
 
 (3R,4S)-1-((1H-Indol-3-yl)methyl)-3-((R)-1-hydroxyethyl)-4-
(methylamino)piperidin-2-one (4.65). ARMV298. A mixture of 4.64 (104 mg, 0.35 
mmol) and zinc (dust, 680 mg, 10.4 mmol) in acetic acid (aq 80%, 21 mL) was stirred for 
48 h at room temperature. Excess zinc was removed via vacuum filtration, and washed 
with ethyl acetate (150 mL), whereupon zinc acetate immediately precipitated out of 
solution as a fluffy white solid. The zinc acetate was removed by vacuum filtration and 
washed with ethyl acetate. The combined filtrate and washes were concentrated in vacuo, 
and the residue dissolved in aqueous HCl (1 M, 50 mL). The resulting solution was 
washed with ether (50 mL), and carefully basified to pH ~14 with solid NaOH. The basic 
solution was extracted with CH2Cl2 (3 x 75 mL). The combined organic fractions were 
washed with brine (100 mL), dried (Na2SO4), filtered, and concentrated in vacuo to give 
150 mg (quant) of crude 4.65 as the acetate salt with residual acetic acid. The crude 
material was taken up in aqueous HCl (1 M, 50 mL) and washed with ether (2 x 50 mL). 
The aqueous fraction was basified to pH ~14 with solid NaOH, and extracted with 
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CH2Cl2 (3 x 75 mL). The combined organic fractions were successively washed with 
aqueous NaOH (1 M, 100 mL), saturated aqueous NaHCO3 (100 mL), water (100 mL), 
and brine (100 mL). The organic fraction was dried (Na2SO4), filtered, and concentrated 
in vacuo to give 69 mg (66%) of pure 4.65 as an off white solid: 1H NMR (400 MHz, 
CD3OD) d 7.59 (dt, J = 7.9, 0.9 Hz, 1 H), 7.35 (dt, J = 8.1, 0.9 Hz, 1 H), 7.24 (s, 1 H), 
7.09 (ddd, J = 8.1, 7.0, 1.1 Hz, 1 H), 6.98 (ddd, J = 7.9, 7.0, 1.0 Hz, 1 H), 4.89 (d, J = 
14.4 Hz, 1 H), 4.56 (d, J = 14.4, 1 H), 4.42 (p, J = 6.4 Hz, 1 H), 3.38 (dt, J = 12.9, 6.6 Hz, 
1 H), 3.28 - 3.21 (comp, 2 H), 2.55 (dd, J = 6.5, 4.1 Hz, 1 H), 2.43 (s, 3 H), 2.10 - 2.02 
(m, 1 H), 1.88 - 1.83 (m, 1 H), 1.33 (d, J = 6.4 Hz, 3 H); 13C NMR (100 MHz, CD3OD) d 
169.7, 136.8, 126.7, 124.4, 121.3, 118.7, 118.4, 110.9, 110.1, 66.3, 54.8, 50.1, 42.1, 40.8, 
32.4, 23.8, 21.0; HRMS (ESI) m/z calcd for C17H23N3O2 (M+Na)+, 324.1682; found, 
324.1686. 
 NMR Assignment. 1H NMR (400 MHz, CD3OD) d 7.59 (dt, J = 7.9, 0.9 Hz, 1 H, 
C5-H), 7.35 (dt, J = 8.1, 0.9 Hz, 1 H, C2-H), 7.24 (s, 1 H, C1-H), 7.09 (ddd, J = 8.1, 7.0, 
1.1 Hz, 1 H, C3-H), 6.98 (ddd, J = 7.9, 7.0, 1.0 Hz, 1 H, C4-H), 4.89 (d, J = 14.4 Hz, 1 H, 
C6-H), 4.56 (d, J = 14.4, 1 H, C6-H), 4.42 (p, J = 6.4 Hz, 1 H, C11-H), 3.38 (dt, J = 12.9, 
6.6 Hz, 1 H, C7-H), 3.28 - 3.21 (comp, 2 H, C9-H and C7-H), 2.55 (dd, J = 6.5, 4.1 Hz, 1 
H, C10-H), 2.43 (s, 3 H, C13-H), 2.10 - 2.02 (m, 1 H, C8-H), 1.88 - 1.83 (m, 1 H, C8-H), 
1.33 (d, J = 6.4 Hz, 3 H, C12-H). 
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 (3R,4S)-1-((1H-Indol-3-yl)methyl)-4-((3,5-dichlorobenzyl)(methyl)amino)-3-
((R)-1-hydroxyethyl)piperidin-2-one (4.53). ARMVI41. A solution of 4.65 (75 mg, 
0.25 mmol) and 3,5-dichlorobenzaldehyde (131 mg, 0.75 mmol) in acetonitrile (2 mL) 
was heated under reflux for 5 h. The reaction was cooled to room temperature, and 
sodium borohydride (28 mg, 0.75 mmol) was added. The solution was stirred at room 
temperature for 14 h, at which point, LC/MS analysis showed no trace of the desired 
product. Methanol (1 mL) and acetic acid (0.2 mL) were added, and the solution was 
stirred for 24 h at room temperature, no product detected by LC/MS. Acetic acid (0.1 
mL) and NaBH3CN (62 mg, 1.0 mmol) were added, and the solution was stirred for an 
additional 24 h at room temperature. LC/MS analysis showed complete conversion to 
product and the reaction mixture was partitioned between aqueous NaOH (1 M, 20 mL) 
and CH2Cl2 (25 mL). The two phases were separated, and the aqueous phase extracted 
with CH2Cl2 (2 x 25 mL). The combined organic fractions were washed with water (50 
mL), brine (50 mL), dried (Na2SO4), filtered, and concentrated in vacuo to give crude 
4.53 as an amorphous solid. The crude material was purified via silica gel flash column 
chromatography eluting with CH2Cl2 : methanol (1 : 0 → 95 : 5 along a gradient) to give 
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59 mg (51%) of 4.53 as a white solid: 1H NMR (400 MHz) d 8.54 (brs, 1 H), 7.68 (d, J = 
8.0 Hz, 1 H), 7.38 (d, J = 8.4 Hz, 1 H), 7.25 - 7.18 (comp, 3 H), 7.09 (ddd, J = 8.0, 7.2, 
0.8 Hz, 1 H), 7.06 (d, J = 2.0 Hz, 2 H), 4.96 (d, J = 14.4 Hz, 1 H), 4.51 (d, J = 14.4 Hz, 1 
H), 4.36 (dq, J = 8.4, 5.6 Hz, 1 H), 3.42 - 3.35 (comp, 3 H), 3.23 - 3.11 (comp, 2 H), 2.75 
(dd, J = 8.8, 6.0 Hz, 1 H), 2.06 (s, 3 H), 1.99 - 1.92 (m, 1 H), 1.86 - 1.78 (m, 1 H), 1.41 
(d, J = 6.0 Hz, 3 H); 13C NMR (100 MHz) d 169.7, 141.2, 136.3, 135.1, 127.7, 127.0, 
126.8, 124.3, 122.4, 119.9, 119.3, 111.5, 111.3, 66.5, 60.4, 57.5, 50.3, 43.5, 40.8, 38.6, 
22.6, 21.6; HRMS (ESI) m/z calcd for C26H31Cl2N3O3 (M+Na)+, 482.1373 and 484.1348; 
found, 482.1373 and 484.1349. 
 NMR Assignment. 1H NMR (400 MHz) d 8.54 (brs, 1 H, N2-H), 7.68 (d, J = 8.0 
Hz, 1 H, C6-H), 7.38 (d, J = 8.4 Hz, 1 H, C3-H), 7.25 - 7.18 (comp, 3 H, C17-H, C4-H, 
and C1-H), 7.09 (ddd, J = 8.0, 7.2, 0.8 Hz, 1 H, C5-H), 7.06 (d, J = 2.0 Hz, 2 H, C16-H), 
4.96 (d, J = 14.4 Hz, 1 H, C7-H), 4.51 (d, J = 14.4 Hz, 1 H, C7-H), 4.36 (dq, J = 8.4, 5.6 
Hz, 1 H, C12-H), 3.42 - 3.35 (comp, 3 H, C15-H and C10-H), 3.23 - 3.11 (comp, 2 H, 
C8-H), 2.75 (dd, J = 8.8, 6.0 Hz, 1 H, C11-H), 2.06 (s, 3 H, C14-H), 1.99 - 1.92 (m, 1 H, 
C9-H), 1.86 - 1.78 (m, 1 H, C9-H), 1.41 (d, J = 6.0 Hz, 3 H, C13-H). 
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 N-(3,3-Dimethoxypropyl)-2-(5-methoxy-1H-indol-3-yl)-2-oxoacetamide (4.68). 
ARMV233/ARMV236. Oxalyl chloride (0.95 g, 7.5 mmol) was added dropwise over 10 
min to a solution of 5-methoxyindole (1.00 g, 6.8 mmol) in ether (15 mL) at 0 ºC, 
whereupon a red precipitate immediately crashed out of solution and the resulting 
suspension was stirred for 1 h at room temperature. The precipitate was collected via 
vacuum filtration, and dried in vacuo to give 1.21 g (75%) of 5-methoxyindole-3-glyoxal 
chloride as a red powder. A slurry of 5-methoxyindole-3-glyoxal chloride (1.21 g, 5.1 
mmol) in CH2Cl2 (10 mL) was added dropwise over 10 min to a solution of 4.18 (1.02 g, 
5.1 mmol) and triethylamine (1.29 g, 12.8 mmol) in CH2Cl2 (50 mL) at 0 ºC, and the 
reaction was stirred for 2 h at room temperature. Saturated aqueous NaHCO3 (50 mL) 
was added, the two phases were separated, and the aqueous phase extracted with CH2Cl2 
(3 x 100 mL). The combined organic fractions were washed with water (100 mL), brine 
(100 mL), dried (Na2SO4), filtered, and concentrated in vacuo to give 1.59 g (98%) of 
4.68 as a light pale yellow solid of (>95% purity, by 1H NMR): 1H NMR (400 MHz) d 
9.10 (brs, 1 H), 9.03 (d, J = 3.2 Hz, 1 H), 7.93 (d, J = 2.5 Hz, 1 H), 7.87 (t, J = 5.3 Hz, 1 
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H), 7.32 (d, J = 8.8 Hz, 1 H), 6.93 (dd, J = 8.8, 2.5 Hz, 1 H) 4.50 (t, J = 5.4 Hz, 1 H), 
3.90 (s, 3 H), 3.49 (t, J = 6.1 Hz, 2 H), 3.39 (s, 6 H), 1.92 (q, J = 5.8 Hz, 2 H); 13C NMR 
(125 MHz) d 180.6, 162.5, 156.9, 138.2, 130.4, 127.6, 114.3, 113.2, 112.4, 103.9, 103.6, 
55.8, 53.4, 35.2, 31.8; HRMS (ESI) m/z calcd for C16H20N2O5 (M+Na)+, 343.1264; 
found, 343.1264. 
 NMR Assignment. 1H NMR (400 MHz) d 9.10 (brs, 1 H, N2-H), 9.03 (d, J = 3.2 
Hz, 1 H, C1-H), 7.93 (d, J = 2.5 Hz, 1 H, C6-H), 7.87 (t, J = 5.3 Hz, 1 H, N7-H), 7.32 (d, 
J = 8.8 Hz, 1 H, C3-H), 6.93 (dd, J = 8.8, 2.5 Hz, 1 H, C4-H) 4.50 (t, J = 5.4 Hz, 1 H, 
C10-H), 3.90 (s, 3 H, C5-H), 3.49 (t, J = 6.1 Hz, 2 H, C8-H), 3.39 (s, 6 H, C11-H), 1.92 
(q, J = 5.8 Hz, 2 H, C9-H). 
 
 
3,3-Dimethoxy-N-(2-(5-Methoxy-1H-indol-3-yl)ethyl)propan-1-amine (4.69).  
ARMVII110. A solution of 4.68 (200 mg, 0.62 mmol) in THF (5 mL) was added 
dropwise over 5 min to a suspension of lithium aluminum hydride (231 mg, 6.2 mmol) in 
THF (15 mL) at 0 ºC. The reaction heated to 65 ºC for 14 h. The reaction was then cooled 
to 0 ºC, and the Fieser work-up was carefully performed by successive addition of water 
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(0.25 mL), aqueous NaOH (15%, 0.25 mL), and water (1 mL). The suspension was 
warmed to room temperature and MgSO4 was added. The solids were removed by 
vacuum filtration through a fritted funnel and washed with copious amounts of CH2Cl2. 
The filtrate was concentrated in vacuo to give crude 4.69 as an opaque viscous oil. The 
crude material was purified via acid/base extraction. The crude oil was taken up into 
aqueous HCl (0.2 M, 100 mL) and washed with ether (2 x 75 mL). The aqueous fraction 
was basified to pH 12 - 14 by dropwise addition of aqueous NaOH (40% w/v). The basic 
solution was extracted with CH2Cl2 (4 x 100 mL). The combined organic fractions were 
washed with saturated aqueous NaHCO3 (200 mL), water (200 mL), brine (200 mL), 
dried (Na2SO4), filtered, and concentrated in vacuo to give 164 mg (90%) of 4.69 as an 
oil (>95% purity, by 1H NMR): 1H NMR (400 MHz) d 8.58 (brs, 1 H), 7.23 (dd, J = 8.0, 
0.5 Hz, 1 H), 7.05 (d, J = 2.4 Hz, 1 H), 6.99 (d, J = 2.4 Hz, 1 H), 6.83 (dd, J = 8.0, 2.4 
Hz, 1 H), 4.38 (t, J = 5.6 Hz, 1 H), 3.85 (s, 3 H), 3.24 (s, 6 H), 2.95 (app s, 4 H), 2.72 (t, J 
= 7.2 Hz, 2 H), 1.80 (td, J = 7.2, 5.6 Hz, 2 H); 13C NMR (100 MHz) d 153.8, 131.6, 
127.7, 123.0, 113.0, 112.1, 111.9, 103.6, 100.6, 55.9, 53.0, 49.8, 45.2, 32.5, 25.4; HRMS 
(ESI) m/z calcd for C16H24N2O3 (M+1)+, 293.1860; found, 293.1870. 
 NMR Assignment. 1H NMR (400 MHz) d 8.58 (brs, 1 H, N2-H), 7.23 (dd, J = 8.0, 
0.5 Hz, 1 H, C3-H), 7.05 (d, J = 2.4 Hz, 1 H, C1-H), 6.99 (d, J = 2.4 Hz, 1 H, C6-H), 
6.83 (dd, J = 8.0, 2.4 Hz, 1 H, C4-H), 4.38 (t, J = 5.6 Hz, 1 H, C12-H), 3.85 (s, 3 H, C5-
H), 3.24 (s, 6 H, C13-H), 2.95 (app s, 4 H, C7-H and C8-H), 2.72 (t, J = 7.2 Hz, 2 H, 
C10-H), 1.80 (td, J = 7.2, 5.6 Hz, 2 H, C11-H). 
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 (E)-N-(3,3-Dimethoxypropyl)-N-(2-(5-methoxy-1H-indol-3-yl)ethyl)but-2-
enamide (4.70). ARMVII109. Crotonoyl chloride (0.53 g, 5.1 mmol) was added 
dropwise over 5 min to a solution of 4.69 (1.24 g, 4.2 mmol) and Hünig’s base (1.32 g, 
10.8 mmol) in CH2Cl2 (42 mL) at -78 ºC. The reaction was stirred for 2 h at -78 ºC. 
Saturated aqueous NaHCO3 (40 mL) was added and the mixture was stirred for 20 min at 
room temperature. The phases were separated, and the aqueous phase was extracted with 
CH2Cl2 (3 x 40 mL). The combined organic fractions were washed with saturated 
aqueous NH4Cl (100 mL), water (100 mL), brine (100 mL), dried (Na2SO4), filtered, and 
concentrated in vacuo to give crude 4.70 as an opaque oil. The crude material was 
purified via silica gel flash column chromatography eluting with hexanes : ethyl acetate 
(1 : 1 → 1 : 2 along a gradient) to give 1.08 g (71%) of 4.70 as an oil: 1H NMR (400 
MHz) (1:1 mixture of rotamers)  d 8.78 (brs, 0.5 H), 8.65 (brs, 0.5 H), 7.21 (app t, J = 8.9 
Hz, 1H), 7.11 (d, J = 2.2 Hz, 0.5 H), 7.05 - 6.74 (comp, 3.5 H), 6.30 (dd, J = 14.9, 1.6 Hz, 
0.5 H), 6.02 (dd, J = 14.9, 1.6 Hz, 0.5 H), 4.39 (t, J = 5.6 Hz, 0.5 H), 4.31 (t, J = 5.6 Hz, 
0.5 H), 3.87 (s, 1.5 H), 3.84 (s, 1.5 H), 3.66 (t, J = 7.1 Hz, 1 H), 3.61 (t, J = 7.1 Hz, 1 H), 
3.44 (t, J = 7.3 Hz, 1 H), 3.35 (t, J = 7.3 Hz, 1 H), 3.30 (s, 3 H), 3.28 (s, 3 H), 3.01 (t, J = 
7.1 Hz, 1 H), 2.96 (t, J = 7.1 Hz, 1 H) 1.94 - 1.79 (comp, 3.5 H), 1.66 (dd, J = 6.8, 1.4 
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Hz, 1.5 H); 13C NMR (100 MHz) (1:1 mixture of rotamers)  d 166.7, 166.5, 154.0, 153.8, 
141.9, 141.0, 131.6, 131.5, 127.8, 127.5, 123.3, 122.9, 121.8, 121.7, 112.7, 112.2, 112.1, 
112.0, 111.4, 102.9, 102.1, 100.5, 100.1, 55.9, 55.9, 53.1, 53.0, 48.6, 47.7, 44.2, 42.9, 
32.5, 30.9, 25.4, 23.7, 18.3, 18.0; HRMS (ESI) m/z calcd for C20H28N2O4 (M+Na)+, 
383.1941; found, 383.1943. 
 NMR Assignment. 1H NMR (400 MHz) (1:1 mixture of rotamers) d 8.78 (brs, 0.5 
H, N2-H), 8.65 (brs, 0.5 H, N2-H), 7.21 (app t, J = 8.9 Hz, 1H, C3-H), 7.11 (d, J = 2.2 
Hz, 0.5 H, C6-H), 7.05 - 6.74 (comp, 3.5 H, C10-H, C6-H, and C4-H), 6.30 (dd, J = 14.9, 
1.6 Hz, 0.5 H, C9-H), 6.02 (dd, J = 14.9, 1.6 Hz, 0.5 H, C9-H), 4.39 (t, J = 5.6 Hz, 0.5 H, 
C14-H), 4.31 (t, J = 5.6 Hz, 0.5 H, C14-H), 3.87 (s, 1.5 H, C5-H), 3.84 (s, 1.5 H, C5-H), 
3.66 (t, J = 7.1 Hz, 1 H, C8-H), 3.61 (t, J = 7.1 Hz, 1 H, C8-H), 3.44 (t, J = 7.3 Hz, 1 H, 
C16-H), 3.35 (t, J = 7.3 Hz, 1 H, C16-H), 3.30 (s, 3 H, C15-H), 3.28 (s, 3 H, C15-H), 
3.01 (t, J = 7.1 Hz, 1 H, C7-H), 2.96 (t, J = 7.1 Hz, 1 H, C7-H) 1.94 - 1.79 (comp, 3.5 H, 
C13-H and C11-H), 1.66 (dd, J = 6.8, 1.4 Hz, 1.5 H, C11-H). 
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 (3R,3aR,7aS)-5-(2-(5-Methoxy-1H-indol-3-yl)ethyl)-1,3-
dimethylhexahydroisoxazolo[4,3-c]pyridin-4(1H)-one (4.71). ARMVII113-
ARMVII114. A solution of 4.70 (250 mg, 0.69 mmol) and TFA (5 drops) in a mixture of 
TFE/water (3 : 1, 12 mL) was stirred for 1 h at room temperature. The reaction was 
poured into saturated aqueous NaHCO3 (30 mL), and extracted with CH2Cl2 (3 x 50 mL). 
The combined organic fractions were washed with water (50 mL), dried (Na2SO4), 
filtered, and concentrated in vacuo. The resulting residue was dissolved in toluene (10 
mL), followed by the addition of N-methylhydroxylamine hydrochloride (86 mg, 1.04 
mmol) and triethylamine (175 mg, 1.73 mmol). The reaction was heated under reflux for 
2 h, whereupon the mixture was cooled to room temperature, and partitioned between 
saturated aqueous NaHCO3 (50 mL), ethyl acetate (50 mL) and methanol (2 mL). The 
phases were separated, and the aqueous phase was extracted with ethyl acetate (3 x 50 
mL). The combined organic fractions were washed with water (100 mL), brine (100 mL), 
dried (Na2SO4), filtered, and concentrated in vacuo to give 202 mg (85%) of 4.71 as a 
viscous oil (>95% purity, by 1H NMR): 1H NMR (400 MHz) d 8.11 (brs, 1 H), 7.25 (d, J 
= 8.8 Hz, 1 H), 7.07 (d, J = 2.4 Hz, 1 H), 7.01 (d, J = 2.1 Hz, 1 H), 6.85 (dd, J = 8.8, 2.4 
Hz, 1 H), 3.92 - 3.87 (comp, 4 H), 3.76 (dt, J = 13.3, 7.7 Hz, 1 H), 3.65 (dt, J = 13.3, 7.0 
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Hz, 1 H), 3.56 (td, J = 11.8, 3.0 Hz, 1 H), 3.01 - 2.95 (comp, 3 H), 2.87 - 2.79 (comp, 2 
H), 2.66 (s, 3 H), 1.79 (tt, J = 11.2, 4.2 Hz, 1 H), 1.61 (dq, J = 11.2, 3.4 Hz, 1 H), 1.46 (d, 
J = 6.1 Hz, 3 H); 13C NMR (100 MHz) d 169.1, 154.0, 131.6, 127.8, 123.0, 112.5, 
112.13, 112.06, 100.7, 77.5, 66.2, 56.1, 55.4, 48.5, 44.1, 43.3, 25.1, 23.5, 19.4; HRMS 
(ESI) m/z calcd for C19H25N3O3 (M+Na)+, 366.1788; found, 266.1794. 
 NMR Assignment. 1H NMR (400 MHz) d 8.11 (brs, 1 H, N2-H), 7.25 (d, J = 8.8 
Hz, 1 H, C3-H), 7.07 (d, J = 2.4 Hz, 1 H, C6-H), 7.01 (d, J = 2.1 Hz, 1 H, C1-H), 6.85 
(dd, J = 8.8, 2.4 Hz, 1 H, C4-H), 3.92 - 3.87 (comp, 4 H, C13-H and C5-H), 3.76 (dt, J = 
13.3, 7.7 Hz, 1 H, C8-H), 3.65 (dt, J = 13.3, 7.0 Hz, 1 H, C8-H), 3.56 (td, J = 11.8, 3.0 
Hz, 1 H, C11-H), 3.01 - 2.95 (comp, 3 H, C12-H and C9-H), 2.87 - 2.79 (comp, 2 H, C7-
H), 2.66 (s, 3 H, C15-H), 1.79 (tt, J = 11.2, 4.2 Hz, 1 H, C10-H), 1.61 (dq, J = 11.2, 3.4 
Hz, 1 H, C10-H), 1.46 (d, J = 6.1 Hz, 3 H, C14-H) 
 
 
 (3R,4S)-3-((R)-1-Hydroxyethyl)-1-(2-(5-methoxy-1H-indol-3-yl)ethyl)-4-
(methylamino)piperidin-2-one (4.72). ARMVII129. Zinc (powder, 588 mg, 9.00 
mmol) was added in three portions over 1.5 h to a solution of 4.71 (100 mg, 0.30 mmol) 
in acetic acid (aq 80%, 20 mL) at 60 ºC. The reaction was stirred for 1 h at 60 ºC. The 
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suspension was cooled to room temperature, excess zinc was filtered and washed with 
ethyl acetate. To the filtrate was added ethyl acetate (100 mL), upon which zinc acetate 
immediately precipitated out of solution as a fluffy white solid. The zinc acetate was 
filtered and washed with ethyl acetate. The solvent was removed in vacuo to give crude 
4.72. the crude material was taken up in aqueous HCl (1 M, 30 mL), and washed with 
ether (2 x 30 mL). The aqueous fraction was basified to pH ~14 with aqueous NaOH 
(40% w/v), and extracted with CH2Cl2 (4 x 50 mL). The organic fractions were washed 
with saturated aqueous NaHCO3 (100 mL), water (100 mL), and brine (1 x 100 mL). The 
organic fractions were dried (Na2SO4), filtered, and concentrated in vacuo to give 86 mg 
(85%) of 4.72 as an oil (>95% purity, by 1H NMR): 1H NMR (400 MHz, CD3OD) d 7.22 
(d, J = 8.8 Hz, 1 H), 7.08 (d, J = 2.3 Hz, 1 H), 7.04 (s, 1 H), 6.75 (dd, J = 8.8, 2.3 Hz, 1 
H), 4.40 (p, J = 6.2 Hz, 1 H), 3.83 (s, 3 H), 3.71 - 3.65 (m, 1 H), 3.52 (dt, J = 13.2, 7.2 
Hz, 1 H), 3.14 - 2.92 (comp, 5 H), 2.38 (dd, J = 5.8, 4.1 Hz, 1 H), 2.33 (s, 3 H), 1.97 (dq, 
J = 13.7, 6.1 Hz, 1 H), 1.70 (dtd, J = 13.7, 6.9, 3.5 Hz, 1 H), 1.23 (d, J = 6.4 Hz, 3 H); 13C 
NMR (100 MHz, CD3OD) d 169.7, 135.6, 131.9, 127.8, 123.0, 111.6, 111.4, 111.2, 99.9, 
66.1, 54.9, 54.6, 50.0, 48.2, 44.3, 32.2, 23.6, 22.3, 21.0; HRMS (ESI) m/z calcd for 
C19H27N3O3 (M+H)+, 346.2125; found, 346.2124. 
 NMR Assignment. 1H NMR (400 MHz, CD3OD) d 7.22 (d, J = 8.8 Hz, 1 H, C2-
H), 7.08 (d, J = 2.3 Hz, 1 H, C5-H), 7.04 (s, 1 H, C1-H), 6.75 (dd, J = 8.8, 2.3 Hz, 1 H, 
C3-H), 4.40 (p, J = 6.2 Hz, 1 H, C12-H), 3.83 (s, 3 H, C4-H), 3.71 -3.65 (m, 1 H, C7-H), 
3.52 (dt, J = 13.2, 7.2 Hz, 1 H, C7-H), 3.14 - 2.92 (comp, 5 H, C10-H, C8-H, and C6-H), 
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2.38 (dd, J = 5.8, 4.1 Hz, 1 H, C11-H), 2.33 (s, 3 H, C14-H), 1.97 (dq, J = 13.7, 6.1 Hz, 1 
H, C9-H), 1.70 (dtd, J = 13.7, 6.9, 3.5 Hz, 1 H, C9-H), 1.23 (d, J = 6.4 Hz, 3 H, C13-H). 
 
 
(3R,4S)-4-((3,5-Dichlorobenzyl)(methyl)amino)-3-((R)-1-hydroxyethyl)-1-(2-
(5-methoxy-1H-indol-3-yl)ethyl)piperidin-2-one (4.73). ARMV252. Prepared 
according to the representative procedure for compound 4.12; scaled to 4.72 (75 mg, 0.22 
mmol). The crude material was purified via silica gel flash column chromatography 
eluting with hexanes : ethyl acetate (3 : 1 → 1 : 3 along a gradient) to give 97 mg (89%) 
of 4.73 as a white solid: 1H NMR (600 MHz, CD3OD) d 7.34 (t, J = 1.9 Hz, 1 H), 7.22 - 
7.21 (comp, 3 H), 7.07 (d, J = 2.1 Hz, 1 H), 7.04 (s, 1 H), 6.76 (ddd, J = 8.7, 2.4, 0.3 Hz, 
1 H), 4.22 (dq, J = 8.7, 6.1, 1 H), 3.82 (s, 3 H), 3.76 (dt, J = 13.3, 7.6 Hz, 1 H), 3.55 (ddd, 
J = 13.4, 7.7, 5.8 Hz, 1 H), 3.50 (d, J = 13.4 Hz, 1 H), 3.41 (d, J = 13.4 Hz, 1 H), 3.36 - 
3.32 (m, 1 H), 3.17 - 3.08 (comp, 2 H), 3.02 (p, J = 7.2 Hz, 1 H), 2.93 (ddd, J = 13.7, 7.8, 
5.9 Hz, 1 H), 2.58 (dd, J = 8.4, 5.7 Hz, 1 H), 2.07 (s, 3 H), 1.99 (dt, J = 12.3, 5.7 Hz, 1 
H), 1.96 - 1.91 (m, 1 H), 1.21 (d, J = 6.1 Hz, 3 H); 13C NMR (150 MHz, CD3OD) d 
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172.0, 155.0, 143.7, 136.2, 133.4, 129.2, 128.5, 128.5, 124.5, 113.0, 112.6, 112.6, 101.5, 
67.7, 61.2, 58.4, 56.4, 51.2, 48.8, 46.6, 38.5, 24.0, 22.8, 22.5; HRMS (ESI) m/z calcd for 
C26H31Cl2N3O3 (M+H)+, 504.1815 and 506.1792; found, 504.1815 and 506.1795. 
NMR Assignment. 1H NMR (600 MHz, CD3OD) d 7.34 (t, J = 1.9 Hz, 1 H, C17-
H), 7.22 - 7.21 (comp, 3 H, C16-H and C2-H), 7.07 (d, J = 2.1 Hz, 1 H, C5-H), 7.04 (s, 1 
H, C1-H), 6.76 (ddd, J = 8.7, 2.4, 0.3 Hz, 1 H, C3-H), 4.22 (dq, J = 8.7, 6.1, 1 H, C12-H), 
3.82 (s, 3 H, C4-H), 3.76 (dt, J = 13.3, 7.6 Hz, 1 H, C7-H), 3.55 (ddd, J = 13.4, 7.7, 5.8 
Hz, 1 H, C7-H), 3.50 (d, J = 13.4 Hz, 1 H, C15-H), 3.41 (d, J = 13.4 Hz, 1 H, C15-H), 
3.36 - 3.32 (m, 1 H, C8-H), 3.17 - 3.08 (comp, 2 H, C10-H and C8-H), 3.02 (dt, J = 14.5, 
7.2 Hz, 1 H, C6-H), 2.93 (ddd, J = 13.7, 7.8, 5.9 Hz, 1 H, C6-H), 2.58 (dd, J = 8.4, 5.7 
Hz, 1 H, C11-H), 2.07 (s, 3 H, C14-H), 1.99 (dt, J = 12.3, 5.7 Hz, 1 H, C9-H), 1.96 - 1.91 
(m, 1 H, C9-H), 1.21 (d, J = 6.1 Hz, 3 H, C13-H). 
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2-(5-(Benzyloxy)-1H-indol-3-yl)-N-(3,3-dimethoxypropyl)-2-oxoacetamide 
(4.75). ARMV281/ARMV237. Oxalyl chloride (1.25 g, 9.9 mmol) was added dropwise 
over 10 min to a solution of 5-benzyloxyindole (2.0 g, 9.0 mmol) in ether (18 mL) at 0 
ºC. The solution was stirred for 2 h at 0 ºC, whereupon a red precipitate was isolated via 
vacuum filtration, and dried in vacuo to give 2.37 g (84%) of 5-benzyloxyindole-3-
glyoxal chloride. A suspension of 5-benzyloxyindole-3-glyoxal chloride (0.97 g, 3.1 
mmol) in CH2Cl2 (10 mL) was added dropwise over 10 min to a solution of 4.18 (0.62 g, 
3.1 mmol) and triethylamine (0.78 g, 7.8 mmol) in CH2Cl2 (30 mL) at 0 ºC. The reaction 
was stirred for 2 h at 0 ºC. The reaction was poured into saturated aqueous NaHCO3 (40 
mL), the phases were separated, and the aqueous phase was extracted with CH2Cl2 (3 x 
40 mL). The combined organic fractions were washed with water (100 mL) and brine 
(100 mL), dried (Na2SO4), filtered, and concentrated in vacuo to give 1.16 (95%) of 4.75 
as a yellow solid (>95% purity, by 1H NMR): 1H NMR (400 MHz) d 9.16 (brs, 1 H), 9.03 
(d, J = 2.8 Hz, 1 H), 8.05 (d, J = 2.5 Hz, 1 H), 7.88 (t, J = 5.6 Hz, 1 H), 7.50 (d, J = 7.1 
Hz, 2 H), 7.40 (t, J = 7.1 Hz, 2 H), 7.35 - 7.32 (comp, 2 H), 7.02 (dd, J = 8.7, 2.5 Hz, 1 
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H), 5.16 (s, 2 H), 4.51 (t, J = 5.4 Hz, 1 H), 3.59 (q, J = 6.7 Hz, 2 H), 3.39 (s, 6 H), 1.93 
(q, J = 6.7 Hz, 2 H); 13C NMR (100 MHz, CD3CN) d 181.5, 162.9, 155.9, 139.2, 138.0, 
131.3, 128.7, 128.1, 127.9, 126.3, 114.4, 113.4, 112.7, 105.2, 103.7, 70.3, 53.0, 35.1, 
32.3; HRMS (ESI) m/z calcd for C22H24N2O5 (M+Na)+, 419.1577; found, 419.1575. 
NMR Assignment. 1H NMR (400 MHz) d 9.16 (brs, 1 H, N2-H), 9.03 (d, J = 2.8 
Hz, 1 H, C1-H), 8.05 (d, J = 2.5 Hz, 1 H, C9-H), 7.88 (t, J = 5.6 Hz, 1 H, N10-H), 7.50 
(d, J = 7.1 Hz, 2 H, C6-H), 7.40 (t, J = 7.1 Hz, 2 H, C7-H), 7.35 - 7.32 (comp, 2 H, C8-H 
and C3-H), 7.02 (dd, J = 8.7, 2.5 Hz, 1 H, C4-H), 5.16 (s, 2 H, C5-H), 4.51 (t, J = 5.4 Hz, 
1 H, C13-H), 3.59 (q, J = 6.7 Hz, 2 H, C11-H), 3.39 (s, 6 H, C14-H), 1.93 (q, J = 6.7 Hz, 
2 H, C12-H). 
 
 
N-(2-(5-(Benzyloxy)-1H-indol-3-yl)ethyl)-3,3-dimethoxypropan-1-amine 
(4.76). ARMV256. A solution of 4.75 (1.16 g, 2.93 mmol) in THF (15 mL) was added 
dropwise over 20 min to a suspension of lithium aluminum hydride (1.10 g, 29.3 mmol) 
in THF (70 mL) at 0 ºC. The reaction heated under reflux for 14 h, whereupon the 
reaction was cooled to 0 ºC, and the Fieser work-up was carefully performed by 
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successive addition of water (1.1 mL), aqueous NaOH (15%, 1.1 mL), and water (3.3 
mL). The suspension was warmed to room temperature and MgSO4 was added. The 
solids were removed by vacuum filtered through a fritted funnel, and washed with 
copious amounts of CH2Cl2. The filtrate was concentrated in vacuo to give crude 4.76 as 
an opaque viscous oil. The crude oil was taken up into aqueous HCl (0.2 M, 200 mL) and 
washed with ether (2 x 150 mL). The aqueous fraction was basified to pH 12-14 by 
addition of solid NaOH, as judged by pH paper. The basic solution was extracted with 
CH2Cl2 (4 x 200 mL). The combined organic fractions were washed with saturated 
aqueous NaHCO3 (400 mL), water (400 mL), brine (400 mL), dried (Na2SO4), filtered, 
and concentrated in vacuo to give 1.02 g (94%) of 4.76 as an oil (>95% purity, by 1H 
NMR): 1H NMR (400 MHz) d 8.41 (brs, 1 H), 7.49 (d, J = 7.2 Hz, 2 H), 7.34 (td, J = 7.2, 
1.6 Hz, 2 H), 7.33 (tt, J = 7.2, 1.6 Hz, 1 H), 7.23 (d, J = 8.8 Hz, 1 H), 7.16 (d, J = 2.4 Hz, 
1 H), 6.97 (d, J = 2.0 Hz, 1 H), 6.94 (dd, J = 8.8, 2.4 Hz, 1 H), 5.11 (s, 2 H), 4.41 (t, J = 
5.6 Hz, 1 H), 3.28 (s, 6 H), 2.94 (app s, 4 H), 2.72 (t, J = 7.2 Hz, 2 H), 1.82 (td, J = 7.2, 
5.6 Hz, 2 H); 13C NMR (100 MHz) d 153.0, 137.7, 131.8, 128.5, 127.82, 127.77 127.6, 
123.0, 113.5, 112.8, 111.9, 103.6, 102.5, 71.0, 52.9, 49.9, 45.3, 32.8, 25.7; HRMS (CI) 
m/z calcd for C22H28N2O3 (M+H)+, 369.2178; found, 369.2181. 
 NMR Assignment. 1H NMR (400 MHz) d 8.41 (brs, 1 H, NH), 7.49 (d, J = 7.2 
Hz, 2 H, C5-H), 7.34 (td, J = 7.2, 1.6 Hz, 2 H, C6-H), 7.33 (tt, J = 7.2, 1.6 Hz, 1 H, C7-
H), 7.23 (d, J = 8.8 Hz, 1 H, C2-H), 7.16 (d, J = 2.4 Hz, 1 H, C8-H), 6.97 (d, J = 2.0 Hz, 
1 H, C1-H), 6.94 (dd, J = 8.8, 2.4 Hz, 1 H, C3-H), 5.11 (s, 2 H, C4-H), 4.41 (t, J = 5.6 
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Hz, 1 H, C13-H), 3.28 (s, 6 H, C14-H), 2.94 (app s, 4 H, C9-H and C10-H), 2.72 (t, J = 
7.2 Hz, 2 H, C11-H), 1.82 (td, J = 7.2, 5.6 Hz, 2 H, C12-H). 
 
 
(E)-N-(2-(5-(Benzyloxy)-1H-indol-3-yl)ethyl)-N-(3,3-dimethoxypropyl)but-2-
enamide (4.77). ARMV259. Crotonoyl chloride (0.35 g, 3.3 mmol) was added dropwise 
over 5 min to a solution of 4.76 (1.02 g, 2.8 mmol) and Hünig’s base (0.85 g, 6.6 mmol) 
in CH2Cl2 (30 mL) at -78 ºC. The reaction was stirred for 2 h at –78 ºC, whereupon 
saturated aqueous NaHCO3 (30 mL) was added, and the resulting solution was stirred for 
20 min at room temperature. The phases were separated, and the aqueous phase was 
extracted with CH2Cl2 (3 x 30 mL). The combined organic fractions were washed with, 
water (50 mL), brine (50 mL), dried (Na2SO4), filtered, and concentrated in vacuo to give 
crude 4.77 as an opaque oil. The crude material was purified via silica gel flash column 
chromatography eluting with hexanes : ethyl acetate (2 : 1 → 1 : 1 along a gradient) to 
give 0.73 g (61%) of 4.77 as an oil: 1H NMR (400 MHz) (1:1 mixture of rotamers)  d 
8.65 (brs, 0.5 H), 8.53 (brs, 0.5), 7.50 - 7.48 (comp, 2 H), 7.41 - 7.37 (comp, 2 H), 7.34 - 
7.30 (m ,1 H), 7.26 - 7.23 (comp, 1.5 H), 7.11 (d, J = 2.2 Hz, 0.5), 7.02 (dq, J = 13.8, 6.9 
Hz, 0.5 H), 6.96 - 6.88 (comp, 2 H), 6.78 (dq, J = 13.8, 6.9 Hz, 0.5 H), 6.32 (dd, J = 14.9, 
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1.6 Hz, 0.5 H), 5.98 (dd, J = 14.9, 1.6 Hz, 0.5 H), 5.13 (s, 1 H), 5.10 (s, 1 H), 4.41 (t, J = 
5.6 Hz, 0.5 H), 4.33 (t, J = 5.6 Hz, 0.5 H), 3.67 (t, J = 7.3 Hz, 1 H), 3.60 (t, J = 7.3 Hz, 1 
H), 3.45 (t, J = 7.5 Hz, 1 H), 3.37 - 3.30 (comp, 7 H), 3.03 (t, J = 7.3 Hz, 1 H), 2.96 (t, J 
= 7.3 Hz, 1 H), 1.96 - 1.90 (comp, 2 H), 1.85 - 1.80 (comp, 1.5 H), 1.66 (dd, J = 6.8, 1.5 
Hz, 1.5); 13C NMR (100 MHz) (1:1 mixture of rotamers) d 166.7, 166.6, 153.1, 153.1, 
141.9, 141.0, 137.7, 137.6, 131.8, 131.7, 128.5, 128.5, 127.8, 127.7, 127.6, 127.5, 123.4, 
123.0, 121.8, 121.8, 112.9, 112.8, 112.7, 112.0, 111.4, 102.9, 102.1, 102.0, 71.1, 70.9, 
53.2, 53.0, 48.6, 47.8, 44.2, 42.9, 32.5, 31.0, 25.4, 23.7, 18.3, 18.1; HRMS (ESI) m/z 
calcd for C26H32N2O4 (M+Na)+, 459.2254; found, 459.2253. 
NMR Assignment. 1H NMR (400 MHz) (1:1 mixture of rotamers) d 8.65 (brs, 
0.5 H, N2-H), 8.53 (brs, 0.5, N2-H), 7.50 -7.48 (comp, 2 H, C6-H), 7.41 - 7.37 (comp, 2 
H, C7-H), 7.34 - 7.30 (m, 1 H, C8-H), 7.26 - 7.23 (comp, 1.5 H, C9-H and C3-H), 7.11 
(d, J = 2.2 Hz, 0.5, C9-H), 7.02 (dq, J = 13.8, 6.9 Hz, 0.5 H, C13-H), 6.96 - 6.88 (comp, 2 
H, C4-H and C1-H), 6.78 (dq, J = 13.8, 6.9 Hz, 0.5 H, C13-H), 6.32 (dd, J = 14.9, 1.6 Hz, 
0.5 H, C12-H), 5.98 (dd, J =14.9, 1.6 Hz, 0.5 H, C12-H), 5.13 (s, 1 H, C5-H), 5.10 (s, 1 
H, C5-H), 4.41 (t, J = 5.6 Hz, 0.5 H, C17-H), 4.33 (t, J = 5.6 Hz, 0.5 H, C17-H), 3.67 (t, J 
= 7.3 Hz, 1 H, C11-H), 3.60 (t, J = 7.3 Hz, 1 H, C11-H), 3.45 (t, J = 7.5 Hz, 1 H, C15-H), 
3.37 - 3.30 (comp, 7 H, C18-H and C15-H), 3.03 (t, J = 7.3 Hz, 1 H, C10-H), 2.96 (t, J = 
7.3 Hz, 1 H, C10-H), 1.96 - 1.90 (comp, 2 H, C16-H and C14-H), 1.85 - 1.80 (m, 1.5 H, 
C16-H), 1.66 (dd, J = 6.8, 1.5 Hz, 1.5 H, C14-H). 
 
 
 
 
326 
 
(3R,3aR,7aS)-5-(2-(5-(Benzyloxy)-1H-indol-3-yl)ethyl)-1,3-
dimethylhexahydroisoxazolo[4,3-c]pyridin-4(1H)-one (4.78). ARMV296-ARMV297. 
A solution of 4.77 (250 mg, 0.57 mmol) and TFA (65 mg, 0.57 mmol) in TFE/water (3 : 
1, 12 mL) was stirred for 1 h at room temperature. The reaction was poured into saturated 
aqueous NaHCO3 (30 mL), and extracted with CH2Cl2 (3 x 50 mL). The combined 
organic fractions were washed with water (50 mL), dried (Na2SO4), filtered, and 
concentrated in vacuo. The resulting residue was dissolved in toluene (8 mL), followed 
by addition of N-methylhydroxylamine hydrochloride (71 mg, 0.86 mmol) and 
triethylamine (127 mg, 1.30 mmol). The reaction was heated under reflux for 2 h, then 
cooled to room temperature, and partitioned between saturated aqueous NaHCO3 (50 
mL), ethyl acetate (50 mL) and methanol (2 mL). The phases were separated, and the 
aqueous phase was extracted with ethyl acetate (3 x 50 mL). The combined organic 
fractions were washed with water (100 mL), brine (100 mL), dried (Na2SO4), filtered, 
and concentrated in vacuo to give crude 4.78. The crude material was purified via silica 
gel flash column chromatography eluting with hexanes : ethyl acetate (1 : 1 → 0 : 1 along 
a gradient) to give 163 mg (68%, two-steps) of 4.78 as a viscous oil: 1H NMR (400 MHz) 
d 8.52 (brs, 1 H), 7.50 - 7.48 (comp, 2 H), 7.41 - 7.35 (comp, 2 H), 7.32 (tt, J = 7.2, 1.4 
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Hz, 1 H), 7.22 (d, J = 8.8 Hz, 1 H), 7.16 (d, J = 2.3 Hz, 1 H), 6.95 (s, 1 H), 5.11 (s, 2 H), 
3.93 (p, J = 6.2 Hz, 1 H), 3.74 (dt, J = 13.3, 7.5 Hz, 1 H), 3.61 (dt, J = 13.3, 7.2 Hz, 1 H), 
3.52 (td, J = 11.6, 2.5 Hz, 1 H), 2.99 - 2.92 (comp, 3 H), 2.83 - 2.79 (comp, 2 H), 2.66 (s, 
3 H), 1.76 (tt, J = 11.1, 4.0 Hz, 1 H), 1.58 (dq, J = 11.1, 2.9 Hz, 1 H), 1.47 (d, J = 6.0 Hz, 
3 H); 13C NMR (100 MHz) d 169.0, 153.0, 137.7, 131.7, 128.5, 127.8, 127.7, 127.7, 
123.1, 112.7, 112.4, 112.0, 102.3, 77.5, 71.0, 66.1, 55.3, 48.4, 44.0, 43.2, 25.1, 23.5, 
19.3; HRMS (ESI) m/z calcd for C25H29N3O3 (M+Na)+, 442.2101; found, 442.2106. 
NMR Assignment. 1H NMR (400 MHz) d 8.52 (brs, 1 H, N2-H), 7.50 - 7.48 
(comp, 2 H, C6-H), 7.41 - 7.35 (comp, 2 H, C7-H), 7.32 (tt, J = 7.2, 1.4 Hz, 1 H, C8-H), 
7.22 (d, J = 8.8 Hz, 1 H, C3-H), 7.16 (d, J = 2.3 Hz, 1 H, C9-H), 6.95 (s, 1 H, C1-H), 
5.11 (s, 2 H, C5-H), 3.93 (p, J = 6.2 Hz, 1 H, C16-H), 3.74 (dt, J = 13.3, 7.5 Hz, 1 H, 
C11-H), 3.61 (dt, J = 13.3, 7.2 Hz, 1 H, C11-H), 3.52 (td, J = 11.6, 2.5 Hz, 1 H, C14-H), 
2.99 - 2.92 (comp, 3 H, C12-H and C10-H), 2.83 - 2.79 (comp, 2 H, C15-H and C10-H), 
2.66 (s, 3 H, C18-H), 1.76 (tt, J = 11.1, 4.0 Hz, 1 H, C13-H), 1.58 (dq, J = 11.1, 2.9 Hz, 1 
H, C13-H), 1.47 (d, J = 6.0 Hz, 3 H, C17-H). 
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 (3R,4S)-1-(2-(5-(Benzyloxy)-1H-indol-3-yl)ethyl)-3-((R)-1-hydroxyethyl)-4-
(methylamino)piperidin-2-one (4.79). ARMV293. Zinc (dust, 586 mg, 9.0 mmol) was 
slowly added to a solution of 4.78 (126 mg, 0.30 mmol) in acetic acid (aq, 80%, 18 mL), 
and the mixture was stirred for 48 h at room temperature. Excess zinc was filtered, and 
washed with ethyl acetate. To the filtrate was added ethyl acetate (200 mL), at which 
point zinc acetate immediately precipitated out of solution as a fluffy white solid. The 
zinc acetate was removed by vacuum filtration, and the solvent was removed in vacuo. 
The resulting residue was dissolved in aqueous HCl (1 M, 30 mL), and washed with ether 
(30 mL). The aqueous fraction was basified to pH ~12-14 by addition of solid NaOH, as 
judged by pH paper. The basic solution was extracted with CH2Cl2 (3 x 50 mL), and the 
combined organic fractions were washed with brine (100 mL), dried (Na2SO4), filtered, 
and concentrated in vacuo to give crude 4.79 as an off white solid. The crude material 
was purified via silica gel flash column chromatography eluting with CH2Cl2 : methanol 
(1 : 0 → 9 : 1 along a gradient) to give 106 mg (85%) of 4.79 as an off white solid: 1H 
NMR (400 MHz, CD3OD) d 7.48 - 7.46 (comp, 2 H), 7.38 - 7.34 (comp, 2 H), 7.29 (tt, J 
= 7.4, 1.4 Hz, 1 H), 7.24 (dd, J = 8.8, 0.4 Hz, 1 H), 7.17 (d, J = 2.1 Hz, 1 H), 7.04 (s, 1 
H), 6.85 (dd, J = 8.8, 2.1 Hz, 1 H), 5.09 (s, 2 H), 4.27 (dq, J = 7.3, 6.4 Hz, 1 H), 3.62 - 
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3.52 (comp, 2 H), 3.31 - 3.26 (comp, 2 H), 3.14 - 3.06 (m, 1 H), 3.03 - 2.88 (comp, 2 H), 
2.54 (dd, J = 6.8, 3.4 Hz, 1 H), 2.50 (s, 3 H), 2.07 - 2.01 (m, 1 H), 1.91 - 1.81 (m, 1 H), 
1.24 (d, J = 6.3 Hz, 3H); 13C NMR (100 MHz, CD3OD) d 169.4, 154.0, 139.4, 133.6, 
129.4, 129.1, 128.7, 124.6, 113.4, 113.1, 112.6, 103.3, 72.1, 67.2, 56.6, 51.0, 49.3, 45.5, 
32.5, 23.6, 23.0, 23.0; HRMS (ESI) m/z calcd for C25H31N3O3 (M+H)+, 422.2438; found, 
422.2447. 
 NMR Assignment. 1H NMR (400 MHz, CD3OD) d 7.48 - 7.46 (comp, 2 H, C5-
H), 7.38 - 7.34 (comp, 2 H, C6-H), 7.29 (tt, J = 7.4, 1.4 Hz, 1 H, C7-H), 7.24 (dd, J = 8.8, 
0.4 Hz, 1 H, C2-H), 7.17 (d, J = 2.1 Hz, 1 H, C8-H), 7.04 (s, 1 H, C1-H), 6.85 (dd, J = 
8.8, 2.1 Hz, 1 H, C3-H), 5.09 (s, 2 H, C4-H), 4.27 (dq, J = 7.3, 6.4 Hz, 1 H, C15-H), 3.62 
- 3.52 (comp, 2 H, C10-H), 3.31 - 3.26 (comp, 2 H, C11-H), 3.14 - 3.06 (m, 1 H, C13-H), 
3.03 - 2.88 (comp, 2 H, C9-H), 2.54 (dd, J = 6.8, 3.4 Hz, 1 H, C14-H), 2.50 (s, 3 H, C17-
H), 2.07 - 2.01 (m, 1 H, C12-H), 1.91 - 1.81 (m, 1 H, C12-H), 1.24 (d, J = 6.3 Hz, 3H, 
C16-H). 
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 (3R,4S)-1-(2-(5-(Benzyloxy)-1H-indol-3-yl)ethyl)-4-((3,5-
dichlorobenzyl)(methyl)amino)-3-((R)-1-hydroxyethyl)piperidin-2-one (4.80). 
ARMVI98. Prepared according to representative procedure for compound 4.12; scaled to 
4.79 (100 mg, 0.24 mmol). The crude material was purified via silica gel flash column 
chromatography eluting with hexanes : ethyl acetate (2 : 1 → 0 : 1 along a gradient) to 
give 50 mg (37%) of 4.80 as a white solid: 1H NMR (600 MHz) d 8.07 (brs, 1 H), 7.47 (d, 
J = 7.5 Hz, 2 H), 7.38 - 7.35 (comp, 2 H), 7.31 - 7.28 (m, 1 H), 7.25 - 7.23 (comp, 2 H), 
7.13 (d, J = 2.4 Hz, 1 H), 7.08 (d, J = 1.9 Hz, 2 H), 6.99 (d, J = 2.3 Hz, 1 H), 6.93 (dd, J 
= 8.7, 2.3 Hz, 1 H), 5.11 (s, 2 H), 4.26 (dq, J = 8.8, 6.1 Hz, 1 H), 3.77 (dt, J = 13.4, 7.7 
Hz, 1 H), 3.49 (dq, J = 7.8, 6.1 Hz, 1 H), 3.42 (d, J = 13.3, 1 H), 3.34 (d, J = 13.3, 1 H), 
3.21 (ddd, J = 12.8, 6.7, 2.3 Hz, 1 H), 3.12 - 3.03 (comp, 2 H), 2.99 (p, J = 7.3 Hz, 1 H), 
2.91 (p, J = 7.3 Hz, 1 H) 2.65 (dd, J = 8.7, 5.8 Hz, 1 H), 2.07 (s, 3 H), 1.96 - 1.84 (comp, 
2 H), 1.31 (d, J = 6.1 Hz, 3 H); 13C NMR (150 MHz) d 169.8, 153.1, 141.2, 137.6, 135.1, 
131.6, 128.5, 127.8, 127.8, 127.7, 127.6, 127.1, 123.0, 112.7, 112.5, 111.9, 102.4, 71.0, 
66.5, 60.3, 57.6, 50.1, 47.2, 45.3, 38.6, 23.1, 22.5, 21.8; HRMS (ESI) m/z calcd for 
C32H35Cl2N3O3 (M+Na)+, 602.1948 and 604.1927; found, 602.1950 and 604.1931. 
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 NMR Assignment. 1H NMR (600 MHz) d 8.07 (brs, 1 H, N2-H), 7.47 (d, J = 7.5 
Hz, 2 H, C6-H), 7.38 - 7.35 (comp, 2 H, C7-H), 7.31 - 7.28 (m, 1 H, C8-H), 7.25 - 7.23 
(m, 2 H, C3-H), 7.13 (d, J = 2.4 Hz, 1 H, C21-H), 7.08 (d, J = 1.9 Hz, 2 H, C20-H), 6.99 
(d, J = 2.3 Hz, 1 H, C9-H), 6.93 (dd, J = 8.7, 2.3 Hz, 1 H, C4-H), 5.11 (s, 2 H, C5-H), 
4.26 (dq, J = 8.8, 6.1 Hz, 1 H, C16-H), 3.77 (dt, J = 13.4, 7.7 Hz, 1 H, C11-H), 3.49 (dq, 
J = 7.8, 6.1 Hz, 1 H, C11-H), 3.42 (d, J = 13.3, 1 H, C19-H), 3.34 (d, J = 13.3, 1 H, C19-
H), 3.21 (ddd, J = 12.8, 6.7, 2.3 Hz, 1 H, C14-H), 3.12 - 3.03 (comp, 2 H, C12-H), 2.99 
(p, J = 7.3 Hz, 1 H, C20-H), 2.91 (p, J = 7.3 Hz, 1 H, C20-H) 2.65 (dd, J = 8.7, 5.8 Hz, 1 
H, C15-H), 2.07 (s, 3 H, C18-H), 1.96 - 1.84 (comp, 2 H, C13-H), 1.31 (d, J = 6.1 Hz, 3 
H, C17-H) 
 
 
 (3R,4S)-4-((3,5-Dichlorobenzyl)(methyl)amino)-1-(2-(5-hydroxy-1H-indol-3-
yl)ethyl)-3-((R)-1-hydroxyethyl)piperidin-2-one (4.81). ARMVI58/ARMVI60. A 
solution of 4.78 (150 mg, 0.36 mmol) in ethanol (2 mL) was added over 5 min to a 
degassed of ethanol (12 mL) and Pd/C (10% w/w, 150 mg) at room temperature. A 
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balloon of hydrogen gas was bubbled through the suspension, followed immediately by 
addition of TFA (3 drops), and the reaction was stirred for 5 h at 60 ºC. The suspension 
was then cooled to room temperature, and filtered through a pad of Celite washing with 
copious amounts of methanol. The solvent was removed in vacuo, followed by azeotropic 
removal of water with toluene. The crude mixture was dissolved in acetonitrile (10 mL), 
and 3,5-dichlorobenzaldehyde (189 mg, 1.1 mmol) was added in one portion. The 
reaction was held under reflux for 2 h, after which the solution was cooled to room 
temperature. NaBH3CN (68 mg, 1.1 mmol) and acetic acid (glacial, 129 µL, 2.2 mmol) 
were added, and the reaction was stirred for 14 h at room temperature. Saturated aqueous 
NaHCO3 (30 mL) was added to the mixture, followed by extraction with CH2Cl2 (3 x 30 
mL). The combined organic fractions were washed with water (30 mL), dried (Na2SO4), 
filtered, and concentrated in vacuo to give crude 4.81. The crude material was purified 
via flash column chromatography eluting with hexanes : ethyl acetate (1 : 1 → 0 : 1 along 
a gradient) to give 48 mg (28%, two-steps) of 4.81 as a white solid: 1H NMR (600 MHz, 
CD3OD) d 7.32 (t, J = 1.9 Hz, 1 H), 7.20 (d, J = 1.9 Hz, 1 H), 7.15 (dd, J = 8.6, 0.4 Hz, 1 
H), 7.00 (s, 1 H), 6.94 (d, J = 2.0 Hz, 1 H), 6.67 (dd, J = 8.6, 2.3 Hz, 1 H), 4.20 (dq, J = 
8.6, 6.1 Hz, 1 H), 3.67 (dt, J = 13.2, 7.6 Hz, 1 H), 3.52 (ddd, J = 13.3, 7.6, 5.8 Hz, 1 H), 
3.46 (d, J = 13.4 Hz, 1 H), 3.36 (d, J = 13.4 Hz, 1 H), 3.28 - 3.25 (m, 1 H), 3.09 - 3.01 
(comp, 2 H), 2.96 (p, J = 7.1 Hz, 1 H), 2.88 - 2.84 (m, 1 H), 2.57 (dd, J = 8.0, 5.2 Hz, 1 
H), 2.03 (s, 3 H), 1.94 - 1.91 (m, 1 H), 1.86 - 1.80 (m, 1 H), 1.21 (d, J = 6.1 Hz, 3 H); 13C 
NMR (150 MHz, CD3OD) d 171.9, 151.3, 143.7, 136.2, 133.0, 129.6, 128.5, 128.4, 
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124.5, 112.8, 112.5, 112.1, 103.5, 67.7, 61.2, 58.4, 51.1, 49.8, 46.6, 38.5, 24.0, 22.8, 
22.5; HRMS (ESI) m/z calcd for C25H29Cl2N3O3 (M+H)+, 512.1478 and 514.1455; found, 
512.1483 and 514.1459. 
 NMR Assignment. 1H NMR (600 MHz, CD3OD) d 7.32 (t, J = 1.9 Hz, 1 H, C16-
H), 7.20 (d, J = 1.9 Hz, 1 H, C15-H), 7.15 (dd, J = 8.6, 0.4 Hz, 1 H, C2-H), 7.00 (s, 1 H, 
C1-H), 6.94 (d, J = 2.0 Hz, 1 H, C4-H), 6.67 (dd, J = 8.6, 2.3 Hz, 1 H, C3-H), 4.20 (dq, J 
= 8.6, 6.1 Hz, 1 H, C11-H), 3.67 (dt, J = 13.2, 7.6 Hz, 1 H, C6-H), 3.52 (ddd, J = 13.3, 
7.6, 5.8 Hz, 1 H, C6-H), 3.46 (d, J = 13.4 Hz, 1 H, C14-H), 3.36 (d, J = 13.4 Hz, 1 H, 
C14-H), 3.28 - 3.25 (m, 1 H, C7-H), 3.09 - 3.01 (comp, 2 H, C9-H and C7-H), 2.96 (p, J 
= 7.1 Hz, 1 H, C5-H), 2.88 - 2.84 (m, 1 H, C5-H), 2.57 (dd, J = 8.0, 5.2 Hz, 1 H, C10-H), 
2.03 (s, 3 H, C13-H), 1.94 - 1.91 (m, 1 H, C8-H), 1.86 - 1.80 (m, 1 H, C8-H), 1.21 (d, J = 
6.1 Hz, 3 H, C12-H). 
 
 
 
 
 
 
 
334 
 
 N-(2-(4-(Benzyloxy)-1H-indol-3-yl)ethyl)-3,3-dimethoxypropan-1-amine 
(4.85). ARMVII128/ARMVII149. A solution of oxalyl chloride (0.57 g, 4.5 mmol) in 
ether (1 mL) was added dropwise over 20 min to a solution of 4-benzyloxyindole (1.40 g, 
4.5 mmol) in ether (10 mL) at 0 ºC. The reaction was stirred for 2 h at 0 ºC, at which 
point the solution was transferred dropwise over 20 min via cannula into a solution of 
4.18 (0.73 g, 3.7 mmol) and triethylamine (1.9 g, 18.5 mmol) in CH2Cl2 (50 mL) at 0 ºC. 
During the transfer, HCl gas was removed from the reaction through intermittent 
ventilation with a stream of nitrogen. The reaction was warmed to room temperature, and 
stirred for 1 h. Saturated aqueous NaHCO3 (100 mL) was added, and the solution was 
stirred for 20 min at room temperature. The mixture was extracted with CH2Cl2 (3 x 100 
mL). The combined organic fractions were washed with aqueous NaOH (1 M, 100 mL), 
water (100 mL), brine (100 mL), dried (Na2SO4), filtered, and concentrated in vacuo to 
give crude 4.83 as a thick orange semi-solid, which was carried onto the next step 
without further purification. 
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 A solution of crude 4.83 (0.37 g, 0.93 mmol) in THF (5 mL) was added dropwise 
over 10 min to a suspension of lithium aluminum hydride (0.35 g, 9.30 mmol) in THF 
(20 mL) at 0 ºC. The reaction was heated to 60 ºC for 14 h. The reaction was then cooled 
to 0 ºC, and the Fieser work-up was carefully performed by successive addition of water 
(0.3 mL), aqueous NaOH (15%, 0.3 mL), and water (1 mL). The suspension was warmed 
to room temperature, and MgSO4 was added. The solids were removed by vacuum 
filtration through a fritted funnel, and washed with copious amounts of CH2Cl2. The 
filtrate was concentrated in vacuo to give crude 4.85 as an opaque viscous oil. The crude 
residue was taken up into aqueous HCl (0.2 M, 100 mL), and washed with ether (2 x 50 
mL). The aqueous fraction was basified to pH 12-14 by dropwise addition of aqueous 
NaOH (40% w/v), as judged by pH paper. The basic solution was extracted with CH2Cl2 
(4 x 100 mL). The combined organic fractions were washed with saturated aqueous 
NaHCO3 (100 mL), water (100 mL), brine (100 mL), dried (Na2SO4), filtered, and 
concentrated in vacuo to give 230 mg (67%) of 4.85 as a viscous oil (>95% purity, by 1H 
NMR): 1H NMR (400 MHz) d 8.31 (brs, 1 H), 7.51 (d, J = 6.8 Hz, 2 H), 7.40 (td, J = 6.8, 
1.4 Hz, 2 H), 7.34 (tt, J = 6.8, 1.4 Hz, 1 H), 7.06 (t, J = 7.8 Hz, 1 H), 6.98 (dd, J = 7.8 Hz, 
0.7 Hz, 1 H), 6.91 (d, J = 2.1 Hz, 1 H), 6.55 (dd, J = 7.8, 0.7 Hz, 1 H), 5.17 (s, 2 H), 4.38 
(t, J = 5.6 Hz, 1 H), 3.27 (s, 6 H), 3.06 (t, J = 6.8 Hz, 2 H), 2.89 (t, J = 6.8 Hz, 2 H), 2.58 
(t, J = 7.2 Hz, 2 H), 1.71 (td, J = 7.2, 5.6 Hz, 2 H); 13C NMR (100 MHz) d 153.8, 138.4, 
137.5, 128.5, 127.8, 127.4, 122.7, 121.0, 117.4, 114.5, 104.7, 103.5, 100.4, 69.8, 52.7, 
 
 
 
336 
51.1, 45.1, 33.0, 27.4; HRMS (CI) m/z calcd for C22H28N2O3 (M+H)+, 369.2178 found, 
369.2180. 
 NMR Assignment. 1H NMR (400 MHz) d 8.31 (brs, 1 H, N2-H), 7.51 (d, J = 6.8 
Hz, 2 H, C7-H), 7.40 (td, J = 6.8, 1.4 Hz, 2 H, C8-H), 7.34 (tt, J = 6.8, 1.4 Hz, 1 H, C9-
H), 7.06 (t, J = 7.8 Hz, 1 H, C4-H), 6.98 (dd, J = 7.8 Hz, 0.7 Hz, 1 H, C3-H), 6.91 (d, J = 
2.1 Hz, 1 H, C1-H), 6.55 (dd, J = 7.8, 0.7 Hz, 1 H, C5-H), 5.17 (s, 2 H, C6-H), 4.38 (t, J 
= 5.6 Hz, 1 H, C15-H), 3.27 (s, 6 H, C16-H), 3.06 (t, J = 6.8 Hz, 2 H, C11-H), 2.89 (t, J = 
6.8 Hz, 2 H, C10-H), 2.58 (t, J = 7.2 Hz, 2 H, C13-H), 1.71 (td, J = 7.2, 5.6 Hz, 2 H, 
C14-H). 
 
 
 (E)-N-(2-(4-(Benzyloxy)-1H-indol-3-yl)ethyl)-N-(3,3-dimethoxypropyl)but-2-
enamide (4.86). ARMVI32. Crotonoyl chloride (200 mg, 1.90 mmol) was added 
dropwise over 5 min to a solution of 4.85 (588 mg, 1.60 mmol) and Hünig’s base (495 
mg, 3.80 mmol) in CH2Cl2 (16 mL) at -78 ºC. The reaction was stirred for 1 h at –78 ºC. 
Saturated aqueous NaHCO3 (20 mL) was added, and the resulting solution was stirred for 
20 min at room temperature. The aqueous phase was extracted with CH2Cl2 (3 x 20 mL). 
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The combined organic fractions were washed with water (25 mL), brine (25 mL), dried 
(Na2SO4), filtered, and concentrated in vacuo to give crude 4.86 as an opaque oil. The 
crude material was purified via silica gel flash column chromatography eluting with 
hexanes : ethyl acetate (2 : 1 → 1 : 1 along a gradient) to give 590 mg (86%) of 4.86 as 
an oil: 1H NMR (400 MHz) (1:1 mixture of rotamers) d 8.51 (brs, 1 H), 7.50 - 7.47 
(comp, 2 H), 7.39 (app td, J = 7.0, 1.4 Hz, 2 H), 7.35 - 7.31 (m, 1 H), 7.06 - 7.02 (comp, 
1 H), 6.98 - 6.94 (comp, 1 H), 6.84 (d, J = 1.9 Hz, 0.5), 6.73 (d, J = 1.9 Hz, 0.5 H), 6.64 
(dq, J = 13.6, 6.7 Hz, 1 H), 6.57 - 6.53 (comp, 1 H), 6.26 (dd, J = 13.6, 1.6 Hz, 0.5 H), 
5.92 (dd, J = 13.6, 1.6 Hz, 0.5 H), 5.25 (s, 1 H), 5.22 (s, 1 H), 4.32 (t, J = 5.7 Hz, 0.5 H), 
4.09 (t, J = 5.7 Hz, 0.5 H), 3.63 - 3.59 (comp, 2 H), 3.31 - 3.27 (comp, 4 H), 3.19 (s, 3 
H), 3.17 - 3.04 (comp, 3 H), 1.88 (dd, J = 6.8, 1.5 Hz, 1.5 H), 1.82 (q, J = 7.0 Hz, 1 H), 
1.58 (q, J = 7.0 Hz, 1 H), 1.50 (dd, J = 6.8, 1.5 Hz, 1.5 H); 13C NMR (100 MHz) (1 : 1 
mixture of rotamers) d 166.8, 166.3, 153.6, 153.5, 141.3, 140.3, 138.3, 138.2, 137.5, 
137.3, 128.6, 128.6, 127.9, 127.9, 127.5, 127.3, 122.8, 122.5, 121.8, 121.8, 117.4, 117.3, 
113.4, 112.3, 105.0, 102.8, 101.9, 100.6, 100.4, 70.0, 69.9, 52.9, 52.8, 49.7, 48.8, 43.8, 
42.7, 32.2, 30.8, 27.0, 25.2, 18.3, 18.2, 17.8; HRMS (ESI) m/z calcd for C26H32N2O4 
(M+Na)+, 459.2254; found, 459.2262 
 NMR Assignment. 1H NMR (400 MHz) (1:1 mixture of rotamers) d 8.51 (brs, 1 
H, N2-H), 7.50 - 7.47 (comp, 2 H, C7-H), 7.39 (app td, J = 7.0, 1.4 Hz, 2 H, C8-H), 7.35 
- 7.31 (m, 1 H, C9-H), 7.06 - 7.02 (comp, 1 H, C4-H), 6.98 - 6.94 (comp, 1 H, C3-H), 
6.84 (d, J = 1.9 Hz, 0.5, C1-H), 6.73 (d, J = 1.9 Hz, 0.5 H, C1-H), 6.64 (dq, J = 13.6, 6.7 
 
 
 
338 
Hz, 1 H, C13-H), 6.57 - 6.53 (comp, 1 H, C5-H), 6.26 (dd, J = 13.6, 1.6 Hz, 0.5 H, C12-
H), 5.92 (dd, J = 13.6, 1.6 Hz, 0.5 H, C12-H), 5.25 (s, 1 H, C6-H), 5.22 (s, 1 H, C6-H), 
4.32 (t, J = 5.7 Hz, 0.5 H, C17-H), 4.09 (t, J = 5.7 Hz, 0.5 H, C17-H), 3.63 - 3.59 (comp, 
2 H, C11-H), 3.31 - 3.27 (comp, 4 H, C18-H and C15-H), 3.19 (s, 3 H, C18-H), 3.17 - 
3.04 (comp, 3 H, C15-H and C10-H), 1.88 (dd, J = 6.8, 1.5 Hz, 1.5 H, C14-H), 1.82 (q, J 
= 7.0 Hz, 1 H, C16-H), 1.58 (q, J = 7.0 Hz, 1 H, C16-H), 1.50 (dd, J = 6.8, 1.5 Hz, 1.5 H, 
C14-H). 
 
 
 (3R,3aR,7aS)-5-(2-(4-(Benzyloxy)-1H-indol-3-yl)ethyl)-1,3-
dimethylhexahydroisoxazolo[4,3-c]pyridin-4(1H)-one (4.87). ARMVII158-
ARMVII159. A solution of 4.86 (149 mg, 0.34 mmol) and TFA (5 drops) in TFE/water 
(3 : 1, 6 mL) was stirred for 1 h at room temperature. The reaction was poured into 
saturated aqueous NaHCO3 (20 mL), and extracted with CH2Cl2 (3 x 20 mL). The 
combined organic fractions were washed with water (20 mL), dried (Na2SO4), filtered, 
and concentrated in vacuo. The resulting residue was dissolved in toluene (4 mL), 
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followed by addition of N-methylhydroxylamine hydrochloride (34 mg, 0.41 mmol) and 
triethylamine (70 mg, 0.69 mmol). The reaction was heated under reflux for 1 h, at which 
point the reaction was cooled to room temperature, and portioned between saturated 
aqueous NaHCO3 (20 mL), ethyl acetate (20 mL) and methanol (1 mL). The phases were 
separated, and the aqueous phase was extracted with ethyl acetate (3 x 20 mL). The 
combined organic fractions were washed with water (40 mL), brine (40 mL), dried 
(Na2SO4), filtered, and concentrated in vacuo to give 133 mg (93%) of 4.87 as an oil 
(>95% purity, by 1H NMR): 1H NMR (600 MHz) d 8.12 (brs, 1 H), 7.49 - 7.47 (comp, 2 
H), 7.40 - 7.38 (comp, 2 H), 7.32 (tt, J = 7.4, 1.3 Hz, 1 H), 7.06 (t, J = 8.0 Hz, 1 H), 6.98 
(dd, J = 8.0, 0.6 Hz, 1 H), 6.90 (d, J = 2.3 Hz, 1 H), 5.57 (d, J = 8.0 Hz, 1 H), 5.14 (s, 2 
H), 3.94 (p, J = 6.2 Hz, 1 H), 3.62 (ddd, J = 12.9, 9.7, 5.9 Hz, 1 H), 3.45 (ddd, J = 12.9, 
9.7, 5.6 Hz, 1 H), 3.09 - 3.02 (comp, 2 H), 2.95 (ddd, J = 13.7, 9.5, 5.8 Hz, 1 H), 2.78 - 
2.69 (comp, 2 H), 2.62 (s, 3 H), 2.41 (dt, J = 12.9, 4.2 Hz, 1 H), 1.57 - 1.52 (m, 1 H), 1.41 
(d, J = 6.1 Hz, 3 H), 1.29 (dq, J = 14.3, 3.6 Hz, 1 H); 13C NMR (150 MHz) d 168.7, 
153.8, 138.2, 137.2, 128.6, 128.4, 128.0, 122.7, 121.6, 117.2, 113.3, 104.9, 100.3, 77.5, 
77.4, 70.2, 66.2, 55.2, 49.7, 43.2, 25.1, 25.0, 19.2; HRMS (ESI) m/z calcd for 
C25H29N3O3 (M+H)+, 420.2282; found, 420.2289 
 NMR Assignment. 1H NMR (600 MHz) d 8.12 (brs, 1 H, N2-H), 7.49 - 7.47 
(comp, 2 H, C7-H), 7.40 - 7.38 (comp, 2 H, C8-H), 7.32 (tt, J = 7.4, 1.3 Hz, 1 H, C9-H), 
7.06 (t, J = 8.0 Hz, 1 H, C4-H), 6.98 (dd, J = 8.0, 0.6 Hz, 1 H, C3-H), 6.90 (d, J = 2.3 Hz, 
1 H, C1-H), 5.57 (d, J = 8.0 Hz, 1 H, C5-H), 5.14 (s, 2 H, C6-H), 3.94 (p, J = 6.2 Hz, 1 
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H, C16-H), 3.62 (ddd, J = 12.9, 9.7, 5.9 Hz, 1 H, C11-H), 3.45 (ddd, J = 12.9, 9.7, 5.6 
Hz, 1 H, C1-H), 3.09 - 3.02 (comp, 2 H, C12-H and C10-H), 2.95 (ddd, J = 13.7, 9.5, 5.8 
Hz, 1 H, C10-H), 2.78 - 2.69 (comp, 2 H, C15-H and C14-H), 2.62 (s, 3 H, C18-H), 2.41 
(dt, J = 12.9, 4.2 Hz, 1 H, C12-H), 1.57 - 1.52 (m, 1 H, C13-H), 1.41 (d, J = 6.1 Hz, 3 H, 
C17-H), 1.29 (dq, J = 14.3, 3.6 Hz, 1 H, C13-H). 
 
 
 (3R,4S)-1-(2-(4-(Benzyloxy)-1H-indol-3-yl)ethyl)-3-((R)-1-hydroxyethyl)-4-
(methylamino)piperidin-2-one (4.88). ARMVII163. Zinc (powder, 584 mg, 9.00 
mmol) was added in three portions over 1.5 h to a solution of 4.87 (125 mg, 0.30 mmol) 
in acetic acid (aq 80%, 18 mL) at 60 ºC. The suspension was stirred for 1 h at 60 ºC. The 
suspension was cooled to room temperature, followed by the removal of excess zinc by 
filtration. Ethyl acetate (100 mL) was added to the filtrate, upon which zinc acetate 
immediately precipitated out of solution as a fluffy white solid. The zinc acetate was 
filtered and washed with ethyl acetate. The filtrate was concentrated in vacuo to give 
crude 4.88. the crude material was taken up in aqueous HCl (1 M, 30 mL), and washed 
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with ether (2 x 30 mL). The aqueous fraction was basified to pH ~14 with aqueous NaOH 
(40% w/v). The basic solution was extracted with CH2Cl2 (4 x 50 mL). The combined 
organic fractions were washed with saturated aqueous NaHCO3 (100 mL), water (100 
mL), and brine (1 x 100 mL). The organic fractions were dried (Na2SO4), filtered, and 
concentrated in vacuo to give 72 mg (57%) of 4.88 as an oil (>95% purity, by 1H NMR): 
1H NMR (500 MHz, CD3OD) d 7.47 (d, J = 7.0 Hz, 2 H) 7.39 – 7.33 (comp, 3 H), 7.03 (t, 
J = 8.0 Hz, 1 H), 6.98 (dd, J = 8.0, 0.5 H, 1 H), 6.90 (s, 1 H), 6.55 (dd, J = 8.0, 0.5 Hz, 1 
H), 5.13 (s, 2 H), 4.39 (p, J = 6.0 Hz, 1 H), 3.48 – 3.44 (comp, 2 H), 3.03 – 2.98 (comp, 3 
H), 2.80 – 2.78 (m, 1 H), 2.63 – 2.58 (m, 1 H), 2.27 – 2.23 (comp, 4 H), 1.73 (dq, J = 
13.5, 6.0 Hz, 1 H), 1.46 – 1.40 (m, 1 H), 1.20 (d, J = 6.0 Hz, 3 H); 13C NMR (125 MHz, 
CD3OD) d 169.5, 153.6, 138.3, 137.3, 128.5, 128.3, 128.0, 122.2, 122.0, 117.1, 112.2, 
105.1, 99.9, 70.1, 66.4, 54.4, 50.0, 43.6, 33.3, 24.4, 23.3, 20.9; HRMS (ESI) m/z calcd for 
C25H31N3O3 (M+H)+, 422.2438; found, 422.2442. 
 NMR Assignment. 1H NMR (500 MHz, CD3OD) d 7.47 (d, J = 7.0 Hz, 2 H, C6-
H) 7.39 – 7.33 (comp, 3 H, C7-H and C8-H), 7.03 (t, J = 8.0 Hz, 1 H, C3-H), 6.98 (dd, J 
= 8.0, 0.5 H, 1 H, C2-H), 6.90 (s, 1 H, C1-H), 6.55 (dd, J = 8.0, 0.5 Hz, 1 H, C4-H), 5.13 
(s, 2 H, C5-H), 4.39 (p, J = 6.0 Hz, 1 H, C15-H), 3.48 – 3.44 (comp, 2 H, C10-H), 3.03 – 
2.98 (comp, 3 H, C11-H and C13-H), 2.80 – 2.78 (m, 1 H, C9-H), 2.63 – 2.58 (m, 1 H, 
C9-H), 2.27 – 2.23 (comp, 4 H, C17-H and C14-H), 1.73 (dq, J = 13.5, 6.0 Hz, 1 H, C12-
H), 1.46 – 1.40 (m, 1 H, C12-H), 1.20 (d, J = 6.0 Hz, 3 H, C16-H). 
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 (3R,4S)-1-(2-(4-(Benzyloxy)-1H-indol-3-yl)ethyl)-4-((3,5-
dichlorobenzyl)(methyl)amino)-3-((R)-1-hydroxyethyl)piperidin-2-one (4.89). 
ARMVI76. Prepared according to the representative procedure for compound 4.12 scaled 
to 4.88 (100 mg, 0.24 mmol). The crude material was purified via flash column 
chromatography eluting with CH2Cl2 : acetone : methanol (9 : 1 : 0 → 5 : 4 : 1 along a 
gradient) to give 26 mg (19%) of 4.89 as a white solid: 1H NMR (400 MHz) d 9.14 (brs, 1 
H), 7.38 (dd, J = 8.4, 1.6 Hz, 2 H), 7.30 - 7.28 (comp, 2 H), 7.23 (d, J = 7.2 Hz, 1 H), 
7.13 (s, 1 H), 7.01 (s, 2 H), 6.94 - 6.87 (comp, 2 H), 6.77 (d, J = 2.4 Hz, 1 H), 6.44 (dd, J 
= 7.2, 0.8 Hz, 1 H), 5.01 (s, 2 H), 4.09 (dq, J = 9.2, 6.8 Hz, 1 H), 3.55 - 3.48 (m, 1 H), 
3.36 (d, J = 12.4 Hz, 1 H), 3.28 - 3.1 (comp, 2 H), 2.90 - 2.84 (comp, 3 H), 2.59 - 2.54 
(m, 1 H), 1.97 (s, 3 H), 1.55 - 1.50 (comp, 2 H), 1.22 (d, J = 6.0 Hz, 3 H); 13C NMR (125 
MHz) d 169.6, 153.8, 141.4, 138.2, 137.3, 135.2, 128.6, 128.5, 128.1, 127.8, 126.6, 
122.8, 121.6, 117.2, 113.1, 105.0, 100.3, 70.2, 66.4, 60.4, 57.7, 50.1, 48.7, 44.6, 24.7, 
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22.5, 21.9; HRMS (ESI) m/z calcd for C32H35Cl2N3O3 (M+Na)+, 602.1948 and 604.1945; 
found, 602.1927 and 604.1954. 
 NMR Assignment. 1H NMR (400 MHz) d 9.41 (brs, 1 H, N2-H), 7.38 (dd, J = 
8.4, 1.6 Hz, 2 H, C7-H), 7.30 - 7.28 (comp, 2 H, C8-H), 7.23 (d, J = 7.2 Hz, 1 H, C9-H), 
7.13 (s, 1 H, C21-H), 7.01 (s, 2 H, C20-H), 6.94 - 6.87 (comp, 2 H, C4-H and C3-H), 
6.77 (d, J = 2.4 Hz, 1 H, C1-H), 6.44 (dd, J = 7.2, 0.8 Hz, 1 H, C5-H), 5.01 (s, 2 H, C6-
H), 4.09 (dq, J = 9.2, 6.8 Hz, 1 H, C16-H), 3.55 - 3.48 (m, 1 H, C11-H), 3.36 (d, J = 12.4 
Hz, 1 H, C19-H), 3.28 - 3.1 (comp, 2 H, C19-H and C11-H), 2.90 - 2.84 (comp, 3 H, 
C14-H and C12-H), 2.59 - 2.54 (m, 1 H, C15-H), 1.97 (s, 3 H, C18-H), 1.55 - 1.50 
(comp, 2 H, C13-H), 1.22 (d, J = 6.0 Hz, 3 H, C17-H). 
 
 
Erythromycin A-9-oxime (ERY-9-OX, 6.2). ARMVI151. A solution of 
erythromycin A (15.0 g, 20.4 mmol) and hydroxylamine hydrochloride (14.0 g, 204.0 
mmol) in pyridine (100 mL) was stirred at room temperature for 72 h. The solvent was 
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removed in vacuo, whereupon the resulting slurry was taken up into aqueous NaOH (1 
M, 200 mL) and extracted with CH2Cl2 (3 x 250 mL). The combined organic fractions 
were washed with brine (400 mL), dried (Na2SO4), filtered, and concentrated in vacuo to 
give 15.7 g (quant.) of crude 6.2. The crude material was dissolved in boiling ethanol 
(~100 mL) then allowed to cool to room temperature, whereupon water (~5 mL) was 
added, the beaker was scratched, and placed in the refrigerator. The crystalline precipitate 
was isolated via vacuum filtration to give 7.56 g (49%) of 6.2. The mother liquor was 
boiled down to ~1/2 the total volume, and placed in the refrigerator. The second crop of 
crystals isolated via vacuum filtration, which yielded an additional 3.81 g (25%) of 6.2, to 
give a total of 11.36 g (74%) of 6.2 as a fine white crystalline solid. Spectral data 
matched that for previous reports:301 1H NMR (400 MHz, DMSO-d6) δ 10.62 (s, 1 H), 
5.10 (dd, J = 11.1, 2.3 Hz, 1 H), 4.71 (d, J = 4.9 Hz, 1 H), 4.37 (d, J = 7.3 Hz, 1 H), 4.29 
(d, J = 7.4 Hz, 1 H), 4.10 (d, J = 2.2 Hz, 1 H), 4.00 (d, J = 8.7 Hz, 2 H), 3.84 (d, J = 9.4 
Hz, 1 H), 3.64 (dd, J = 11.0, 6.0 Hz, 1 H), 3.49 (s, 1 H), 3.45 (d, J = 7.0 Hz, 1 H), 3.19 (s, 
3 H), 3.02 (t, J = 8.1 Hz, 1 H), 2.88 (dd, J = 9.4, 7.4 Hz, 1 H), 2.76 (t, J = 8.1 Hz, 1 H), 
2.65 (q, J = 7.2 Hz, 1 H), 2.43 (d, J = 11.6 Hz, 1 H), 2.25 (d, J = 15.5 Hz, 1 H), 2.21 (s, 6 
H), 1.87 (t, J = 7.3 Hz, 1 H), 1.83 – 1.73 (m, 1 H), 1.51 (ddd, J = 31.1, 14.3, 9.9 Hz, 3 H), 
1.30 (s, 3 H), 1.13 (d, J = 6.1 Hz, 3 H), 1.10 (s, 3 H), 1.08 – 1.04 (comp, 11 H), 1.00 - 
0.94 (comp, 10 H), 0.72 (t, J = 7.4 Hz, 3 H). 
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 4-(2-Iodophenoxy)-2-nitrobenzaldehyde (6.7). ARMVI177. A solution of 4-
fluoro-2-nitrobenzaldehyde (1.50 g, 8.9 mmol), 2-iodophenol (1.95 g, 8.9 mmol), copper 
(I) bromide (1.27 g, 8.9 mmol), and K2CO3 (2.45 g, 17.7 mmol) in pyridine (30 mL) was 
heated at 60 ºC for 12 h. The mixture was cooled to room temperature and filtered. The 
filtrate was diluted with ether (300 mL) and washed successively with aqueous NaOH (1 
M, 2 x 200 mL), water (2 x 200 mL), and brine (200 mL). The organic fraction was dried 
(Na2SO4), filtered, and concentrated in vacuo to give crude 6.7 as an opaque viscous oil. 
The crude material was purified via silica gel flash column chromatography eluting with 
hexanes : ethyl acetate (92 : 8). To give 2.80 g (86%) of 6.7 as slightly yellow viscous 
oil: Spectral data matched that of previous reports:181 1H NMR (400 MHz) d 10.31 (d, J = 
0.7 Hz, 1 H), 7.97 (d, J = 8.6 Hz, 1 H), 7.71 (dd, J = 8.0, 1.6 Hz, 1 H), 7.49 (d, J = 2.4 
Hz, 1 H), 7.43 (td, J = 7.8, 1.6 Hz, 1 H), 7.25 - 7.17 (comp, 3 H) 
 NMR Assignment. 1H NMR (400 MHz) d 10.31 (d, J = 0.7 Hz, 1 H, CHO), 7.97 
(d, J = 8.6 Hz, 1 H, C6-H), 7.71 (dd, J = 8.0, 1.6 Hz, 1 H, C1-H), 7.49 (d, J = 2.4 Hz, 1 
H, C5-H), 7.43 (td, J = 7.8, 1.6 Hz, 1 H, C3-H), 7.25 - 7.17 (comp, 3 H, C7-H, C2-H, and 
C4-H) 
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1-(4-(2-Iodophenoxy)-2-nitrophenyl)ethan-1-ol (6.8). ARMVI160. 
Trimethylaluminum (neat, 1.40 g, 20.0 mmol) was added dropwise over 20 min to a 
degassed solution of 6.7 (2.00 g, 13.2 mmol) in CH2Cl2 (90 mL) at 0 ºC. The reaction 
was stirred for 1 h at 0 ºC, whereupon cold water (~3 mL) was carefully added to quench 
excess trimethylaluminum. The mixture was warmed to room temperature, Rochelle’s 
salt (100 mL) was added, and the mixture was stirred for 30 min. The phases were 
separated and the aqueous phase was extracted with CH2Cl2 (2 x 100 mL). The combined 
organic fractions were washed successively with aqueous NaOH (1 M, 200 mL) and 
brine (200 mL). The organic fraction was dried (Na2SO4), filtered, and concentrated in 
vacuo to give 2.11 g (98%) of 6.8 as a viscous yellow oil (>95% purity, by 1H NMR). 
Spectral data matched that of previous reports:181 1H NMR (400 MHz) d 7.90 (dd, J = 
7.9, 1.5 Hz, 1 H), 7.78 (d, J = 8.7 Hz, 1 H), 7.41 (d, J = 2.6 Hz, 1 H), 7.40 - 7.35 (m, 1 
H), 7.21 (dd, J = 8.7, 2.6 Hz, 1 H), 7.02 - 6.96 (comp, 2 H), 5.36 (q, J = 6.3 Hz, 1 H), 
1.56 (d, J = 6.3 Hz, 3 H) 
 NMR Assignment. 1H NMR (400 MHz) d 7.90 (dd, J = 7.9, 1.5 Hz, 1 H, C1-H), 
7.78 (d, J = 8.7 Hz, 1 H, C7-H), 7.41 (d, J = 2.6 Hz, 1 H, C5-H), 7.40 - 7.35 (m, 1 H, C3-
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H), 7.21 (dd, J = 8.7, 2.6 Hz, 1 H, C6-H), 7.02 - 6.96 (comp, 2 H, C2-H and C4-H), 5.36 
(q, J = 6.3 Hz, 1 H, C8-H), 1.56 (d, J = 6.3 Hz, 3 H, C9-H) 
 
 
1-(3-Nitrodibenzo[b,d]furan-2-yl)ethan-1-ol (6.9). ARMVI164. A degassed 
solution of 6.8 (0.31 g, 0.80 mmol), Pd(OAc)2 (18 mg, 0.08 mmol), and Cs2CO3 (0.52 g, 
1.60 mmol) in DMAc (4 mL) was heated at 80 ºC for 6 h. The reaction was cooled to 
room temperature, then partitioned between water (50 mL) and ethyl acetate (50 mL). 
The two phases were separated and the aqueous phase was extracted with ethyl acetate (2 
x 50 mL). The combined organic fractions were washed successively with water (100 
mL) and brine (100 mL). The organic fractions were dried (Na2SO4), filtered, and 
concentrated in vacuo to give crude 6.9 as a viscous oil. The crude material was purified 
via silica gel flash column chromatography eluting with hexanes : ethyl acetate (19 : 1 → 
17 : 3 along a gradient) to give 104 mg (51%) of 6.9 as a viscous oil. Spectra data 
matched that for previous reports:181 1H NMR (400 MHz) d 8.40 (s, 1 H), 8.15 (s, 1 H), 
8.03 (d, J = 7.7 Hz, 1 H), 7.64 - 7.56 (comp, 2 H), 7.45 - 5.41 (m, 1 H), 5.58 (q, J = 6.2 
Hz, 1 H), 2.46 (brs, 1 H), 1.67 (d, J = 6.3 Hz, 3 H) 
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NMR Assignment. 1H NMR (400 MHz) d 8.40 (s, 1 H, C5-H), 8.15 (s, 1 H, C6-
H), 8.03 (d, J = 7.7 Hz, 1 H, C1-H), 7.64 - 7.56 (comp, 2 H, C3-H and C4-H), 7.45 - 5.41 
(m, 1 H, C2-H), 5.58 (q, J = 6.2 Hz, 1 H, C7-H), 2.46 (brs, 1 H, OH), 1.67 (d, J = 6.3 Hz, 
3 H, C8-H) 
 
 
2-(1-((Methylthio)methoxy)ethyl)-3-nitrodibenzo[b,d]furan (6.11). 
ARMVI194. Solid benzoyl peroxide (0.74 g, 3.0 mmol) was added portion-wise over 30 
min to a solution of 6.9 (0.20 g, 0.76 mmol) and dimethylsulfide (0.38 g, 6.1 mmol) in 
acetonitrile (4 mL) at 0 ºC. The solution was stirred for 5 h at 0 ºC, whereupon aqueous 
KOH (2 M, 25 mL) was added, and the mixture was stirred for 12 h at room temperature. 
The mixture was extracted with ethyl acetate (3 x 50 mL), and the combined organic 
fractions were washed successively with water (100 mL) and brine (100 mL), dried 
(Na2SO4), filtered, and concentrated in vacuo to give crude 6.11 as a viscous dark oil. 
The crude material was purified via silica gel flash column chromatography eluting with 
hexanes : ethyl acetate  (10 : 1) to give 0.18 g (74%) of 6.11 as a light brown solid. 
Spectral data matched that of previous reports:181 1H NMR (400 MHz) d 8.32 (s, 1 H), 
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8.17 (s, 1 H), 8.04 (d, J = 7.4 Hz, 1 H), 7.63 (d, J = 8.1 Hz, 1 H), 7.58 (td, J = 7.4, 1.2 Hz, 
1 H), 7.46 - 7.42 (m, 1 H), 5.55 (q, J = 6.3 Hz, 1 H), 4.69 (d, J = 11.5 Hz, 1 H), 4.37 (d, J 
= 11.5 Hz, 1 H), 2.16 (s, 3 H), 1.65 (d, J = 6.3 Hz, 3 H) 
NMR Assignment. 1H NMR (400 MHz) d 8.32 (s, 1 H, C5-H), 8.17 (s, 1 H, C6-
H), 8.04 (d, J = 7.4 Hz, 1 H, C1-H), 7.63 (d, J = 8.1 Hz, 1 H, C4-H), 7.58 (td, J = 7.4, 1.2 
Hz, 1 H, C2-H), 7.46 - 7.42 (m, 1 H, C3-H), 5.55 (q, J = 6.3 Hz, 1 H, C7-H), 4.69 (d, J = 
11.5 Hz, 1 H, C9-H), 4.37 (d, J = 11.5 Hz, 1 H, C9-H), 2.16 (s, 3 H, C10-H), 1.65 (d, J = 
6.3 Hz, 3 H, C8-H) 
 
 
2-(1-(Chloromethoxy)ethyl)-3-nitrodibenzo[b,d]furan (6.12). ARMVI147. 
Sulfuryl chloride (31 mg, 0.23 mmol) was added dropwise to a solution of 6.11 (51 mg, 
0.19 mmol) in CH2Cl2 (1 mL) at 0 ºC. The solution was stirred at 0 ºC for 30 min, at 
which point all volatiles were removed in vacuo to give 48 mg (98%) of 6.12 as an oil 
(>95% purity, by 1H NMR). Spectral data matched that of previous reports:181 1H NMR 
(400 MHz) d 8.25 (s, 1 H), 8.22 (s, 1 H), 8.04 (d, J = 7.2 Hz, 1 H), 7.64 (d, J = 8.2 Hz, 1 
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H), 7.60 (td, J = 7.2, 1.2 Hz, 1 H), 7.46 - 7.42 (m, 1 H), 5.67 (q, J = 6.3 Hz, 1 H), 5.59 (d, 
J = 6.0 Hz, 1 H), 5.31 (d, J = 6.0 Hz, 1 H), 1.69 (d, J = 6.3 Hz, 1 H) 
NMR Assignment. 1H NMR (400 MHz) d 8.25 (s, 1 H, C5-H), 8.22 (s, 1 H, C6-
H), 8.04 (d, J = 7.2 Hz, 1 H, C1-H), 7.64 (d, J = 8.2 Hz, 1 H, C4-H), 7.60 (td, J = 7.2, 1.2 
Hz, 1 H, C2-H), 7.46 - 7.42 (m, 1 H, C3-H), 5.67 (q, J = 6.3 Hz, 1 H, C7-H), 5.59 (d, J = 
6.0 Hz, 1 H, C9-H), 5.31 (d, J = 6.0 Hz, 1 H, C9-H), 1.69 (d, J = 6.3 Hz, 1 H, C8-H) 
 
 
7-(Diethylamino)-4-(hydroxymethyl)-2H-chromen-2-one (6.14). ARMVI130. 
A suspension of 6.13 (5.00 g, 21.6 mmol) in xylenes (50 mL) was heated until complete 
dissolution was observed. Solid SeO2 (3.36 g, 30.3 mmol) was added to the reaction, 
which was then heated under reflux for 16 h. The mixture was cooled to room 
temperature and all solids were removed by filtration. The filtrate was concentrated in 
vacuo, and the resulting residue was dissolved in methanol/THF (1:1, 50 mL). Sodium 
borohydride (0.82 g, 21.6 mmol) was slowly added to minimize effervescence, and the 
reaction was stirred for 4 h at room temperature. Aqueous HCl (1 M, 5 mL) was carefully 
added, and the volatiles were removed in vacuo. The resulting slurry was taken up in 
CH2Cl2 (300 mL), and washed with saturated aqueous K2CO3 (3 x 100 mL), dried 
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(Na2SO4), filtered, and concentrated in vacuo to give crude 6.14 as a dark red oil. The 
crude material was purified via flash column chromatography eluting with CH2Cl2 : 
acetone (5 : 1) to give 1.53 g (29%) of 6.14 as a viscous oil. Spectral data matched that of 
previous reports:250,251 1H NMR (400 MHz) d 7.30 (d, J = 9.0 Hz, 1 H), 6.55 (dd, J = 9.0, 
2.6 Hz, 1 H), 6.48 (d, J = 2.6 Hz, 1 H), 6.26 (t, J = 1.3 Hz, 1 H), 4.82 (s, 2 H), 3.39 (q, J = 
7.1 Hz, 4 H), 2.49 (brs, 1 H), 1.19 (t, J = 7.1 Hz, 6 H) 
NMR Assignment. 1H NMR (400 MHz) d 7.30 (d, J = 9.0 Hz, 1 H, C1-H), 6.55 
(dd, J = 9.0, 2.6 Hz, 1 H, C2-H), 6.48 (d, J = 2.6 Hz, 1 H, C5-H), 6.26 (t, J = 1.3 Hz, 1 H, 
C6-H), 4.82 (s, 2 H, C7-H), 3.39 (q, J = 7.1 Hz, 4 H, C3-H), 2.49 (brs, 1 H, OH), 1.19 (t, 
J = 7.1 Hz, 6 H, C4-H). 
 
 
4-(((tert-Butyldimethylsilyl)oxy)methyl)-7-(diethylamino)-2H-chromen-2-one 
(6.15). ARMVI162. A solution of 6.14 (0.51 g, 2.1 mmol), TBSCl (0.34 g, 2.3 mmol), 
and imidazole (0.21 g, 3.1 mmol) in CH2Cl2 (20 mL) was stirred for 12 h at room 
temperature. The solution was diluted with CH2Cl2 (100 mL) and washed successively 
with saturated aqueous NH4Cl (100 mL), water (100 mL), and brine (100 mL). The 
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organic fraction was dried (Na2SO4), filtered, and concentrated in vacuo to give crude 
6.15 as a viscous oil. The crude material was purified via silica gel flash column 
chromatography eluting with hexanes : ethyl acetate (9 : 1) to give 0.58 g (77%) of 6.15 
as a yellow solid. Spectral data matched that of previous reports:250,251 1H NMR (400 
MHz) d 7.24 (d, J = 8.9 Hz, 1 H), 6.54 (dd, J = 8.9, 2.6 Hz, 1 H), 6.50 (d, J = 2.6 Hz, 1 
H), 6.28 (t, J = 1.3 Hz, 1 H), 4.81 (d, J = 1.3 Hz, 2 H), 3.39 (q, J = 7.1 Hz, 4 H), 1.20 (t, J 
= 7.1 Hz, 6 H), 0.95 (s, 9 H), 0.14 (s, 6 H) 
NMR Assignment. 1H NMR (400 MHz) d 7.24 (d, J = 8.9 Hz, 1 H, C1-H), 6.54 
(dd, J = 8.9, 2.6 Hz, 1 H, C2-H), 6.50 (d, J = 2.6 Hz, 1 H, C5-H), 6.28 (t, J = 1.3 Hz, 1 H, 
C6-H), 4.81 (d, J = 1.3 Hz, 2 H, C7-H), 3.39 (q, J = 7.1 Hz, 4 H, C3-H), 1.20 (t, J = 7.1 
Hz, 6 H, C4-H), 0.95 (s, 9 H, C9-H), 0.14 (s, 6 H, C8-H) 
 
 
3-Bromo-4-(((tert-butyldimethylsilyl)oxy)methyl)-7-(diethylamino)-2H-
chromen-2-one (6.16). ARMVI172. Solid NBS (1.19 g, 6.7 mmol) was added to a 
solution of 6.15 (2.21 g, 6.1 mmol) and NH4OAc (0.047 g, 0.61 mmol) in acetonitrile (40 
mL), and the reaction was stirred for 1 h at room temperature. The solution was poured 
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into water (150 mL) and extracted with ethyl acetate (3 x 150 mL). The combined 
organic fractions were dried (Na2SO4), filtered, and concentrated in vacuo to give crude 
6.16. The crude material was purified via silica gel flash column chromatography eluting 
with hexanes : ethyl acetate (9 :1) to give 2.32 g (86%) of 6.16 as a yellow solid. Spectral 
data matched that of previous reports:250,251 1H NMR (400 MHz) d 7.70 (d, J = 9.2 Hz, 1 
H), 6.58 (dd, J = 9.2, 2.6 Hz, 1 H), 6.42 (d, J = 2.6 Hz, 1 H), 4.95 (s, 2 H), 3.38 (q, J = 
7.1 Hz, 4 H), 1.18 (t, J = 7.1 Hz, 6 H), 0.87 (s, 9 H), 0.11 (s, 6 H) 
NMR Assignment. 1H NMR (400 MHz) d 7.70 (d, J = 9.2 Hz, 1 H, C1-H), 6.58 
(dd, J = 9.2, 2.6 Hz, 1 H, C2-H), 6.42 (d, J = 2.6 Hz, 1 H, C5-H), 4.95 (s, 2 H, C6-H), 
3.38 (q, J = 7.1 Hz, 4 H, C3-H), 1.18 (t, J = 7.1 Hz, 6 H, C4-H), 0.87 (s, 9 H, C8-H), 0.11 
(s, 6 H, C7-H) 
 
 
tert-Butyl (E)-3-(4-(((tert-butyldimethylsilyl)oxy)methyl)-7-(diethylamino)-2-
oxo-2H-chromen-3-yl)acrylate (6.17). ARMVI187. Solid lithium chloride (29 mg, 0.69 
mmol), NaHCO3 (102 mg, 1.22 mmol), and Pd(OAc)2 (18 mg, 0.08 mmol) were 
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sequentially added to a degassed solution of 6.16 (179 mg, 0.41 mmol) and t-butyl 
acrylate (156 mg, 1.22 mmol) in DMF (4 mL), and the reaction was stirred for 30 min at 
110 ºC. The reaction was cooled to room temperature and poured into water (20 mL). The 
mixture was extracted with ether (3 x 20 mL), followed by ethyl acetate (20 mL). The 
combined organic fractions were washed with brine (50 mL), dried (Na2SO4), filtered, 
and concentrated in vacuo to give crude 6.17 as a yellow oil. The crude material was 
purified via silica gel flash column chromatography eluting with hexanes : ethyl acetate 
(9 : 1) to give 81 mg (41%) of 6.17 as a yellow solid and 17 mg (9%) of returned starting 
material (6.16) as a yellow solid. Spectral data matched that of previous reports:250,251 1H 
NMR (400 MHz) d 7.74 (d, J = 15.6 Hz, 1 H), 7.63 (d, J = 9.2 Hz, 1 H), 6.98 (d, J = 15.6 
Hz, 1 H), 6.61 (dd, J = 9.2, 2.6 Hz, 1 H), 6.45 (d, J = 2.6 Hz, 1 H), 4.89 (s, 2 H), 3.42 (q, 
J = 7.1 Hz, 4 H), 1.51 (s, 9 H), 1.21 (t, J = 7.1 Hz, 6 H), 0.89 (s, 9 H), 0.15 (s, 6 H) 
NMR Assignment. 1H NMR (400 MHz) d 7.74 (d, J = 15.6 Hz, 1 H, C6-H), 7.63 
(d, J = 9.2 Hz, 1 H, C1-H), 6.98 (d, J = 15.6 Hz, 1 H, C7-H), 6.61 (dd, J = 9.2, 2.6 Hz, 1 
H, C2-H), 6.45 (d, J = 2.6 Hz, 1 H, C5-H), 4.89 (s, 2 H, C8-H), 3.42 (q, J = 7.1 Hz, 4 H, 
C3-H), 1.51 (s, 9 H, OtBu), 1.21 (t, J = 7.1 Hz, 6 H, C4-H), 0.89 (s, 9 H, C10-H), 0.15 (s, 
6 H, C9-H) 
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tert-Butyl (E)-3-(7-(diethylamino)-4-(hydroxymethyl)-2-oxo-2H-chromen-3-
yl)acrylate (6.18). ARMVI246. 3HF•Et3N (108 mg, 0.67 mmol) was added dropwise to 
a solution of 6.17 (30 mg, 0.067 mmol) and triethylamine (67 mg, 0.67 mmol) in CH2Cl2 
(2 mL), and the reaction was stirred for 2 h at room temperature. Ice cold water (5 mL) 
was added, and the resulting mixture was extracted with CH2Cl2 (3 x 10 mL). The 
combined organic fractions were dried (Na2SO4), filtered, and concentrated in vacuo to 
give 21 mg (92%) of 6.18 as an oil (>95% purity, by 1H NMR): 1H NMR (400 MHz) d 
7.78 (d, J = 15.6 Hz, 1 H), 7.67 (d, J = 9.2 Hz, 1 H), 7.07 (d, J = 15.6 Hz, 1 H), 6.62 (dd, 
J = 9.2, 2.6 Hz, 1 H), 6.46 (d, J = 2.6 Hz, 1 H), 4.95 (s, 2 H), 3.42 (q, J = 7.0 Hz, 4 H), 
1.50 (s, 9 H), 1.25 - 1.19 (comp, 7 H). 
NMR Assignment. 1H NMR (400 MHz) d 7.78 (d, J = 15.6 Hz, 1 H, C6-H), 7.67 
(d, J = 9.2 Hz, 1 H, C1-H), 7.07 (d, J = 15.6 Hz, 1 H, C7-H), 6.62 (dd, J = 9.2, 2.6 Hz, 1 
H, C2-H), 6.46 (d, J = 2.6 Hz, 1 H, C5-H), 4.95 (s, 2 H, C8-H), 3.42 (q, J = 7.0 Hz, 4 H, 
C3-H), 1.50 (s, 9 H, OtBu), 1.25 - 1.19 (comp, 7 H, C4-H and OH). 
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tert-Butyl (E)-3-(7-(diethylamino)-4-(((methylsulfonyl)oxy)methyl)-2-oxo-2H-
chromen-3-yl)acrylate (6.19). ARMVI191. A solution of MsCl (45 mg, 0.39 mmol) in 
CH2Cl2 (1 mL) was added dropwise to a solution of 6.18 (97 mg, 0.26 mmol) and 
triethylamine (53 mg, 0.52 mmol) in CH2Cl2 (15 mL) at 0 ºC, and the reaction was stirred 
for 20 min at 0 ºC. The mixture was poured into water (30 mL), and extracted with 
CH2Cl2 (3 x 30 mL). The combined organic fractions were washed with water (1 x 30 
mL), dried (Na2SO4), filtered, and concentrated in vacuo to give 113 mg (96%) of 6.19 as 
an oil (>95% purity, by 1H NMR): 1H NMR (400 MHz) d 7.68 (d, J = 15.5 Hz, 1 H), 7.62 
(d, J = 9.3 Hz, 1 H), 7.08 (d, J = 15.5 Hz, 1 H), 6.66 (dd, J = 9.3, 2.6 Hz, 1 H), 6.49 (d, J 
=2.6 Hz, 1 H), 5.48 (s, 2 H), 3.44 (q, J = 7.1 Hz, 4 H), 3.10 (s, 3 H), 1.52 (s, 9 H), 1.23 (t, 
J = 7.1 Hz, 6 H). 
NMR Assignment. 1H NMR (400 MHz) d 7.68 (d, J = 15.5 Hz, 1 H, C6-H), 7.62 
(d, J = 9.3 Hz, 1 H, C1-H), 7.08 (d, J = 15.5 Hz, 1 H, C7-H), 6.66 (dd, J = 9.3, 2.6 Hz, 1 
H, C2-H), 6.49 (d, J =2.6 Hz, 1 H, C5-H), 5.48 (s, 2 H, C8-H), 3.44 (q, J = 7.1 Hz, 4 H, 
C3-H), 3.10 (s, 3 H, OMs), 1.52 (s, 9 H, OtBu), 1.23 (t, J = 7.1 Hz, 6 H, C4-H). 
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 Nitrodibenzofuran-caged erythromycin A-9-oxime (NDBF-ERY, 6.20). 
ARMVI203. Solid sodium hydride (60% oil dispersion, 8.4 mg, 0.21 mmol) was added 
to a solution of 6.2 (104 mg, 0.14 mmol) in DMF/THF (1:1, 3 mL) at 0 ºC, and the 
suspension was stirred for 30 min at 0 ºC. A solution of 6.12 (86 mg, 0.28 mmol) in 
DMF/THF (1:1, 2 mL) was added, and the reaction was stirred for 30 min at 0 ºC. The 
reaction was warmed to room temperature, and stirred for 12 h, whereupon water (~1 
mL) was carefully added. The mixture was diluted with CH2Cl2 (50 mL), and was 
washed with saturated aqueous NaHCO3 (3 x 50 mL), dried (Na2SO4), filtered, and 
concentrated in vacuo to give crude 6.20. The crude material was purified via silica gel 
flash column chromatography eluting along a gradient with hexanes : ethyl acetate : Et3N 
(9 : 1 : 1%) → CH2Cl2 (1% Et3N) to give 110 mg (78%) of 6.20 as a white solid: 1H 
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NMR (400 MHz) δ 8.38 (d, J = 7.8 Hz, 1 H), 8.15 (d, J = 11.4 Hz, 1 H), 7.65 – 7.52 
(comp, 3 H), 7.47 – 7.35 (m, 1 H), 5.52 (q, J = 6.2 Hz, 0.5 H), 5.44 (q, J = 6.3 Hz, 0.5 H), 
5.25 – 5.19 (m, 1 H), 5.14 (d, J = 6.6 Hz, 1 H), 5.10 – 5.05 (m, 1 H), 5.02 (dd, J = 6.7, 2.7 
Hz, 1 H), 4.86 (d, J = 4.7 Hz, 1 H), 4.45 – 4.38 (m, 1 H), 4.35 (d, J = 10.5 Hz, 0.5 H), 
4.22 (d, J = 11.4 Hz, 0.5 H), 4.15 – 4.08 (m, 1 H), 4.01 (dd, J = 9.4, 6.1 Hz, 1 H), 3.97 – 
3.93 (m, 1 H), 3.77 (d, J = 18.7 Hz, 1 H), 3.66 – 3.55 (m, 1 H), 3.53 – 3.39 (comp, 2 H), 
3.33 (s, 3 H), 3.28 (s, 1 H) 3.21 (ddd, J = 9.9, 7.3, 2.6 Hz, 1 H), 3.10 (s, 1 H), 3.00 (t, J = 
9.4 Hz, 1 H), 2.96 – 2.82 (comp, 3 H), 2.67 (q, J = 7.1 Hz, 1 H), 2.37 - 2.31 (comp, 4 H), 
2.28 (s, 6 H), 2.03 – 1.85 (comp, 2 H), 1.69 – 1.56 (comp, 4 H), 1.56 – 1.38 (comp, 6 H), 
1.30 (dd, J = 9.1, 6.2 Hz, 2 H), 1.27 – 1.13 (comp, 12 H), 1.14 – 1.06 (comp, 6 H), 0.92 – 
0.76 (m, 4 H), 0.69 (d, J = 6.9 Hz, 1 H). 13C NMR (100 MHz) δ 175.2, 174.0, 158.3, 
154.0, 153.8, 135.1, 134.2, 130.2, 129.6, 129.4, 129.4, 123.7, 122.7, 122.6, 122.4, 121.9, 
120.1, 119.9, 119.8, 119.6, 117.7, 112.1, 112.0, 108.4, 107.9, 103.0, 96.4, 96.3, 96.1, 
95.4, 80.2, 77.9, 77.3, 77.2, 77.0, 76.8, 76.7, 75.1, 75.1, 74.3, 72.7, 71.6, 70.8, 70.4, 70.3, 
68.5, 65.5, 65.4, 56.0, 49.4, 49.4, 44.7, 44.6, 40.1, 38.9, 37.7, 35.0, 33.1, 29.7, 29.3, 27.1, 
27.0, 26.9, 24.4, 23.6, 22.7, 21.5, 21.3, 21.1, 18.6, 18.2, 16.3, 16.2, 16.1, 14.5, 14.4, 14.1, 
10.7, 10.6, 9.2. 
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 Diethylaminocoumarin 450-caged erythromycin A-9-oxime (DEAC450-ERY, 
6.21). ARMVI193. Solid sodium hydride (60% oil dispersion, 6.0 mg, 0.15 mmol) was 
added to a solution of 6.2 (75 mg, 0.10 mmol) in DMF/THF (1:1, 3 mL) at 0 ºC, and the 
resulting suspension was stirred for 30 min at 0 ºC. A solution of 6.19 (113 mg, 0.25 
mmol) in DMF/THF (1:1, 2 mL) was added, and the reaction was stirred for 30 min at 0 
ºC. The ice bath was removed and the reaction was stirred for 12 h at room temperature, 
whereupon water (~1 mL) was carefully added. The mixture was diluted with CH2Cl2 (50 
mL), and washed with saturated aqueous NaHCO3 (3 x 50 mL), dried (Na2SO4), filtered, 
and concentrated in vacuo to give crude 6.21. The crude material was purified via silica 
gel flash column chromatography eluting along a gradient hexanes : CH2Cl2 : Et3N (1 : 1 : 
1% → 0 : 1 : 1%) to give 43 mg (39%) of 6.21 as a yellow solid: 1H NMR (400 MHz) δ 
7.78 (d, J = 15.7 Hz, 1 H), 7.56 (t, J = 9.6 Hz, 1 H), 6.97 (d, J = 15.6 Hz, 1 H), 6.66 (dd, J 
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= 9.3, 2.6 Hz, 1 H), 6.47 (d, J = 2.7 Hz, 1 H), 5.35 (d, J = 11.7 Hz, 1 H), 5.24 (dd, J = 
11.9, 9.1 Hz, 1 H), 5.10 (dt, J = 11.1, 2.5 Hz, 1 H), 4.87 (d, J = 5.0 Hz, 1 H), 4.38 (dd, J = 
11.1, 7.2 Hz, 1 H), 4.20 (d, J = 6.2 Hz, 1 H), 3.97 (t, J = 7.9 Hz, 2 H), 3.74 (d, J = 15.2 
Hz, 1 H), 3.61 - 3.57 (m, 1 H), 3.55 – 3.35 (comp, 7 H), 3.29 (s, 3 H), 3.18 (dd, J = 10.3, 
7.1 Hz, 1 H), 3.09 (s, 1 H), 2.98 (t, J = 9.7 Hz, 1 H), 2.92 – 2.87 (m, 1 H), 2.64 (q, J = 7.3 
Hz, 1 H), 2.46 – 2.30 (comp, 2 H), 2.31 – 2.13 (comp, 7 H), 2.02 – 1.84 (comp, 3 H), 
1.64 (d, J = 11.4 Hz, 1 H), 1.60 - 1.45 (comp, 12 H), 1.32 (s, 2 H), 1.29 – 1.12 (comp, 20 
H), 1.22 - 1.14 (comp, 10 H), 0.90 (d, J = 7.0 Hz, 2 H), 0.83 (t, J = 7.3 Hz, 3 H). 
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 Determination of aqueous solubility. NDBF-ERY (6.20). UV-Vis spectra were 
collected on a DU series 730 UV/Vis scanning spectrophotometer (Beckman Coulter). 
The spectra were collected with a wavelength range 200 – 500 nm, in 0.5 nm increments. 
Samples were places in a quartz cuvette with a 1 cm pathlength. The samples were 
prepared from by adding aqueous phosphate buffer (0.1 M, pH 7.4, 10 mL) to a sample of 
NDBF-ERY (1.17 mg, 1.15 µmol) and sonicating for 15 min. Serial dilutions were 
performed by taking aliquots of the previous solution (0.9 mL, 0.8 mL, 0.7 mL…) and 
diluting each aliquot with phosphate buffer to a final volume of 1 mL. Each sample was 
immediately analyzed by UV-Vis spectrophotometry. The saturated aqueous sample was 
prepared by sonicating a suspension of NDBF-ERY (1.9 mg, 1.9 µmol) in phosphate 
buffer (10 mL) for 30 min and passing the resulting suspension through a syringe filter. 
The UV/Vis spectroscopy results are shown below. For each sample, absorbance (350 
nm) was plotted against concentration to give the Beer’s law plot shown below. 
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Determination of aqueous solubility. DEAC450-ERY (6.21). UV-Vis spectra 
were collected on a DU series 730 UV/Vis scanning spectrophotometer (Beckman 
Coulter). The spectra were collected with a wavelength range 200 – 700 nm, in 1 nm 
increments. Samples were places in a quartz cuvette with a 1 cm pathlength. The samples 
were prepared from by adding aqueous phosphate buffer (0.1 M, pH 7.4, 10 mL) to a 
sample of DEAC450-ERY (1.27 mg, 1.15 µmol) and sonicating for 15 min. Serial 
dilutions were performed by taking aliquots of the previous solution (0.9 mL, 0.8 mL, 0.7 
mL…) and diluting each aliquot with phosphate buffer to a final volume of 1 mL. Each 
sample was immediately analyzed by UV-Vis spectrophotometry. The saturated aqueous 
sample was prepared by sonicating a suspension of DEAC450-ERY (2.1 mg, 1.8 µmol) 
in phosphate buffer (10 mL) for 30 min and passing the resulting suspension through a 
syringe filter. The UV/Vis spectroscopy results are shown below. For each sample, 
absorbance (461 nm) was plotted against concentration to give the Beer’s law plot shown 
below. 
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 Decaging Studies. Samples were irradiated in a QuantaMasterTM 500 
Spectrofluorometer (PTI Inc.), with a 75 W xenon arc lamp light source and a bandpass 
filter of 20 nm. The power output of light at wavelengths of 325 – 500 (± 20) nm was 
measured to be 5-6 mW. Each sample was run in duplicate. Aqueous stock solutions (100 
µM) were prepared by placing solid NDBF-ERY (0.41 mg, 0.4 µmol) and DEAC450-
ERY (0.44 mg, 0.4 µmol), respectively, into water (4 mL) and sonicating for 30 min. The 
negative control sample (100 µL) was placed in a LC/MS vial and kept in the dark for the 
entirety of the study. Aliquots (100 µL) of the stock solution were placed in a quartz 
cuvette (volume = 100 µL, pathlength = 1 cm), which was placed in the 
spectrofluorometer and irradiated at the specified wavelength for 5 min. The sample was 
transferred via a fresh syringe into an LC/MS vial, and the cuvette was rinsed with water 
(3 x 100 µL) before adding the next sample. Each sample was analyzed by LC/MS, and 
the MS trace (example below) of each sample was quantified by peak area of ERY-9-OX 
and compared to area of the respective starting material peak.  
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Appendix A: 
Figure A.1. Crystal structure of 2.54 showing the atom labeling scheme.  Displacement 
ellipsoids are scaled to the 50% probability level.  
 
 
 X-ray Experimental for C26H27NO5S:  Crystals grew as clusters of colorless 
prisms by slow diffusion of hexanes into ethyl acetate.  The data crystal was cut from a 
larger crystal and had approximate dimensions; 0.20 x 0.18 x 0.12 mm.  The data were 
collected on a Rigaku SCX-Mini diffractometer with a Mercury 2 CCD using a graphite 
monochromator with MoKa radiation (l = 0.71075Å).  A total of 481 frames of data 
were collected using w-scans with a scan range of 1° and a counting time of 60 seconds 
per frame.  The data were collected at 163 K using a Rigaku XStream low temperature 
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device.  Details of crystal data, data collection and structure refinement are listed in Table 
1.  Data reduction were performed using the Rigaku Americas Corporation’s Crystal 
Clear version 1.40.314  The structure was solved by direct methods using SIR97315 and 
refined by full-matrix least-squares on F2 with anisotropic displacement parameters for 
the non-H atoms using SHELXL-97.316  Structure analysis was aided by use of the 
programs PLATON98317 and WinGX.318  The hydrogen atoms on carbon were calculated 
in ideal positions with isotropic displacement parameters set to 1.2xUeq of the attached 
atom (1.5xUeq for methyl hydrogen atoms).   
The function, Sw(|Fo|2 - |Fc|2)2, was minimized, where w = 1/[(s(Fo))2 + 
(0.0418*P)2 + (1.55*P)] and P = (|Fo|2 + 2|Fc|2)/3.  Rw(F2) refined to 0.110, with R(F) 
equal to 0.0475 and a goodness of fit, S, = 0.922.  Definitions used for calculating R(F), 
Rw(F2) and the goodness of fit, S, are given below.319  The data were corrected for 
secondary extinction effects.  The correction takes the form:  Fcorr = kFc/[1  +  
(2.3(6)x10-6)* Fc2 l3/(sin2q)]0.25 where k is the overall scale factor.  Neutral atom 
scattering factors and values used to calculate the linear absorption coefficient are from 
the International Tables for X-ray Crystallography (1992).320  All figures were generated 
using SHELXTL/PC.321  Tables of positional and thermal parameters, bond lengths and 
angles, torsion angles and figures are found in the proceeding sections. 
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Table A.1. Crystal data and structure refinement for 2.54. 
________________________________________________________________________ 
Empirical formula  C26 H27 N O5 S 
Formula weight  465.54 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  monoclinic 
Space group  C c 
  Unit cell dimensions a = 10.8751(14) Å a= 90°. 
 b = 23.420(3) Å b= 99.649(6)°. 
 c = 9.0337(12) Å g= 90°. 
Volume 2268.2(5) Å3 
Z 4 
Density (calculated) 1.363 Mg/m3 
Absorption coefficient 0.182 mm-1 
F(000) 984 
Crystal size 0.200 x 0.180 x 0.120 mm 
Theta range for data collection 2.089 to 27.483°. 
Index ranges -14<=h<=14, -30<=k<=30, -11<=l<=11 
Reflections collected 10697 
Independent reflections 4726 [R(int) = 0.0576] 
 
 
 
370 
Completeness to theta = 25.242° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00 and 0.761 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4726 / 2 / 303 
Goodness-of-fit on F2 0.922 
Final R indices [I>2sigma(I)] R1 = 0.0475, wR2 = 0.1031 
R indices (all data) R1 = 0.0581, wR2 = 0.1101 
Absolute structure parameter 0.02(12) 
Extinction coefficient 2.3(6)x10-6 
Largest diff. peak and hole 0.270 and -0.256 e.Å-3 
________________________________________________________________________ 
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Table A.2. Atomic coordinates (x104) and equivalent isotropic displacement parameters 
(Å2x103) for 2.54  
 
 U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________ 
C1 1155(4) 2845(2) 2004(5) 24(1) 
C2 558(4) 3429(2) 2013(5) 24(1) 
C3 1554(4) 3883(2) 2135(5) 20(1) 
C4 1259(4) 4412(2) 1455(5) 22(1) 
C5 2170(4) 4830(2) 1520(5) 21(1) 
C6 3403(3) 4703(2) 2191(4) 18(1) 
C7 3713(4) 4172(2) 2842(4) 17(1) 
C8 5106(4) 4023(2) 3322(5) 20(1) 
C9 5261(4) 3476(2) 4308(5) 25(1) 
C10 4352(4) 3008(2) 3716(5) 25(1) 
C11 3045(3) 3219(2) 3777(5) 20(1) 
C12 2761(4) 3762(2) 2860(4) 19(1) 
C13 5623(4) 3897(2) 1914(5) 21(1) 
C14 6704(4) 4101(2) 1627(5) 23(1) 
C15 7470(4) 4495(2) 2659(5) 23(1) 
C16 6972(4) 4662(2) 4008(5) 23(1) 
C17 5864(4) 4476(2) 4255(5) 24(1) 
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C18 704(4) 5480(2) 195(5) 28(1) 
C19 4276(4) 5601(2) 3026(6) 32(1) 
C20 838(4) 2784(2) 5738(5) 24(1) 
C21 -446(4) 2832(2) 5218(5) 28(1) 
C22 -1152(4) 3182(2) 5989(5) 30(1) 
C23 -621(4) 3487(2) 7252(5) 28(1) 
C24 651(4) 3425(2) 7769(5) 26(1) 
C25 1381(4) 3077(2) 7015(5) 25(1) 
C26 -1418(4) 3879(2) 8037(6) 34(1) 
N1 2106(3) 2757(1) 3344(4) 22(1) 
O1 989(3) 1906(1) 4021(4) 30(1) 
O2 2907(3) 2247(1) 5705(4) 26(1) 
O3 8473(3) 4676(1) 2388(4) 31(1) 
O4 4332(3) 5098(1) 2108(3) 24(1) 
O5 1959(3) 5365(1) 924(3) 25(1) 
S1 1756(1) 2366(1) 4716(1) 23(1) 
________________________________________________________________________ 
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Table A.3. Bond lengths [Å] and angles [°] for 2.54 
________________________________________________________________________ 
C1-N1  1.469(6) C9-H9A  0.99 
C1-C2  1.515(6) C9-H9B  0.99 
C1-H1A  0.99 C10-C11  1.515(5) 
C1-H1B  0.99 C10-H10A  0.99 
C2-C3  1.509(5) C10-H10B  0.99 
C2-H2A  0.99 C11-N1  1.494(5) 
C2-H2B  0.99 C11-C12  1.521(5) 
C3-C4  1.397(5) C11-H11  1.0000 
C3-C12  1.394(5) C13-C14  1.334(5) 
C4-C5  1.386(6) C13-H13  0.95 
C4-H4  0.95 C14-C15  1.468(6) 
C5-O5  1.368(5) C14-H14  0.95 
C5-C6  1.407(6) C15-O3  1.232(5) 
C6-O4  1.382(4) C15-C16  1.466(6) 
C6-C7  1.393(5) C16-C17  1.335(5) 
C7-C12  1.413(5) C16-H16  0.95 
C7-C8  1.544(5) C17-H17  0.95 
C8-C13  1.503(5) C18-O5  1.438(5) 
C8-C17  1.512(6) C18-H18A  0.98 
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C8-C9  1.553(5) C18-H18B  0.98 
C9-C10  1.513(6) C18-H18C  0.98 
C19-O4  1.446(5) C23-C24  1.391(6) 
C19-H19A  0.98 C23-C26  1.518(6) 
C19-H19B  0.98 C24-C25  1.392(6) 
C19-H19C  0.98 C24-H24  0.95 
C20-C25  1.387(6) C25-H25  0.95 
C20-C21  1.401(6) C26-H26A  0.98 
C20-S1  1.765(4) C26-H26B  0.98 
C21-C22  1.388(6) C26-H26C  0.98 
C21-H21  0.95 N1-S1  1.635(3) 
C22-C23  1.388(7) O1-S1  1.442(3) 
C22-H22  0.95 O2-S1  1.438(3) 
N1-C1-C2 111.4(3) H2A-C2-H2B 108.2 
N1-C1-H1A 109.3 C4-C3-C12 121.0(4) 
C2-C1-H1A 109.3 C4-C3-C2 118.9(4) 
N1-C1-H1B 109.3 C12-C3-C2 120.0(3) 
C2-C1-H1B 109.3 C5-C4-C3 119.8(4) 
H1A-C1-H1B 108.0 C5-C4-H4 120.1 
C1-C2-C3 109.5(3) C3-C4-H4 120.1 
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C1-C2-H2A 109.8 O5-C5-C4 123.9(4) 
C3-C2-H2A 109.8 O5-C5-C6 116.6(3) 
C1-C2-H2B 109.8 C4-C5-C6 119.5(4) 
C3-C2-H2B 109.8 O4-C6-C7 119.6(3) 
O4-C6-C5 119.2(3) N1-C11-C10 111.0(3) 
C7-C6-C5 121.1(3) N1-C11-C12 113.4(3) 
C6-C7-C12 119.0(3) C10-C11-C12 111.1(3) 
C6-C7-C8 118.5(3) N1-C11-H11 107.0 
C12-C7-C8 122.0(3) C10-C11-H11 107.0 
C13-C8-C17 111.3(3) C12-C11-H11 107.0 
C13-C8-C7 107.2(3) C3-C12-C7 119.4(4) 
C17-C8-C7 114.5(3) C3-C12-C11 121.0(3) 
C13-C8-C9 107.7(3) C7-C12-C11 119.4(3) 
C17-C8-C9 105.2(3) C14-C13-C8 124.1(4) 
C7-C8-C9 110.8(3) C14-C13-H13 117.9 
C10-C9-C8 113.1(3) C8-C13-H13 117.9 
C10-C9-H9A 109.0 C13-C14-C15 121.8(4) 
C8-C9-H9A 109.0 C13-C14-H14 119.1 
C10-C9-H9B 109.0 C15-C14-H14 119.1 
C8-C9-H9B 109.0 O3-C15-C16 122.4(4) 
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H9A-C9-H9B 107.8 O3-C15-C14 121.1(4) 
C11-C10-C9 108.2(3) C16-C15-C14 116.4(3) 
C11-C10-H10A 110.1 C17-C16-C15 121.5(4) 
C9-C10-H10A 110.1 C17-C16-H16 119.3 
C11-C10-H10B 110.1 C15-C16-H16 119.3 
C9-C10-H10B 110.1 C16-C17-C8 124.0(4) 
H10A-C10-H10B 108.4 C16-C17-H17 118.0 
C8-C17-H17 118.0 C22-C23-C26 120.3(4) 
O5-C18-H18A 109.5 C24-C23-C26 121.4(4) 
O5-C18-H18B 109.5 C23-C24-C25 120.9(4) 
H18A-C18-H18B 109.5 C23-C24-H24 119.5 
O5-C18-H18C 109.5 C25-C24-H24 119.6 
H18A-C18-H18C 109.5 C20-C25-C24 119.9(4) 
H18B-C18-H18C 109.5 C20-C25-H25 120.0 
O4-C19-H19A 109.5 C24-C25-H25 120.0 
O4-C19-H19B 109.5 C23-C26-H26A 109.5 
H19A-C19-H19B 109.5 C23-C26-H26B 109.5 
O4-C19-H19C 109.5 H26A-C26-H26B 109.5 
H19A-C19-H19C 109.5 C23-C26-H26C 109.5 
H19B-C19-H19C 109.5 H26A-C26-H26C 109.5 
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C25-C20-C21 120.0(4) H26B-C26-H26C 109.5 
C25-C20-S1 120.7(3) C1-N1-C11 118.0(3) 
C21-C20-S1 119.2(3) C1-N1-S1 118.8(3) 
C22-C21-C20 118.9(4) C11-N1-S1 116.2(3) 
C22-C21-H21 120.5 C6-O4-C19 114.4(3) 
C20-C21-H21 120.5 C5-O5-C18 115.9(3) 
C21-C22-C23 121.9(4) O2-S1-O1 120.36(18) 
C21-C22-H22 119.1 O2-S1-N1 106.90(18) 
C23-C22-H22 119.1 O1-S1-N1 106.25(18) 
C22-C23-C24 118.4(4) O2-S1-C20 107.0(2) 
O1-S1-C20 107.75(19) N1-S1-C20 108.10(17) 
________________________________________________________________________ 
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Table A.4. Anisotropic displacement parameters (Å2x103) for 2.54. 
 
 The anisotropic displacement factor exponent takes the form:  -2π2[ h2 a*2U11 + 
...  + 2 h k a* b* U12 ] 
________________________________________________________________________ 
 U11 U22  U33 U23 U13 U12 
________________________________________________________________________ 
C1 25(2)  20(2) 26(2)  0(2) 2(2)  -4(2) 
C2 22(2)  24(2) 24(2)  2(2) 1(2)  -2(2) 
C3 19(2)  20(2) 22(2)  -2(2) 4(2)  -2(2) 
C4 20(2)  26(2) 20(2)  -1(2) 2(2)  3(2) 
C5 24(2)  19(2) 19(2)  1(2) 3(2)  2(2) 
C6 17(2)  22(2) 18(2)  -2(2) 6(2)  -2(2) 
C7 17(2)  20(2) 16(2)  -2(1) 5(2)  -2(2) 
C8 14(2)  25(2) 22(2)  -2(2) 2(2)  0(2) 
C9 19(2)  28(2) 27(2)  5(2) 0(2)  0(2) 
C10 23(2)  23(2) 28(2)  5(2) 5(2)  2(2) 
C11 21(2)  19(2) 21(2)  1(2) 4(2)  -4(2) 
C12 17(2)  20(2) 18(2)  -1(2) 2(2)  0(1) 
C13 22(2)  20(2) 20(2)  -1(2) 1(2)  2(2) 
C14 21(2)  22(2) 25(2)  0(2) 6(2)  3(2) 
C15 19(2)  24(2) 26(2)  4(2) 3(2)  1(2) 
C16 19(2)  27(2) 23(2)  -4(2) 1(2)  -1(2) 
C17 23(2)  28(2) 21(2)  -2(2) 2(2)  1(2) 
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C18 27(2)  26(2) 29(2)  7(2) 0(2)  4(2) 
C19 36(3)  25(2) 36(3)  -5(2) 4(2)  -8(2) 
C20 23(2)  23(2) 27(2)  6(2) 7(2)  0(2) 
C21 22(2)  33(2) 29(3)  5(2) 1(2)  -2(2) 
C22 19(2)  39(3) 33(3)  6(2) 4(2)  1(2) 
C23 27(2)  24(2) 34(3)  9(2) 10(2)  4(2) 
C24 26(2)  27(2) 26(2)  5(2) 5(2)  0(2) 
C25 20(2)  28(2) 25(2)  6(2) 2(2)  0(2) 
C26 32(3)  34(2) 38(3)  6(2) 12(2)  7(2) 
N1 22(2)  19(2) 24(2)  1(1) 3(2)  -2(1) 
O1 35(2)  19(1) 36(2)  2(1) 4(2)  -7(1) 
O2 22(2)  27(2) 30(2)  8(1) 4(1)  5(1) 
O3 20(2)  38(2) 36(2)  0(1) 7(1)  -5(1) 
O4 22(1)  23(2) 27(2)  0(1) 5(1)  -7(1) 
O5 25(2)  21(1) 27(2)  6(1) 0(1)  -1(1) 
S1 24(1)  20(1) 26(1)  4(1) 5(1)  0(1) 
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Table A.5. Hydrogen coordinates (x104) and isotropic displacement parameters (Å2x103) 
for 2.54. 
________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________  
H1A 504 2547 1964 29 
H1B 1545 2806 1094 29 
H2A 105 3459 2873 29 
H2B -49 3484 1077 29 
H4 436 4486 950 26 
H9A 6122 3330 4365 30 
H9B 5143 3577 5339 30 
H10A 4434 2912 2670 30 
H10B 4529 2660 4338 30 
H11 3016 3320 4846 24 
H13 5150 3658 1182 25 
H14 6985 3988 731 27 
H16 7449 4907 4721 28 
H17 5531 4639 5066 29 
H18A 480 5219 -654 41 
H18B 646 5875 -168 41 
H18C 130 5425 912 41 
H19A 3574 5840 2577 49 
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H19B 5055 5817 3086 49 
H19C 4163 5485 4037 49 
H21 -827 2629 4352 34 
H22 -2024 3213 5643 36 
H24 1026 3623 8648 32 
H25 2249 3041 7375 30 
H26A -1077 4267 8074 51 
H26B -1420 3741 9061 51 
H26C -2274 3882 7483 51 
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Table A.6. Torsion angles [°] for 2.54 
________________________________________________________________________ 
N1-C1-C2-C3 56.8(5) C13-C8-C9-C10 -73.8(4) 
C1-C2-C3-C4 148.7(4) C17-C8-C9-C10 167.5(3) 
C1-C2-C3-C12 -28.5(5) C7-C8-C9-C10 43.2(5) 
C12-C3-C4-C5 -1.1(6) C8-C9-C10-C11 -63.9(5) 
C2-C3-C4-C5 -178.2(4) C9-C10-C11-N1 -174.6(3) 
C3-C4-C5-O5 -178.1(4) C9-C10-C11-C12 58.3(4) 
C3-C4-C5-C6 3.9(6) C4-C3-C12-C7 -3.2(6) 
O5-C5-C6-O4 -5.1(5) C2-C3-C12-C7 173.9(4) 
C4-C5-C6-O4 173.0(3) C4-C3-C12-C11 171.8(4) 
O5-C5-C6-C7 179.4(3) C2-C3-C12-C11 -11.1(6) 
C4-C5-C6-C7 -2.4(6) C6-C7-C12-C3 4.6(6) 
O4-C6-C7-C12 -177.3(3) C8-C7-C12-C3 -166.9(4) 
C5-C6-C7-C12 -1.8(6) C6-C7-C12-C11 -170.4(3) 
O4-C6-C7-C8 -5.5(5) C8-C7-C12-C11 18.0(5) 
C5-C6-C7-C8 170.0(4) N1-C11-C12-C3 22.4(5) 
C6-C7-C8-C13 -74.5(4) C10-C11-C12-C3 148.1(4) 
C12-C7-C8-C13 97.1(4) N1-C11-C12-C7 -162.6(3) 
C6-C7-C8-C17 49.5(5) C10-C11-C12-C7 -36.9(5) 
C12-C7-C8-C17 -139.0(4) C17-C8-C13-C14 8.5(6) 
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C6-C7-C8-C9 168.3(3) C7-C8-C13-C14 134.5(4) 
C12-C7-C8-C9 -20.2(5) C9-C8-C13-C14 -106.3(4) 
C8-C13-C14-C15 -2.8(6) C10-C11-N1-C1 -117.7(4) 
C13-C14-C15-O3 179.3(4) C12-C11-N1-C1 8.1(5) 
C13-C14-C15-C16 -1.2(6) C10-C11-N1-S1 91.7(4) 
O3-C15-C16-C17 177.7(4) C12-C11-N1-S1 -142.5(3) 
C14-C15-C16-C17 -1.9(6) C7-C6-O4-C19 -113.1(4) 
C15-C16-C17-C8 8.9(6) C5-C6-O4-C19 71.4(5) 
C13-C8-C17-C16 -11.7(6) C4-C5-O5-C18 -0.2(6) 
C7-C8-C17-C16 -133.4(4) C6-C5-O5-C18 177.9(3) 
C9-C8-C17-C16 104.7(4) C1-N1-S1-O2 167.5(3) 
C25-C20-C21-C22 0.8(6) C11-N1-S1-O2 -42.2(3) 
S1-C20-C21-C22 -177.1(3) C1-N1-S1-O1 37.8(3) 
C20-C21-C22-C23 0.5(6) C11-N1-S1-O1 -171.9(3) 
C21-C22-C23-C24 -1.7(6) C1-N1-S1-C20 -77.7(3) 
C21-C22-C23-C26 178.2(4) C11-N1-S1-C20 72.7(3) 
C22-C23-C24-C25 1.8(6) C25-C20-S1-O2 19.6(4) 
C26-C23-C24-C25 -178.1(4) C21-C20-S1-O2 -162.5(3) 
C21-C20-C25-C24 -0.8(6) C25-C20-S1-O1 150.4(3) 
S1-C20-C25-C24 177.1(3) C21-C20-S1-O1 -31.8(4) 
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C23-C24-C25-C20 -0.5(6) C25-C20-S1-N1 -95.2(4) 
C2-C1-N1-C11 -47.8(5) C21-C20-S1-N1 82.7(4) 
C2-C1-N1-S1 102.0(3)   
________________________________________________________________________ 
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Figure A.2. View of N-tosyl p-phenolic C-alkylation dimer showing the atom labeling 
scheme. Displacement ellipsoids are scaled to the 50% probability level.  
 
 
 X-ray Experimental for C52H54N2O10S2:  Crystals grew as thin colorless plates 
by slow diffusion of hexanes into ethyl acetate.  The data crystal was cut from a cluster of 
crystals and had approximate dimensions; 0.28 x 0.10 x 0.04 mm.  The data were 
collected on a Rigaku AFC12 diffractometer with a Saturn 724+ CCD using a graphite 
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monochromator with MoKa radiation (l = 0.71073Å).  A total of 868 frames of data 
were collected using w-scans with a scan range of 0.5° and a counting time of 60 seconds 
per frame.  The data were collected at 153 K using an Oxford Cryostream low 
temperature device.  Details of crystal data, data collection and structure refinement are 
listed in Table 1.  Data reduction were performed using the Rigaku Americas 
Corporation’s Crystal Clear version 1.40.314  The structure was solved by direct methods 
using SIR97315 and refined by full-matrix least-squares on F2 with anisotropic 
displacement parameters for the non-H atoms using SHELXL-97.316  Structure analysis 
was aided by use of the programs PLATON98317 and WinGX.318  The hydrogen atoms on 
carbon were calculated in ideal positions with isotropic displacement parameters set to 
1.2xUeq of the attached atom (1.5xUeq for methyl hydrogen atoms).    
 The function, Sw(|Fo|2 - |Fc|2)2, was minimized, where w = 1/[(s(Fo))2 + 
(0.063*P)2 + (3.6294*P)] and P = (|Fo|2 + 2|Fc|2)/3.  Rw(F2) refined to 0.245, with R(F) 
equal to 0.131 and a goodness of fit, S, = 1.05.  Definitions used for calculating R(F), 
Rw(F2) and the goodness of fit, S, are given below.319  The data were checked for 
secondary extinction effects but no correction was necessary.  Neutral atom scattering 
factors and values used to calculate the linear absorption coefficient are from the 
International Tables for X-ray Crystallography (1992).320  All figures were generated 
using SHELXTL/PC.321  Tables of positional and thermal parameters, bond lengths and 
angles, torsion angles and figures are found elsewhere.    
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  Table A.7. Crystal data and structure refinement for N-tosyl p-phenolic C-alkylation 
dimer 
________________________________________________________________________ 
Empirical formula  C52 H54 N2 O10 S2 
Formula weight  931.09 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  orthorhombic 
Space group  P c a 21 
  Unit cell dimensions a = 17.728(7) Å a= 90°. 
 b = 17.893(7) Å b= 90°. 
 c = 14.312(6) Å g = 90°. 
Volume 4540(3) Å3 
Z 4 
Density (calculated) 1.362 Mg/m3 
Absorption coefficient 0.181 mm-1 
F(000) 1968 
Crystal size 0.280 x 0.100 x 0.040 mm 
Theta range for data collection 3.066 to 24.967°. 
Index ranges -20<=h<=21, -21<=k<=21, -16<=l<=16 
Reflections collected 37604 
Independent reflections 7904 [R(int) = 0.2231] 
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Completeness to theta = 25.242° 96.6 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00 and 0.293 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7904 / 553 / 602 
Goodness-of-fit on F2 1.054 
Final R indices [I>2sigma(I)] R1 = 0.1308, wR2 = 0.1942 
R indices (all data) R1 = 0.2518, wR2 = 0.2446 
Absolute structure parameter -0.1(3) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.266 and -0.271 e.Å-3 
________________________________________________________________________ 
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Table A.8. Atomic coordinates (x104) and equivalent isotropic displacement parameters 
(Å2x103) for N-tosyl p-phenolic C-alkylation dimer 
 
 U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________ 
C1 -961(8) 4480(8) 5344(11) 47(4) 
C2 -1723(7) 4780(7) 5076(11) 39(4) 
C3 -1791(8) 5633(7) 5030(9) 34(3) 
C4 -2476(9) 5963(7) 4841(10) 35(3) 
C5 -2571(9) 6732(7) 4822(10) 38(3) 
C6 -1935(8) 7174(8) 4933(9) 30(3) 
C7 -1238(8) 6872(7) 5120(9) 31(3) 
C8 -1155(8) 6093(8) 5219(10) 37(3) 
C9 -422(8) 5736(7) 5536(10) 36(3) 
C10 -562(8) 7394(7) 5166(10) 36(3) 
C11 -243(8) 7683(8) 4369(10) 41(4) 
C12 351(8) 8181(7) 4375(10) 38(4) 
C13 663(9) 8392(8) 5254(11) 43(4) 
C14 349(9) 8125(8) 6056(10) 46(4) 
C15 -251(8) 7639(8) 6010(10) 39(4) 
C16 1638(8) 9138(8) 4495(10) 46(4) 
C17 2238(8) 9651(8) 4785(11) 50(4) 
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C18 2832(9) 9254(8) 5417(11) 47(4) 
C19 3713(10) 10326(9) 5726(12) 65(5) 
C20 4114(11) 10131(9) 4902(14) 81(6) 
C21 4096(9) 9325(8) 4603(11) 45(4) 
C22 4706(8) 8995(8) 4115(10) 43(4) 
C23 4679(8) 8251(8) 3904(10) 38(3) 
C24 4084(9) 7815(8) 4172(10) 41(3) 
C25 3462(9) 8118(8) 4641(9) 39(3) 
C26 3490(8) 8886(8) 4886(10) 38(3) 
C27 2822(8) 7599(7) 4933(11) 38(3) 
C28 2376(8) 7262(7) 4249(11) 41(4) 
C29 1840(9) 6734(8) 4502(12) 49(4) 
C30 1746(8) 6552(8) 5417(12) 45(4) 
C31 2197(8) 6886(8) 6120(11) 50(4) 
C32 2738(9) 7412(8) 5867(11) 48(4) 
C33 950(9) 5491(8) 5145(12) 57(4) 
C34 186(8) 5705(8) 4786(11) 45(4) 
C35 -3923(8) 6617(8) 4711(11) 48(4) 
C36 -2143(8) 8234(8) 3979(10) 48(4) 
C37 -1612(9) 5330(8) 7321(11) 55(4) 
C38 -1679(10) 6124(8) 7347(11) 52(4) 
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C39 -2392(10) 6438(8) 7385(11) 52(4) 
C40 -3038(10) 6001(9) 7447(10) 52(4) 
C41 -2965(10) 5234(9) 7446(10) 51(4) 
C42 -2257(9) 4884(9) 7376(10) 50(4) 
C43 -3819(10) 6345(9) 7511(12) 66(5) 
C44 4099(11) 6792(10) 3106(12) 73(6) 
C45 5914(9) 8331(10) 3178(13) 75(6) 
C46 1961(10) 10412(9) 6990(9) 55(4) 
C47 1990(11) 11099(9) 6594(12) 66(5) 
C48 1327(12) 11519(10) 6460(12) 68(5) 
C49 632(12) 11248(11) 6793(11) 67(5) 
C50 612(11) 10549(10) 7185(12) 70(5) 
C51 1251(11) 10132(10) 7290(10) 62(4) 
C52 -78(11) 11710(10) 6673(13) 82(6) 
N1 -524(7) 4983(6) 5957(9) 45(3) 
N2 3195(7) 9778(7) 6088(9) 57(3) 
O1 -164(7) 5390(7) 7555(7) 74(4) 
O2 -776(6) 4160(6) 7320(9) 71(3) 
O3 -3256(5) 7071(5) 4692(7) 44(3) 
O4 -2031(5) 7949(5) 4906(7) 41(3) 
O5 1247(6) 8895(5) 5330(7) 49(3) 
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O6 2588(7) 9148(5) 7431(7) 68(3) 
O7 3316(8) 10304(6) 7658(8) 81(4) 
O8 5265(6) 7904(6) 3437(8) 53(3) 
O9 4124(5) 7044(5) 4053(7) 48(3) 
O10 1264(6) 6011(6) 5780(8) 61(3) 
S1 -705(3) 4932(3) 7098(3) 58(1) 
S2 2794(3) 9875(2) 7113(3) 63(1) 
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Table A.9. Bond lengths [Å] and angles [°] for N-tosyl p-phenolic C-alkylation dimer 
________________________________________________________________________ 
C1-N1  1.476(17) C10-C11  1.374(18) 
C1-C2  1.503(18) C10-C15  1.399(18) 
C1-H1A  0.99 C11-C12  1.380(18) 
C1-H1B  0.99 C11-H11  0.95 
C2-C3  1.533(17) C12-C13  1.424(19) 
C2-H2A  0.99 C12-H12  0.95 
C2-H2B  0.99 C13-C14  1.363(18) 
C3-C4  1.376(18) C13-O5  1.377(16) 
C3-C8  1.421(18) C14-C15  1.376(19) 
C4-C5  1.387(17) C14-H14  0.95 
C4-H4  0.95 C15-H15  0.95 
C5-O3  1.370(16) C16-O5  1.449(16) 
C5-C6  1.386(18) C16-C17  1.465(18) 
C6-C7  1.375(17) C16-H16A  0.99 
C6-O4  1.397(15) C16-H16B  0.99 
C7-C8  1.410(17) C17-C18  1.56(2) 
C7-C10  1.520(18) C17-H17A  0.99 
C8-C9  1.518(18) C17-H17B  0.99 
C9-N1  1.488(17) C18-N2  1.489(17) 
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C9-C34  1.522(19) C18-C26  1.54(2) 
C9-H9  1.00 C18-H18  1.00 
C19-C20  1.42(2) C30-O10  1.393(16) 
C19-N2  1.440(18) C30-C31  1.42(2) 
C19-H19A  0.99 C31-C32  1.392(19) 
C19-H19B  0.99 C31-H31  0.95 
C20-C21  1.506(19) C32-H32  0.95 
C20-H20A  0.99 C33-O10  1.414(17) 
C20-H20B  0.99 C33-C34  1.499(19) 
C21-C26  1.390(18) C33-H33A  0.99 
C21-C22  1.42(2) C33-H33B  0.99 
C22-C23  1.367(19) C34-H34A  0.99 
C22-H22  0.95 C34-H34B  0.99 
C23-C24  1.366(19) C35-O3  1.434(15) 
C23-O8  1.382(17) C35-H35A  0.98 
C24-O9  1.392(16) C35-H35B  0.98 
C24-C25  1.400(19) C35-H35C  0.98 
C25-C26  1.420(18) C36-O4  1.435(16) 
C25-C27  1.524(19) C36-H36A  0.98 
C27-C32  1.39(2) C36-H36B  0.98 
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C27-C28  1.395(19) C36-H36C  0.98 
C28-C29  1.388(19) C37-C42  1.397(19) 
C28-H28  0.95 C37-C38  1.43(2) 
C29-C30  1.36(2) C37-S1  1.787(17) 
C29-H29  0.95 C38-C39  1.38(2) 
C38-H38  0.95 C46-C51  1.42(2) 
C39-C40  1.39(2) C46-S2  1.771(18) 
C39-H39  0.95 C47-C48  1.41(2) 
C40-C41  1.38(2) C47-H47  0.95 
C40-C43  1.52(2) C48-C49  1.41(2) 
C41-C42  1.41(2) C48-H48  0.95 
C41-H41  0.95 C49-C50  1.37(2) 
C42-H42  0.95 C49-C52  1.51(3) 
C43-H43A  0.98 C50-C51  1.36(2) 
C43-H43B  0.98 C50-H50  0.95 
C43-H43C  0.98 C51-H51  0.95 
C44-O9  1.428(18) C52-H52A  0.98 
C44-H44A  0.98 C52-H52B  0.98 
C44-H44B  0.98 C52-H52C  0.98 
C44-H44C  0.98 N1-S1  1.667(13) 
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C45-O8  1.430(17) N2-S2  1.640(13) 
C45-H45A  0.98 O1-S1  1.421(11) 
C45-H45B  0.98 O2-S1  1.423(11) 
C45-H45C  0.98 O6-S2  1.427(10) 
C46-C47  1.35(2) O7-S2  1.433(12) 
N1-C1-C2 114.0(11) C2-C1-H1A 108.8 
N1-C1-H1A 108.8 N1-C1-H1B 108.8 
C2-C1-H1B 108.8 C7-C8-C3 118.0(13) 
H1A-C1-H1B 107.7 C7-C8-C9 122.4(13) 
C1-C2-C3 115.9(12) C3-C8-C9 119.6(12) 
C1-C2-H2A 108.3 N1-C9-C8 113.4(11) 
C3-C2-H2A 108.3 N1-C9-C34 109.9(11) 
C1-C2-H2B 108.3 C8-C9-C34 114.2(12) 
C3-C2-H2B 108.3 N1-C9-H9 106.2 
H2A-C2-H2B 107.4 C8-C9-H9 106.2 
C4-C3-C8 119.3(13) C34-C9-H9 106.2 
C4-C3-C2 120.3(12) C11-C10-C15 115.8(13) 
C8-C3-C2 120.4(13) C11-C10-C7 121.4(13) 
C3-C4-C5 122.4(14) C15-C10-C7 122.7(13) 
C3-C4-H4 118.8 C10-C11-C12 123.6(14) 
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C5-C4-H4 118.8 C10-C11-H11 118.2 
O3-C5-C6 118.9(12) C12-C11-H11 118.2 
O3-C5-C4 123.4(13) C11-C12-C13 118.2(14) 
C6-C5-C4 117.7(14) C11-C12-H12 120.9 
C7-C6-C5 121.9(13) C13-C12-H12 120.9 
C7-C6-O4 120.3(12) C14-C13-O5 118.1(14) 
C5-C6-O4 117.7(13) C14-C13-C12 119.5(14) 
C6-C7-C8 120.2(13) O5-C13-C12 122.3(13) 
C6-C7-C10 118.4(12) C13-C14-C15 119.8(14) 
C8-C7-C10 121.4(13) C13-C14-H14 120.1 
C15-C14-H14 120.1 C20-C19-H19A 108.1 
C14-C15-C10 123.0(14) N2-C19-H19A 108.1 
C14-C15-H15 118.5 C20-C19-H19B 108.1 
C10-C15-H15 118.5 N2-C19-H19B 108.1 
O5-C16-C17 107.5(12) H19A-C19-H19B 107.3 
O5-C16-H16A 110.2 C19-C20-C21 117.4(15) 
C17-C16-H16A 110.2 C19-C20-H20A 108.0 
O5-C16-H16B 110.2 C21-C20-H20A 108.0 
C17-C16-H16B 110.2 C19-C20-H20B 108.0 
H16A-C16-H16B 108.5 C21-C20-H20B 108.0 
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C16-C17-C18 111.7(12) H20A-C20-H20B 107.2 
C16-C17-H17A 109.3 C26-C21-C22 119.9(14) 
C18-C17-H17A 109.3 C26-C21-C20 118.4(15) 
C16-C17-H17B 109.3 C22-C21-C20 121.5(14) 
C18-C17-H17B 109.3 C23-C22-C21 119.2(14) 
H17A-C17-H17B 107.9 C23-C22-H22 120.4 
N2-C18-C26 105.1(12) C21-C22-H22 120.4 
N2-C18-C17 112.3(12) C22-C23-C24 121.4(16) 
C26-C18-C17 114.8(13) C22-C23-O8 121.2(14) 
N2-C18-H18 108.1 C24-C23-O8 117.4(14) 
C26-C18-H18 108.1 C23-C24-O9 119.5(14) 
C17-C18-H18 108.1 C23-C24-C25 121.4(15) 
C20-C19-N2 116.8(15) O9-C24-C25 118.9(13) 
C24-C25-C26 117.7(14) C26-C25-C27 123.2(14) 
C24-C25-C27 118.9(13) C21-C26-C25 120.2(15) 
C21-C26-C18 119.2(13) C31-C32-H32 120.4 
C25-C26-C18 120.6(13) O10-C33-C34 114.0(12) 
C32-C27-C28 120.7(14) O10-C33-H33A 108.7 
C32-C27-C25 119.4(14) C34-C33-H33A 108.7 
C28-C27-C25 119.5(14) O10-C33-H33B 108.7 
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C29-C28-C27 119.9(15) C34-C33-H33B 108.7 
C29-C28-H28 120.0 H33A-C33-H33B 107.6 
C27-C28-H28 120.0 C33-C34-C9 114.0(13) 
C30-C29-C28 119.9(16) C33-C34-H34A 108.7 
C30-C29-H29 120.1 C9-C34-H34A 108.7 
C28-C29-H29 120.1 C33-C34-H34B 108.7 
C29-C30-O10 126.9(15) C9-C34-H34B 108.7 
C29-C30-C31 120.9(15) H34A-C34-H34B 107.6 
O10-C30-C31 112.1(14) O3-C35-H35A 109.5 
C32-C31-C30 119.3(15) O3-C35-H35B 109.5 
C32-C31-H31 120.4 H35A-C35-H35B 109.5 
C30-C31-H31 120.4 O3-C35-H35C 109.5 
C27-C32-C31 119.2(16) H35A-C35-H35C 109.5 
C27-C32-H32 120.4 H35B-C35-H35C 109.5 
H36A-C36-H36C 109.5 C40-C43-H43C 109.5 
H36B-C36-H36C 109.5 H43A-C43-H43C 109.5 
C42-C37-C38 119.9(16) H43B-C43-H43C 109.5 
C42-C37-S1 121.3(12) O9-C44-H44A 109.5 
C38-C37-S1 118.5(12) O9-C44-H44B 109.5 
C39-C38-C37 118.8(15) H44A-C44-H44B 109.5 
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C39-C38-H38 120.6 O9-C44-H44C 109.5 
C37-C38-H38 120.6 H44A-C44-H44C 109.5 
C38-C39-C40 121.8(15) H44B-C44-H44C 109.5 
C38-C39-H39 119.1 O8-C45-H45A 109.5 
C40-C39-H39 119.1 O8-C45-H45B 109.5 
C41-C40-C39 118.9(17) H45A-C45-H45B 109.5 
C41-C40-C43 119.3(15) O8-C45-H45C 109.5 
C39-C40-C43 121.8(15) H45A-C45-H45C 109.5 
C40-C41-C42 121.8(15) H45B-C45-H45C 109.5 
C40-C41-H41 119.1 C47-C46-C51 118.7(18) 
C42-C41-H41 119.1 C47-C46-S2 120.1(15) 
C37-C42-C41 118.7(15) C51-C46-S2 121.1(13) 
C37-C42-H42 120.6 C46-C47-C48 120.6(18) 
C41-C42-H42 120.6 C46-C47-H47 119.7 
C40-C43-H43A 109.5 C48-C47-H47 119.7 
C40-C43-H43B 109.5 C49-C48-C47 120.1(18) 
H43A-C43-H43B 109.5 C49-C48-H48 120.0 
C47-C48-H48 120.0 C19-N2-S2 121.7(11) 
C50-C49-C48 118(2) C18-N2-S2 117.2(10) 
C50-C49-C52 121(2) C5-O3-C35 118.5(11) 
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C48-C49-C52 120.1(18) C6-O4-C36 113.3(10) 
C51-C50-C49 122(2) C13-O5-C16 119.4(11) 
C51-C50-H50 119.2 C23-O8-C45 119.4(13) 
C49-C50-H50 119.2 C24-O9-C44 115.3(12) 
C50-C51-C46 120.5(17) C30-O10-C33 117.4(13) 
C50-C51-H51 119.7 O1-S1-O2 121.2(7) 
C46-C51-H51 119.7 O1-S1-N1 106.8(7) 
C49-C52-H52A 109.5 O2-S1-N1 106.8(7) 
C49-C52-H52B 109.5 O1-S1-C37 107.1(8) 
H52A-C52-H52B 109.5 O2-S1-C37 105.5(7) 
C49-C52-H52C 109.5 N1-S1-C37 109.0(7) 
H52A-C52-H52C 109.5 O6-S2-O7 118.7(7) 
H52B-C52-H52C 109.5 O6-S2-N2 107.4(7) 
C1-N1-C9 112.0(12) O7-S2-N2 105.3(7) 
C1-N1-S1 116.7(10) O6-S2-C46 108.3(8) 
C9-N1-S1 118.0(9) O7-S2-C46 107.6(7) 
C19-N2-C18 118.2(13) N2-S2-C46 109.3(7) 
________________________________________________________________________  
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Table A.10. Anisotropic displacement parameters (Å2x103) for N-tosyl p-phenolic C-
alkylation dimer 
 
 The anisotropic displacement factor exponent takes the form:  -2p2[ h2 a*2U11 + 
...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
__________________________________________________________________ 
C1 34(8)  45(7) 61(9)  -11(7) -5(7)  0(6) 
C2 24(7)  44(6) 49(10)  -5(6) 0(7)  -6(5) 
C3 34(6)  42(6) 25(8)  -4(5) -3(6)  -6(5) 
C4 35(7)  43(6) 28(8)  -11(6) -11(6)  -6(5) 
C5 33(6)  40(6) 42(9)  -7(6) -15(6)  -4(5) 
C6 36(6)  43(6) 12(7)  -11(5) -7(5)  -5(4) 
C7 38(6)  43(6) 13(7)  -2(5) 2(5)  -4(4) 
C8 33(6)  44(6) 34(8)  -5(5) -3(6)  -3(4) 
C9 33(6)  39(6) 35(7)  -4(5) -4(5)  -4(5) 
C10 40(7)  35(7) 33(6)  2(6) -4(5)  0(5) 
C11 43(8)  47(9) 33(7)  4(6) -1(6)  1(6) 
C12 44(8)  39(8) 32(7)  13(6) -2(6)  4(6) 
C13 40(8)  50(8) 40(7)  9(6) -5(6)  1(6) 
C14 57(9)  51(9) 31(7)  -3(6) -2(6)  -17(7) 
C15 48(8)  33(8) 36(7)  5(6) -1(6)  -2(6) 
C16 43(8)  54(9) 41(8)  8(7) -7(6)  -4(7) 
C17 52(8)  57(9) 42(9)  2(7) 0(6)  -12(6) 
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C18 51(7)  44(7) 46(7)  -4(6) -3(6)  -17(5) 
C19 75(11)  54(9) 67(9)  -1(7) 1(8)  -27(8) 
C20 99(13)  52(8) 92(11)  5(7) 28(10)  -23(7) 
C21 42(7)  49(6) 45(9)  18(6) -7(6)  -14(5) 
C22 22(7)  48(7) 58(9)  18(6) -12(6)  -17(5) 
C23 30(7)  46(6) 39(8)  20(6) -11(6)  -12(5) 
C24 39(7)  49(6) 35(8)  5(6) -1(6)  -15(5) 
C25 46(7)  47(6) 25(7)  1(5) -3(5)  -15(5) 
C26 44(7)  45(6) 24(7)  5(5) -6(6)  -14(5) 
C27 47(8)  26(7) 41(7)  -6(5) 9(6)  -4(5) 
C28 41(8)  33(8) 49(8)  -13(6) 8(6)  -2(6) 
C29 55(10)  33(8) 60(8)  -6(6) 3(7)  -10(7) 
C30 39(8)  33(7) 63(8)  -1(6) 13(6)  6(6) 
C31 52(9)  45(9) 52(8)  1(6) 14(6)  4(7) 
C32 51(9)  54(9) 40(7)  3(6) 10(6)  -2(7) 
C33 41(8)  52(9) 77(11)  0(8) 5(7)  -11(6) 
C34 39(7)  47(9) 48(8)  -7(7) 2(6)  -9(6) 
C35 33(8)  56(10) 56(11)  1(9) -9(7)  -11(7) 
C36 48(11)  47(9) 48(8)  3(7) -20(8)  -11(8) 
C37 63(7)  51(7) 52(10)  1(7) -12(6)  -20(5) 
C38 71(9)  49(7) 36(10)  0(7) 5(7)  -20(6) 
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C39 77(8)  42(7) 38(10)  -5(7) 6(7)  -16(6) 
C40 77(8)  56(8) 24(8)  -9(7) 12(7)  -18(6) 
C41 68(8)  51(7) 35(9)  -8(7) -4(7)  -25(6) 
C42 71(8)  50(8) 28(9)  -4(7) -9(7)  -22(6) 
C43 86(10)  77(11) 34(10)  -3(9) 23(8)  -4(8) 
C44 91(16)  74(12) 54(9)  -11(8) -5(9)  -2(10) 
C45 49(10)  103(14) 73(13)  6(11) 13(9)  -28(9) 
C46 97(8)  59(8) 9(7)  -6(6) 0(6)  -15(6) 
C47 96(11)  63(9) 39(10)  6(8) 9(8)  -18(7) 
C48 109(10)  61(10) 33(10)  0(8) 3(8)  -11(7) 
C49 103(10)  69(9) 27(10)  -12(7) -8(8)  -15(7) 
C50 99(10)  76(9) 36(10)  -1(8) -2(9)  -15(7) 
C51 100(9)  68(10) 18(9)  -4(8) 0(7)  -20(7) 
C52 107(12)  84(12) 54(12)  1(10) -11(10)  -11(9) 
N1 46(7)  38(6) 53(6)  3(5) -9(5)  -7(5) 
N2 69(8)  53(7) 48(6)  -5(5) -5(5)  -23(6) 
O1 74(8)  97(8) 51(7)  21(6) -20(6)  -29(6) 
O2 63(8)  68(6) 83(8)  27(6) -19(7)  -10(5) 
O3 32(5)  50(6) 49(7)  3(5) -10(5)  -4(4) 
O4 44(6)  43(5) 38(6)  -5(4) -3(5)  2(4) 
O5 51(6)  60(6) 37(6)  1(5) 2(5)  -11(5) 
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O6 119(9)  52(6) 32(6)  3(5) -6(6)  -20(6) 
O7 128(10)  63(8) 51(7)  5(6) -8(7)  -37(7) 
O8 41(6)  62(7) 58(7)  23(6) 4(5)  -9(5) 
O9 43(7)  50(6) 51(6)  2(5) 6(5)  -12(5) 
O10 56(7)  49(6) 77(8)  17(5) -6(6)  -15(5) 
S1 62(3)  60(3) 52(3)  16(2) -17(3)  -13(2) 
S2 103(4)  47(2) 38(2)  4(2) -10(3)  -23(2) 
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Table A.11. Hydrogen coordinates (x104) and isotropic  displacement parameters 
(Å2x103) for N-tosyl p-phenolic C-alkylation dimer. 
________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________ 
H1A -1029 3995 5666 56 
H1B -667 4387 4768 56 
H2A -2098 4591 5532 46 
H2B -1859 4573 4457 46 
H4 -2898 5652 4718 43 
H9 -219 6063 6044 43 
H11 -442 7532 3783 49 
H12 548 8378 3809 46 
H14 544 8273 6646 56 
H15 -465 7462 6577 47 
H16A 1283 9396 4068 55 
H16B 1855 8703 4163 55 
H17A 2014 10075 5131 61 
H17B 2493 9853 4224 61 
H18 2568 8857 5784 56 
H19A 3426 10790 5600 78 
H19B 4085 10442 6221 78 
H20A 4648 10276 4990 97 
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H20B 3913 10437 4382 97 
H22 5129 9288 3935 51 
H28 2439 7394 3611 49 
H29 1540 6500 4037 59 
H31 2131 6752 6757 60 
H32 3046 7640 6329 58 
H33A 912 4999 5458 68 
H33B 1297 5434 4608 68 
H34A 31 5341 4302 54 
H34B 222 6202 4484 54 
H35A -3870 6205 4265 72 
H35B -4361 6923 4540 72 
H35C -3995 6415 5341 72 
H36A -1656 8272 3659 71 
H36B -2376 8731 4014 71 
H36C -2475 7896 3631 71 
H38 -1242 6431 7340 62 
H39 -2441 6966 7367 63 
H41 -3406 4934 7494 61 
H42 -2219 4355 7365 60 
H43A -4149 6115 7043 98 
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H43B -3785 6884 7395 98 
H43C -4026 6258 8136 98 
H44A 3892 7189 2710 109 
H44B 3778 6348 3064 109 
H44C 4610 6668 2897 109 
H45A 5770 8707 2713 112 
H45B 6297 7998 2912 112 
H45C 6119 8581 3732 112 
H47 2462 11299 6404 79 
H48 1349 11986 6145 81 
H50 143 10350 7387 84 
H51 1220 9650 7567 74 
H52A -33 12020 6111 122 
H52B -146 12032 7220 122 
H52C -513 11376 6610 122 
______________________________________________________________________   
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Table A.12. Torsion angles [°] for N-tosyl p-phenolic C-alkylation dimer 
______________________________________________________________________ 
N1-C1-C2-C3 29.3(19) C4-C3-C8-C9 173.1(13) 
C1-C2-C3-C4 -176.5(13) C2-C3-C8-C9 -4(2) 
C1-C2-C3-C8 1(2) C7-C8-C9-N1 156.7(13) 
C8-C3-C4-C5 0(2) C3-C8-C9-N1 -22.0(18) 
C2-C3-C4-C5 177.8(14) C7-C8-C9-C34 -76.4(17) 
C3-C4-C5-O3 -175.8(13) C3-C8-C9-C34 104.9(15) 
C3-C4-C5-C6 5(2) C6-C7-C10-C11 -75.6(17) 
O3-C5-C6-C7 176.2(12) C8-C7-C10-C11 101.3(16) 
C4-C5-C6-C7 -4(2) C6-C7-C10-C15 101.0(16) 
O3-C5-C6-O4 -0.1(19) C8-C7-C10-C15 -82.1(18) 
C4-C5-C6-O4 179.4(12) C15-C10-C11-C12 0(2) 
C5-C6-C7-C8 -1(2) C7-C10-C11-C12 177.4(13) 
O4-C6-C7-C8 175.1(12) C10-C11-C12-C13 2(2) 
C5-C6-C7-C10 175.9(12) C11-C12-C13-C14 -3(2) 
O4-C6-C7-C10 -8.0(19) C11-C12-C13-O5 -178.9(13) 
C6-C7-C8-C3 6(2) O5-C13-C14-C15 178.0(13) 
C10-C7-C8-C3 -170.7(12) C12-C13-C14-C15 2(2) 
C6-C7-C8-C9 -172.7(12) C13-C14-C15-C10 0(2) 
C10-C7-C8-C9 11(2) C11-C10-C15-C14 -2(2) 
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C4-C3-C8-C7 -6(2) C7-C10-C15-C14 -178.4(14) 
C2-C3-C8-C7 176.8(13) O5-C16-C17-C18 62.8(16) 
C16-C17-C18-N2 -150.9(13) C24-C25-C26-C18 -178.9(13) 
C16-C17-C18-C26 89.2(16) C27-C25-C26-C18 -4(2) 
N2-C19-C20-C21 -13(3) N2-C18-C26-C21 -41.8(18) 
C19-C20-C21-C26 25(3) C17-C18-C26-C21 82.1(17) 
C19-C20-C21-C22 -149.7(17) N2-C18-C26-C25 141.7(13) 
C26-C21-C22-C23 2(2) C17-C18-C26-C25 -94.5(16) 
C20-C21-C22-C23 176.4(15) C24-C25-C27-C32 106.5(16) 
C21-C22-C23-C24 -1(2) C26-C25-C27-C32 -68.3(19) 
C21-C22-C23-O8 -179.3(13) C24-C25-C27-C28 -67.2(18) 
C22-C23-C24-O9 -171.6(13) C26-C25-C27-C28 118.0(15) 
O8-C23-C24-O9 6(2) C32-C27-C28-C29 0(2) 
C22-C23-C24-C25 3(2) C25-C27-C28-C29 173.7(14) 
O8-C23-C24-C25 -179.4(13) C27-C28-C29-C30 1(2) 
C23-C24-C25-C26 -4(2) C28-C29-C30-O10 -176.5(13) 
O9-C24-C25-C26 170.1(13) C28-C29-C30-C31 -1(2) 
C23-C24-C25-C27 -179.1(13) C29-C30-C31-C32 1(2) 
O9-C24-C25-C27 -5(2) O10-C30-C31-C32 176.7(13) 
C22-C21-C26-C25 -4(2) C28-C27-C32-C31 -1(2) 
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C20-C21-C26-C25 -178.2(15) C25-C27-C32-C31 -174.2(13) 
C22-C21-C26-C18 179.9(13) C30-C31-C32-C27 0(2) 
C20-C21-C26-C18 5(2) O10-C33-C34-C9 -64.1(17) 
C24-C25-C26-C21 5(2) N1-C9-C34-C33 -62.3(15) 
C27-C25-C26-C21 179.4(14) C8-C9-C34-C33 168.9(12) 
C42-C37-C38-C39 -3(2) C34-C9-N1-C1 -76.9(14) 
S1-C37-C38-C39 170.8(12) C8-C9-N1-S1 -87.5(13) 
C37-C38-C39-C40 4(2) C34-C9-N1-S1 143.3(10) 
C38-C39-C40-C41 -2(2) C20-C19-N2-C18 -29(2) 
C38-C39-C40-C43 178.6(14) C20-C19-N2-S2 170.6(14) 
C39-C40-C41-C42 -1(2) C26-C18-N2-C19 54.6(18) 
C43-C40-C41-C42 179.1(14) C17-C18-N2-C19 -70.8(18) 
C38-C37-C42-C41 1(2) C26-C18-N2-S2 -144.2(10) 
S1-C37-C42-C41 -172.9(12) C17-C18-N2-S2 90.3(14) 
C40-C41-C42-C37 1(2) C6-C5-O3-C35 -171.2(13) 
C51-C46-C47-C48 -2(2) C4-C5-O3-C35 9(2) 
S2-C46-C47-C48 177.6(13) C7-C6-O4-C36 108.0(14) 
C46-C47-C48-C49 4(3) C5-C6-O4-C36 -75.7(15) 
C47-C48-C49-C50 -5(2) C14-C13-O5-C16 174.5(13) 
C47-C48-C49-C52 178.3(15) C12-C13-O5-C16 -9(2) 
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C48-C49-C50-C51 3(3) C17-C16-O5-C13 -178.6(12) 
C52-C49-C50-C51 179.8(16) C22-C23-O8-C45 1(2) 
C49-C50-C51-C46 0(3) C24-C23-O8-C45 -177.4(14) 
C47-C46-C51-C50 0(2) C23-C24-O9-C44 -69.8(18) 
S2-C46-C51-C50 -179.5(13) C25-C24-O9-C44 115.9(16) 
C2-C1-N1-C9 -56.4(17) C29-C30-O10-C33 14(2) 
C2-C1-N1-S1 84.0(14) C31-C30-O10-C33 -162.0(12) 
C8-C9-N1-C1 52.3(16) C34-C33-O10-C30 -94.4(16) 
C1-N1-S1-O1 173.1(10) C19-N2-S2-O6 -156.2(13) 
C9-N1-S1-O1 -48.9(12) C18-N2-S2-O6 43.4(13) 
C1-N1-S1-O2 42.1(12) C19-N2-S2-O7 -28.7(16) 
C9-N1-S1-O2 -179.9(10) C18-N2-S2-O7 170.8(11) 
C1-N1-S1-C37 -71.5(11) C19-N2-S2-C46 86.6(14) 
C9-N1-S1-C37 66.6(11) C18-N2-S2-C46 -73.8(13) 
C42-C37-S1-O1 -149.4(12) C47-C46-S2-O6 -172.3(13) 
C38-C37-S1-O1 36.9(15) C51-C46-S2-O6 6.8(14) 
C42-C37-S1-O2 -19.1(15) C47-C46-S2-O7 58.2(15) 
C38-C37-S1-O2 167.2(13) C51-C46-S2-O7 -122.7(12) 
C42-C37-S1-N1 95.3(14) C47-C46-S2-N2 -55.6(14) 
C38-C37-S1-N1 -78.4(14) C51-C46-S2-N2 123.5(12) 
______________________________________________________________________  
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Figure A.3.  View of 2.59 showing the atom labeling scheme.  Displacement ellipsoids 
are scaled to the 50% probability level  
 
 X-ray Experimental for C26H26NO5S - CH3OH: Crystals grew as colorless 
needles by slow evaporation from methanol.  The data crystal was cut from a longer 
crystal and had approximate dimensions; 0.29 x 0.13 x 0.09 mm.  The data were collected 
at -140 °C on a Nonius Kappa CCD diffractometer using a Bruker AXS Apex II detector 
and a graphite monochromator with MoKa radiation (l = 0.71073Å).  Reduced 
temperatures were maintained by use of an Oxford Cryosystems 600 low-temperature 
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device.  A total of 366 frames of data were collected using w and f-scans with a scan 
range of 1.0° and a counting time of 199 seconds per frame.  Details of crystal data, data 
collection and structure refinement are listed in Table 1.  Data reduction were performed 
using SAINT V8.27B.322 The structure was solved by direct methods using SIR97315 and 
refined by full-matrix least-squares on F2 with anisotropic displacement parameters for 
the non-H atoms using SHELXL-2013.316  Structure analysis was aided by use of the 
programs PLATON98317 and WinGX.318  The hydrogen atoms were calculated in 
idealized positions.    
The function, Sw(|Fo|2 - |Fc|2)2, was minimized, where w = 1/[(s(Fo))2 + 
(0.0516*P)2] and P = (|Fo|2 + 2|Fc|2)/3.  Rw(F2) refined to 0.146, with R(F) equal to 
0.0618 and a goodness of fit, S, = 1.01.  Definitions used for calculating R(F),Rw(F2) and 
the goodness of fit, S, are given below.319  The data were checked for secondary 
extinction but no correction was necessary.  Neutral atom scattering factors and values 
used to calculate the linear absorption coefficient are from the International Tables for X-
ray Crystallography (1992).320  All figures were generated using SHELXTL/PC.321  
Tables of positional and thermal parameters, bond lengths and angles, torsion angles and 
figures are found elsewhere.   
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Table A.13.  Crystal data and structure refinement for 2.59 
________________________________________________________________________ 
Empirical formula  C27 H30 N O6 S 
Formula weight  496.58 
Temperature  133(2) K 
Wavelength  0.71073 Å 
Crystal system  monoclinic 
Space group  P 21/c 
  Unit cell dimensions a = 12.620(2) Å a= 90°. 
 b = 22.056(3) Å b= 109.127(8)°. 
 c = 9.224(2) Å g = 90°. 
Volume 2425.7(7) Å3 
Z 4 
Density (calculated) 1.360 Mg/m3 
Absorption coefficient 0.177 mm-1 
F(000) 1052 
Crystal size 0.290 x 0.130 x 0.090 mm 
Theta range for data collection 1.708 to 24.997°. 
Index ranges -14<=h<=13, -26<=k<=24, -10<=l<=10 
Reflections collected 17000 
Independent reflections 4255 [R(int) = 0.1285] 
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Completeness to theta = 25.242° 96.7 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00 and 0.817 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4255 / 0 / 321 
Goodness-of-fit on F2 1.005 
Final R indices [I>2sigma(I)] R1 = 0.0618, wR2 = 0.1065 
R indices (all data) R1 = 0.1769, wR2 = 0.1456 
Extinction coefficient n/a 
Largest diff. peak and hole 0.477 and -0.311 e.Å-3 
________________________________________________________________________  
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Table A.14. Atomic coordinates (x104) and equivalent isotropic displacement parameters 
(Å2x103) for 2.59 
 
 U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________ 
C1 1447(4) 7146(2) 3164(4) 28(1) 
C2 1590(4) 6723(2) 1937(5) 27(1) 
C3 2746(4) 6438(2) 2410(5) 21(1) 
C4 3075(4) 6143(2) 1287(5) 24(1) 
C5 4112(4) 5880(2) 1647(5) 26(1) 
C6 4848(4) 5900(2) 3163(5) 21(1) 
C7 4530(4) 6182(2) 4301(5) 20(1) 
C8 5311(4) 6204(2) 5896(5) 21(1) 
C9 5843(4) 5681(2) 6662(5) 28(1) 
C10 6610(4) 5705(2) 8119(5) 30(1) 
C11 6893(4) 6250(2) 8849(5) 28(1) 
C12 6341(4) 6773(2) 8159(5) 29(1) 
C13 5570(4) 6754(2) 6687(5) 23(1) 
C14 5004(4) 7325(2) 5905(5) 31(1) 
C15 3760(4) 7352(2) 5750(5) 31(1) 
C16 3130(4) 6756(2) 5182(5) 22(1) 
C17 3467(4) 6458(2) 3908(5) 20(1) 
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C18 3853(4) 5598(2) -943(5) 42(1) 
C19 6664(4) 5978(2) 3013(5) 44(1) 
C20 814(4) 5802(2) 4348(5) 26(1) 
C21 1633(4) 5355(2) 4603(5) 31(1) 
C22 1413(4) 4846(2) 3675(5) 33(1) 
C23 409(5) 4773(2) 2505(5) 34(1) 
C24 -405(4) 5223(2) 2296(5) 36(1) 
C25 -199(4) 5730(2) 3208(5) 33(1) 
C26 182(4) 4223(2) 1481(5) 46(1) 
C27 8263(5) 7707(2) 11766(6) 66(2) 
N1 1922(3) 6891(1) 4723(4) 24(1) 
O1 84(3) 6809(1) 5071(3) 38(1) 
O2 1755(3) 6348(1) 6951(3) 32(1) 
O3 4518(3) 5581(1) 636(3) 32(1) 
O4 5891(3) 5628(1) 3515(3) 28(1) 
O5 7718(3) 6266(1) 10261(4) 44(1) 
O6 8729(3) 7368(2) 10848(4) 56(1) 
S1 1122(1) 6480(1) 5400(1) 30(1) 
________________________________________________________________________  
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Table A.15. Bond lengths [Å] and angles [°] for 2.59 
______________________________________________________________________ 
C1-N1  1.475(5) C10-C11  1.368(6) 
C1-C2  1.522(5) C10-H10  0.95 
C1-H1A  0.99 C11-O5  1.376(5) 
C1-H1B  0.99 C11-C12  1.390(6) 
C2-C3  1.516(6) C12-C13  1.388(6) 
C2-H2A  0.99 C12-H12  0.95 
C2-H2B  0.99 C13-C14  1.509(6) 
C3-C17  1.384(5) C14-C15  1.530(6) 
C3-C4  1.396(5) C14-H14A  0.99 
C4-C5  1.369(6) C14-H14B  0.99 
C4-H4  0.95 C15-C16  1.537(5) 
C5-O3  1.372(5) C15-H15A  0.99 
C5-C6  1.403(6) C15-H15B  0.99 
C6-O4  1.385(5) C16-N1  1.473(5) 
C6-C7  1.388(5) C16-C17  1.524(5) 
C7-C17  1.409(6) C16-H16  1.00 
C7-C8  1.479(6) C18-O3  1.423(5) 
C8-C13  1.400(5) C18-H18A  0.98 
C8-C9  1.403(5) C18-H18B  0.98 
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C9-C10  1.375(6) C18-H18C  0.98 
C9-H9  0.95 C19-O4  1.433(5) 
C19-H19A  0.98 C24-H24  0.95 
C19-H19B  0.98 C25-H25  0.95 
C19-H19C  0.98 C26-H26A  0.98 
C20-C25  1.374(6) C26-H26B  0.98 
C20-C21  1.392(6) C26-H26C  0.98 
C20-S1  1.755(4) C27-O6  1.396(5) 
C21-C22  1.383(6) C27-H27A  0.98 
C21-H21  0.95 C27-H27B  0.98 
C22-C23  1.378(6) C27-H27C  0.98 
C22-H22  0.95 N1-S1  1.626(3) 
C23-C24  1.396(6) O1-S1  1.441(3) 
C23-C26  1.506(6) O2-S1  1.421(3) 
C24-C25  1.371(6) O6-H6  0.84 
N1-C1-C2 112.5(3) C3-C2-H2B 109.2 
N1-C1-H1A 109.1 C1-C2-H2B 109.2 
C2-C1-H1A 109.1 H2A-C2-H2B 107.9 
N1-C1-H1B 109.1 C17-C3-C4 119.9(4) 
C2-C1-H1B 109.1 C17-C3-C2 122.0(4) 
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H1A-C1-H1B 107.8 C4-C3-C2 118.2(4) 
C3-C2-C1 112.2(3) C5-C4-C3 120.7(4) 
C3-C2-H2A 109.2 C5-C4-H4 119.7 
C1-C2-H2A 109.2 C3-C4-H4 119.7 
C4-C5-O3 125.4(4) C11-C12-H12 119.7 
C4-C5-C6 119.8(4) C12-C13-C8 120.4(4) 
O3-C5-C6 114.8(4) C12-C13-C14 120.9(4) 
O4-C6-C7 120.3(4) C8-C13-C14 118.8(4) 
O4-C6-C5 119.2(4) C13-C14-C15 112.8(3) 
C7-C6-C5 120.5(4) C13-C14-H14A 109.0 
C6-C7-C17 119.1(4) C15-C14-H14A 109.0 
C6-C7-C8 120.2(4) C13-C14-H14B 109.0 
C17-C7-C8 120.7(4) C15-C14-H14B 109.0 
C13-C8-C9 117.3(4) H14A-C14-H14B 107.8 
C13-C8-C7 120.8(4) C14-C15-C16 113.5(3) 
C9-C8-C7 121.9(4) C14-C15-H15A 108.9 
C10-C9-C8 121.9(4) C16-C15-H15A 108.9 
C10-C9-H9 119.1 C14-C15-H15B 108.9 
C8-C9-H9 119.1 C16-C15-H15B 108.9 
C11-C10-C9 120.1(4) H15A-C15-H15B 107.7 
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C11-C10-H10 119.9 N1-C16-C17 112.9(3) 
C9-C10-H10 119.9 N1-C16-C15 107.2(3) 
C10-C11-O5 118.9(4) C17-C16-C15 112.8(3) 
C10-C11-C12 119.6(4) N1-C16-H16 107.9 
O5-C11-C12 121.5(4) C17-C16-H16 107.9 
C13-C12-C11 120.6(4) C15-C16-H16 107.9 
C13-C12-H12 119.7 C3-C17-C7 120.1(4) 
C3-C17-C16 121.7(4) C22-C23-C24 118.1(4) 
C7-C17-C16 118.1(4) C22-C23-C26 121.5(5) 
O3-C18-H18A 109.5 C24-C23-C26 120.4(5) 
O3-C18-H18B 109.5 C25-C24-C23 120.9(5) 
H18A-C18-H18B 109.5 C25-C24-H24 119.6 
O3-C18-H18C 109.5 C23-C24-H24 119.6 
H18A-C18-H18C 109.5 C24-C25-C20 120.4(4) 
H18B-C18-H18C 109.5 C24-C25-H25 119.8 
O4-C19-H19A 109.5 C20-C25-H25 119.8 
O4-C19-H19B 109.5 C23-C26-H26A 109.5 
H19A-C19-H19B 109.5 C23-C26-H26B 109.5 
O4-C19-H19C 109.5 H26A-C26-H26B 109.5 
H19A-C19-H19C 109.5 C23-C26-H26C 109.5 
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H19B-C19-H19C 109.5 H26A-C26-H26C 109.5 
C25-C20-C21 120.0(4) H26B-C26-H26C 109.5 
C25-C20-S1 120.3(3) O6-C27-H27A 109.5 
C21-C20-S1 119.5(4) O6-C27-H27B 109.5 
C22-C21-C20 118.9(4) H27A-C27-H27B 109.5 
C22-C21-H21 120.5 O6-C27-H27C 109.5 
C20-C21-H21 120.5 H27A-C27-H27C 109.5 
C23-C22-C21 121.7(4) H27B-C27-H27C 109.5 
C23-C22-H22 119.1 C16-N1-C1 114.2(3) 
C21-C22-H22 119.1 C16-N1-S1 119.4(3) 
C1-N1-S1 118.8(3) O2-S1-N1 106.64(18) 
C5-O3-C18 117.1(3) O1-S1-N1 105.92(18) 
C6-O4-C19 112.7(3) O2-S1-C20 109.37(19) 
C27-O6-H6 109.5 O1-S1-C20 106.9(2) 
O2-S1-O1 119.18(18) N1-S1-C20 108.39(18) 
______________________________________________________________________ 
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Table A.16. Anisotropic displacement parameters (Å2x103) for 2.59 
 
 The anisotropic displacement factor exponent takes the form:  -2p2[ h2 a*2U11 + 
...  + 2 h k a* b* U12 ] 
________________________________________________________________________ 
 U11 U22  U33 U23 U13 U12 
________________________________________________________________________ 
C1 24(3)  32(3) 32(3)  3(2) 13(2)  10(2) 
C2 28(3)  26(2) 28(3)  5(2) 10(2)  5(2) 
C3 22(3)  10(2) 33(3)  3(2) 13(2)  -1(2) 
C4 24(3)  19(2) 29(3)  2(2) 8(2)  -2(2) 
C5 34(3)  20(3) 29(3)  -3(2) 20(3)  -2(2) 
C6 20(3)  14(2) 32(3)  3(2) 12(2)  3(2) 
C7 27(3)  9(2) 28(3)  3(2) 14(2)  -1(2) 
C8 16(3)  25(3) 26(3)  1(2) 13(2)  1(2) 
C9 25(3)  31(3) 33(3)  -2(2) 16(3)  -1(2) 
C10 26(3)  32(3) 31(3)  4(2) 9(3)  -2(2) 
C11 27(3)  35(3) 23(3)  -2(2) 10(2)  -1(2) 
C12 22(3)  33(3) 35(3)  -9(2) 12(2)  -4(2) 
C13 20(3)  22(3) 31(3)  -2(2) 12(2)  -4(2) 
C14 27(3)  26(3) 40(3)  -9(2) 13(2)  -3(2) 
C15 32(3)  25(3) 37(3)  -5(2) 11(2)  3(2) 
C16 18(3)  21(2) 29(3)  2(2) 10(2)  2(2) 
C17 27(3)  12(2) 24(3)  2(2) 13(2)  -2(2) 
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C18 47(4)  54(3) 25(3)  -2(2) 13(3)  18(3) 
C19 29(4)  54(3) 56(4)  11(3) 24(3)  3(3) 
C20 22(3)  30(3) 29(3)  3(2) 11(3)  2(2) 
C21 29(3)  34(3) 31(3)  5(2) 10(2)  1(2) 
C22 40(4)  23(3) 41(3)  3(2) 17(3)  8(2) 
C23 43(4)  32(3) 36(3)  -1(2) 26(3)  -11(3) 
C24 24(3)  44(3) 42(3)  0(3) 12(3)  -9(3) 
C25 28(3)  35(3) 40(3)  3(2) 17(3)  3(2) 
C26 44(4)  48(3) 52(3)  -9(3) 24(3)  -7(3) 
C27 62(5)  72(4) 74(4)  -9(3) 38(4)  14(3) 
N1 19(2)  27(2) 30(2)  3(2) 12(2)  6(2) 
O1 25(2)  43(2) 52(2)  -3(2) 23(2)  14(2) 
O2 32(2)  42(2) 24(2)  2(1) 12(2)  1(2) 
O3 39(2)  35(2) 26(2)  0(1) 14(2)  12(2) 
O4 23(2)  30(2) 35(2)  4(1) 14(2)  9(2) 
O5 34(2)  56(2) 36(2)  1(2) 4(2)  2(2) 
O6 52(3)  59(2) 62(2)  -19(2) 24(2)  -22(2) 
S1 26(1)  35(1) 33(1)  -2(1) 17(1)  3(1) 
________________________________________________________________________ 
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Table A.17. Hydrogen coordinates (x104) and isotropic displacement parameters 
(Å2x103) for 2.59 
________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________ 
H1A 1819 7537 3116 34 
H1B 638 7227 2948 34 
H2A 1018 6398 1732 33 
H2B 1463 6953 974 33 
H4 2574 6125 263 29 
H9 5668 5300 6161 34 
H10 6943 5342 8618 36 
H12 6493 7147 8699 35 
H14A 5078 7349 4871 37 
H14B 5391 7681 6500 37 
H15A 3398 7681 5025 38 
H15B 3692 7456 6761 38 
H16 3316 6469 6069 27 
H18A 3131 5400 -1081 63 
H18B 4244 5384 -1550 63 
H18C 3726 6020 -1284 63 
H19A 6343 6053 1908 66 
H19B 7370 5755 3229 66 
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H19C 6806 6366 3561 66 
H21 2331 5398 5402 38 
H22 1969 4539 3848 40 
H24 -1110 5178 1513 44 
H25 -762 6033 3049 39 
H26A 875 4098 1304 68 
H26B -389 4322 497 68 
H26C -89 3892 1975 68 
H27A 8864 7876 12637 98 
H27B 7784 7445 12147 98 
H27C 7812 8038 11159 98 
H6 8425 7025 10684 84 
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Table A.18. Torsion angles [°] for 2.59 
________________________________________________________________________ 
N1-C1-C2-C3 -42.8(5) C8-C9-C10-C11 -1.5(6) 
C1-C2-C3-C17 13.7(5) C9-C10-C11-O5 -175.6(4) 
C1-C2-C3-C4 -166.9(3) C9-C10-C11-C12 4.8(6) 
C17-C3-C4-C5 -0.9(6) C10-C11-C12-C13 -5.1(6) 
C2-C3-C4-C5 179.7(4) O5-C11-C12-C13 175.3(4) 
C3-C4-C5-O3 -180.0(3) C11-C12-C13-C8 2.0(6) 
C3-C4-C5-C6 0.7(6) C11-C12-C13-C14 -177.4(4) 
C4-C5-C6-O4 179.5(4) C9-C8-C13-C12 1.3(6) 
O3-C5-C6-O4 0.1(5) C7-C8-C13-C12 -177.2(4) 
C4-C5-C6-C7 0.4(6) C9-C8-C13-C14 -179.3(4) 
O3-C5-C6-C7 -179.0(3) C7-C8-C13-C14 2.3(6) 
O4-C6-C7-C17 179.7(3) C12-C13-C14-C15 -109.2(5) 
C5-C6-C7-C17 -1.2(6) C8-C13-C14-C15 71.4(5) 
O4-C6-C7-C8 1.1(6) C13-C14-C15-C16 -45.3(5) 
C5-C6-C7-C8 -179.8(4) C14-C15-C16-N1 -166.1(3) 
C6-C7-C8-C13 127.3(4) C14-C15-C16-C17 -41.1(5) 
C17-C7-C8-C13 -51.2(6) C4-C3-C17-C7 0.0(6) 
C6-C7-C8-C9 -51.1(6) C2-C3-C17-C7 179.4(4) 
C17-C7-C8-C9 130.4(4) C4-C3-C17-C16 -178.0(3) 
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C13-C8-C9-C10 -1.6(6) C2-C3-C17-C16 1.4(6) 
C7-C8-C9-C10 176.9(4) C6-C7-C17-C3 1.1(6) 
C8-C7-C17-C3 179.6(3) C15-C16-N1-S1 -128.5(3) 
C6-C7-C17-C16 179.1(3) C2-C1-N1-C16 59.3(4) 
C8-C7-C17-C16 -2.3(5) C2-C1-N1-S1 -90.0(4) 
N1-C16-C17-C3 12.4(5) C4-C5-O3-C18 6.7(6) 
C15-C16-C17-C3 -109.4(4) C6-C5-O3-C18 -174.0(4) 
N1-C16-C17-C7 -165.7(3) C7-C6-O4-C19 -104.8(4) 
C15-C16-C17-C7 72.5(5) C5-C6-O4-C19 76.0(5) 
C25-C20-C21-C22 1.1(6) C16-N1-S1-O2 37.9(3) 
S1-C20-C21-C22 -174.4(3) C1-N1-S1-O2 -174.4(3) 
C20-C21-C22-C23 0.2(6) C16-N1-S1-O1 165.8(3) 
C21-C22-C23-C24 -1.5(6) C1-N1-S1-O1 -46.5(3) 
C21-C22-C23-C26 179.0(4) C16-N1-S1-C20 -79.8(3) 
C22-C23-C24-C25 1.5(6) C1-N1-S1-C20 67.9(3) 
C26-C23-C24-C25 -179.0(4) C25-C20-S1-O2 143.5(3) 
C23-C24-C25-C20 -0.1(6) C21-C20-S1-O2 -41.0(4) 
C21-C20-C25-C24 -1.2(6) C25-C20-S1-O1 13.2(4) 
S1-C20-C25-C24 174.3(3) C21-C20-S1-O1 -171.3(3) 
C17-C16-N1-C1 -42.5(4) C25-C20-S1-N1 -100.6(4) 
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C15-C16-N1-C1 82.4(4) C21-C20-S1-N1 74.9(4) 
________________________________________________________________________ 
 
 
Table A.19. Hydrogen bonds for 2.59 [Å and °]. 
________________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
________________________________________________________________________ 
 O6-H6...O5 0.84 1.88 2.715(4) 178.3 
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